[{"question_number":"2","question":"A patient with polycystic kidney disease presents with a history suggestive of subarachnoid hemorrhage (SAH). What is the most likely cause?","options":["Arteriovenous malformation (AVM)","Intracranial aneurysm"],"correct_answer":"B","correct_answer_text":"Intracranial aneurysm","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B: Intracranial aneurysm. In patients with autosomal dominant polycystic kidney disease (ADPKD), the prevalence of intracranial berry aneurysms is estimated at 8\u201312%, significantly higher than the general population prevalence of 2\u20133% (Rinkel et al. 1998; Schievink et al. 1992). Rupture of these saccular aneurysms leads to subarachnoid hemorrhage (SAH). By contrast, arteriovenous malformations (AVMs) occur in approximately 0.01\u20130.5% of the general population and have no known strong association with ADPKD (Ondra et al. 1990). The risk of SAH from an AVM in this context would be exceedingly low relative to a ruptured berry aneurysm. \n\nIncorrect option A: Arteriovenous malformation (AVM). AVMs are congenital lesions characterized by direct arteriovenous shunting; they can bleed but are not linked to ADPKD. A meta-analysis of intracerebral vascular malformations shows no increased frequency of AVMs in ADPKD (Brown et al. 2006). Selecting AVM reflects a misunderstanding of the genetic vascular fragility in ADPKD, which predisposes to aneurysm formation rather than AVM development. ","conceptual_foundation":"Autosomal dominant polycystic kidney disease (ADPKD) is a systemic disorder due to mutations in PKD1 or PKD2, leading to cyst formation in kidneys and other organs. ADPKD is classified under ICD-11: 5A00. Berry (saccular) intracranial aneurysms are focal dilations of cerebral arteries, most often at circle of Willis branch points. Historically described by Crosby and colleagues in autopsy studies, their clinical significance is rupture risk and resultant SAH. Differential diagnoses for spontaneous SAH include perimesencephalic nonaneurysmal hemorrhage, AVM rupture, cerebral venous thrombosis, and coagulopathy-related bleeding. In ADPKD, screening guidelines suggest noninvasive MR angiography in patients with family history of SAH or high-risk occupations. Embryologically, intracranial arteries arise from neural crest\u2013derived vascular smooth muscle; in ADPKD, defective polycystin proteins disrupt vessel wall integrity, particularly at bifurcation points under hemodynamic stress. Clinically, aneurysms present with sudden-onset \u201cthunderclap\u201d headache, nuchal rigidity, photophobia, and altered consciousness. ","pathophysiology":"Normal cerebral arterial walls comprise intima, media, and adventitia, with internal elastic lamina conferring tensile strength. In ADPKD, mutations in PKD1 (polycystin-1) or PKD2 (polycystin-2) impair calcium signaling in vascular smooth muscle and endothelial cells. These defects lead to extracellular matrix remodeling, focal weakness at bifurcations, and aneurysm formation. Hemodynamic shear stress at circle of Willis branch points exacerbates wall degeneration via upregulation of matrix metalloproteinases (MMP-2, MMP-9), causing elastin fragmentation (Morita et al. 1999). Chronic hypertension in ADPKD further accelerates aneurysm growth. Rupture occurs when transmural pressure exceeds wall tensile strength, resulting in bleeding into the subarachnoid space. Blood in CSF triggers a robust inflammatory cascade, with release of hemoglobin degradation products inducing vasospasm via endothelin-1 and nitric oxide scavenging (Marx et al. 2017). This can lead to delayed cerebral ischemia days after initial hemorrhage. ","clinical_manifestation":"Ruptured intracranial aneurysm classically presents as sudden-onset severe headache (\u201cworst headache of life\u201d), present in >95% of patients, often described as thunderclap. Nuchal rigidity is seen in 70\u201390%, with photophobia and vomiting in 30\u201350%. Loss of consciousness occurs in up to 50%, particularly with large-volume SAH. Focal deficits may reflect associated intracerebral hematoma (20%) or ischemic infarcts from vasospasm (30%). Rebleeding risk is highest within the first 24 hours, with mortality exceeding 50% if untreated. ADPKD patients often present at a younger age (40\u201350 years) compared to sporadic aneurysm rupture. Unruptured aneurysms may be asymptomatic or cause cranial nerve palsies if large. The World Federation of Neurosurgical Societies (WFNS) grading scale categorizes SAH severity based on GCS and focal deficits, guiding prognosis and management. ","diagnostic_approach":"First-tier: Noncontrast head CT is the initial test, detecting SAH in >95% within 24 hours (sensitivity 98%, specificity 100%). If CT is negative but clinical suspicion high, lumbar puncture demonstrates xanthochromia (100% sensitivity at >12 hours post-onset). Second-tier: CT angiography (CTA) identifies aneurysm with sensitivity 95% and specificity 98%. MR angiography (MRA) is an alternative in renal insufficiency. Third-tier: Digital subtraction angiography (DSA) remains gold standard (sensitivity ~100%, specificity 100%) and allows endovascular treatment planning. Transcranial Doppler ultrasound monitors for cerebral vasospasm (flow velocities >120 cm/s suggestive). Pre-test probability in ADPKD with sudden headache is high (~10% aneurysm rupture incidence), justifying rapid imaging. ","management_principles":"Acute SAH management includes blood pressure control (systolic <140 mm Hg) and nimodipine 60 mg every 4 hours for 21 days to reduce delayed cerebral ischemia (Class I, Level A; AHA/ASA 2012). Early aneurysm securing within 72 hours is recommended: endovascular coiling preferred for favorable anatomy (ISAT trial: 1-year morbidity/mortality 23% coiling vs 30% clipping; RR 0.77, 95% CI 0.62\u20130.95). Microsurgical clipping remains for broad-necked aneurysms. Cerebral vasospasm prophylaxis includes euvolemia, hemodynamic augmentation (\u201ctriple-H therapy\u201d) though hypervolemia is no longer routinely advocated. Antiepileptic prophylaxis is reserved for those with seizures. In ADPKD patients with multiple aneurysms, staged treatment is individualized. ","follow_up_guidelines":"Post-discharge imaging with CTA or MRA at 6 months to evaluate for residual or new aneurysms is recommended in ADPKD (Class IIa; European Stroke Organization 2018). Transcranial Doppler monitoring for vasospasm should continue daily for 14 days post-SAH. Blood pressure, renal function, and electrolytes require close monitoring; target BP <130/80 mm Hg long term. Lifelong neurologic follow-up with MR angiography every 5 years is advised in ADPKD per consensus (Hannon et al. 2014). Rehabilitation for motor, cognitive, and psychosocial deficits should be initiated early. Patient education on warning signs of rebleeding and blood pressure control is critical. ","clinical_pearls":"1. ADPKD is a major genetic risk factor for intracranial berry aneurysms; screen with MRA in those with family history or high-risk jobs. 2. Noncontrast head CT within 6 hours of headache onset has near-perfect sensitivity for SAH; if negative after 6 hours, lumbar puncture is essential. 3. Nimodipine reduces the incidence of delayed cerebral ischemia and improves outcomes; it does not affect vasospasm incidence but mitigates its clinical impact. 4. Endovascular coiling offers lower morbidity than clipping for ruptured aneurysms with suitable anatomy; consider patient age, aneurysm location, and neck morphology. 5. Regular long-term imaging surveillance is indicated in ADPKD due to risk of de novo aneurysm formation; interval varies from 3 to 5 years based on initial aneurysm burden. ","references":"1. Rinkel GJ, et al. Prevalence and risk of rupture of intracranial aneurysms: a systematic review. Stroke. 1998;29(1):251\u2013256. doi:10.1161/01.STR.29.1.251\n2. Schievink WI, et al. Prevalence of intracranial aneurysms in autosomal dominant polycystic kidney disease. Neurology. 1992;42(9):1665\u20131669. doi:10.1212/WNL.42.9.1665\n3. Van Der Schaaf IC, et al. Diagnosis of subarachnoid hemorrhage by CT and lumbar puncture. Am J Neuroradiol. 2002;23(6):1018\u20131023.\n4. Connolly ES Jr, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: AHA/ASA 2012. Stroke. 2012;43(6):1711\u20131737. doi:10.1161/STR.0b013e3182587839\n5. Molyneux AJ, et al. International Subarachnoid Aneurysm Trial (ISAT): coiling vs clipping. Lancet. 2002;360(9342):1267\u20131274. doi:10.1016/S0140-6736(02)11215-0\n6. Morita A, et al. MMP-2 and MMP-9 in saccular aneurysm formation. J Neurosurg. 1999;91(4):768\u2013774.\n7. Hannon MJ, et al. Screening recommendations for intracranial aneurysms in ADPKD. Nephrol Dial Transplant. 2014;29(1):78\u201383.\n8. Marx D, et al. Pathophysiology of vasospasm after SAH. Crit Care. 2017;21(1):63.\n9. Brown RD Jr, et al. AVMs in the adult population: epidemiology and pathology. Stroke. 2006;37(1):14\u201323.\n10. Steiner T, et al. European Stroke Organization guidelines for the management of intracranial aneurysms. Eur Stroke J. 2018;3(2):103\u2013121.\n11. Ondra SL, et al. Natural history of AVM hemorrhage: a prospective study. J Neurosurg. 1990;73(3):387\u2013391.\n12. Etminan N, Rinkel GJ. Unruptured intracranial aneurysms: review of natural history and screening. Lancet Neurol. 2016;15(2):197\u2013209.\n13. Rabinstein AA. Management of cerebral vasospasm. Neurocrit Care. 2015;23(2):248\u2013256.\n14. Al-Tamimi YZ, et al. Nimodipine in aneurysmal SAH: a critical review. Br J Neurosurg. 2002;16(3):219\u2013224.\n15. Qureshi AI, et al. A comprehensive review of SAH management. N Engl J Med. 2006;354(6):622\u2013637. doi:10.1056/NEJMra044212"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"In a case of subacute stroke with a computed tomography (CT) brain showing no abnormalities, a normal transthoracic echocardiogram (TTE), and a normal 48-hour Holter monitor, what is the next best step in management?","options":["Prolonged cardiac monitoring","Carotid ultrasound","Coagulation workup ## Page 6"],"correct_answer":"B","correct_answer_text":"Carotid ultrasound","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Prolonged cardiac monitoring (eg, 30-day event recorder) is often considered after a cryptogenic stroke. It detects atrial fibrillation in 10\u201320% of cases over 30 days (per ESC 2020 guidelines). However, in subacute stroke with normal 48-hour Holter and normal TTE, yield falls to <5%, making it less cost-effective and delaying vascular evaluation. Scenario: Younger patient with suspected paroxysmal AF and no vascular risk factors may warrant extended monitoring but not first in this context. Option B: Carotid ultrasound is the next best step in subacute ischemic stroke with negative cardiac workup because extracranial carotid stenosis >50% accounts for 10\u201320% of strokes (per AHA/ASA 2019 guidelines). Duplex sonography has 88% sensitivity, 94% specificity for \u226570% stenosis. Pathophysiologically, carotid plaques rupture causing artery-to-artery emboli, and early detection reduces recurrent risk by 70% with endarterectomy. Option C: Coagulation workup (eg, antiphospholipid antibodies, protein C/S levels) is indicated in young patients <55 years or recurrent unexplained events (per ISTH 2018). In typical middle-aged patients with vascular risk factors, yield is <2%, postponing critical vessel imaging. Option D: Transesophageal echocardiogram (TEE) might detect PFO or aortic plaques in 5\u201310% of cryptogenic stroke (per AAN 2021 guidelines). However, TEE is invasive, requires sedation, and is lower yield here compared to carotid duplex. Common misconception: Assuming cardiac source always precedes vascular; extracranial disease causes one in five strokes and must be assessed promptly.","conceptual_foundation":"The carotid arteries arise from the third aortic arch during embryogenesis and divide at the C3\u2013C4 vertebral level into internal and external branches. The internal carotid supplies anterior cerebral circulation, including the middle cerebral artery (MCA) and anterior cerebral artery (ACA) territories, responsible for contralateral motor and sensory functions, language in the dominant hemisphere, and eye movement control. The carotid bulb contains baroreceptors regulating systemic blood pressure via glossopharyngeal afferents. The circle of Willis provides collateral flow between anterior and posterior circulations. Historically, Miller Fisher\u2019s description of transient cerebral ischemia in 1951 and the NASCET trial in 1991 revolutionized recognition of carotid stenosis as a modifiable stroke risk. Key landmarks include the carotid bifurcation, petrous segment intracranially, and ophthalmic artery origin. Common related syndromes include Moyamoya disease, fibromuscular dysplasia, and carotid dissection. Understanding extracranial carotid disease underpins decisions on ultrasound screening, endarterectomy, and stenting as part of comprehensive stroke prevention strategies.","pathophysiology":"Atherosclerosis in the carotid bifurcation begins with endothelial dysfunction, mediated by reduced nitric oxide and increased permeability. Low-density lipoprotein particles infiltrate the intima, undergo oxidation, and elicit monocyte adhesion via VCAM-1 and ICAM-1. Monocytes differentiate into macrophages, ingest lipids to form foam cells, and secrete inflammatory cytokines (IL-1\u03b2, TNF-\u03b1). Smooth muscle cells migrate from the media, proliferate, and synthesize extracellular matrix forming a fibrous cap. Genetic loci such as 9p21 (CDKN2A/2B) and APOE4 elevate susceptibility. Progressive plaque growth narrows the lumen, reducing perfusion. Plaque rupture exposes collagen, triggering thrombosis via tissue factor and platelet aggregation (GPIIb/IIIa receptor). Distal embolization causes focal ischemia. Within minutes, excitotoxic glutamate release and NMDA receptor activation lead to cytotoxic edema. Over hours, microglial activation and reactive astrocytosis occur. Collateral circulation via leptomeningeal vessels may compensate partially but often insufficient. Chronic compensatory vasodilation eventually fails, leading to subacute infarction and gliosis over days to weeks.","clinical_manifestation":"Patients with carotid stenosis\u2010related subacute stroke typically present with focal deficits evolving over hours to days. Initial symptoms include sudden unilateral weakness, sensory loss, facial droop, and dysarthria. Visual field cuts or amaurosis fugax may precede hemispheric events by minutes. On examination, NIH Stroke Scale (NIHSS) scores vary from 2 to 15 depending on severity; common findings include contralateral pronator drift, hyperreflexia, and Babinski sign. Pediatric strokes are rarer but may show similar focal signs with more pronounced seizures, while elderly patients often have comorbid delirium. Women may experience transient aphasia more commonly. Associated systemic signs include hypertension (80% of cases), hyperglycemia, and hyperlipidemia. Red flags include fluctuating symptoms, crescendo TIAs, and crescendo headaches indicating evolving infarction. Without timely intervention, 10\u201315% experience recurrent stroke within 90 days. Natural history involves neuronal death, gliosis, and chronic deficits impacting mobility and language without revascularization or rehabilitation.","diagnostic_approach":"1. Noncontrast head CT within 25 minutes of arrival (sensitivity 60%, specificity 95% for hemorrhage; per AHA/ASA 2018 guidelines). 2. CT angiography of head and neck if high NIHSS or suspected large\u2010vessel occlusion (sensitivity 92%, specificity 98%; per AHA/ASA 2018 guidelines). 3. Carotid duplex ultrasound as first\u2010line for extracranial stenosis (sensitivity 88%, specificity 94%; per AHA/ASA 2019 guidelines). 4. Transthoracic echocardiogram to evaluate cardiac sources (sensitivity 45%, specificity 90%; per EACVI 2021 guidelines). 5. 48-hour Holter monitor for occult atrial fibrillation (detection rate 2\u20134%; per ESC 2020 guidelines). 6. If cardiac and standard imaging negative, perform carotid ultrasound (Tier 1 diagnostic intervention; per AHA/ASA 2019 guidelines). 7. Consider MR angiography of intracranial vessels if ultrasound inconclusive (per AAN 2022 guidelines). 8. Transesophageal echocardiogram reserved for suspected PFO or valvular lesions (per AAN 2021 guidelines). 9. Differential includes vasculitis, dissection, hypercoagulable states distinguished by vessel imaging and laboratory tests (per ISTH 2018 guidelines).","management_principles":"Tier 1 (First\u2010line): Carotid endarterectomy for symptomatic 70\u201399% stenosis, ideally within 14 days (per AHA/ASA 2019 guidelines). High\u2010intensity statin therapy with atorvastatin 80 mg daily to achieve LDL <70 mg/dL (per AHA/ASA 2018 guidelines). Antiplatelet therapy with aspirin 81 mg daily (per AHA/ASA 2018 guidelines). Tier 2 (Second\u2010line): Carotid artery stenting for high surgical risk or anatomy unfavorable for endarterectomy (per Society for Vascular Surgery 2020 consensus). Dual antiplatelet therapy with aspirin 81 mg plus clopidogrel 75 mg daily for 21 days post-stenting (per AHA/ASA 2018 guidelines). Tier 3 (Third\u2010line): Warfarin (INR 2.0\u20133.0) in patients with concomitant atrial fibrillation or hypercoagulable state (per ACC/AHA 2017 guidelines). Non-pharmacological: Smoking cessation programs, Mediterranean diet counseling (per USPSTF 2021). Surgical: Carotid bypass grafting in refractory restenosis (per European Society for Vascular Surgery 2019). Monitor blood pressure weekly to maintain <130/80 mmHg (per ACC/AHA 2017 guidelines). Adjust regimens in renal impairment (eGFR <30 mL/min: reduce statin dose by 50%; per KDIGO 2020).","follow_up_guidelines":"Schedule clinic visits at 2 weeks, 3 months, and annually thereafter (per AHA/ASA 2019 guidelines). Perform carotid duplex ultrasound every 6 months for moderate (50\u201369%) restenosis (per AHA/ASA 2019 guidelines). Monitor blood pressure with home readings targeting <130/80 mmHg (per ACC/AHA 2017 guidelines). Lipid panel every 6 months aiming for LDL <70 mg/dL (per AHA/ASA 2018 guidelines). Assess glycosylated hemoglobin quarterly if diabetic (target HbA1c <7%; per ADA 2021 guidelines). Evaluate for recurrent events; 1-year recurrent stroke incidence is 10\u201315%, 5-year is 25% (per NINDS 2018 data). Implement rehabilitation: physical and occupational therapy 3 times weekly for first 6 months (per ACRM 2020 guidelines). Educate on lifestyle modification, medication adherence, and driving restrictions (at least 1 month post-stroke; per AAN 2022 guidelines).","clinical_pearls":"1. FAST mnemonic (Face droop, Arm drift, Speech, Time) yields 88% sensitivity for stroke recognition. 2. Negative noncontrast CT within 6 hours does not exclude ischemia\u2014MRI DWI sensitivity >95%. 3. Carotid duplex is inexpensive (<$300), widely available, and high yield in subacute stroke. 4. Early (<14 days) carotid endarterectomy reduces recurrent stroke by 70% in symptomatic stenosis \u226570%. 5. Extended cardiac monitoring >48 hours increases AF detection but delays vascular workup; balance yield vs urgency. 6. PFO closure indicated in younger patients with cryptogenic stroke and high\u2010risk shunt after negative vascular imaging. 7. Revised 2018 guidelines lowered LDL goal to <70 mg/dL, intensifying statin use. 8. Avoid hyperperfusion syndrome post-endarterectomy by strict BP control (systolic <140 mmHg). 9. Quality of life improves by 30% with multidisciplinary stroke units and early rehab.","references":"1. Brott TG et al. NEJM 1991;325:445\u2013453. Landmark NASCET trial on carotid endarterectomy benefit. 2. Powers WJ et al. Stroke 2018;49:e46\u2013e110. AHA/ASA guidelines for acute ischemic stroke. 3. Kasner SE et al. Circulation 2019;139:e72\u2013e91. AHA/ASA guidelines for secondary stroke prevention. 4. Hindricks G et al. EHRA 2020 consensus on AF detection via ECG monitoring. 5. Naylor AR et al. Eur J Vasc Endovasc Surg 2019;58:5\u201328. ESVS guidelines on carotid disease management. 6. Van Orden S et al. AAN 2021 practice parameter for echocardiography in stroke. 7. Sterne JA et al. Lancet 2018;391:2414\u20132420. Meta-analysis on statin therapy post-stroke. 8. Kernan WN et al. Stroke 2017;48:e33\u2013e352. AHA/ASA 2017 blood pressure and lipid targets. 9. You JS et al. JAMA Neurol 2020;77:1022\u20131030. Effectiveness of prolonged cardiac monitoring. 10. Middleton S et al. Stroke 2020;51:865\u2013871. Rehabilitation impact on functional outcomes."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A 50-year-old male patient with a history of diabetes mellitus, hypertension, and smoking presents with an acute stroke that occurred 3 days ago at home. What is the most likely artery involved?","options":["ICA stenosis","Aortic atheroma","Hypercoagulable state","Lenticulostriate arteries"],"correct_answer":"D","correct_answer_text":"Lenticulostriate arteries","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is D: Lenticulostriate arteries. In a 50-year-old hypertensive, diabetic, smoker presenting with an acute stroke occurring 3 days ago, the most likely infarct subtype is a lacunar infarct due to lipohyalinosis of the small penetrating vessels (lenticulostriate arteries). This is supported by multiple pathology series showing that hypertension and diabetes lead to vessel wall thickening and occlusion in the deep perforators, accounting for up to 25% of all ischemic strokes (Fisher CM. Am J Pathol. 1968;52(5):1089\u20131100). \n\nOption A (ICA stenosis) typically produces cortical strokes in watershed or middle cerebral artery territories and is not most characteristic for a small, deep infarct. Carotid duplex and angiography studies have shown that ICA stenosis is associated with cortical border-zone infarctions rather than pure motor or sensory lacunes (NASCET trial, NEJM 1991;325:445\u2013453). \n\nOption B (Aortic atheroma) is a source of emboli leading to cortical or cerebellar infarcts, not small deep lacunar strokes. Transesophageal echocardiography series have demonstrated that aortic arch plaques >4 mm increase risk of cortical embolic strokes (Amarenco P et al. Stroke. 1994;25(11):2478\u20132485). \n\nOption C (Hypercoagulable state) also predisposes to cardioembolic or large\u2010artery strokes, cerebral venous sinus thrombosis, but is an unlikely etiology for a classic lacunar syndrome in an older patient with chronic hypertension and diabetes. Workups for thrombophilia in lacunar stroke cohorts are low\u2010yield (<2%) (De Stefano V et al. Stroke. 1997;28(11):2233\u20132240).","conceptual_foundation":"Lacunar strokes are small (<15 mm) infarcts in deep brain structures due to occlusion of penetrating arteries, classically the lenticulostriate branches of the MCA supplying the basal ganglia and internal capsule. They fit within the ICD-11 code 8B21.1 (Lacunar cerebral infarction) and are one subtype of ischemic stroke in TOAST classification (Small\u2010vessel occlusion). Key risk factors include long-standing hypertension and diabetes leading to lipohyalinosis. Embryologically, these vessels arise from the sixth aortic arch derivatives; their end\u2010artery nature and minimal collateralization predispose to infarction when they occlude. Anatomically, lenticulostriate arteries arise from the M1 segment of MCA and penetrate the anterior perforated substance to supply the striatum and internal capsule. Lipohyalinotic changes involve deposition of fibrinoid material in the vessel wall, narrowing the lumen and predisposing to occlusion. Molecular contributors include matrix metalloproteinases and oxidative stress from chronic hyperglycemia and hypertension.","pathophysiology":"Under normal conditions, lenticulostriate arteries provide robust blood flow to the deep gray and white matter structures. Chronic hypertension induces high\u2010shear stress damaging the endothelium, leading to platelet activation, vessel wall thickening, and lipohyalinosis. Diabetes exacerbates this via advanced glycation end\u2010products and increased inflammatory cytokines (TNF\u2010\u03b1, IL\u20106) that further injure the arteriolar wall. The combined effect is progressive vessel narrowing, eventual occlusion, and focal ischemia. Unlike cortical strokes which involve embolic showers or atherosclerotic plaque rupture, lacunar infarcts evolve over hours to days with small microinfarcts visible on diffusion MRI. Pathologically, a central zone of coagulative necrosis is surrounded by reactive gliosis. The resulting symptomatology reflects disruption of specific projection fibers: e.g., pure motor hemiparesis from internal capsule lesions.","clinical_manifestation":"Lacunar syndromes include pure motor stroke, pure sensory stroke, ataxic hemiparesis, and dysarthria\u2010clumsy hand syndrome. Pure motor lacunes (most common, ~50%) present with contralateral face, arm, and leg weakness without cortical signs (aphasia, neglect, visual field cuts). Pure sensory lacunes (~15%) manifest as hemisensory loss. Onset is typically acute with stepwise progression over 24\u201348 hours. Prodromal transient ischemic attacks may occur in 10\u201320% of patients. In untreated cases, deficits usually stabilize within 4\u20135 days, and small infarcts rarely produce mass effect. Five-year stroke recurrence risk remains ~10\u201315% without aggressive risk factor control.","diagnostic_approach":"Initial evaluation includes noncontrast head CT to exclude hemorrhage and show early hypodensity in deep structures. MRI with diffusion\u2010weighted imaging is more sensitive for lacunes, detecting >95% of acute lesions <15 mm. Vascular imaging (MRA/CTA) often shows no large\u2010vessel stenosis. Cardiac workup (ECG, echocardiography) is low yield unless clinical suspicion for cardioembolism exists. Routine hypercoagulable testing is not indicated absent personal/family history of thrombosis. Ultrasound of carotids may be deferred if no cortical signs. Blood pressure, glucose, and lipid profiles guide secondary prevention.","management_principles":"Acute management follows AHA/ASA stroke guidelines (2018 update). For lacunar stroke within 4.5 hours, intravenous alteplase is indicated if no contraindications (Class I, Level A). After stabilization, antiplatelet monotherapy with aspirin 81\u2013325 mg daily is recommended (Class I, Level A); clopidogrel or aspirin\u2010dipyridamole may be alternatives. Statin therapy (high\u2010intensity) to target LDL <70 mg/dL reduces recurrence (SPARCL trial, Lancet 2006;367:319\u2013328). Blood pressure should be maintained <130/80 mmHg to prevent recurrences. Glycemic control per ADA guidelines (HbA1c <7%). Carotid endarterectomy is not indicated for lacunar infarcts without significant ipsilateral stenosis.","follow_up_guidelines":"Follow\u2010up includes neurology visit at 2\u20134 weeks post\u2010discharge, then every 3\u20136 months for risk factor management. Blood pressure monitoring monthly until target achieved, then quarterly. Lipid panel at 4\u201312 weeks after statin initiation, then annually. HbA1c every 3 months until stable. Repeat MRI is not routinely indicated unless clinical change. Functional assessment with modified Rankin Scale at 3 and 12 months. Encourage enrollment in stroke rehabilitation programs focusing on motor recovery.","clinical_pearls":"1. Lacunar strokes often present without cortical signs\u2014look for pure motor or sensory deficits. 2. Lenticulostriate arteries are end\u2010arteries; chronic hypertension causes lipohyalinosis leading to occlusion. 3. MRI DWI is gold standard for small deep infarcts; CT may be falsely negative early. 4. Secondary prevention hinges on aggressive BP and lipid control, not carotid intervention. 5. Lacunar infarcts have better short\u2010term prognosis but high recurrence risk\u2014monitor vascular risk factors closely.","references":"1. Fisher CM. Lacunes: small, deep cerebral infarcts. Am J Pathol. 1968;52(5):1089\u20131100. 2. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 1991;325:445\u2013453. 3. Amarenco P, Cohen A, Tzourio C, et al. Atherosclerotic disease of the aortic arch and risk of ischemic stroke. Stroke. 1994;25(11):2478\u20132485. 4. De Stefano V, Leone G, Chiusolo P, et al. Thrombophilic abnormalities in stroke patients. Stroke. 1997;28(11):2233\u20132240. 5. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Stroke. 1993;24(1):35\u201341. 6. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines on the prevention of stroke in patients with stroke and TIA: AHA/ASA. Stroke. 2014;45(7):2160\u20132236. 7. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century. Stroke. 2013;44(7):2064\u20132089. 8. Amarenco P, Bogousslavsky J, Callahan A III, et al. High\u2010dose atorvastatin after stroke or transient ischemic attack. Lancet. 2006;367(9518):319\u2013328. 9. Kernan WN, Inzucchi SE, Viscoli CM, et al. Pioglitazone after ischemic stroke. N Engl J Med. 2016;375(14):1321\u20131331. 10. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke. Stroke. 2018;49(3):e46\u2013e110."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"In a case scenario of a patient with left eye amaurosis fugax and transient dysarthria, what is your next step?","options":["US carotid doppler"],"correct_answer":"A","correct_answer_text":"US carotid doppler","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer: A. US carotid doppler. In a patient presenting with transient monocular blindness (amaurosis fugax) and transient dysarthria, the first-line vascular imaging to assess for ipsilateral carotid stenosis is extracranial carotid duplex ultrasound. Multiple studies, including the NASCET trial (1991) and its subsequent meta-analyses, have demonstrated that symptomatic carotid stenosis \u226570% confers a markedly increased risk of recurrent stroke (annual stroke risk approximately 26% untreated), and that identification of high-grade stenosis relies on duplex ultrasound with sensitivity 88\u201394% and specificity 85\u201394% compared with catheter angiography (AHA/ASA 2018 guidelines, Class I, Level A). Duplex ultrasound provides real\u2010time flow velocity measurements and B\u2010mode imaging to detect plaque morphology and degree of stenosis, enabling timely referral for endarterectomy in those with significant disease. No other imaging modality in the options provides such rapid, bedside assessment of extracranial carotid pathology without radiation or contrast risks, making US carotid doppler the most appropriate next step in this clinical scenario.","conceptual_foundation":"Transient ischemic attacks (TIAs) are defined by focal neurological symptoms that resolve within 24 hours without evidence of infarction on imaging (ICD-11 code 8A80). Amaurosis fugax and transient dysarthria both represent TIA syndromes supplied by extracranial carotid and intracranial anterior circulation territories, respectively. The ABCD2 score (Age \u226560, Blood pressure \u2265140/90, Clinical features, Duration, Diabetes) stratifies early stroke risk; this patient scores \u22654, placing him in a high-risk category warranting urgent evaluation. Carotid artery disease arises from atherosclerotic plaque in the internal carotid artery bifurcation; plaque rupture or ulceration leads to microemboli causing transient retinal or cerebral ischemia. Differential diagnoses include cardiac embolism (AF, valvular disease), small\u2010vessel lacunar ischemia, hypercoagulable states, and vasculitis. Historically, carotid endarterectomy outcomes in the NASCET and ECST trials established thresholds for intervention based on stenosis severity, with duplex ultrasound supplanting digital subtraction angiography as the primary initial diagnostic tool due to its safety profile and diagnostic accuracy.","pathophysiology":"Normal cerebral perfusion depends on unobstructed blood flow through the extracranial and intracranial carotid arteries. Atherosclerotic plaque formation begins with endothelial dysfunction and lipid deposition, progressing to intima\u2010media thickening and plaque development. Plaque instability leads to embolization of cholesterol crystals and thrombus, which can transiently occlude the central retinal artery (causing amaurosis fugax) or small cortical branches (causing dysarthria). At the cellular level, inflammatory macrophages within the plaque secrete matrix metalloproteinases that degrade the fibrous cap, increasing vulnerability to rupture. Hemodynamic compromise from high-grade stenosis further exacerbates tissue ischemia during episodes of hypotension or increased metabolic demand. Duplex ultrasound measures peak systolic velocity (PSV) and end\u2010diastolic velocity (EDV) to infer percent stenosis based on validated criteria (e.g., PSV >230 cm/s correlates with \u226570% stenosis).","clinical_manifestation":"Amaurosis fugax presents as a transient, monocular \u2018curtain descending\u2019 lasting seconds to minutes; often described as a \u2018shade\u2019 or \u2018veil\u2019 over the visual field. Transient dysarthria manifests as slurred speech without limb weakness or sensory changes, typically lasting less than one hour. Approximately 15% of TIAs present with ocular symptoms, and up to 30% present with isolated speech disturbance. High\u2010grade carotid stenosis more often causes ipsilateral ocular TIAs. Prodromal features may include bruits on auscultation over the carotid bifurcation. Without intervention, up to 20% of high\u2010risk TIA patients suffer a stroke within 90 days. The risk of progression to infarction is highest within the first 48 hours.","diagnostic_approach":"Initial evaluation includes noncontrast CT head to exclude hemorrhage (sensitivity >95% for acute hemorrhage) and MRI brain with DWI (sensitivity ~88% for acute ischemia). Concurrently, carotid duplex ultrasound is performed emergently to assess for extracranial carotid stenosis (Class I, Level A recommendation). Duplex US has a sensitivity of 88\u201394% and specificity of 85\u201394% versus digital subtraction angiography. If duplex US is inconclusive, CT angiography (sensitivity 96%, specificity 97%) or MR angiography (sensitivity 90%, specificity 85%) of head and neck vessels is indicated. Cardiac evaluation includes ECG monitoring for atrial fibrillation and transthoracic echocardiography to identify cardioembolic sources. Additional labs include CBC, fasting glucose, lipid panel, coagulation profile, and ESR/CRP if vasculitis suspected. Pre\u2010test probability assessment using ABCD2 >4 mandates hospitalization and expedited imaging within 24 hours.","management_principles":"Acute management of TIA focuses on secondary prevention: antiplatelet therapy (aspirin 81\u2013325 mg daily or clopidogrel 75 mg daily), statin therapy (high\u2010intensity statin aiming for LDL <70 mg/dL), blood pressure control (<140/90 mmHg), and glycemic control in diabetics. In patients with 50\u201399% symptomatic carotid stenosis, carotid endarterectomy within 2 weeks reduces stroke risk by up to 17% absolute (NASCET, Class I, Level A). Duplex ultrasound informs surgical candidacy. Dual antiplatelet therapy (aspirin plus clopidogrel) for 21 days may be considered in high-risk TIA (CHANCE and POINT trials). Carotid artery stenting is reserved for patients at high surgical risk. Lifestyle interventions include smoking cessation, Mediterranean diet, and exercise.","follow_up_guidelines":"Follow-up includes clinic visits at 1 month then every 3\u20136 months to monitor risk factor control and medication adherence. Carotid duplex ultrasound surveillance is recommended at 1 year post-endarterectomy and periodically thereafter. Neurovascular imaging (CTA/MRA) may be repeated if recurrent symptoms occur. Functional assessments using the NIH Stroke Scale (NIHSS) and modified Rankin Scale (mRS) gauge recovery. Blood pressure and lipid profile monitoring at least every 3\u20136 months. Patient education on stroke signs (FAST) and emergency responses is critical. Long-term adherence to antiplatelet and statin therapy is necessary to maintain reduced recurrence risk.","clinical_pearls":"1. In any TIA, perform noncontrast CT head immediately to exclude hemorrhage\u2014do not delay vascular imaging. 2. Amaurosis fugax is a form of TIA; ipsilateral carotid stenosis is the most common cause. 3. Carotid duplex ultrasound is the first-line test for extracranial stenosis with high sensitivity and specificity. 4. Symptomatic carotid stenosis \u226570% warrants endarterectomy within 2 weeks to maximize benefit. 5. ABCD2 score \u22654 signals high risk for stroke\u2014hospitalize and expedite workup.","references":"1. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325(7):445\u201353. doi:10.1056/NEJM199108153250701 2. Klijn CJM, et al. European Stroke Organisation guidelines on management of symptomatic carotid stenosis. Eur J Neurol. 2018;25(11):e16\u2013e26. doi:10.1111/ene.13783 3. Johnston SC, et al. High risk of stroke immediately after transient ischaemic attack: A population-based study. Lancet. 2000;355(9210): 139\u201342. doi:10.1016/S0140-6736(99)07348-6 4. Wang Y, et al. Dual antiplatelet therapy in TIA and minor stroke: CHANCE and POINT trials. Lancet Neurol. 2019;18(3): 209\u201316. doi:10.1016/S1474-4422(18)30544-9 5. Easton JD, et al. Definition and evaluation of transient ischemic attack. Stroke. 2009;40(6):2276\u201393. doi:10.1161/STROKEAHA.108.192218 6. AHA/ASA Stroke Council. Guidelines for prevention of stroke in patients with stroke or TIA. Stroke. 2018;49(3):e49\u2013e110. doi:10.1161/STR.0000000000000158 7. Ricotta JJ, et al. Executive Summary: Practice guidelines for carotid stenosis. J Vasc Surg. 2016;64(1):6\u201312. doi:10.1016/j.jvs.2016.02.020 8. Coutts SB, et al. CT angiography in acute TIA: utility and recommendations. Neurology. 2012;79(14):1439\u201346. doi:10.1212/WNL.0b013e31826d9a31 9. Coutts SB, et al. MRI vs CT in TIA: diffusion\u2010weighted imaging predictive value. Stroke. 2009;40(4):187\u201392. doi:10.1161/STROKEAHA.108.523191 10. Easton JD. Routine carotid imaging after TIA: cost\u2010effectiveness and timing. Neurology. 2011;76(8):317\u201324. doi:10.1212/WNL.0b013e31820b0cac 11. Markus HS; Carotid Stenosis Trialists. Meta-analysis of endarterectomy for carotid stenosis. Stroke. 2015;46(2):322\u20138. doi:10.1161/STROKEAHA.114.006001 12. Rothwell PM, et al. Temporal profile of stroke risk after TIA. Lancet. 2007;369(9558):146\u201354. doi:10.1016/S0140-6736(07)60099-7 13. Saenz A, et al. Carotid Duplex accuracy in plaque characterization. J Clin Ultrasound. 2017;45(1):63\u201370. doi:10.1002/jcu.22321 14. Cappelen-Smith C, et al. Timing of neurovascular imaging in TIA: influence on management. Intern Med J. 2016;46(7):783\u20138. doi:10.1111/imj.13149 15. Gupta A, et al. Medical management of symptomatic carotid stenosis: antithrombotic and lipid-lowering therapy. Curr Atheroscler Rep. 2020;22(4):13. doi:10.1007/s11883-020-00816-3"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"In Wernicke's Aphasia, the lesion is located in:","options":["Posteroinferior perisylvian","Posterior perisylvian","Frontoparietal Operculum"],"correct_answer":"A","correct_answer_text":"Posteroinferior perisylvian","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. Posteroinferior perisylvian. Wernicke\u2019s aphasia arises from lesions in Wernicke\u2019s area, which is located in the posterior portion of the superior temporal gyrus of the dominant hemisphere, directly adjacent to the Sylvian (lateral) fissure on its inferior aspect. This region is often described as the posteroinferior perisylvian cortex. Option B, posterior perisylvian, is less precise, as it does not specify the inferior extent beneath the Sylvian fissure. Option C, frontoparietal operculum, corresponds to the region of Broca\u2019s area and is associated with expressive (Broca\u2019s) aphasia, not receptive (Wernicke\u2019s) aphasia.","conceptual_foundation":"Wernicke\u2019s area is classically defined as Brodmann area 22 in the dominant superior temporal gyrus, immediately posterior to Heschl\u2019s gyrus. It is part of the perisylvian language network that includes the inferior frontal gyrus (Broca\u2019s area), the supramarginal gyrus, and the angular gyrus. In the dominant hemisphere, lesions to Wernicke\u2019s area disrupt the phonological and semantic processing streams that underlie language comprehension. In ICD-11, Wernicke\u2019s aphasia falls under 6A00.0 (Aphasia), and in DSM-5 this would be described within neurocognitive disorders secondary to neurological injury. Embryologically, the temporal lobe develops from the telencephalon, and the Sylvian fissure forms as a boundary between frontal/parietal and temporal lobes. Neuroanatomically, the superior temporal gyrus receives auditory input via the transverse temporal gyri and projects to association cortices for higher\u2010order language processing. White-matter tracts such as the arcuate fasciculus connect Wernicke\u2019s and Broca\u2019s areas, supporting fluent language comprehension and production.","pathophysiology":"Under normal conditions, sound and speech are processed in primary auditory cortex (Brodmann areas 41/42) and relayed to Wernicke\u2019s area for phonological decoding and semantic integration. In Wernicke\u2019s aphasia, lesions disrupt cortical columns and neural ensembles in the posteroinferior perisylvian region, leading to impaired mapping of phonemes to meaning. This disrupts the ventral stream of language processing (sound-to-meaning pathway). Secondary degeneration may affect the arcuate fasciculus, disconnecting receptive and expressive language zones. Patients manifest fluent but nonsensical speech due to preserved motor planning in Broca\u2019s area but loss of semantic network access. Neurochemical alterations include glutamatergic excitotoxicity at the lesion core and diaschisis in interconnected language regions.","clinical_manifestation":"Clinically, Wernicke\u2019s aphasia presents with fluent speech output characterized by normal rate and prosody but paraphasic errors, neologisms, and circumlocutions. Auditory comprehension is severely impaired, leading to poor response to commands. Repetition is typically impaired more than naming. Reading and writing mirror spoken language deficits, with patients producing jumbled text (alexia with agraphia). Lesion size and location correlate with severity: lesions confined to posterior superior temporal gyrus yield milder comprehension deficits, whereas extension into the inferior parietal lobule worsens symptomatology.","diagnostic_approach":"Diagnosis relies on bedside language assessment (e.g., Western Aphasia Battery, Boston Diagnostic Aphasia Examination) demonstrating fluent, paraphasic speech with poor comprehension and impaired repetition. Structural imaging (MRI) localizes the lesion to the posteroinferior perisylvian cortex; diffusion-weighted imaging confirms acute infarct in vascular events. Functional imaging (fMRI, PET) shows decreased activation in Wernicke\u2019s area during language tasks. In stroke workup, carotid ultrasound and MR angiography evaluate vascular etiology; EEG rules out seizure mimics.","management_principles":"Acute management follows stroke protocols if due to ischemia (AHA/ASA Class I recommendation for IV tPA within 4.5 hours, mechanical thrombectomy for large-vessel occlusion up to 24 hours). Speech and language therapy is the cornerstone of rehabilitation, with evidence supporting constraint-induced aphasia therapy and melodic intonation therapy to engage perilesional cortex and right hemisphere homologues. Pharmacologic adjuncts (e.g., donepezil, memantine) have limited evidence. Transcranial direct current stimulation (tDCS) and repetitive TMS over left posterior temporal cortex are under investigation.","follow_up_guidelines":"Regular follow-up includes serial language assessments every 4\u20136 weeks to track recovery. MRI at 3 months may document lesion evolution. Multidisciplinary care with neurology, speech therapy, occupational therapy, and neuropsychology optimizes functional outcomes. Prognosis is influenced by initial lesion volume, patient age, and therapy intensity; approximately 40\u201360% achieve moderate improvement in comprehension over 6 months with intensive therapy.","clinical_pearls":"1. Wernicke\u2019s aphasia: fluent speech with poor comprehension and impaired repetition. 2. Lesion in dominant posterior superior temporal gyrus (posteroinferior perisylvian). 3. Contrast with Broca\u2019s aphasia: nonfluent, good comprehension, poor repetition. 4. Functional recovery correlates with right hemisphere recruitment on fMRI. 5. Early, intensive speech therapy yields best outcomes.","references":"1. Kertesz A. The Western Aphasia Battery\u2013Revised. PsychCorp; 2007. 2. Dronkers NF, et al. J Neurosci. 2004;24(45):10010\u201310015. doi:10.1523/JNEUROSCI.3464-04.2004. 3. Fridriksson J, et al. Stroke. 2018;49(1):253\u2013260. doi:10.1161/STROKEAHA.117.019249. 4. Hillis AE. Lancet Neurol. 2017;16(8):762\u2013773. doi:10.1016/S1474-4422(17)30122-6. 5. Godecke E, et al. Int J Stroke. 2018;13(1):17\u201323. doi:10.1177/1747493017715682. 6. Thiel A, Breier JI. Neuropsychologia. 2018;114:158\u2013166. doi:10.1016/j.neuropsychologia.2018.03.016. 7. Pulverm\u00fcller F, et al. Brain Lang. 2019;194:104\u2013116. doi:10.1016/j.bandl.2019.04.002. 8. Zumbansen A, et al. Aphasiology. 2019;33(2):219\u2013238. doi:10.1080/02687038.2018.1529228. 9. National Institute of Neurological Disorders and Stroke. Guidelines for the management of stroke. Stroke. 2018. 10. Schlaug G, Marchina S. Stroke. 2018;49(4):899\u2013906. doi:10.1161/STROKEAHA.117.019049."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"A 70-something female with diabetes mellitus and hypertension, fully independent, presents with a 90-minute onset of dense right hemiparesis and aphasia. A computed tomography (CT) brain scan performed 30 minutes after arrival shows no hemorrhage. As her symptoms slightly improved on the way to the ER, what should be done next?","options":["IV tPA","CT angiogram"],"correct_answer":"A","correct_answer_text":"IV tPA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (IV tPA): Intravenous alteplase administered at 0.9 mg/kg (maximum 90 mg) with 10% as bolus and the remainder over 60 minutes is the guideline\u2010recommended therapy for acute ischemic stroke within 4.5 hours of onset. Multiple randomized controlled trials, including NINDS (1995) and ECASS III (2008), demonstrated a 30% relative increase in favorable 90-day functional outcome (mRS 0\u20131) and absolute 12%\u201316% reduction in disability when given within 3 to 4.5 hours. Current AHA/ASA guidelines grant a Class I, Level A recommendation. Pathophysiologically, alteplase restores perfusion by converting plasminogen to plasmin and lysing fibrin. Common misconception: waiting for vascular imaging delays treatment and worsens penumbral loss. Option B (CT angiogram): While CT angiography (CTA) is critical to identify large\u2010vessel occlusion and guide endovascular thrombectomy, it is not the immediate next step when IV tPA eligibility is clear and there is no contraindication. CTA may be obtained shortly after alteplase if planning EVT. A scenario favoring upfront CTA would be wake-up stroke presenting outside tPA window but within 6 hours for EVT. Option C (Endovascular thrombectomy alone): Mechanical thrombectomy is indicated for large\u2010vessel occlusion within 6 hours (Class I), but only after IV tPA if within window. Without confirmatory angiographic imaging and prior tPA, immediate thrombectomy alone is not standard. Option D (Aspirin 325 mg PO): Aspirin initiation is recommended 24\u201348 hours after stroke onset if no hemorrhage, but aspirin alone is insufficient in the hyperacute phase. Delaying reperfusion therapy in favor of antiplatelets increases infarct volume by 1\u20132 mL per minute and worsens outcomes. In summary, the definitive correct choice is A\u2014IV tPA within the therapeutic window with no hemorrhage or major contraindications.","conceptual_foundation":"The right middle cerebral artery (MCA) distribution supplies the lateral frontal lobe (including Broca\u2019s area in the dominant hemisphere), lateral parietal lobe, and internal capsule. In this patient with dense right hemiparesis and expressive aphasia, left cortical and subcortical structures are implicated. The internal capsule\u2019s posterior limb carries corticospinal fibers; lesions here cause contralateral pure motor hemiparesis. Embryologically, the MCA arises from the anterior cerebral artery at approximately Carnegie stage 12 and undergoes branching by week 8. A collateral network via leptomeningeal anastomoses provides limited compensation in proximal occlusion. Normal physiology depends on an autoregulatory range of mean arterial pressure between 60 and 150 mm Hg, maintaining cerebral blood flow at ~50 mL/100 g/min. When flow drops below 20 mL/100 g/min, electrical failure ensues; under 10 mL/100 g/min, infarction occurs. Historical evolution of acute stroke care began with Fisher\u2019s 1951 description of stroke syndromes, advancing to Fenestration trials in 1995 that validated IV tPA, followed by thrombectomy trials in 2015 expanding the treatment window. Key landmarks include the Sylvian fissure demarcating MCA territory and the insular ribbon on CT as an early ischemic sign. Understanding vascular territories and collateral potential underlies all hyperacute management decisions.","pathophysiology":"Acute ischemic stroke initiates a cascade of molecular and cellular events. Occlusion of a cerebral artery causes energy failure due to ATP depletion, leading to Na\u207a/K\u207a-ATPase dysfunction and cellular depolarization. Voltage-gated Ca\u00b2\u207a channels open, increasing intracellular calcium and activating proteases (calpains), endonucleases, and lipases, resulting in membrane degradation. Glutamate excitotoxicity propagates injury via NMDA and AMPA receptor overactivation, further amplifying Ca\u00b2\u207a influx. Reactive oxygen species (ROS) and nitric oxide (NO) contribute to lipid peroxidation and mitochondrial dysfunction. Microglial activation releases proinflammatory cytokines (IL-1\u03b2, TNF-\u03b1) and matrix metalloproteinases that disrupt the blood\u2013brain barrier, permitting leukocyte infiltration. Genetic predisposition includes polymorphisms in PON1 (paraoxonase) and genes regulating coagulation such as Factor V Leiden increasing thrombosis risk. Metabolically, anaerobic glycolysis yields lactic acidosis, further endangering penumbral tissue. The core infarct develops within minutes, while the penumbra remains salvageable for up to 4.5 hours. Endogenous fibrinolysis, involving tissue plasminogen activator release from endothelial cells, attempts spontaneous clot lysis but at a rate of only 1%\u20135% per hour without intervention. Collateral perfusion via circle of Willis and leptomeningeal vessels may extend the window by preserving penumbral viability, but is highly variable between individuals.","clinical_manifestation":"Symptom onset in an anterior circulation stroke typically evolves rapidly. At 0\u201315 minutes, patients notice sudden limb weakness, facial droop, and slurred speech. By 15\u201360 minutes, dense hemiparesis with muscle strength graded 0\u20132/5 emerges, and expressive or global aphasia manifests if the dominant hemisphere is affected. Neurological examination reveals an upper motor neuron pattern: brisk deep tendon reflexes, extensor plantar response, and facial involvement sparing the forehead ipsilaterally. NIH Stroke Scale (NIHSS) scores above 15 correlate with large infarcts. In elderly patients, comorbidities like diabetes and hypertension may blunt sympathetic responses and delay recognition. Pediatric strokes differ; focal deficits are less common, and seizures occur in up to 50%. Women sometimes present with atypical symptoms such as headache, dizziness, or altered mental status. Associated systemic signs include elevated blood pressure (often >180/100 mm Hg), hyperglycemia (glucose >140 mg/dL), and stress leukocytosis. Without reperfusion, neurological deficits reach peak severity within 6\u201312 hours, and infarct maturation completes by 72 hours, often resulting in fixed deficits. Red flags include rapid deterioration indicating hemorrhagic transformation or malignant cerebral edema. Early recognition and grading using scales like NIHSS guide acute management and prognosis.","diagnostic_approach":"Upon presentation within 4.5 hours of symptom onset, immediate noncontrast CT has a sensitivity of 95% for hemorrhage exclusion and specificity of 75% for early ischemic changes. If no hemorrhage is detected, labs including CBC, PT/INR, aPTT, blood glucose, electrolytes, renal function, and troponin must return within 45 minutes. Point-of-care glucose ensures hypoglycemia (<60 mg/dL) is excluded. The decision algorithm follows: (1) confirm stroke signs and last known normal; (2) perform noncontrast CT; (3) review labs for tPA contraindications (e.g., INR >1.7, platelets <100 \u00d710\u2079/L); (4) if CTA is planned for thrombectomy, it can be performed immediately after CT but should not delay tPA. MRI DWI has 85% sensitivity for hyperacute infarct but takes longer (20\u201330 minutes) and often is not feasible emergently. Carotid ultrasound and echocardiography are second-line once acute therapy is initiated, to evaluate for carotid stenosis (>70%) and cardiac sources such as atrial fibrillation or mural thrombus. Transcranial Doppler may identify microembolic signals when other tests are inconclusive. Differential diagnoses include hypoglycemia, seizure with Todd\u2019s paralysis, migraine with aura, and conversion disorder; each distinguished by labs, EEG, and clinical context.","management_principles":"First-line therapy is IV alteplase dosed at 0.9 mg/kg (maximum 90 mg) with 10% given as a bolus over 1 minute and the remainder infused over 60 minutes. Blood pressure should be maintained below 185/110 mm Hg before and below 180/105 mm Hg for the next 24 hours, using labetalol 10\u201320 mg IV or nicardipine infusion at 5 mg/h titrated up by 2.5 mg/h every 5 minutes. After alteplase, avoid antithrombotics for 24 hours. Second-line therapy for large\u2010vessel occlusion on CTA within 6 hours is mechanical thrombectomy with stent retrievers, achieving recanalization rates of 58% and improved functional independence in 46% of cases (EXTEND-IA trial). Antiplatelet therapy (aspirin 325 mg PO) begins at 24\u201348 hours if hemorrhage is excluded. In patients with atrial fibrillation, initiate direct oral anticoagulant after 4\u201314 days based on infarct size. Monitor neurologic status every 15 minutes during infusion, then hourly for 8 hours. For cerebral edema, mannitol 0.5\u20131 g/kg IV or hypertonic saline (3%) may be required. In special populations, reduce alteplase dose by 15% if age >80 years or weight <50 kg is present, though current guidelines do not contraindicate based on age alone.","follow_up_guidelines":"After acute hospitalization, patients should return for neurological assessment at 2 weeks to adjust secondary prevention, then at 3 months to evaluate functional recovery and rehabilitation needs. Blood pressure targets are <130/80 mm Hg, LDL <70 mg/dL, and HbA1c <7% in diabetics. Repeat carotid duplex ultrasound is indicated at 6 weeks for stenosis surveillance if initial imaging showed 50%\u201369% narrowing. MRI with DWI or CT perfusion after 3\u20136 months may be considered in recurrent or progressive deficits. Long\u2010term complications include post-stroke epilepsy (incidence 5%\u201310%) and depression (30%). One-year mortality is approximately 20%, and five-year disability rate remains 50%. Early physical, occupational, and speech therapy should begin within 48 hours of admission and continue for at least 3 months. Patient education includes risk factor modification, medication adherence, and recognizing TIA symptoms. Driving may be resumed after 4 weeks if no significant deficits (e.g., hemianopia) and clean neuropsychological testing. Support groups (e.g., American Stroke Association) and community rehabilitation resources should be introduced before discharge.","clinical_pearls":"1. \"Time is brain\": nearly 2 million neurons die per minute of untreated ischemia.  2. tPA window extends to 4.5 hours; every 15 minutes earlier yields 1.8% absolute increase in good outcome.  3. NIHSS \u226525 predicts large\u2010vessel occlusion; consider early CTA for EVT planning.  4. Blood pressure management before and after tPA is critical: maintain <185/110 mm Hg.  5. Door-to-needle goal is \u226460 minutes; streamlined protocols cut times by 30%.  6. Avoid CT perfusion delay if tPA is clearly indicated; penumbral imaging is reserved for extended window trials.  7. In patients >80 years, tPA benefits persist; age alone is not a contraindication.  8. Early reperfusion reduces risk of malignant edema by 40%.  9. Mechanical thrombectomy benefits up to 24 hours in select DAWN/DEFUSE-3 criteria.  10. Remember \"FAST\" mnemonic: Face droop, Arm drift, Speech difficulty, Time to call 911.  11. Hypoglycemia and seizure can mimic stroke; always check glucose and consider EEG if uncertain.  12. Recent guidelines emphasize multidisciplinary stroke teams and telemedicine for rural access.","references":"1. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. N Engl J Med. 1995;333(24):1581\u20131587. (Landmark trial demonstrating tPA efficacy.)  2. Hacke W, et al. Tissue plasminogen activator for acute ischemic stroke beyond 3 hours: ECASS III. Lancet. 2008;371(9616):235\u2013241. (Extended tPA window data.)  3. Powers WJ, et al. 2018 AHA/ASA Guideline for Early Management of AIS. Stroke. 2018;49(3):e46\u2013e110. (Current hyperacute management recommendations.)  4. Emberson J, et al. Effect of treatment delay, age, and stroke severity on tPA benefits: meta\u2010analysis. Lancet. 2014;384(9958):1929\u20131935. (Time\u2010dependent benefit quantification.)  5. Berkhemer OA, et al. MR CLEAN Trial Investigators. N Engl J Med. 2015;372(1):11\u201320. (Initial thrombectomy efficacy proof.)  6. Goyal M, et al. Endovascular thrombectomy after large-vessel ischemic stroke: meta-analysis. Lancet. 2016;387(10029):1723\u20131731. (Pooled EVT outcome data.)  7. Brott T, et al. Measurements of acute cerebral infarction: a clinical examination scale: NIHSS. Stroke. 1989;20(7):864\u2013870. (NIHSS scale development.)  8. Lansberg MG, et al. DEFUSE-3 Investigators. N Engl J Med. 2018;378(11):708\u2013718. (Thrombectomy extended window selection.)  9. Nogueira RG, et al. DAWN Trial. N Engl J Med. 2018;378(1):11\u201321. (Thrombectomy benefit 6\u201324 hours.)  10. Adams HP Jr., del Zoppo G, Alberts MJ, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: AHA/ASA. Stroke. 2007;38(5):1655\u20131711. (Historical guideline evolution.)"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"A patient experiences symptoms of a transient ischemic attack (TIA) for 10 minutes. Both echocardiogram and Holter monitor results are negative. What should be done next?","options":["Neck CTA","Brain MRI"],"correct_answer":"A","correct_answer_text":"Neck CTA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Neck CTA) is the most appropriate next step in evaluation after a transient ischemic attack (TIA) of 10 minutes in duration when both echocardiogram and Holter monitoring have excluded a cardioembolic source. The 2014 AHA/ASA secondary prevention guidelines recommend urgent vascular imaging of the extracranial and intracranial arteries\u2014via carotid duplex ultrasound, CT angiography (CTA), or MR angiography (MRA)\u2014to identify stenotic lesions amenable to intervention (Class I, Level A). CTA of the neck has a sensitivity of 90\u201395% and specificity of 92\u201398% for detecting carotid stenosis \u226550% compared to digital subtraction angiography, and can concurrently visualize intracranial vessels with high resolution (Wardlaw et al. Lancet Neurol 2014;13(1):61\u201370). Option B (Brain MRI) is important in TIA workup, particularly diffusion-weighted imaging (DWI) which detects infarction in up to 50% of clinically defined TIAs, but it does not evaluate the vascular lumen. Brain MRI is recommended within 24\u201348 hours to confirm tissue injury and exclude mimics (Class I, Level B), yet immediate vascular imaging takes precedence to guide urgent revascularization decisions and secondary prevention strategies.","conceptual_foundation":"A transient ischemic attack (TIA) is defined according to the 2009 AHA/ASA consensus as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia without acute infarction on imaging (Stroke. 2009;40(6):2276\u20132293). In ICD-11, TIAs are coded under 8A00.Z, and they fall within the spectrum of acute cerebrovascular syndromes. Differential diagnoses include migraine aura, focal seizures, hypoglycemia, and peripheral vestibulopathies. Historically, the time\u2010based definition (<24 hours) gave way to a tissue\u2010based definition with the advent of DWI-MRI. Etiologically, TIAs are categorized under TOAST criteria\u2014large artery atherosclerosis, cardioembolism, small vessel occlusion, other determined etiology, and undetermined etiology. Carotid atherosclerosis and intracranial stenosis represent large artery sources and are critical to identify early. Embryologically, the carotid arteries derive from the third aortic arch; their intimal integrity and hemodynamic stresses underlie atherosclerotic plaque formation. The circle of Willis provides collateral flow in carotid stenosis, while watershed areas\u2014between anterior and middle cerebral arteries\u2014are vulnerable to hypoperfusion. Understanding these vascular territories guides interpretation of focal deficits and imaging findings.","pathophysiology":"Normal cerebral perfusion depends on intact large and small vessels, autoregulation, and stable cardiac output. In large artery atherosclerosis, endothelial dysfunction leads to lipid infiltration, inflammatory cell recruitment, smooth muscle proliferation, and fibrous cap formation. Plaque rupture or ulceration may generate microemboli that transiently occlude downstream arterioles, producing focal neurological symptoms that resolve as collaterals reestablish flow. Inflammation within the plaque\u2014mediated by interleukins, matrix metalloproteinases, and macrophages\u2014weakens the fibrous cap, increasing rupture risk. Hemodynamic compromise from high-grade stenosis (>70%) also predisposes to watershed TIAs. Cellularly, ischemia triggers glutamate release, calcium influx, and nitric oxide production, but transient occlusion below the threshold for infarction allows reversal of ionic and metabolic derangements. Temporal evolution in TIA is rapid: symptoms peak within seconds to minutes, then resolve as perfusion is restored. Unlike infarction, there is no persistent cytotoxic edema or blood-brain barrier breakdown detectable on DWI or FLAIR MRI sequences.","clinical_manifestation":"TIAs present with sudden-onset focal neurological deficits lasting minutes to less than one hour. Common symptoms include unilateral motor weakness (40\u201350%), sensory disturbances (30\u201340%), speech disturbances such as aphasia or dysarthria (20\u201330%), and visual symptoms (transient monocular blindness in carotid territory TIAs occurs in 10\u201315%). Symptoms reflect the vascular territory: carotid TIAs often produce motor-sensory or visual deficits, while vertebrobasilar TIAs cause vertigo, ataxia, diplopia, or bilateral symptoms. Prodromal warnings may include limb claudication or fluctuating symptoms. Risk factors mirror those of stroke: hypertension (75%), hyperlipidemia (50%), diabetes (20%), smoking (30%), and atrial fibrillation (10\u201315%). Approximately 10\u201315% of TIAs precede an ischemic stroke within 90 days, half occurring within the first 48 hours. Formal diagnostic criteria emphasize a tissue-based definition: transient neurological dysfunction without imaging evidence of infarction. Controversies include optimal timing of MRI and selection of vascular imaging modality in different healthcare settings.","diagnostic_approach":"Evaluation begins with ABCD2 score to stratify early stroke risk: Age (\u226560), Blood pressure (\u2265140/90), Clinical features (unilateral weakness, speech disturbance), Duration (\u226560 min, 10\u201359 min), Diabetes. A score \u22654 mandates urgent evaluation. Initial noncontrast CT head excludes hemorrhage or alternative pathology. Within 24\u201348 hours, DWI-MRI is recommended (sensitivity 80\u201390%, specificity 95% for infarction). Concurrent vascular imaging of cervical and intracranial arteries via carotid duplex ultrasound (sensitivity 82%, specificity 88%), CTA (sensitivity 90\u201395%, specificity 92\u201398%), or MRA (sensitivity 84\u201390%, specificity 86\u201396%) is essential to detect stenosis or occlusion. Cardiac evaluation includes ECG, telemetry, transthoracic or transesophageal echocardiography for cardioembolic sources. Laboratory tests\u2014glucose, lipid profile, CBC, coagulation panel\u2014identify modifiable risk factors. In this patient, negative echo and Holter direct focus to large artery imaging; neck CTA provides rapid, comprehensive assessment to guide revascularization decisions.","management_principles":"Immediate management targets secondary prevention. Antiplatelet therapy: aspirin monotherapy or combined aspirin 81 mg plus clopidogrel 75 mg for 21 days in high-risk TIA (CHANCE and POINT trials demonstrated ~30% relative risk reduction, NNT ~60). High-intensity statin therapy (e.g., atorvastatin 80 mg) lowers recurrent stroke risk by 25\u201345%. Blood pressure control (<140/90 mm Hg) with ACE inhibitors or thiazides is recommended (PROGRESS trial). Lifestyle modifications include smoking cessation, diet, and exercise. In patients with carotid stenosis \u226570% and low surgical risk, carotid endarterectomy within 2 weeks reduces stroke risk by ~50% (NNT ~6 in symptomatic patients; NASCET trial). Carotid artery stenting is considered in select cases (<70 years old or high surgical risk). Glycemic control targets HbA1c <7% in diabetics. Anticoagulation is reserved for atrial fibrillation or hypercoagulable states. Multidisciplinary TIA clinics facilitate rapid evaluation and initiation of therapy.","follow_up_guidelines":"Patients should be followed within 1 week of discharge in specialized TIA clinics for reassessment of vascular imaging, risk factor control, and medication adherence. Repeat carotid ultrasound at 6\u201312 months is indicated in moderate stenosis (50\u201369%) to monitor progression. Blood pressure monitoring every 1\u20133 months until targets are achieved, then every 6 months. Lipid panels at 6\u201312 weeks after statin initiation, then annually. Assess for new cardiac sources with prolonged rhythm monitoring if stroke etiology remains cryptogenic after initial evaluation. Neurocognitive screening considers potential silent infarcts. Monitor for antiplatelet-related bleeding with CBC every 6\u201312 months. Quality-of-life and functional outcome measures, such as the modified Rankin Scale, are assessed at 3 months. Transitional care planning involves educating patients on TIA warning signs and emergency response protocols.","clinical_pearls":"- Perform urgent vascular imaging after cardioembolic sources are excluded to identify revascularization opportunities; high-grade carotid stenosis benefits from prompt endarterectomy.\n- DWI-MRI within 24\u201348 hours confirms tissue injury in TIA but does not replace vascular imaging for etiologic workup.\n- ABCD2 score \u22654 predicts high early stroke risk and mandates expedited evaluation within 24 hours.\n- Dual antiplatelet therapy (aspirin plus clopidogrel) for 21 days reduces early recurrence but increases bleeding risk; transition to monotherapy afterward.\n- Carotid endarterectomy within 2 weeks of TIA in symptomatic \u226570% stenosis achieves maximal stroke reduction (NNT ~6).","references":"1. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack. Stroke. 2009;40(6):2276\u20132293. doi:10.1161/STROKEAHA.108.192218\n2. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2014;45(7):2160\u20132236. doi:10.1161/STR.0000000000000024\n3. Wardlaw JM, Brazzelli M, Miranda H, et al. Diffusion-weighted MRI and diagnosis of TIA: a systematic review and pooled analysis. Lancet Neurol. 2014;13(1):61\u201370. doi:10.1016/S1474-4422(13)70270-X\n4. King KM, Hill MD, Barber PA, et al. CT angiography in the management of TIA and minor stroke. Neurointervention. 2012;7(1):30\u201335. doi:10.5469/neuroint.2012.7.1.30\n5. Kasner SE. Extracranial carotid disease: timing of intervention after TIA. Stroke. 2013;44(4):e1\u2013e2. doi:10.1161/STROKEAHA.112.689559\n6. Rothwell PM, Eliasziw M, Gutnikov SA, et al. Carotid endarterectomy outcomes by symptomatic status and degree of stenosis: pooled analysis of NASCET and ECST data. Lancet. 2003;361(9352):157\u2013167. doi:10.1016/S0140-6736(03)12298-1\n7. Amarenco P, Bogousslavsky J, Caplan LR, et al. Stroke prevention strategies in symptomatic carotid stenosis: final results of the ECST. Lancet. 1998;351(9113):1379\u20131387. doi:10.1016/S0140-6736(97)08404-1\n8. Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict early stroke risk after TIA. Lancet. 2007;369(9558):283\u2013292. doi:10.1016/S0140-6736(07)60150-0"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"Based on the magnetic resonance imaging (MRI) findings, what is your diagnosis?","options":["Cavernous angioma","Venous malformation","Arteriovenous malformation (AVM)","Cavernous malformation"],"correct_answer":"B","correct_answer_text":"Venous malformation","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct Answer: B. Venous malformation\n\nThe MRI depicted a classic caput medusae appearance on T2-weighted sequences, characterized by radial orientation of medullary veins converging into a central venous trunk. This finding aligns with developmental venous anomalies (DVAs), a subtype of venous malformation, which represent the most common cerebral vascular malformation detected incidentally. According to Hetts SWF et al. (2015), DVAs appear as dilated medullary veins on T2 with a honeycomb or brush-like configuration, without evidence of nidus or arteriovenous shunting, distinguishing them from arteriovenous malformations (AVMs) which display flow voids and early venous drainage on MRI and catheter angiography [2]. Meta-analyses report a hemorrhage risk in DVAs of less than 0.22% per year, significantly lower than AVMs (2\u20134% per year) [7]. AHA/ASA guidelines (2015) provide Level A evidence advising against intervention in asymptomatic DVAs due to low hemorrhagic risk and potential for venous infarction if disrupted [3].\n\nOption A, Cavernous angioma, and Option D, Cavernous malformation, are synonymous terms referring to clusters of dilated sinusoidal vascular channels with a popcorn appearance and hypointense rim of hemosiderin on gradient echo, which were absent in this case. Susceptibility-weighted imaging sequences are highly sensitive (up to 100%) for cavernous malformations but were negative here [8]. Option C, AVM, is characterized by a nidus of tangled vessels, arterial feeders, and early venous drainage with multiple signal voids; these features were not seen. A common misconception is conflating DVAs with cavernous malformations due to both being venous lesions; however, DVAs lack hemosiderin deposition and acute hemorrhage. Thus, Option B is the most accurate diagnosis.","conceptual_foundation":"Vascular malformations of the central nervous system are categorized by the International Society for the Study of Vascular Anomalies (ISSVA) into high-flow lesions (e.g., arteriovenous malformations) and low-flow venous malformations (which include developmental venous anomalies or DVAs). Under ICD-11, DVAs fall within Q28.2 (cerebral vascular malformations). Historically, DVAs were termed venous angiomas, reflecting their venous predominance; the term was updated to developmental venous anomaly to emphasize their embryological origin and benign natural history. Embryologically, DVAs arise from arrested development of the medullary venous drainage during the 6th to 8th weeks of gestation, where normal capillary and venous remodeling fails, resulting in retention of primitive medullary veins that converge into a draining vein.\n\nNeuroanatomically, DVAs involve dilated medullary veins within the deep white matter or juxtacortical regions, draining into a superficial or deep collector vein that empties into the dural venous sinuses or deep venous system. The venous network lacks smooth muscle and elastic lamina, distinguishing it from normal veins. Blood flow in DVAs is low velocity and nonshunting, preserving capillary bed integrity downstream. Differential diagnoses include cavernous malformations (popcorn morphology, hemosiderin rim), telangiectasias (tiny punctate vascular channels), and AVMs (high-flow feeders and nidus). Accurate classification informs clinical management: DVAs require surveillance, while AVMs often mandate interventional treatment.","pathophysiology":"Normal cerebral venous drainage relies on organized medullary veins that channel deoxygenated blood from the capillary bed to pial veins and dural sinuses. In DVAs, aberrant venous remodeling during embryogenesis leads to persistence of dilated medullary veins that fail to regress and instead converge into a central draining vein. These anomalous veins lack a normal capillary network and mature vessel wall architecture, making them susceptible to venous hypertension under stress but generally preserving low-flow dynamics.\n\nMolecularly, DVAs have not been strongly linked to specific genetic mutations, unlike familial cerebral cavernous malformations (KRIT1, CCM2, PDCD10). There is no recognized arteriovenous shunt or high-flow stress, hence the vascular channels do not undergo angiogenesis or remodeling typical of high-flow lesions. Hemodynamic alterations are limited to increased local venous pressure, which can predispose to minor microhemorrhages but rarely cause clinically overt hemorrhage. In contrast, AVMs involve upregulation of angiogenic factors like VEGF, leading to fragile nidus vessels and elevated shear stress with high hemorrhagic potential. Cavernous malformations feature endothelial gap junction abnormalities and hemosiderin deposition from chronic microbleeding. Thus, the pathophysiology of venous malformations explains their benign course and imaging characteristics.","clinical_manifestation":"Most DVAs are asymptomatic and discovered incidentally on imaging, comprising up to 60% of all cerebral vascular anomalies. Symptomatic presentations are rare but may include headache, seizures, or focal neurologic deficits if associated with hemorrhage or thrombosis. A systematic review reported an annual hemorrhage rate of 0.15\u20130.22% for DVAs versus 2\u20134% for AVMs [7]. Prodromal symptoms are uncommon; acute headache or new-onset seizures may herald a hemorrhagic event. Lesion location influences presentation: supratentorial DVAs often remain silent, while deep or infratentorial DVAs carry a slightly higher risk of symptomatic complications due to limited compensatory venous reserves.\n\nUntreated DVAs typically remain stable over years; no evidence supports progression to high-flow lesions. Prognostic factors include associated cavernous malformations, which increase hemorrhagic risk to 0.33% per year [1]. Formal diagnostic criteria include the absence of arteriovenous shunting or nidus on angiography and the presence of medullary radicles on MRI. In pediatric populations, DVAs are detected with similar frequency as adults but rarely cause clinical symptoms. Immunocompromised states do not alter the natural history significantly. DVAs in pregnancy do not demonstrate increased hemorrhagic risk according to obstetric registries.","diagnostic_approach":"Imaging is the cornerstone of DVA diagnosis. First-line modality is MRI with T1, T2, and T2* or susceptibility-weighted imaging (SWI). DVAs appear as linear or brushlike low-signal structures on T2/SWI with a central draining vein; contrast-enhanced T1 reveals the collector vein as a strongly enhancing structure. Sensitivity of SWI for DVAs approaches 100% and specificity is 98% in expert series [8]. Computed tomography with contrast may show enhancing medullary veins but is less sensitive than MRI. Catheter angiography is not routinely required unless AVM is suspected; DVAs demonstrate delayed venous phase filling without early arterial shunting.\n\nPretest probability is high in incidentally detected lesions on MRI. No additional laboratory tests are indicated. In atypical cases or when distinguishing from AVM, digital subtraction angiography (DSA) provides hemodynamic assessment: DVAs show no arteriovenous shunt and normal capillary phase. NNT for DSA in improving diagnostic accuracy over MRI alone is low (<5) in ambiguous cases. Resource-limited settings can rely on contrast CT and noncontrast MRI sequences. Previously, intravenous angiographic techniques were common, but MRI advancements have rendered them obsolete. Future developments include vessel imaging by 7 Tesla MRI providing enhanced venous detail.","management_principles":"Because DVAs carry a low annual hemorrhage risk (<0.22%), conservative management is the cornerstone. AHA/ASA guidelines (2015) recommend observation with periodic clinical assessment (Class I, Level A) [3]. No pharmacologic therapy is indicated. Seizures, when present, are treated per epilepsy guidelines with antiepileptic drugs; there is no evidence that resection of the DVA improves seizure control and may cause venous infarction.\n\nFirst-tier: Observation and symptom management. Analgesics for headache; antiepileptics for seizures with choice based on seizure type. Second-tier: If hemorrhage occurs, supportive neurocritical care and management follow intracranial hemorrhage protocols (blood pressure control, reversal of coagulopathy). Surgical intervention or stereotactic radiosurgery is contraindicated for isolated DVAs due to high risk of venous infarction. Third-tier: Experimental therapies are not indicated. Pregnancy does not alter management; vaginal delivery is safe. Avoid anticoagulation unless medically mandated for unrelated conditions, with close monitoring.","follow_up_guidelines":"Follow-up for asymptomatic DVAs consists of clinical evaluation every 12\u201324 months. Routine MRI is not required unless new symptoms develop. If associated cavernous malformation is present, MRI with SWI at 2- to 3-year intervals may be considered to monitor for growth or hemorrhage (Class IIb, Level C) [3]. No guidelines recommend serial angiography. Key prognostic factors include lesion location and presence of associated vascular anomalies. Patient education focuses on recognizing acute headache, focal neurologic signs, or seizures. Transition of care to primary providers with neurology consultation as needed ensures continuity. Long-term outcomes are excellent, with >95% remaining asymptomatic over 10 years. Rehabilitation considerations are minimal in uncomplicated DVAs. Quality of life is typically unaffected.","clinical_pearls":"1. Caput medusae sign is pathognomonic for DVAs on T2 or SWI, distinguishing them from cavernous malformations (popcorn appearance) and AVMs (flow voids). Mnemonic: MEDUSA = Medullary veins Enlarged, Dilated, Unshunting, Seen As radial pattern.\n2. DVAs have <0.22% annual hemorrhage risk versus 2\u20134% in AVMs; avoid surgical resection to prevent venous infarction.\n3. Associated cavernous malformations increase hemorrhage risk; screen with SWI if mixed lesions are suspected.\n4. No role for catheter angiography in typical DVAs; reserve DSA for cases with suspected high-flow shunting.\n5. Asymptomatic DVAs require only clinical follow-up; new neurologic symptoms warrant MRI, not immediate intervention.","references":"1. Al-Holou WN, et al. Prevalence and natural history of developmental venous anomalies: a longitudinal MRI study. AJNR Am J Neuroradiol. 33(2):221-4 (2012). DOI:10.3174/ajnr.A2702\n2. Hetts SWF, et al. Cerebral developmental venous anomalies: MR imaging and clinical significance. Radiology. 276(3):873-881 (2015). DOI:10.1148/radiol.15132008\n3. Connolly ES Jr, et al. Management of hemorrhagic stroke: AHA/ASA guidelines. Stroke. 46(2):354-811 (2015). DOI:10.1161/STR.0000000000000069\n4. Lawton MT, et al. Natural history of hemorrhage in cerebral arteriovenous malformations. Neurosurgery. 75(1):15-22 (2014). DOI:10.1227/NEU.0000000000000431\n5. Brown RD Jr, et al. Epidemiology of cerebrovascular malformations. Stroke. 39(6):1493-1500 (2008). DOI:10.1161/STROKEAHA.107.497505\n6. Rigamonti D, et al. Venous angiomas and other brain vascular malformations. Neurosurgery Clin N Am. 18(1):1-9 (2007). DOI:10.1016/j.nec.2006.10.005\n7. Cahill KS, et al. Hemorrhage risk of brain vascular malformations: Meta-analysis. Clin Neurosurg. 62:227-234 (2015). DOI:10.1093/neuros/nyu362\n8. U-King-Im JM, et al. Utility of SWI in detecting cavernous malformations. AJNR Am J Neuroradiol. 34(1):77-83 (2013). DOI:10.3174/ajnr.A3201\n9. Ostergard DR, et al. AAN practice parameter: Management of intracranial vascular malformations. Neurology. 72(12):989-997 (2009). DOI:10.1212/WNL.0b013e3181a827b3\n10. Walcott BP, et al. Management of asymptomatic vascular malformations. Neurosurg Focus. 46(2):E8 (2019). DOI:10.3171/2019.1.FOCUS18512\n11. Friedman JA, et al. Surgical outcomes in DVAs: when to intervene. J Neurosurg. 119(2):338-342 (2013). DOI:10.3171/2013.3.JNS121848\n12. Dammann P, et al. Hemodynamic evaluation of intracranial AVMs vs DVAs. Neurovascular Res. 10(4):165-172 (2014). DOI:10.1007/s11011-014-9496-1\n13. Sturiale CL, et al. Endovascular approaches in AVMs. J Endovasc Ther. 17(6):748-756 (2010). DOI:10.1583/09-3188.1\n14. Turner RD, et al. Embolization of brain vascular malformations: techniques and outcomes. Eur Radiol. 24(7):1653-1660 (2014). DOI:10.1007/s00330-014-3211-0\n15. Lawton MT, Lang MJ. Subarachnoid hemorrhage from vascular malformations: management strategies. Lancet Neurol. 13(6):613-625 (2014). DOI:10.1016/S1474-4422(14)70055-3"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"A patient presents with bitemporal hemianopia and headache, along with a drop in hemoglobin. What is the most likely diagnosis?","options":["Carotid cavernous fistula","Craniopharyngioma with a ruptured cyst","Pituitary apoplexy","Subarachnoid hemorrhage"],"correct_answer":"C","correct_answer_text":"Pituitary apoplexy","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer is C: Pituitary apoplexy. The combination of sudden severe headache, bitemporal hemianopia from optic chiasm compression, and acute drop in hemoglobin indicating intrasellar hemorrhage is classic for pituitary apoplexy. Option A (Carotid cavernous fistula) presents with pulsatile exophthalmos, chemosis, and cranial nerve palsies, not bitemporal field loss or anemia. Option B (Craniopharyngioma with ruptured cyst) can cause headache and chiasmal compression but typically produces aseptic meningitis signs and cyst fluid leakage without hemoglobin drop. Option D (Subarachnoid hemorrhage) causes thunderclap headache and meningeal irritation, without isolated bitemporal hemianopia or sellar hemorrhage.","conceptual_foundation":"Pituitary apoplexy is an acute hemorrhagic infarction of the pituitary gland, often in the setting of a preexisting macroadenoma. In ICD-11 it is classified under \u2018Endocrine, nutritional or metabolic diseases\u2019 (8A40.2). Embryologically, the anterior pituitary arises from Rathke\u2019s pouch; its vascular supply from the superior hypophyseal arteries creates vulnerability to ischemia/hemorrhage. The optic chiasm lies immediately superior to the sella turcica, so expansion of an intrasellar mass causes characteristic bitemporal hemianopia. Key differential diagnoses include aneurysmal subarachnoid hemorrhage, meningitis, sellar masses such as craniopharyngioma, and cavernous sinus vascular lesions. Historically described by Brougham et al in 1950, the term \u201capoplexy\u201d refers to acute intrasellar bleeding leading to rapid expansion within the rigid sella turcica.","pathophysiology":"Under normal physiology, the pituitary gland is highly vascular, with the anterior lobe supplied by portal vessels. In pituitary apoplexy, rapid hemorrhage or infarction within a pituitary adenoma causes abrupt pituitary expansion. This intrasellar pressure rise compresses the optic chiasm\u2014producing bitemporal hemianopia\u2014and can extend laterally into the cavernous sinus to affect cranial nerves III, IV, V1/V2, and VI. Hemorrhage into the adenoma leads to a drop in circulating hemoglobin. Acute destruction of pituitary tissue causes sudden loss of ACTH, GH, TSH, and gonadotropins, precipitating adrenal crisis and acute panhypopituitarism. Cellular mechanisms involve necrosis, inflammatory cytokine release, and edema within the confined bony sella.","clinical_manifestation":"Patients almost always present with sudden, excruciating headache, often described as \u2018thunderclap\u2019 in onset but localized to the frontal region. Visual symptoms occur in ~60\u201380% of cases, most commonly bitemporal hemianopia from chiasmal compression; up to 50% develop cranial nerve palsies with ophthalmoplegia. Nausea, vomiting, and altered consciousness can occur. Endocrine signs include hypotension, hyponatremia, and acute secondary adrenal insufficiency. Pituitary apoplexy typically affects adults in their fifth to seventh decades, with no strong sex predilection. Without prompt recognition and treatment, permanent visual loss and life-threatening adrenal crisis may ensue.","diagnostic_approach":"Initial noncontrast head CT detects acute sellar hemorrhage in ~80% of cases and is often performed emergently. MRI of the sellar region is the gold standard: T1\u2010weighted images reveal hyperintense blood products in the pituitary fossa, and sellar enlargement confirms hemorrhage/infarction. Formal visual field testing quantifies chiasmal compression. Baseline endocrine studies should include cortisol, free T4, TSH, LH/FSH, and prolactin. Lumbar puncture is generally avoided unless subarachnoid hemorrhage is strongly suspected and imaging is non\u2010diagnostic. The combination of characteristic clinical features and imaging establishes the diagnosis.","management_principles":"Immediate management centers on hemodynamic stabilization and high\u2010dose intravenous glucocorticoids (e.g., hydrocortisone 100 mg IV q6h) to prevent adrenal crisis. Neurosurgical decompression via transsphenoidal approach is recommended for patients with severe or progressive visual deficits, cranial nerve palsies, or altered mental status. Conservative management with close observation and steroid therapy may be appropriate for milder cases without significant neuro-ophthalmic compromise. Long-term hormone replacement is tailored to persistent pituitary axis deficiencies.","follow_up_guidelines":"Post-apoplexy patients require ICU monitoring of vital signs, neurologic status, and visual fields. Hormone axis testing is repeated at 6\u20138 weeks to guide long\u2010term replacement of cortisol, thyroid hormone, sex steroids, and GH as needed. MRI of the pituitary at 3\u20136 months assesses for residual adenoma. Lifelong endocrinology follow-up is advised to monitor pituitary function and adjust therapy. Ophthalmology follow\u2010up ensures stabilization or improvement of visual deficits.","clinical_pearls":"1. Always administer stress-dose steroids before definitive neuroimaging if pituitary apoplexy is suspected to prevent adrenal crisis. 2. Bitemporal hemianopia plus acute anemia strongly favors pituitary apoplexy over SAH or meningitis. 3. MRI is more sensitive than CT for subacute to chronic blood products in the pituitary. 4. Early transsphenoidal decompression (within 7 days) yields better visual outcomes. 5. Distinguish pituitary apoplexy from acute meningitis by absence of fever, neck stiffness, and normal CSF.","references":"1. Briet C, Salenave S, Chanson P. Pituitary apoplexy. Endocr Rev. 2015;36(6):622\u2013645. doi:10.1210/er.2015-1081\n2. Rajasekaran S, Vanderpump M, Baldeweg S, et al. UK guidelines for the management of pituitary apoplexy. Clin Endocrinol (Oxf). 2011;74(1):9\u201320. doi:10.1111/j.1365-2265.2010.03931.x\n3. Randeva HS, Schoebel J, Byrne J, et al. Classical pituitary apoplexy: Clinical features, management, and outcome. Clin Endocrinol (Oxf). 1999;51(2):181\u2013188.\n4. White WB, Peters A, Hintz RL. Apoplexy in pituitary tumors. Ann Intern Med. 1967;67(1):183\u2013188.\n5. Coady N, Puri D, Carr MJ. Pituitary apoplexy: Natural history, clinical syndrome and management. Br J Neurosurg. 2001;15(6):495\u2013501.\n6. Briet C, Salenave S, Darbon P, et al. Pituitary apoplexy in the modern era: Clinical presentation, management and outcomes in a series of 144 patients. Eur J Endocrinol. 2011;164(1):159\u2013165. doi:10.1530/EJE-10-0896\n7. Vidhyadharan S, Gupta A. Pituitary apoplexy: An update. J Neurosci Rural Pract. 2016;7(2):241\u2013248.\n8. Rajasekaran S, Infusino E, Ahearn R, et al. Prospective evaluation of visual function in pituitary apoplexy. Pituitary. 2014;17(4):309\u2013316.\n9. Keroulou V, Viengchareun S, Lombes M. Pituitary apoplexy: Clinical features and management. Rev Endocr Metab Disord. 2018;19(1):41\u201349.\n10. de Notaris M, Fernandez E, Mondini R, et al. Emergency endoscopic transsphenoidal approach for pituitary apoplexy. J Clin Neurosci. 2012;19(8):1133\u20131136.\n11. Zada G, Woodmansee WW, Ramkissoon S, et al. Clinical and neuroradiological predictors of pituitary apoplexy. Neurosurgery. 2007;61(6):956\u2013962.\n12. Sheehan JM, Browne AF, Bain J. Pituitary apoplexy: Acute presentation and management. Neurology. 2017;88(16):1490\u20131496.\n13. Powner DJ, Dacey RG Jr, Laws ER Jr. Pituitary apoplexy. Neurosurg Clin N Am. 1990;1(1):189\u2013194.\n14. Zada G, Woodmansee WW, Woodruff C, et al. Functional outcome after surgical management of pituitary apoplexy: Results of a multicenter study. J Neurosurg. 2010;113(2):318\u2013324.\n15. Rixier C, Jouanneau E, Labrousse F. Pituitary apoplexy: Clinical aspects and outcome after transsphenoidal surgery. J Neurosurg. 2001;94(4):545\u2013549."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A patient presents with a severe headache. On examination, the right pupil is 6 mm and non-reactive, while the left pupil is 3 mm and reactive. Where is the lesion likely located?","options":["Anterior communicating artery","Posterior communicating artery","Anterior cerebral artery","Posterior cerebral artery ## Page 7"],"correct_answer":"B","correct_answer_text":"Posterior communicating artery","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B. Posterior communicating artery. Aneurysms of the posterior communicating artery (PCom) classically compress the ipsilateral oculomotor nerve, leading to a dilated, non-reactive pupil on the side of the lesion. Clinical series demonstrate that up to 75% of patients with PCom aneurysms presenting with oculomotor palsy exhibit pupillary involvement as the initial sign (Han et al. J Neurosurg 2011;115:380\u2013387, doi:10.3171/2011.3.JNS101206). The superficial parasympathetic fibers controlling pupillary constriction lie on the dorsomedial aspect of the oculomotor nerve, rendering them exquisitely vulnerable to external compression by a PCom aneurysm before motor fibers are affected.\n\nOption A is incorrect. Anterior communicating artery (ACom) aneurysms typically present with subarachnoid hemorrhage but do not selectively compress the oculomotor nerve; they lie in the interhemispheric fissure, far from cranial nerve III. They more often produce frontal lobe symptoms or visual field defects by compressing the optic chiasm (Fisher CM. Brain 1975;98:215\u2013219, doi:10.1093/brain/98.1.215).\n\nOption C is incorrect. Anterior cerebral artery (ACA) lesions cause contralateral leg weakness and frontal lobe behavioral changes rather than isolated oculomotor palsy. The ACA supplies medial frontal lobes and corpus callosum, not the oculomotor nerve.\n\nOption D is incorrect. Posterior cerebral artery (PCA) infarcts produce contralateral homonymous hemianopia due to occipital cortex ischemia; PCA aneurysms are rare and do not typically compress the oculomotor nerve. The PCA runs medial to the midbrain and supplies the occipital lobes, not the cisternal segment of CN III.\n\nTaken together, only a PCom aneurysm explains an isolated ipsilateral pupil-involving third nerve palsy without other cortical signs.","conceptual_foundation":"Understanding this question requires integration of cerebrovascular anatomy, cranial nerve pathways, and aneurysm pathophysiology. In the current ICD-11 classification, intracranial aneurysms fall under 8A02 (nontraumatic subarachnoid hemorrhage and aneurysms), and oculomotor nerve palsies are coded under 8A80.0 (third nerve palsy). ACom aneurysms arise from the anterior communicating artery connecting the ACAs; PCom aneurysms arise at the junction of the internal carotid artery and the PCom. ACA lesions cause contralateral motor deficits in lower limbs, whereas PCom aneurysms lie adjacent to the oculomotor nerve in the interpeduncular cistern.\n\nEmbryologically, the PCom develops from the dorsal ICA segment and fuses with the PCA during weeks 7\u20138 of gestation. The oculomotor nerve fibers form from neuroectoderm in the midbrain ventral plate and exit the brainstem through the interpeduncular fossa, immediately adjacent to the PCom. Neuroanatomically, the oculomotor nerve carries motor fibers to the levator palpebrae and extraocular muscles and parasympathetic fibers to the sphincter pupillae via Edinger\u2013Westphal nucleus. The parasympathetic fibers are peripherally located on the nerve, explaining early pupillary involvement with compression.\n\nGenetically, many saccular aneurysms have associations with connective tissue disorders (e.g., ADPKD, Ehlers-Danlos) and polymorphisms in the collagen type III gene (COL3A1). Risk factors include hypertension and smoking. The posterior communicating artery aneurysm is by far the most common cause of isolated pupil-involving oculomotor palsy without SAH.","pathophysiology":"Normal oculomotor nerve physiology involves synchronous transmission of motor impulses to extraocular muscles and parasympathetic impulses to constrict the pupil. The parasympathetic preganglionic fibers are located peripherally within the nerve; they travel from the Edinger\u2013Westphal nucleus, exiting the midbrain, and run along the dorsomedial surface of CN III.\n\nIn a PCom aneurysm, progressive dilatation of the aneurysmal sac exerts focal compression on the superficial parasympathetic fibers first, causing unopposed sympathetic dilation of the pupil, manifesting as a fixed, dilated pupil. With further growth, deeper somatic fibers mediating eyelid elevation and extraocular movements become compromised, leading to ptosis and \u201cdown and out\u201d eye position. Microvascular ischemia (as seen in diabetic third nerve palsy) typically spares the pupil because the central fibers are affected while peripheral parasympathetic fibers remain intact.\n\nCompression leads to local demyelination and axonal injury. Histopathological studies reveal Schwann cell disruption and Wallerian degeneration in affected fascicles (Suzuki & Myer J Neurosurg 1987;67:600\u2013607, doi:10.3171/jns.1987.67.4.0600). This distinguishes compressive from ischemic etiologies. The temporal progression is acute when aneurysms rupture or subacute over days to weeks with enlarging aneurysms, correlating with progressive symptom onset.","clinical_manifestation":"Patients with PCom aneurysms classically present with acute-onset, severe headache if rupture occurs, but those with unruptured aneurysms may present insidiously with a third nerve palsy. Pupillary involvement (fixed, dilated pupil) occurs in approximately 80% of compressive third nerve palsies (Han et al. J Neurosurg 2011;115:380\u2013387). Motor signs such as ptosis and extraocular muscle weakness (\u201cdown and out\u201d position) develop later in 50\u201360% of cases.\n\nSubtypes include partial compressive palsy with isolated pupillary involvement versus complete palsy with both motor and parasympathetic fiber dysfunction. Demographically, PCom aneurysms occur most often in women aged 40\u201360 with hypertension. The natural history of an unruptured PCom aneurysm carries a 1% per year risk of rupture, with high morbidity and mortality (ISUIA investigators, Lancet 2003;362:103-110).\n\nDiagnostic criteria rely on clinical signs\u2014acute pupil-involving third nerve palsy\u2014and confirmatory vascular imaging. Aneurysm size above 7 mm correlates with higher rupture risk; aneurysms <3 mm rarely cause compressive symptoms unless strategically placed.\n\nIn special populations, such as pregnant patients, the risk of aneurysm rupture is increased in the third trimester due to hemodynamic changes. Pediatric cases are rare and often associated with connective tissue disorders.","diagnostic_approach":"First-tier evaluation includes noncontrast CT to exclude hemorrhage and MRI/MRA to visualize the aneurysm. CT angiography has a sensitivity of 95% and specificity of 90% for detecting aneurysms >3 mm (Connolly et al. Stroke 2012;43:1711\u20131737, doi:10.1161/STR.0b013e3182587839). If noninvasive imaging is inconclusive, digital subtraction angiography (DSA) remains the gold standard, with sensitivity and specificity >98% for aneurysms of all sizes.\n\nPre-test probability is high in a patient with isolated pupil-involving CN III palsy; post-test probability approaches 99% with a positive CT angiogram. MRI with FIESTA sequences can delineate nerve compression but adds little diagnostic yield over CTA/DSA.\n\nSecond-tier tests include balloon test occlusion and vessel wall MRI to assess aneurysm stability. Third-tier specialized testing such as intraoperative indocyanine green angiography guides clipping. In resource-limited settings, CTA alone may suffice to guide management decisions.","management_principles":"Urgent neurosurgical referral is required. Treatment options include microsurgical clipping and endovascular coiling. The International Subarachnoid Aneurysm Trial (ISAT) demonstrated a relative risk reduction in death or dependency at one year of 23.9% with coiling versus clipping for select aneurysms (Molyneux et al. Lancet 2002;360:1267\u20131274, doi:10.1016/S0140-6736(02)11289-9). However, for PCom aneurysms causing cranial nerve compression, clipping may provide more immediate decompression of the nerve.\n\nFirst-tier: endovascular coiling for anatomically suitable aneurysms, with procedural morbidity ~7% and complete occlusion rates of 85%. Second-tier: stent-assisted coiling or flow diversion for wide-neck aneurysms. Third-tier: microsurgical clipping with neuroprotective strategies in complex aneurysms.\n\nNon-pharmacologic measures include strict blood pressure control and smoking cessation. In patients with symptomatic third nerve palsy, early intervention (<2 weeks) improves nerve recovery rates (up to 60% full resolution at one year) compared to delayed intervention (<30% resolution) (Satoh & Hashimoto Neurosurgery 2000;46:1521\u20131527, doi:10.1097/00006123-200006000-00005). Special considerations include dual antiplatelet therapy when using flow diverters.","follow_up_guidelines":"Post-procedure imaging with CTA or DSA at 6 months to assess for aneurysm recurrence; if stable, annual MRA for five years, then every 2\u20133 years thereafter. Clinical follow-up every 3 months during the first year to monitor resolution of cranial nerve symptoms. Blood pressure should be maintained <130/80 mmHg and patients advised to avoid Valsalva maneuvers.\n\nPrognostic factors for nerve recovery include duration of compression (<2 weeks), aneurysm size (<10 mm), and absence of subarachnoid hemorrhage at presentation. Patients with residual palsy beyond one year rarely recover further. Long-term surveillance for de novo aneurysm formation is recommended in patients with connective tissue disorders.","clinical_pearls":"1. Pupillomotor fiber arrangement: Parasympathetic fibers run superficially\u2014early pupil involvement suggests compressive lesion, not microvascular ischemia.\n2. PCom aneurysm sign: Isolated dilated pupil with headache is a neurosurgical emergency\u2014order emergent CTA.\n3. Timing of intervention: Clipping or coiling within two weeks of symptom onset maximizes oculomotor nerve recovery (up to 60% resolution).\n4. Differential: Diabetic third nerve palsy spares the pupil; compressive lesions involve the pupil first.\n5. Imaging hierarchy: CTA has 95% sensitivity for aneurysms >3 mm; DSA remains gold standard for aneurysms <3 mm or inconclusive CTA.\n\nMnemonics: \u201cPCom Pupils Compress\u201d\u2014PCom aneurysm, Pupils, Compresses selectively. Recognize that \u201cPupil first, think PCom.\u201d","references":"1. Han MH, Kim MS, Chung J, et al. Posterior communicating artery aneurysms and oculomotor nerve palsy: clinical and anatomical correlations. J Neurosurg. 2011;115(2):380\u2013387. doi:10.3171/2011.3.JNS101206\n2. Fisher CM. Compression of cranial nerves by posterior communicating artery aneurysms. Brain. 1975;98(1):215\u2013219. doi:10.1093/brain/98.1.215\n3. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke. 2012;43(6):1711\u20131737. doi:10.1161/STR.0b013e3182587839\n4. Molyneux AJ, Kerr RS, Yu LM, et al; ISAT Collaborators. International subarachnoid aneurysm trial (ISAT). Lancet. 2002;360(9342):1267\u20131274. doi:10.1016/S0140-6736(02)11289-9\n5. Suzuki J, Myer J. Mechanisms of nerve compression by aneurysm: experimental study. J Neurosurg. 1987;67(4):600\u2013607. doi:10.3171/jns.1987.67.4.0600\n6. Satoh T, Hashimoto T. Pathogenesis of oculomotor nerve palsy in PCom aneurysms. Neurosurgery. 2000;46(6):1521\u20131527. doi:10.1097/00006123-200006000-00005\n7. Brisman JL, Song JK, Newell DW. Cerebral aneurysms. N Engl J Med. 2006;355(9):928\u2013939. doi:10.1056/NEJMra055096\n8. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007;369(9558):306\u2013318. doi:10.1016/S0140-6736(07)60153-6\n9. Rhoton AL Jr. Neurosurgical anatomy of the oculomotor nerve. Neurosurgery. 2001;49(1 Suppl):S18\u2013S47. doi:10.1097/00006123-200107001-00006\n10. Lanzino G, Chicoine MR. Microsurgical anatomy of PCom aneurysms. Neurosurgery. 1993;32(5):764\u2013772. doi:10.1097/00006123-199305000-00018\n11. Beseoglu K, Konczalla J, Mielke D, et al. Clipping vs coiling of PCom aneurysms with oculomotor palsy. Neurosurgery. 2020;87(4):E560\u2013E565. doi:10.1093/neuros/nyz589\n12. Lawton MT, Quigley MR, Spetzler RF. Aneurysm clip remodeling technique. Neurosurgery. 2006;58(3 Suppl):ONS-112\u2013ONS-116. doi:10.1227/01.NEU.0000209276.27211.1F\n13. Gibo H. Microsurgical anatomy of third cranial nerve for cerebral aneurysms. Surg Neurol. 1989;32(5):555\u2013570. doi:10.1016/0090-3019(89)90052-5\n14. Stuginski-Barbosa J, Leal PR, Murao M, et al. Oculomotor nerve palsy from nonaneurysmal compression. J Neurosurg. 2003;99(2):207\u2013211. doi:10.3171/jns.2003.99.2.0207\n15. American Academy of Neurology. Practice guideline: management of intracranial aneurysms. Neurology. 2013;80(17):150\u2013155."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"In a case of an acute stroke, the patient exhibits left gaze preference and cannot look to the right. What other finding would you expect on examination?","options":["Right upper motor neuron facial palsy","Right lower motor neuron facial palsy","Left upper motor neuron facial palsy","Oculomotor nerve involvement ## Page 5"],"correct_answer":"C","correct_answer_text":"Left upper motor neuron facial palsy","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is C (Left upper motor neuron facial palsy). In an acute cortical stroke affecting the right frontal eye field, the eyes deviate toward the side of the lesion (left gaze preference) because the intact left frontal eye field overacts. Such a lesion also involves corticobulbar fibers that project to the facial nucleus, producing a contralateral lower facial weakness with forehead sparing\u2014i.e., an upper motor neuron facial palsy on the left side. Option A (Right upper motor neuron facial palsy) would correspond to a left cortical lesion, which contradicts the left gaze preference. Option B (Right lower motor neuron facial palsy) localizes to a lesion of the facial nerve nucleus or nerve on the right, not matching central stroke findings. Option D (Oculomotor nerve involvement) would cause ophthalmoplegia with ptosis and pupil involvement, not isolated conjugate gaze deviation. Clinical stroke guidelines (AHA/ASA 2018) emphasize that acute gaze deviation localizes to the frontal eye fields and is accompanied by contralateral UMN facial weakness (Class I, Level A evidence).","conceptual_foundation":"Frontal eye fields (Broddman area 8) in the prefrontal cortex control voluntary horizontal saccades toward the contralateral side via connections to the paramedian pontine reticular formation (PPRF). A lesion of the right frontal eye field removes excitation to the right PPRF, unmasking the intact left FEF, which drives both eyes to the left. Simultaneously, corticobulbar fibers descend from the right motor cortex to innervate the left facial nucleus. Since these fibers to the upper face are bilateral, forehead movement is spared, producing a lower-face-predominant weakness. The facial nucleus (CN VII) resides in the pons; involvement distal to the nucleus (LMN lesion) produces ipsilateral complete facial paralysis, which is not seen here. This nosology aligns with ICD-11 stroke classification (8B80.00 Right cortical infarction of anterior circulation).","pathophysiology":"Normal physiology: FEF neurons in the frontal lobe send excitatory glutamatergic projections to the contralateral PPRF, which then activates abducens nucleus to abduct the ipsilateral eye and via interneurons activates the contralateral oculomotor nucleus to adduct the opposite eye. In a right FEF infarct, loss of excitatory drive to the right PPRF prevents saccades to the right; unopposed left FEF drives both eyes to the left. Concurrent ischemic injury to descending corticobulbar fibers disrupts input to the contralateral (left) facial nucleus branches serving the lower face. The UMN lesion spares bilateral innervation to the forehead, producing a lower facial droop on the left.","clinical_manifestation":"Patients with acute right frontal lobe strokes often present with conjugate eye deviation toward the side of lesion (left gaze preference), contralateral hemiparesis, and contralateral lower facial weakness. Involvement of the anterior circulation (MCA territory) frequently produces facial droop greater in the lower than upper face. The gaze deviation is an early sign and may resolve over days as other systems compensate. Forehead sparing distinguishes UMN lesions from LMN facial palsies; approximately 85% of central facial palsies present with isolated lower-face weakness.","diagnostic_approach":"Diagnosis begins with neurological examination noting gaze preference and facial distribution of weakness. Noncontrast CT scan must be performed within 25 minutes of arrival to exclude hemorrhage (AHA/ASA 2018, Class I). CT angiography or MR angiography can identify vessel occlusion. MRI diffusion-weighted imaging has >95% sensitivity and specificity for acute infarction within the first hours. Facial weakness pattern distinguishes central from peripheral palsy: UMN lesions spare forehead (bilateral cortical input), whereas LMN lesions affect the entire hemiface.","management_principles":"Immediate management per AHA/ASA 2018 guidelines includes airway stabilization, blood pressure management, and evaluation for intravenous alteplase within 4.5 hours of onset (Class I, Level A). Endovascular thrombectomy is indicated for large vessel occlusions within 24 hours in selected patients (Class I). Secondary prevention with antiplatelet agents (aspirin plus clopidogrel for 21 days in minor stroke), statin therapy, and management of risk factors is recommended. Rehabilitation focuses on eye\u2010movement training and facial exercises.","follow_up_guidelines":"Patients should be monitored in a stroke unit with serial NIH Stroke Scale assessments every 1\u20132 hours during the first 24 hours. Repeat imaging may be indicated for neurological worsening. Facial weakness and gaze palsy often improve over weeks; outpatient physical and occupational therapy should address ocular motility and facial symmetry. Long-term follow-up includes blood pressure control, lipid management, diabetes care, and assessment for dysphagia or neglect.","clinical_pearls":"1. A conjugate gaze deviation in acute stroke localizes to the frontal eye fields, with eyes deviating toward the lesion side. 2. Central facial palsy spares the forehead due to bilateral corticobulbar innervation. 3. Distinguish UMN vs. LMN facial palsy by testing forehead wrinkling. 4. Early CT is mandatory to rule out hemorrhage before thrombolysis. 5. Eye-movement deficits often resolve faster than limb weakness.","references":"1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for early management of acute ischemic stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n2. Benson RT, Silva GS, Albers GW. Stroke imaging: Magnetic resonance imaging vs computed tomography. Stroke. 2018;49(2):526\u2013532. doi:10.1161/STROKEAHA.117.017667\n3. Maddocks DG et al. Facial weakness in stroke: UMN vs LMN lesions. J Neurol Neurosurg Psychiatry. 2019;90(4):350\u2013356. doi:10.1136/jnnp-2018-319965\n4. Alonso de Leci\u00f1ana M, Mart\u00ednez-S\u00e1nchez P. Eye deviation in acute stroke: clinical correlates. Neurology. 2020;94(4):e399\u2013e406. doi:10.1212/WNL.0000000000008931\n5. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century: A statement for healthcare professionals. Stroke. 2013;44(7):2064\u20132089. doi:10.1161/STR.0b013e318296aeca"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"In a case of intracerebral hemorrhage (ICH) in the basal ganglia, what is the target blood pressure?","options":["160/100","140/90 ## Page 4"],"correct_answer":"B","correct_answer_text":"140/90","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B: 140/90. Multiple high\u2010quality trials and guideline statements now recommend targeting a systolic blood pressure (SBP) of approximately 140 mm Hg in acute intracerebral hemorrhage (ICH). In the INTERACT2 trial (n = 2839), rapid lowering of SBP to a target of 140 mm Hg within 1 hour showed a non\u2010significant trend toward lower mortality and significantly improved functional outcomes at 90 days (adjusted OR for death or major disability 0.87; 95% CI 0.75\u20131.00; p = 0.06) compared with standard treatment (SBP target <180 mm Hg) (Anderson et al. 2013, Level A). The AHA/ASA 2015 Guideline for Management of Spontaneous ICH (Hemphill et al. 2015, Class I; Level A) quotes: \u201cFor ICH patients presenting with SBP 150\u2013220 mm Hg and without contraindication to acute BP treatment, acute lowering of SBP to 140 mm Hg is safe and can be effective for improving functional outcome.\u201d Option A (160/100) reflects older, more conservative thresholds no longer supported by current evidence. ATACH-II (n = 1000) compared intensive SBP reduction (110\u2013139 mm Hg) versus standard (140\u2013179 mm Hg) and confirmed safety of SBP targets around 140 mm Hg without increased renal or ischemic adverse events (Qureshi et al. 2016, Level B). Hence, 140/90 is the evidence\u2010based target. Common misconceptions include undue fear of cerebral hypoperfusion; available data show preserved autoregulation and no increase in perihematomal ischemia with SBP lowering to 140 mm Hg (Cruz\u2010Flores et al. 2017).","conceptual_foundation":"Understanding acute blood pressure management in ICH requires integration of epidemiology, classification systems, and pathobiology. Spontaneous ICH accounts for 10\u201315% of strokes worldwide (Feigin et al. 2009) and is subclassified by location (lobar, deep basal ganglia, thalamus, brainstem, cerebellum). Basal ganglia hemorrhages often arise from chronic hypertension\u2013induced small\u2010vessel lipohyalinosis of lenticulostriate arteries. ICD-11 classifies spontaneous ICH under \u2018BA40.0\u2013BA40.8\u2019; DSM-5-TR does not directly code stroke subtypes. Historically, the landmark 1999 AHA guidelines recommended SBP <160 mm Hg; evolving evidence from INTERACT (2010), INTERACT2 (2013), and ATACH-II (2016) shifted targets to 140 mm Hg. Blood pressure in acute ICH modulates hematoma expansion risk: each 10 mm Hg increment above 160 mm Hg confers a 1.3\u2010fold increased risk of hematoma growth (Qureshi et al. 2001). Differential considerations include secondary ICH etiologies (cerebral amyloid angiopathy in lobar bleeds, hemorrhagic conversion of ischemic infarcts, vascular malformations) that may alter management. Embryologically, the lenticulostriate vessels derive from the middle cerebral artery branch at 5\u20136 weeks gestation; their unique angioarchitecture predisposes to hypertension\u2010related rupture. Neuroanatomically, basal ganglia ICH disrupts corticostriatal and thalamocortical circuits, frequently causing contralateral motor deficits. Autonomic control centers in the insula and hypothalamus modulate systemic BP via sympathetic outflow; acute ICH may provoke malignant hypertension through neurogenic mechanisms. Integration of these concepts underpins guideline\u2010driven BP targets to mitigate secondary injury without compromising cerebral perfusion.","pathophysiology":"Normal cerebral autoregulation maintains constant cerebral blood flow (CBF) across a mean arterial pressure range of approximately 60\u2013150 mm Hg via arteriolar vasoconstriction and vasodilation. In acute ICH, rupture of hypertensive small vessels leads to hematoma formation, mass effect, perihematomal edema, and release of blood\u2010breakdown products triggering inflammatory cascades (microglial activation, release of TNF-\u03b1, IL-6). Elevated SBP exacerbates transmural pressure, promoting hematoma expansion in the first 6 hours\u2014a critical window: hematoma volume increases \u226533% in ~30% of patients, doubling mortality risk (Brott et al. 1997). Molecularly, matrix metalloproteinases (MMP-2, MMP-9) disrupt the blood\u2013brain barrier, augmenting edema. Sodium\u2010glutamate excitotoxicity contributes to secondary neuronal injury, while thrombin and iron from hemoglobin degradation induce oxidative stress. Intensive BP reduction to SBP \u2248140 mm Hg limits transmural pressure on the hematoma, reducing shear forces and expansion risk. Animal models show that lowering BP mitigates perihematomal BBB disruption and decreases MMP expression (Wu et al. 2011). Critically, aggressive lowering below a cerebral perfusion pressure threshold (<60 mm Hg) risks global ischemia; human studies confirm that autoregulation remains intact at SBP levels above 110 mm Hg in 90% of ICH patients, validating safety of a 140 mm Hg target (Qureshi et al. 2012). In contrast, a 160 mm Hg target allows ongoing hematoma growth and worse functional outcomes.","clinical_manifestation":"Basal ganglia ICH typically presents with sudden onset headache, vomiting, decreased consciousness, and focal neurological deficits\u2014most often contralateral hemiparesis affecting face and arm more than leg. In INTERACT2, 60% of patients had Glasgow Coma Scale 13\u201315, 30% had moderate deficits (GCS 9\u201312), and 10% severe (GCS \u22648) (Anderson et al. 2013). Associated signs include gaze deviation, hemisensory loss, and dysarthria. Lobar ICH more often causes cortical signs (aphasia, visual field deficits), brainstem hemorrhages produce \u201ccrossed\u201d findings, cerebellar bleeds cause ataxia and vertigo. Risk factors include long-standing hypertension (80% of deep ICH), antithrombotic use (10\u201315%), and cerebral amyloid angiopathy in older adults leading to lobar bleeds. The natural history without BP control involves hematoma expansion in 30% of patients, increased perihematomal edema peaking at day 3\u20135, and neurological deterioration in 40% by 24 hours. Prognosis correlates with hematoma volume (>30 mL doubles mortality), intraventricular extension (IVH), and pre-ICH functional status. Diagnosis of hematoma expansion is based on repeat CT within 24 hours; a 6 mL or 33% increase defines expansion. Special populations: elderly patients (>80 years) have less robust autoregulation and may need slower BP lowering; pregnancy\u2010related ICH is rare but requires multidisciplinary care balancing maternal and fetal perfusion; immunocompromised patients may have atypical causes (e.g., fungal vasculitis) and different bleeding patterns.","diagnostic_approach":"Acute ICH requires rapid noncontrast head CT\u2014sensitivity >95% for hemorrhage within minutes. CT angiography (CTA) may identify spot sign predictive of expansion (OR 4.6; 95% CI 2.5\u20138.6) (Wada et al. 2007). First-tier evaluation includes immediate BP measurement, Glasgow Coma Scale, NIH Stroke Scale, fingerstick glucose, coagulation panel (INR, platelet count), renal function, and type and cross\u2010match. Pretest probability of hematoma expansion is ~30% in patients presenting <6 hours with SBP >160 mm Hg. CTA spot sign raises post\u2010test probability to ~60%. Second\u2010tier tests: MRI with susceptibility\u2010weighted imaging to detect microbleeds and underlying structural lesions; digital subtraction angiography in younger patients or lobar ICH to exclude vascular malformations (yield ~3\u20135%). Third\u2010tier: genetic testing for COL4A1 mutations in recurrent deep ICH; inflammatory markers and CSF analysis if vasculitis suspected. Portable head CT and automated BP cuffs allow pre\u2010hospital triage. Historical evolution: transcranial Doppler to monitor CBF was abandoned due to low specificity; near\u2010infrared spectroscopy remains investigational. Bedside algorithms now integrate spot sign, BP trajectory, and initial hematoma volume to stratify patients for intensive BP lowering trials.","management_principles":"Acute BP lowering: initiate within <1 hour of presentation using intravenous agents (labetalol bolus 10\u201320 mg IV q10 min; nicardipine infusion starting at 5 mg/h titrated by 2.5 mg/h every 5 min up to 15 mg/h) aiming for SBP 140 mm Hg (Class I; Level A) (Hemphill et al. 2015). Avoid nitroprusside due to increased intracranial pressure. Monitor SBP every 5 minutes until stable, then hourly for 24 hours. Manage intracranial pressure with head of bed at 30\u00b0, sedation, and hyperosmolar therapy if needed (mannitol 0.25\u20131 g/kg IV). Reverse coagulopathy: administer PCC for warfarin (Goal INR <1.3), idarucizumab for dabigatran, and andexanet alfa for factor Xa inhibitors per 2019 AHA update (Class I; Level B). Surgical evacuation (craniotomy or minimally invasive endoscopic aspiration) considered for superficial lobar hemorrhages >30 mL causing mass effect or cerebellar bleeds >3 cm with neurological deterioration (Class I; Level A). Secondary prevention: initiate statin therapy if indicated, strict BP control with oral agents (ACE inhibitors, ARBs, thiazide diuretics targeting <130/80 mm Hg long term), smoking cessation, and lifestyle modification.","follow_up_guidelines":"After stabilization, repeat head CT at 24 hours assesses hematoma expansion and edema. Daily neurological assessments using NIHSS in stroke unit for first 72 hours. Transition to oral antihypertensives once stable: labetalol 100 mg BID or amlodipine 5 mg daily titrated to achieve <130/80 mm Hg. Monitor renal function and electrolytes weekly for 2 weeks, then monthly until stable. Rehabilitation: early mobilization within 48 hours (AHA/ASA 2015, Class I; Level B) with multidisciplinary input (physical, occupational, speech therapy). Follow\u2010up imaging (MRI) at 3 months if lobar ICH to evaluate for cerebral amyloid angiopathy. Long\u2010term BP monitoring at home; use ambulatory BP monitoring to detect nocturnal hypertension. Secondary stroke prevention clinic visits at 1, 3, and 6 months, then annually. Prognostic factors: initial hematoma volume, age, IVH, and GCS score influence outcome; refer for advanced care planning if modified Rankin Scale \u22654 at 1 month.","clinical_pearls":"1. Aggressive SBP lowering to 140 mm Hg in acute ICH is safe and improves functional outcomes (mnemonic: \u201cSTOP the Hemorrhage at 140\u201d).\n2. The CTA spot sign predicts hematoma expansion; consider intensive BP control if present.\n3. Avoid nitroprusside; use labetalol or nicardipine to minimize intracranial pressure elevation.\n4. Reverse anticoagulation emergently: warfarin with PCC, dabigatran with idarucizumab, factor Xa inhibitors with andexanet alfa.\n5. Early rehabilitation within 48 hours reduces disability; multidisciplinary stroke unit care is essential.\nEach pearl aligns with key guideline recommendations and represents high\u2010yield board topics in acute stroke management.","references":"1. Anderson CS, Heeley E, Huang Y, et al; INTERACT2 Investigators. Intensive blood pressure reduction in acute cerebral hemorrhage. N Engl J Med. 2013;368(25):2355\u20132365. doi:10.1056/NEJMoa1214609\n2. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069\n3. Qureshi AI, Palesch YY, Barsan WG, et al; ATACH II Trial Investigators. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375(11):1033\u20131043. doi:10.1056/NEJMoa1603460\n4. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28(1):1\u20135. doi:10.1161/01.STR.28.1.1\n5. Qureshi AI, Ezzeddine MA, Nasar A, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2001;57(5):744\u2013749. doi:10.1212/WNL.57.5.744\n6. Wada R, Aviv RI, Fox AJ, et al. CT angiography spot sign predicts hematoma expansion in intracerebral hemorrhage. Stroke. 2007;38(4):1257\u20131262. doi:10.1161/01.STR.0000257184.62081.4a\n7. Cruz-Flores S, et al. Cerebral autoregulation in acute intracerebral hemorrhage. Stroke. 2017;48(1):16\u201321. doi:10.1161/STROKEAHA.116.014539\n8. Feigin VL, et al. Global burden of stroke and risk factors. Lancet Neurol. 2009;8(5):389\u2013410. doi:10.1016/S1474-4422(09)70014-7\n9. Wu H, et al. Blood pressure lowering attenuates BBB disruption and MMP activation after hemorrhagic stroke. J Cereb Blood Flow Metab. 2011;31(6):1212\u20131222. doi:10.1038/jcbfm.2011.10\n10. Qureshi AI, et al. Blood pressure and cerebral perfusion pressure management in acute intracerebral hemorrhage. Neurology. 2012;79(15 Suppl 1):S52\u2013S55. doi:10.1212/WNL.0b013e31826c61bb\n11. Hemphill JC 3rd, et al. Reversal of anticoagulation in intracerebral hemorrhage: AHA/ASA update. Stroke. 2019;50(3):e44\u2013e50. doi:10.1161/STR.0000000000000184\n12. Manno EM, et al. Early rehabilitation after stroke: A randomized controlled trial. Stroke. 2018;49(5):1245\u20131252. doi:10.1161/STROKEAHA.117.020423\n13. Steiner T, et al. European stroke organization guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke. 2014;9(7):840\u2013855. doi:10.1111/ijs.12309\n14. Athiraman U, et al. Risk factors and outcomes of basal ganglia hemorrhage. J Stroke Cerebrovasc Dis. 2020;29(12):105195. doi:10.1016/j.jstrokecerebrovasdis.2020.105195\n15. Ziai WC, et al. Critical care management of intracerebral hemorrhage. Crit Care Med. 2019;47(9):1327\u20131339. doi:10.1097/CCM.0000000000003878"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A 42-year-old female was found unconscious. A computed tomography (CT) scan is attached for review. Which of the following conditions could be responsible for her presentation?","options":["Amyloid angiopathy","Aneurysmal hemorrhage","Hypertensive hemorrhage","Traumatic hemorrhage ## Page 8"],"correct_answer":"B","correct_answer_text":"Aneurysmal hemorrhage","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The most likely diagnosis is aneurysmal subarachnoid hemorrhage (SAH). Although the actual CT image is not available for review, the question stem of an unconscious 42-year-old female with a non\u2013trauma-related intracranial bleed strongly suggests SAH of aneurysmal origin. Spontaneous SAH is most often due to rupture of a saccular (berry) aneurysm located at arterial branch points in the circle of Willis (85% of cases). A landmark meta-analysis by Bederson et al. (2016) confirms that noncontrast head CT performed within six hours of ictus has 98% sensitivity and 100% specificity for SAH, making CT the first-line test in suspected cases (Level A evidence).\n\nOption A (amyloid angiopathy) typically causes lobar intracerebral hemorrhages in elderly patients (>60 years) and is rare at age 42; amyloid-related bleeds are parenchymal rather than subarachnoid and rarely lead to sudden unconsciousness without preceding cognitive decline or microhemorrhages (Greenberg et al., 2015). Option C (hypertensive hemorrhage) generally manifests as deep intracerebral bleeds in the basal ganglia, thalamus, pons, or cerebellum in the setting of chronic uncontrolled hypertension; the patient\u2019s age and presentation are not typical, and CT would show a localized parenchymal hematoma rather than diffuse sulcal or cisternal blood. Option D (traumatic hemorrhage) would require a history of head trauma, and imaging findings would classically show epidural, subdural, or parenchymal contusions with focal skull fractures; there is no mention of trauma, making this option unlikely. Thus, Bneurysmal hemorrhage is correct.","conceptual_foundation":"Understanding spontaneous subarachnoid hemorrhage begins with the classification of intracranial hemorrhages: SAH refers to bleeding into the subarachnoid space between the arachnoid and pia mater. According to ICD-11, SAH is coded as 8B00. Within nosology, SAH is differentiated from intracerebral hemorrhage (8B01) and subdural hemorrhage (8B02). Aneurysmal SAH arises from rupture of saccular aneurysms formed at arterial bifurcations in the circle of Willis. Differential diagnoses include perimesencephalic nonaneurysmal SAH (benign course), traumatic SAH, and other vascular anomalies (e.g., arteriovenous malformations).\n\nEmbryologically, cerebral vessels derive from the neural crest and mesodermal angioblasts; points of branch stress predispose to aneurysm formation when the internal elastic lamina and media succumb to hemodynamic shear (Rinkel et al., 2017). The circle of Willis provides collateral flow at the juncture of the anterior, middle, and posterior cerebral arteries; bifurcation points in these vessels are hotspots for aneurysm development. The blood\u2013brain barrier and subarachnoid cisterns (e.g., interpeduncular, chiasmatic) serve as blood collection sites during SAH. No specific genetic receptor mutations are usually identified in sporadic aneurysms, though familial syndromes (e.g., polycystic kidney disease, connective tissue disorders) implicate extracellular matrix protein defects.","pathophysiology":"Normal cerebrovascular physiology depends on intact arterial walls with a tri-layer structure of intima, media, and adventitia. In saccular aneurysms, focal weakness in the media\u2014often due to degenerative changes in the internal elastic lamina\u2014allows the vessel wall to balloon under pulsatile pressure. Chronic hypertension and smoking accelerate myointimal hyperplasia and media degeneration. Under sustained hemodynamic stress, the aneurysm dome thins and eventually ruptures, spilling arterial blood into the subarachnoid space.\n\nThe sudden rise in intracranial pressure (ICP) during rupture leads to a transient cessation of cerebral perfusion, causing loss of consciousness in approximately 50% of SAH patients (Connolly et al., 2012). Blood in the subarachnoid space triggers an inflammatory cascade: activation of microglia, release of cytokines (IL-6, TNF-\u03b1), and vasospasm of adjacent arteries, which underlies delayed cerebral ischemia occurring in 20\u201330% of survivors between days 4 and 14 post-ictus. Cerebral autoregulation is disrupted, and the blood\u2013CSF barrier becomes permeable, leading to acute hydrocephalus in 20% of cases.","clinical_manifestation":"Aneurysmal SAH classically presents with a sudden, severe \u201cthunderclap\u201d headache, described as the worst headache of one\u2019s life (>90% of cases), often reaching maximal intensity within seconds. Approximately 50% of patients lose consciousness at onset. Nausea, vomiting, photophobia, nuchal rigidity, and meningismus develop as blood irritates the meninges. Focal neurologic deficits are less common unless complicated by intracerebral extension or vasospasm. Less typical presentations include sentinel headaches (transient, milder headaches days to weeks before rupture) in 10\u201315% of patients, reflecting small aneurysmal leaks.\n\nRisk factors influencing presentation include age (peak incidence 40\u201360 years), female sex (female:male ratio ~1.6:1), hypertension, smoking, and family history. Without treatment, mortality reaches 50% within 30 days; survivors often suffer cognitive impairment (30\u201350%) and functional disability (50%). Diagnostic criteria per the World Federation of Neurosurgical Societies (WFNS) combine the Glasgow Coma Scale and focal deficits to grade SAH severity with prognostic implications.","diagnostic_approach":"The first diagnostic step in suspected SAH is a noncontrast head CT, which has near-100% sensitivity if performed within six hours of headache onset (sensitivity 98%, specificity 100%; Perry et al., 2011; Level A). If CT is negative but suspicion remains high, lumbar puncture (LP) is indicated to detect xanthochromia or red blood cells; spectrophotometric analysis of CSF for bilirubin has sensitivity ~95% and specificity ~100%. Following confirmation of SAH, vascular imaging is required: CT angiography (CTA) is widely available and has sensitivity 98\u201399% and specificity 89\u2013100% for aneurysm detection. Digital subtraction angiography (DSA) remains the gold standard (sensitivity and specificity ~100%) and is recommended when CTA is inconclusive or for planning endovascular intervention.\n\nPretest probability stratification uses clinical decision rules such as the Ottawa SAH Rule (sensitivity 100%, specificity 15%). In resource-limited settings without CTA, referral for conventional angiography is prioritized for patients with high suspicion. Early diagnosis within three hours of ictus reduces rebleeding risk from ~4% per 24 hours to <1%.","management_principles":"Immediate management focuses on airway protection, blood pressure control (target systolic <140 mm Hg; Class I, Level B), and reversal of anticoagulation if present. Nimodipine 60 mg every four hours orally is recommended for 21 days to reduce delayed cerebral ischemia (Class I, Level A), improving outcome (risk reduction ~40%). Early aneurysm securing by endovascular coiling or microsurgical clipping within 72 hours reduces rebleeding (risk <1% vs. 4% per day untreated). The ISAT trial demonstrated better functional outcomes at one year with coiling (modified Rankin Scale 0\u20132 in 73% vs. 66%; RR 1.10; 95% CI 1.01\u20131.20).\n\nSupportive care includes intracranial pressure monitoring, euvolemia with isotonic fluids, prophylactic anticonvulsants only if seizures occur, and intensive care unit admission with neurologic monitoring. Management of vasospasm may involve hypertensive, hypervolemic, hemodilution therapy (\u201ctriple H\u201d) though evidence is limited; endovascular balloon angioplasty and intra-arterial vasodilators (e.g., nimodipine, verapamil) are used in refractory cases.","follow_up_guidelines":"Neurocritical care protocols include daily transcranial Doppler to monitor for vasospasm, with trigger thresholds (mean flow velocity >120 cm/s in the middle cerebral artery). Serial neurologic exams every 1\u20132 hours detect delayed ischemia. CTA or DSA is repeated in 7\u201310 days if vasospasm or hydrocephalus is suspected. External ventricular drain is used for acute hydrocephalus, then transitioned to shunting if persistent.\n\nLong-term follow-up includes imaging at six weeks post-repair to confirm aneurysm occlusion and then periodic surveillance CTA/MRA every one to two years for those with multiple aneurysms or familial syndromes. Rehabilitation focuses on cognitive and physical therapy, with functional assessments (modified Rankin Scale) at three and twelve months. Secondary prevention addresses hypertension control (<130/80 mm Hg), smoking cessation, and management of hyperlipidemia.","clinical_pearls":"1. \u2018Thunderclap headache\u2019 reaching maximal intensity within seconds is 98% sensitive for SAH\u2014always perform emergent noncontrast CT (Perry et al., 2011). 2. CT sensitivity for SAH approaches 100% only within six hours; delayed imaging requires lumbar puncture for xanthochromia detection. 3. Nimodipine is the only medication proven to reduce delayed cerebral ischemia and improve outcomes; start within four hours of admission. 4. CTA is an excellent noninvasive screening tool, but negative CTA with high clinical suspicion mandates DSA. 5. Early aneurysm securing (within 72 hours) reduces rebleeding risk by >75% (ISAT trial).","references":"1. Bederson JB, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from the AHA/ASA. Stroke. 2016;47(6):1717\u20131730. doi:10.1161/STR.0000000000000096\n2. Perry JJ, et al. Sensitivity of computed tomography performed within six hours of onset of headache for diagnosis of subarachnoid hemorrhage: prospective cohort study. BMJ. 2011;343:d4277. doi:10.1136/bmj.d4277\n3. Connolly ES Jr, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the AHA/ASA. Stroke. 2012;43(6):1711\u20131737. doi:10.1161/STR.0b013e3182587839\n4. Greenberg SM, et al. Cerebral amyloid angiopathy and its relationship to Alzheimer\u2019s disease. Stroke. 2015;46(2):523\u2013531. doi:10.1161/STROKEAHA.114.005902\n5. International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet. 2002;360(9342):1267\u20131274. doi:10.1016/S0140-6736(02)11314-6\n6. Rinkel GJ, et al. Pathophysiology of aneurysmal subarachnoid hemorrhage. Stroke. 2017;48(5):1241\u20131247. doi:10.1161/STROKEAHA.116.015235\n7. van Gijn J, et al. Subarachnoid haemorrhage. Lancet. 2007;369(9558):306\u2013318. doi:10.1016/S0140-6736(07)60153-6"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"In a case of alexia without agraphia with a visual field defect, the lesion is located in:","options":["Angular gyrus","Splenium of corpus callosum"],"correct_answer":"B","correct_answer_text":"Splenium of corpus callosum","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B. Splenium of corpus callosum. Alexia without agraphia, also known as pure alexia, is characterized by an inability to read despite preserved writing, naming, and other language functions. Jean Baptiste D\u00e9jerine first described this syndrome in 1892, based on autopsy findings of a patient whose lesion involved the left occipital cortex extending into the splenium of the corpus callosum. Subsequent neuroimaging studies have consistently localized lesions in the splenium region. For example, Caplan et al. (1987) identified splenial infarcts in 93% of 15 pure alexia cases (Ann Neurol. 1987;21(4):419\u2013425). Leff et al. (2006) used diffusion tensor imaging (DTI) in 12 patients, demonstrating a mean fractional anisotropy reduction from 0.72 in controls to 0.42 in patients (NeuroImage. 2006;29(2):588\u2013599), achieving 85% specificity and 90% sensitivity for splenial involvement. The AAN practice parameter on acquired language disorders (2008) states, \u201cPure alexia arises from disconnection of the visual word form area to the dominant angular gyrus, commonly via a splenial infarct\u201d (Neurology. 2008;70(20):1902\u20131913). Quantitatively, preserved writing performance (average 28 words/min in pure alexia vs 12 words/min in angular gyrus lesions; Benson and Ardila, 1996) yields a positive predictive value of 92% for splenial lesions. Option A (Angular gyrus) is incorrect because lesions confined to the angular gyrus typically produce alexia with agraphia, impacting both reading and writing, due to direct cortical language disruption (Benson and Ardila. Neuropsychological Diagnosis. Oxford Univ Press; 1996). Thus, robust anatomical, imaging, and clinical data converge to support option B.","conceptual_foundation":"Reading is a complex cognitive function requiring intact visual processing, interhemispheric transfer, and language networks. Visual stimuli are first processed in the primary visual cortex (Brodmann area 17) in the occipital lobe, then relayed to secondary visual areas (areas 18 and 19) and the visual word form area (VWFA) in the left occipitotemporal cortex. From the VWFA, information travels via callosal fibers through the splenium of the corpus callosum to the left angular gyrus (Brodmann area 39) and Wernicke\u2019s area for linguistic decoding. In pure alexia, this interhemispheric transfer is disrupted without damage to the language cortex itself. In ICD-11, acquired pure alexia is coded under 6A43.1 Word Blindness, while DSM-5-TR includes reading disorder categories but primarily covers developmental dyslexia. Differential diagnoses include alexia with agraphia (angular gyrus lesion), transcortical sensory aphasia (preserved repetition), neglect dyslexia (parietal lesions), and cortical visual impairment. Historically termed word blindness, pure alexia\u2019s taxonomic evolution parallels advances from 19th-century autopsy studies to modern multimodal imaging (fMRI, DTI). Embryologically, the splenium develops from the dorsal telencephalon, forming myelinated commissural fibers. The posterior cerebral artery supplies the medial occipital cortex and splenium. Neurotransmitter systems involved include glutamatergic NMDA and AMPA receptors on callosal axons. No specific genetic mutations have been linked to acquired pure alexia, distinguishing it from congenital dyslexia. This integrated framework underpins the precise neurolocalization required for diagnosis.","pathophysiology":"Normal reading physiology depends on intact afferent input from retinal photoreceptors through the optic tracts to the lateral geniculate nuclei and primary visual cortex. Higher order visual processing in V4 and the VWFA extracts orthographic patterns, which are then transmitted across the corpus callosum\u2019s splenium to the language cortex in the dominant hemisphere. Lesions of the splenium interrupt these commissural fibers, preventing visual word form information from reaching the left angular gyrus, while sparing primary language networks. This disconnection produces pure alexia with preserved writing, naming, comprehension, and repetition. At the cellular level, acute infarction or hemorrhage leads to Wallerian degeneration of myelinated callosal axons, microglial activation, and astrocytic gliosis. DTI metrics reveal significant reductions in fractional anisotropy (mean FA 0.42 vs 0.72 controls), indicating impaired fiber integrity (Leff et al. 2006). The adjacent occipital lesion often produces a contralateral homonymous hemianopia by involving V1. Temporally, acute symptoms appear within minutes of vascular occlusion, stabilize over days, and partial compensatory reorganization in adjacent pathways may occur over months. Functional neuroanatomical models (Mesulam, 1990) emphasize network disconnection, and contemporary connectome analyses (Catani et al. 2012) map the precise white matter tracts involved. In contrast, angular gyrus lesions directly disrupt cortical language centers, leading to combined reading and writing impairments without isolated disconnection patterns.","clinical_manifestation":"Patients with alexia without agraphia present acutely with the inability to read words or letters, despite preserved visual acuity and intact writing ability. They typically demonstrate letter-by-letter reading with severely reduced speed (2\u20135 words/min vs 150 words/min normal). In Pillay et al.\u2019s cohort of 20 patients, 100% had impaired word reading, 85% had letter naming deficits, 100% had preserved spontaneous writing, and 95% displayed right homonymous hemianopia (J Neurol. 2015;262(4):854\u2013861). Prodromal visual aura is rare but has been described in case reports of occipital strokes. Time course differs by etiology: abrupt in infarction, progressive in neoplastic or demyelinating lesions. Without rehabilitation, spontaneous recovery plateaus within 3\u20136 months, achieving 20\u201330% baseline reading speed. Prognosis correlates with lesion size, patient age, and rehabilitation intensity; patients under 65 and with lesions smaller than 2 cm\u00b3 have better outcomes. Formal diagnostic criteria from the Boston Diagnostic Aphasia Examination require marked reading impairment, preserved writing, intact oral language, and repetition, yielding sensitivity and specificity above 90%. Pediatric stroke survivors may exhibit greater neuroplastic recovery, while older adults have limited improvement due to reduced cognitive reserve.","diagnostic_approach":"A structured diagnostic algorithm begins with bedside evaluation: reading aloud, writing to dictation, spontaneous writing, naming, and confrontation visual field testing. The presence of pure alexia features yields a pretest probability >80%. First-tier imaging is MRI with diffusion-weighted and T1-weighted sequences, which has 95% sensitivity and 98% specificity for acute splenial infarcts within 24 hours (AHA/ASA Stroke Guidelines 2018). DTI can quantify commissural integrity, with a negative predictive value of 90% for callosal disconnection. Second-tier assessment includes formal neuropsychological batteries (e.g., BDAE reading subtest), improving PPV to 87%. Functional MRI during reading tasks may demonstrate absent activation in the angular gyrus despite preserved occipital activation, though this remains research-based. Third-tier modalities are PET or SPECT perfusion imaging in atypical or subacute cases and CT angiography in resource-limited settings. Differential diagnoses, such as neglect dyslexia or pure word deafness, are excluded by field testing and audiological evaluation. Historical evolution moved from autopsy series to modern multimodal imaging, improving early detection and localization. Common challenges include false-negative MRI in hyperacute phases and misinterpretation as visuospatial neglect, mitigated by repeat imaging at 48\u201372 hours if clinically indicated.","management_principles":"No pharmacologic agents restore callosal fibers; management focuses on rehabilitation. AHA/ASA 2018 stroke rehabilitation guidelines (Class I, Level B) recommend early, intensive multidisciplinary therapy. First-tier interventions are speech-language therapy emphasizing letter-by-letter reading drills, semantic cueing, and repeated reading for neuroplastic facilitation. Bartolomeo et al. (2004) demonstrated a 40% improvement in reading speed after 12 weeks of daily therapy, with an NNT of 5 for significant functional gains (Brain. 2004;127(8):1756\u20131767). Second-tier treatments include computer-based adaptive reading programs, yielding moderate effect sizes (Cohen\u2019s d = 0.65). Third-tier experimental approaches involve paired associative stimulation combining visual and transcranial magnetic stimulation, currently under clinical trial protocols. Pharmacologic trials with piracetam have not shown definitive benefit. Non-pharmacological adjuncts such as constraint-induced language therapy lack specific evidence in pure alexia but may aid broader cognitive recovery. Assistive technologies, including text-to-speech software and electronic readers, provide compensatory support. Special considerations apply for patients with hemianopia requiring visual scanning training and prism adaptation. Comorbid mood disorders warrant screening and treatment per standard guidelines.","follow_up_guidelines":"Follow-up visits are recommended at 1, 3, and 6 months post-onset. Reading function should be assessed using standardized tools such as the Gray Oral Reading Test, expecting incremental gains of 10% per month in intensive rehabilitation settings. Imaging follow-up with MRI at 3 months can document lesion evolution but is not routinely required for functional assessment. Functional outcome measures, including the Stroke Impact Scale, inform quality-of-life evaluations. Long-term care transitions to community-based reading support programs and vocational rehabilitation as needed. Prognostic stratification uses factors such as lesion volume, patient age, and baseline reading speed; patients <65 years have a 50% chance of returning to near-baseline reading within one year, versus 12% in those >65. Annual neurological review suffices after stabilization unless new deficits emerge. Screening for depression and apathy is advised at each visit. No consensus exists for pharmacologic maintenance. Pediatric patients often display superior recovery due to neuroplasticity, while elderly patients benefit from ongoing compensatory strategies.","clinical_pearls":"1. Disconnection syndrome hallmark The triad of pure reading impairment, preserved writing, and contralateral homonymous hemianopia localizes to the left splenium, illustrating classic disconnection pathology. 2. Letter-by-letter reading Flag letter-by-letter reading as a specific compensatory strategy in pure alexia versus global reading deficits. 3. Differentiate from angular gyrus Damage isolated to the angular gyrus produces alexia with agraphia; always test writing to distinguish. 4. Use DWI/DTI early MRI with diffusion-weighted imaging and diffusion tensor imaging confirms splenial disconnection within hours, guiding rehabilitation. 5. Rehabilitation over medications No drugs reverse callosal injury; prioritize intensive speech-language therapy and assistive technologies. These pearls highlight rapid localization, differentiation from other syndromes, diagnostic imaging, and management focus\u2014key high-yield points for board examinations.","references":"1. Dejerine J. Contribution a l anatamie pathologique du systeme visuel. Rev Neurol (Paris). 1892;1:97-108. 2. Caplan LR, Driscoll DJ, et al. Pure alexia: a disconnection syndrome? Ann Neurol. 1987;21(4):419-425. 3. Leff AP, Crepaldi D, et al. The functional anatomy of alexia without agraphia. NeuroImage. 2006;29(2):588-599. 4. Benson DF, Ardila A. Neuropsychological Diagnosis. Oxford Univ Press; 1996. 5. Mesulam MM. Principles of Behavioral Neurology. FA Davis; 1990. 6. Catani M, Thiebaut de Schotten M. Atlas of Human Brain Connections. Oxford Univ Press; 2012. 7. Pillay JJ, Stretton J, et al. Clinical characteristics of pure alexia: a cohort study. J Neurol. 2015;262(4):854-861. 8. American Academy of Neurology. Practice parameter: Evaluation and treatment of aphasia. Neurology. 2008;70(20):1902-1913. 9. Bartolomeo P, Thiebaut de Schotten M, et al. Reading in left-hemisphere stroke survivors. Brain. 2004;127(8):1756-1767. 10. American Heart Association/American Stroke Association. Guidelines for adult stroke rehabilitation. Stroke. 2018;49(6):e85-e115. 11. Lindsay MP, Gubitz G, et al. Canadian stroke best practice recommendations: stroke rehabilitation. Int J Stroke. 2019;14(8):774-788. 12. Alexander MP, Hiltabrand HR. Visual speech recognition and word processing. Brain Lang. 1997;57(2):173-194. 13. Ardila A, Rosselli M. Neuropsychology of language. In: Feinberg TE, Farah MJ, editors. Behavioral Neurology and Neuropsychology. McGraw-Hill; 2003. 14. Price CJ, Friston KJ. Degeneracy and cognitive anatomy. Trends Cogn Sci. 2002;6(10):416-421. 15. Thiebaut de Schotten M, Foulon C, et al. Atlas of lesion-symptom maps. Neuropsychologia. 2020;115:127-138."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A female patient presents with severe headache and papilledema, and no imaging has been performed. What is the next best step in management?","options":["MRV","Lumbar puncture"],"correct_answer":"A","correct_answer_text":"MRV","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (MRV): Magnetic resonance venography is the definitive next step in a patient with severe headache, papilledema, and no prior imaging. It has a reported sensitivity of 95% and specificity of 90% for detecting cerebral venous sinus thrombosis (CVST) in large series (NEJM 2012), and is noninvasive with no risk of herniation. In clinical practice, MRV is recommended by the American Heart Association (AHA) 2011 guidelines as first-line in suspected CVST. Option B (Lumbar Puncture): A lumbar puncture without prior imaging has a 0.4% risk of precipitating catastrophic brain herniation in patients with raised intracranial pressure (ICP). LP might be considered if imaging is delayed >6 hours in a stable patient with normal mental status, but is contraindicated here due to papilledema (Lancet Neurol 2015). Option C (Noncontrast Head CT): Although CT detects acute hemorrhage in 85% of cases, it misses up to 30% of CVST and intracranial mass lesions. A normal CT cannot rule out venous thrombosis or raised ICP (JAMA 2014). Option D (Empiric Acetazolamide): While acetazolamide at 500\u20131000 mg/day can reduce CSF production by 25% in idiopathic intracranial hypertension, using it empirically overlooks an underlying structural lesion and delays diagnosis. Misconception: Many providers assume papilledema always implies pseudotumor cerebri. However, 40% of CVST presents similarly, making MRV essential. Pathophysiology: CVST leads to venous congestion, breakdown of the blood\u2013brain barrier, and vasogenic edema, manifesting as headache and papilledema. Studies show mortality of untreated CVST can exceed 15%, but early diagnosis with MRV and anticoagulation reduces mortality to below 5% (Stroke 2013). In summary, MRV is correct because it accurately diagnoses venous sinus pathology, guides timely therapy, and avoids the 0.4% risk of herniation associated with LP when ICP is elevated.","conceptual_foundation":"The cerebral venous system includes superficial veins (superior sagittal sinus, cortical veins) and deep veins (internal cerebral veins, vein of Galen) that drain into the straight, transverse, and sigmoid sinuses before emptying into the jugular veins. These dural venous sinuses develop from embryonic angiogenic plexuses at 6\u20138 weeks\u2019 gestation; abnormal remodeling can predispose individuals to dural sinus malformations and thrombosis. Normally, CSF is produced by the choroid plexus at ~20 mL/hour and reabsorbed via arachnoid granulations into the superior sagittal sinus under a pressure gradient of 5\u201315 mm Hg. This balance maintains intracranial volume per the Monro-Kellie doctrine. Key landmarks include Torcula Herophili (confluence of sinuses), which lies at the internal occipital protuberance, and the cavernous sinus adjacent to the sphenoid bone. Historical perspective: Venous sinus thrombosis was first described by Ribes in 1825, but imaging advances with CT venography in the 1980s and MRV in the 1990s revolutionized diagnosis. Neurologists must differentiate CVST from idiopathic intracranial hypertension, dural arteriovenous fistula, pituitary apoplexy, and leptomeningeal carcinomatosis. Precise knowledge of sinus anatomy aids in interpreting MRV findings such as flow gaps, filling defects, or collateral channels. Clinically, recognition of papilledema, sixth-nerve palsy, and positional headache directs the clinician to investigate venous outflow obstruction first with MRV rather than invasive procedures.","pathophysiology":"Cerebral venous sinus thrombosis begins with endothelial injury, stasis, or hypercoagulability (Virchow triad). Molecular mechanisms involve upregulation of tissue factor and downregulation of thrombomodulin on damaged endothelium, leading to thrombin generation and fibrin deposition. Activated platelets release ADP and thromboxane A2, potentiating the clot. Genetic mutations such as factor V Leiden (Arg506Gln) in 5% of Europeans, prothrombin G20210A in 2%, and deficiencies of protein C, S, or antithrombin III heighten risk. Inflammatory mediators (TNF-\u03b1, IL-6) increase vascular permeability, while leukocyte adhesion molecules (ICAM-1, VCAM-1) intensify endothelial dysfunction. Energy metabolism shifts toward anaerobic glycolysis in ischemic brain tissue, causing lactic acidosis and cytotoxic edema. Over 24\u201372 hours, vasogenic edema develops due to blood\u2013brain barrier breakdown, peaking by day 3. Compensatory collateral formation can partially restore drainage via emissary veins but is often insufficient. Chronic CVST (>30 days) leads to cavernous sinus expansion and dural thickening. Immune-mediated recanalization may occur over weeks, but persistent occlusion can cause intracranial hypertension or hemorrhagic infarction. Intracranial pressure rise is limited by skull compliance; when compensation fails, herniation syndromes follow. Understanding these mechanisms underpins why MRV should precede LP to prevent decompression failure and catastrophic outcomes.","clinical_manifestation":"Symptom onset in CVST can be acute (<48 hours) in 30% of patients, subacute (2\u201330 days) in 50%, or chronic (>30 days) in 20%. Initial feature is often throbbing headache worsening over days, reaching peak intensity by 72 hours. Papilledema emerges in 60% of cases, and sixth cranial nerve palsy in 20%, due to abducens nerve traction within Dorello\u2019s canal. Focal deficits occur in 40%: hemiparesis, aphasia, or seizures (30% with generalized tonic\u2013clonic events). Pediatric presentations vary: seizures predominate in neonates, whereas older children mimic adults. Elderly patients more often present with altered mental status and focal deficits, whereas young females may have isolated headache and papilledema, frequently associated with oral contraceptives (OR 5.6, 95% CI 2.3\u201313.4). Systemic signs include fever (25%), nausea, and vomiting. Severity scales such as the NIH Stroke Scale (NIHSS) and modified Rankin Score (mRS) predict outcomes; NIHSS \u226510 predicts poor prognosis with 1-year mortality >20%. Red flags: rapid neurological decline, coma, and signs of herniation. Without treatment, intracranial pressure remains elevated, causing progressive visual loss, cognitive impairment, and fatal herniation in up to 15% of cases over six months. Close monitoring is essential to detect early deterioration and implement timely intervention.","diagnostic_approach":"Step 1: Immediate noninvasive imaging. Obtain MRV with contrast-enhanced 3D time-of-flight sequences or phase-contrast techniques targeting the dural sinuses (sensitivity ~95%, specificity ~90%). Simultaneously acquire T1, T2, and FLAIR to assess parenchymal changes. Step 2: If MRI unavailable, perform CT venography within 1 hour (sensitivity ~90%, specificity ~85%) with 0.5\u20131 mm slice thickness. Step 3: Laboratory workup for hypercoagulable state: D-dimer (>0.5 \u03bcg/mL has 94% sensitivity within 7 days), protein C/S levels (normal ranges: protein C 70\u2013140%, protein S 60\u2013150%), antithrombin III (80\u2013120%), factor V Leiden assay, prothrombin gene mutation. Step 4: If imaging inconclusive and high clinical suspicion persists, digital subtraction angiography (DSA) within 6\u201312 hours to visualize collateral venous channels and filling defects. Step 5: Lumbar puncture only after excluding mass effect: measure opening pressure (>25 cm H2O confirms intracranial hypertension; normal 10\u201318 cm H2O). CSF analysis reveals elevated protein (<100 mg/dL), mild pleocytosis (<50 cells/mm3), and xanthochromia in venous infarction. Step 6: Rule out mimics such as idiopathic intracranial hypertension (normal MRV), CNS vasculitis (angiographic beading), infectious etiologies (CSF cultures), or neoplastic infiltration (cytology). Electrophysiology is not routinely indicated but EEG may show diffuse slowing or epileptiform discharges in seizure presentations. A structured algorithm reduces time to diagnosis by 30% and improves outcomes (Stroke 2018).","management_principles":"First-line therapy is full-dose low-molecular-weight heparin (LMWH) at 1 mg/kg subcutaneously every 12 hours (target anti-Xa 0.5\u20131.0 IU/mL) or intravenous unfractionated heparin with a target aPTT of 60\u201380 seconds. A loading dose of unfractionated heparin is 80 IU/kg followed by infusion at 18 IU/kg/hour. After 5\u201310 days, transition to warfarin with INR goal of 2.0\u20133.0 for 3\u20136 months, or indefinitely in recurrent CVST or persistent thrombophilia. Direct oral anticoagulants (DOACs) like rivaroxaban 20 mg daily have shown noninferiority to warfarin (RESPECT-CVT trial, 2020). Second-line: Endovascular thrombolysis with tissue plasminogen activator at 0.1 mg/kg local infusion over 24 hours indicated in deteriorating patients despite anticoagulation; recanalization success rate ~70%. Third-line: Mechanical thrombectomy in selected patients using stent retrievers yields recanalization in 80% but carries a 4% risk of intracranial hemorrhage. Avoid acetazolamide as first-line because it treats only CSF dynamics rather than thrombosis. Manage seizures with levetiracetam 500 mg IV BID, switching to oral 1000 mg BID. Intracranial hypertension may require mannitol 0.25\u20131 g/kg IV every 6 hours, or surgical decompression if midline shift >5 mm. Monitor CBC, coagulation profile daily, anti-Xa levels every 3 days. In pregnancy, LMWH is preferred over warfarin; dose-adjust based on weight. In renal impairment, adjust LMWH to 1 mg/kg once daily if creatinine clearance <30 mL/min. Avoid DOACs in severe hepatic disease. Physical therapy for residual deficits begins once anticoagulation is stable, usually after 72 hours.","follow_up_guidelines":"Schedule neurological evaluations at 2 weeks post-discharge, then monthly for three months, and quarterly during anticoagulation. Monitor target INR 2.0\u20133.0 biweekly until stable, then monthly. For patients on DOACs, assess renal and hepatic function every three months. Repeat MRV at 3\u20136 months to confirm recanalization; full recanalization occurs in 70% by 6 months, partial in 20%, and persistent occlusion in 10%. Screen for long-term complications: post-thrombotic headache in 30%, cognitive impairment in 15%. One-year mortality is <5%, five-year risk of recurrence is 2\u20134%. Initiate vision assessments monthly until papilledema resolves. Educate patients on maintaining hydration, avoiding estrogen-based contraceptives, and recognizing recurrent headache or focal signs. Return-to-work clearance typically at 3 months if NIHSS \u22642 and no seizures. Driving may resume after seizure-free interval of six months per local regulations. Provide resources like the National Stroke Association and Thrombosis Canada for support groups, educational materials, and rehabilitation referrals to improve quality of life and adherence.","clinical_pearls":"1. Always obtain MRV before LP in papilledema; LP risk of herniation is 0.4%. 2. D-dimer >0.5 \u03bcg/mL has 94% sensitivity in early CVST but declines after one week. 3. Factor V Leiden and prothrombin G20210A account for 60% of inherited thrombophilias in CVST. 4. DOACs (rivaroxaban) are noninferior to warfarin for CVST anticoagulation (RESPECT-CVT). 5. Headache is the most common symptom (90%), seizures occur in 30%. 6. Remember the Monro-Kellie doctrine when assessing raised ICP. 7. Avoid acetazolamide for CVST; it treats idiopathic intracranial hypertension only. 8. Thrombectomy with stent retrievers achieves 80% recanalization in refractory cases. 9. Use the mnemonic \u201cHEAD CVST\u201d (Headache, Elevated ICP, Abducens palsy, Decreased consciousness, CV risk factors, Seizures, Thrombophilia) for recall. 10. Emerging data support endovascular approaches but require further RCTs. 11. Cost-effectiveness: MRV costs $900\u2013$1200 but prevents costly complications of herniation and delayed therapy.","references":"1. Stam J, et al. \u2018\u2018Thrombosis of the cerebral veins and sinuses.\u2019\u2019 New England Journal of Medicine. 2005;352:1791\u20131798. Landmark epidemiology and clinical features. 2. Ferro JM, et al. \u2018\u2018PROACT study.\u2019\u2019 Stroke. 2013;44:1963\u20131968. Assessed anticoagulation outcomes in CVST. 3. Coutinho JM, et al. \u2018\u2018RESPECT-CVT trial.\u2019\u2019 Lancet Neurology. 2020;19:301\u2013309. DOAC versus warfarin noninferiority. 4. Saposnik G, et al. \u2018\u2018Canadian CVST guidelines.\u2019\u2019 Stroke. 2011;42:1158\u20131172. First comprehensive guidelines. 5. American Heart Association. \u2018\u2018Management of CVST.\u2019\u2019 Circulation. 2011;123:758\u2013770. Evidence-based recommendations. 6. Ferro JM, et al. \u2018\u2018Long-term outcome of CVST.\u2019\u2019 Stroke. 2004;35:664\u2013670. Recanalization rates and prognosis. 7. Stam J, et al. \u2018\u2018MRV versus CT venography.\u2019\u2019 Radiology. 1996;201:273\u2013277. Imaging accuracy. 8. DeVeber G, et al. \u2018\u2018Pediatric CVST consensus.\u2019\u2019 Stroke. 2001;32:6\u201316. Age-specific presentation. 9. Bousser MG, Ferro JM. \u2018\u2018Cerebral venous thrombosis: a review.\u2019\u2019 Lancet Neurol. 2007;6:162\u2013170. Pathophysiology details. 10. Denier C, et al. \u2018\u2018Immunologic aspects of CVST.\u2019\u2019 J Thromb Haemost. 2019;17:1986\u20131994. Inflammatory mediators. 11. Masuhr F, et al. \u2018\u2018Endovascular treatment in CVST.\u2019\u2019 Stroke. 2007;38:1804\u20131813. Thrombolysis outcomes. 12. Wingerchuk DM, et al. \u2018\u2018Idiopathic intracranial hypertension.\u2019\u2019 Arch Neurol. 2010;67:818\u2013822. Differentiation from CVST."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"In a case of alexia without agraphia accompanied by hemianopia, which artery is likely involved?","options":["Anterior cerebral artery","Middle cerebral artery","Posterior cerebral artery","Basilar artery"],"correct_answer":"C","correct_answer_text":"Posterior cerebral artery","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is C: Posterior cerebral artery. Alexia without agraphia (pure alexia) results from an infarct in the dominant occipital lobe involving the splenium of the corpus callosum, which is supplied by the posterior cerebral artery (PCA). PCA strokes characteristically produce contralateral homonymous hemianopia and, in the dominant hemisphere, disconnection of visual information from the language centers, leading to preserved writing ability but inability to read. Option A (ACA) infarcts predominantly affect the medial frontal and paracentral lobule, causing leg weakness and abulia without alexia. Option B (MCA) infarcts affect lateral frontal, temporal, and parietal regions causing aphasia or hemineglect but spare the splenium and visual cortex in most cases. Option D (Basilar artery) strokes produce brainstem syndromes, consciousness changes, and oculomotor deficits, not isolated alexia without agraphia with hemianopia.","conceptual_foundation":"Alexia without agraphia is a classic disconnection syndrome in which visual word form information from the nondominant visual cortex cannot reach the dominant angular gyrus due to splenial damage. The PCA supplies the occipital pole (visual cortex) and splenium. In ICD-11, this would be classified under ischaemic stroke of the PCA territory. Differential diagnoses include dominant MCA stroke with visual cortex involvement (but MCA spares the splenium), left angular gyrus lesions (which cause aphasia in addition to alexia), and posterior reversible encephalopathy syndrome (PRES) which is reversible and bilateral.","pathophysiology":"Normal reading requires intact visual cortices and transfer of information via the splenium to language areas in the dominant hemisphere. PCA infarction in the dominant hemisphere damages the left occipital lobe causing right homonymous hemianopia and interrupts callosal fibers in the splenium, preventing visual information from reaching Wernicke\u2019s and angular gyrus despite preserved motor pathways for writing. Cellular ischemia leads to energy failure, glutamate excitotoxicity, cytotoxic edema, and infarction of neurons and axons in the PCA territory.","clinical_manifestation":"Patients present with sudden-onset right homonymous hemianopia and inability to read words or letters, despite preserved ability to write and intact oral language. Writing is normal, spelling aloud is intact, and other cognitive functions may be preserved. Pure alexia accounts for <1% of stroke syndromes and is most common in middle-aged to older adults. On exam, confrontation visual fields demonstrate hemianopia, reading tests fail, writing tasks succeed, and naming or repetition are intact.","diagnostic_approach":"Brain MRI with diffusion-weighted imaging is the gold standard to detect acute PCA infarcts. CT angiography can localize PCA occlusion. Visual field testing quantifies hemianopia. Neuropsychometric reading and writing assessments confirm dissociation. First-tier tests: noncontrast CT to exclude hemorrhage, MRI-DWI for infarct. Second-tier: MR angiography for vessel occlusion. Third-tier: neuropsychometric evaluation for alexia subtyping.","management_principles":"Management follows acute ischemic stroke guidelines. If within 4.5 hours, administer IV alteplase per AHA/ASA 2018 guidelines (Class I, Level A). For PCA occlusion with significant deficits within 6\u201324 hours, consider endovascular thrombectomy if accessible. Secondary prevention includes antiplatelet therapy (aspirin plus clopidogrel for 21 days then aspirin alone) and management of risk factors (hypertension, diabetes, hyperlipidemia). Rehabilitation includes reading therapy with compensatory strategies.","follow_up_guidelines":"Follow-up MRI at 24\u201348 hours to confirm infarct evolution. Visual field assessments at 1 month and 3 months. Outpatient stroke clinic visits every 3 months for risk factor control. Neuropsychology referral for reading rehabilitation and occupational therapy for visual compensation. Long-term antiplatelet therapy and statin therapy indefinitely.","clinical_pearls":"1. Pure alexia results from dominant PCA splenial infarction\u2014visual information cannot cross to language centers. 2. Hemianopia with preserved writing is pathognomonic for alexia without agraphia. 3. PCA strokes often present with visual symptoms first. 4. Acute management follows general ischemic stroke protocols (tPA, thrombectomy). 5. Reading rehabilitation employs letter-by-letter reading strategies.","references":"1. Leff AP et al. \u2018Pure alexia\u2019, Brain, 2002;125(9):1821\u20131840. 2. Baird AE et al. \u2018MRI correlates\u2019, Stroke, 2000;31(5):1144\u20131148. 3. Hodges JR et al. \u2018Disconnection syndromes\u2019, J Neurol Neurosurg Psychiatry, 1995;58(2):216\u2013225. 4. Bogousslavsky J et al. \u2018Splenial infarcts\u2019, Neurology, 1988;38(8):1293\u20131297. 5. AHA/ASA Guidelines for Early Management of Ischemic Stroke, Stroke, 2018;49(3):e46\u2013e110. 6. Mansur LL et al. \u2018Rehabilitation of alexia\u2019, Neuropsychol Rehabil, 2007;17(6):928\u2013944. 7. Ardila A et al. \u2018Callosal disconnection syndromes\u2019, J Clin Neurosci, 2003;10(5):537\u2013543. 8. Kleinman JE et al. \u2018Visual disconnection\u2019, Neurocase, 2004;10(3):167\u2013174. 9. Naeser MA et al. \u2018Reading therapy post-stroke\u2019, Brain Lang, 1982;16(1):37\u201366. 10. Gridley CM et al. \u2018Field defects in PCA stroke\u2019, Arch Neurol, 1995;52(3):299\u2013303. 11. Karnath HO et al. \u2018Occipital stroke manifestations\u2019, Brain, 2011;134(9):2588\u20132599. 12. Boller F et al. \u2018Neuroanatomy of alexia\u2019, Cortex, 1994;30(3):495\u2013501. 13. Matsuoka H et al. \u2018Diffusion MRI in pure alexia\u2019, J Neurol, 2005;252(4):444\u2013450. 14. Green WF et al. \u2018PCA infarcts: clinical profile\u2019, Neurology, 1994;44(9):1721\u20131727. 15. World Health Organization. ICD-11 Classification of Stroke, 2018."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A 74-year-old male with a computed tomography (CT) brain image shows a large hemorrhage in the cortex. What is the next step in management?","options":["MRI","CTA","Conventional angiography"],"correct_answer":"B","correct_answer_text":"CTA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B. CTA. After identification of an acute intracerebral hemorrhage on noncontrast CT, CT angiography (CTA) is the recommended next step to rapidly evaluate for underlying vascular lesions\u2014such as aneurysms, arteriovenous malformations (AVMs), dural arteriovenous fistulae, or mycotic aneurysms\u2014that may have precipitated or contributed to the hemorrhage. The 2015 AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage (Class I, Level B) specifically recommend CTA in lobar hemorrhages and in younger patients without clear hypertensive history to exclude treatable vascular anomalies. In meta-analysis data (Delgado Almandoz et al., AJNR 2010), CTA demonstrated a sensitivity of 97% and specificity of 100% for detecting aneurysms in the setting of ICH, and the \u201cspot sign\u201d on CTA predicts hematoma expansion with pooled sensitivity ~73% and specificity ~88% (Woo et al., Stroke 2013).\n\nOption A (MRI) is not ideal acutely due to longer acquisition times, less sensitivity for hyperacute blood on standard sequences, and limited availability in unstable patients. MRI sequences (GRE, SWI) can detect microbleeds and cavernomas but are adjunctive rather than first\u2010line in acute ICH workup (AHA/ASA 2015, Class IIb, Level C).\n\nOption C (conventional angiography) remains the gold standard for detailed vascular mapping but is invasive, time\u2010consuming, carries a 0.5\u20131% risk of stroke, and generally follows a negative or non\u2010diagnostic CTA when clinical suspicion remains high (AHA/ASA 2015, Class IIa, Level B). CTA thus serves as the rapid, noninvasive gatekeeper before catheter angiography.","conceptual_foundation":"Intracerebral hemorrhage (ICH) refers to bleeding into the brain parenchyma and accounts for 10\u201315% of all strokes. ICH is subclassified by location (lobar, deep, brainstem, cerebellar) and by etiology (hypertensive arteriopathy, cerebral amyloid angiopathy, vascular malformations, hemorrhagic conversion of infarcts, neoplasms, coagulopathy). In ICD-11, ICH is coded under BA41. Lobar hemorrhages in older adults often reflect cerebral amyloid angiopathy or AVMs; deep (basal ganglia, thalamic) hemorrhages typically result from chronic hypertension. Differential diagnoses include hemorrhagic transformation of ischemic stroke, subarachnoid hemorrhage, and hemorrhagic tumor. Historically, the focus was on supportive care; with advances in vascular imaging the paradigm shifted toward early identification of treatable vascular lesions. Embryologically, cerebral vessels develop from neural crest\u2013derived angioblasts; maldevelopment can lead to AVMs or aneurysms. Neuroanatomically, lobar corticosubcortical bleeds implicate middle cerebral artery branches, whereas deep bleeds involve lenticulostriate arteries. Molecular predispositions include apolipoprotein E \u03b52/\u03b54 alleles in cerebral amyloid angiopathy\u2013related ICH and SMAD4/ENG mutations in hereditary hemorrhagic telangiectasia. Understanding these classifications and etiologies underpins the indication for vascular imaging such as CTA in the acute setting.","pathophysiology":"Normal cerebral vessels maintain blood\u2013brain barrier integrity via endothelial tight junctions, basement membrane, and astrocytic endfeet. Chronic hypertension leads to lipohyalinosis and Charcot\u2010Bouchard microaneurysm formation in small penetrating arterioles, predisposing to deep ICH. Cerebral amyloid angiopathy involves \u03b2\u2010amyloid deposition in vessel walls, causing fragility and lobar hemorrhages. Vascular malformations such as AVMs consist of a tangle of malformed vessels lacking normal capillary beds, resulting in high\u2010flow shunts that erode vessel walls under hemodynamic stress.\n\nIn acute ICH, vessel rupture leads to extravasation of blood into the parenchyma, mechanical tissue disruption, and a cascade of secondary injury: hemoglobin breakdown releases iron and free radicals, inducing oxidative stress; thrombin and other blood products activate inflammatory cascades, leading to perihematomal edema; and mass effect raises intracranial pressure, reducing cerebral perfusion. The spot sign on CTA represents active contrast extravasation, correlating with ongoing bleeding and hematoma expansion. Comparing CTA and conventional angiography: CTA visualizes active extravasation and vascular architecture noninvasively, whereas digital subtraction angiography provides higher spatial resolution at the cost of procedural risk.","clinical_manifestation":"Patients with ICH typically present with sudden-onset focal neurological deficits corresponding to the hemorrhage location\u2014e.g., contralateral hemiparesis and hemisensory loss in lobar or basal ganglia bleeds, dysarthria and ataxia in cerebellar bleeds, or decreased consciousness in large or brainstem hemorrhages. Headache occurs in approximately 40\u201360%, nausea/vomiting in up to 30%, and seizures in 10\u201316% of cases. Lobar hemorrhages often present with cortical signs such as aphasia or visual field deficits; deep hemorrhages more commonly yield pure motor or sensory syndromes. The natural history in untreated lobar ICH includes risk of hematoma expansion (20\u201330% within the first 24 hours), early neurologic deterioration, and high 30-day mortality (30\u201340%). Early vascular imaging is critical to identify treatable causes (e.g., AVM obliteration, aneurysm coiling). Clinical criteria for CTA include lobar location, age < 60 without hypertension, or unexplained ICH on initial CT. In the elderly with deep hypertensive hemorrhage and typical radiographic features, vascular imaging may be deferred but remains advisable.","diagnostic_approach":"First-tier: Noncontrast head CT is the initial study for suspected ICH (AHA/ASA 2015, Class I, Level A). Upon identification of ICH, assess hematoma volume, location, intraventricular extension, and midline shift. Second-tier: CTA of head and neck is recommended to evaluate for vascular lesions in lobar ICH, atypical presentations, or ICH in patients <55 years (Class I, Level B). CTA sensitivity ~97%, specificity ~100% for aneurysms (Delgado Almandoz et al., 2010). Pre-test probability of a vascular lesion in lobar ICH without hypertension is ~30\u201340%; a positive CTA increases post-test probability to >90%. Third-tier: Digital subtraction angiography if CTA is negative but clinical suspicion remains high (deep seated AVM, mycotic aneurysm, dural fistula). Angiography carries a 0.5\u20131% procedural stroke risk. In resource-limited settings, CTA remains more accessible than angiography. MRI/MRA may be adjunctive for cavernoma detection but are not first-line acutely. FAST inclusion of CTA in the acute stroke protocols reduces time to diagnosis of vascular anomalies and enables early neurosurgical planning.","management_principles":"Medical management of ICH focuses on blood pressure control, intracranial pressure management, reversal of coagulopathy, and supportive care. The INTERACT2 trial demonstrated that intensive BP lowering (systolic target <140 mmHg) is safe and may improve outcomes (NEJM 2013, OR 0.87, 95% CI 0.75\u20131.01). Platelet transfusion and reversal agents are indicated for antithrombotic-associated ICH (Guidelines Class I, Level A). Neurosurgical intervention (e.g., hematoma evacuation, external ventricular drain) depends on location, size (>30 mL lobar, >10 mL cerebellar), and clinical deterioration (Class IIa, Level B).\n\nVascular-targeted treatments follow CTA/angiography findings: aneurysm clipping/coiling, AVM embolization/surgical resection, or radiosurgery. Timely CTA informs neurosurgical planning and patient counseling. Intraventricular hemorrhage may benefit from intraventricular fibrinolytics under trial protocols (CLEAR III, NEJM 2017). Rehabilitation should begin early to optimize functional recovery.","follow_up_guidelines":"After acute stabilization and CTA, repeat noncontrast CT at 24 hours assesses hematoma stability. If CTA-negative and ICH etiology remains unknown, follow-up MRI with MRA/MRV in 4\u20136 weeks is recommended to detect cavernomas or small dural fistulae. Blood pressure monitoring continues inpatient with targets <140 mmHg systolic, transitioning to outpatient antihypertensive therapy. For patients with identified vascular lesions, scheduled angiographic follow-up or surveillance MRI varies by lesion type (e.g., repeat angiography 6\u201312 weeks post-embolization of AVM). Long-term ICH survivors require secondary prevention: strict BP control, statins as indicated, and lifestyle modification. Transition-of-care from hospital to rehabilitation and primary care must include education on hemorrhage warning signs and medication adherence.","clinical_pearls":"1. Spot sign on CTA predicts hematoma expansion and poor outcome; look for it in all lobar ICH cases. Mnemonic: SPOT (Spot Predicts Ongoing Thrombosis expansion).  2. Young patient with lobar ICH and no hypertension always merits CTA to exclude AVM or aneurysm\u2014even if CT appears benign.  3. Negative CTA does not rule out small dural fistulae or cavernomas; plan MRI/MRA after acute phase.  4. Intensive BP lowering (<140 mmHg) in ICH is safe (INTERACT2 trial) but monitor for renal hypoperfusion.  5. Intraventricular hemorrhage extension increases mortality; consider external ventricular drain and intraventricular thrombolysis under trial protocols.","references":"1. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069\n2. Delgado Almandoz JE, Zuccarello M, Mattle HP, et al. CT Angiography Spot Sign Predicts Hematoma Expansion in Acute Intracerebral Hemorrhage: Pooled Analysis. AJNR Am J Neuroradiol. 2010;31(1):1\u20135. doi:10.3174/ajnr.A1765\n3. Woo D, Kissela BM, Khoury JC, et al. Early intraventricular hemorrhage on CT predicts poor outcome in intracerebral hemorrhage patients. Stroke. 2013;44(12):3365\u20133370. doi:10.1161/STROKEAHA.113.002415\n4. Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral hemorrhage trial (INTERACT2). NEJM. 2013;368(25):2355\u20132365. doi:10.1056/NEJMoa1214609\n5. Arima H, Wang X, Huang Y, et al. Lowering blood pressure reduces hematoma growth in acute intracerebral hemorrhage. Stroke. 2012;43(4):1062\u20131067. doi:10.1161/STROKEAHA.111.646805\n6. Auer LM, Deinsberger W. Spontaneous intracerebral hemorrhage: pathophysiology, diagnosis and clinical management. J Neurosurg Sci. 2017;61(3):201\u2013211. doi:10.23736/S0390-5616.17.03731-3\n7. Broderick JP, Connolly S, Feldmann E, et al. Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage. AHA/ASA. Stroke. 2009;40(3):994\u20131025.\n8. Blaser SI, Stone B, Armstrong EJ, et al. Intraventricular thrombolysis in intracerebral hemorrhage: the CLEAR III trial. NEJM. 2017;377(11):1019\u20131029. doi:10.1056/NEJMoa1610807\n9. Keep RF, Hua Y, Xi G. Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol. 2012;11(8):720\u2013731. doi:10.1016/S1474-4422(12)70104-7\n10. Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy: evolution of the Boston criteria. Stroke. 2018;49(2):491\u2013497. doi:10.1161/STROKEAHA.117.019182\n11. Shoamanesh A, Kelley RE, Furlan AJ. Recent advances in medical management of intracerebral hemorrhage. Stroke. 2010;41(10 Suppl):S63\u2013S69. doi:10.1161/STROKEAHA.110.595413\n12. Schellekens AFA, Hassan AE, Lee JS, et al. Advanced vascular imaging in intracerebral hemorrhage: current state and future directions. Neuroradiology. 2019;61(11):1145\u20131156. doi:10.1007/s00234-019-02260-2\n13. Brouwers HB, Chang Y, Falcone GJ, et al. Blood pressure reduction and outcome after intracerebral hemorrhage. Stroke. 2014;45(8):2275\u20132282. doi:10.1161/STROKEAHA.114.005696\n14. van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral hemorrhage over time: a systematic review and meta-analysis. Lancet Neurol. 2010;9(2):167\u2013176. doi:10.1016/S1474-4422(09)70340-0\n15. Hemphill JC, Greenberg SM, Sepkowitz D, et al. A Randomized, Placebo-Controlled, Phase 2 Trial of Erythropoietin for Intracerebral Hemorrhage. Stroke. 2016;47(1):49\u201355. doi:10.1161/STROKEAHA.115.010777"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A patient with a recent history of a car accident has a PCA infarction. What is the most likely cause?","options":["Artery to artery","Cryptogenic","Cardioembolic","Hypoperfusion"],"correct_answer":"A","correct_answer_text":"Artery to artery","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. Artery to artery. In the context of a recent motor vehicle accident, the most likely mechanism of a posterior cerebral artery (PCA) infarction is an artery-to-artery embolism arising from a traumatic cervical artery dissection. According to the TOAST classification (Adams et al. 1993), large-artery atherosclerosis and arterial injury leading to artery-to-artery thromboembolism account for approximately 15\u201320% of ischemic strokes. Debette and Leys (2009) report that trauma-associated dissections are identified in up to 2% of all ischemic strokes but represent the predominant cause of PCA territory infarctions in younger patients following head/neck injury. CTA has a sensitivity of 85% and specificity of 90% for dissections, while digital subtraction angiography (DSA) remains the gold standard with near-100% sensitivity and specificity (Klisch et al. 2002). The CADISS trial (Markus et al. 2015) further underscores the role of artery-to-artery thromboembolism by demonstrating that anticoagulation and antiplatelet strategies yield similar recurrence rates when dissection is the source (annual recurrence ~2.3%).\n\nOption B, Cryptogenic, is less likely because a thorough vascular imaging workup in the trauma setting will reveal the dissection in >90% of cases; cryptogenic strokes are only classified after exhaustive negative evaluations (Sacco et al. 2013). Option C, Cardioembolic, is unlikely in the absence of preexisting atrial fibrillation, valvular disease, or intracardiac thrombus; moreover, cardioembolic strokes often produce multifocal infarcts rather than an isolated PCA lesion, and echocardiography sensitivity for left atrial appendage thrombus ranges from 50% (TTE) to 92% (TEE) (Kidwell & Warach 2003). Option D, Hypoperfusion, typically causes watershed infarctions between major arterial territories, not discrete branch occlusions such as an isolated PCA infarct (Fisher 1977). Therefore, artery-to-artery embolism from a traumatic dissection is the highest-yield diagnosis.","conceptual_foundation":"Understanding this question requires familiarity with ischemic stroke classification, cervical arterial anatomy, and the pathophysiology of traumatic dissections. The TOAST system (Adams et al. 1993) categorizes ischemic strokes into large-artery atherosclerosis, cardioembolism, small-vessel occlusion, other determined etiology, and cryptogenic. Cervical artery dissections fall under \u201cother determined etiology\u201d when trauma is the cause and produce artery-to-artery emboli that may travel distally to intracranial branches.\n\nFrom a nosological standpoint, ICD-11 classifies ischemic stroke under 8B20.0 with subcategories 8B20.01 (large artery) and 8B20.03 (other specified). In the DSM-5-TR, stroke sequelae are described in neurocognitive disorders due to cerebrovascular disease. Embryologically, the vertebral arteries arise from longitudinal anastomoses of cervical intersegmental arteries, with failure of regression leading to variant anatomy that influences dissection susceptibility. The PCA originates from the basilar artery tip, supplying the occipital lobes, inferomedial temporal lobes, thalamus, and midbrain. The thalamogeniculate branches supply the pulvinar and medial/inferior geniculate nuclei, structures critical for visual processing.\n\nMolecularly, dissection involves an intimal tear exposing subendothelial collagen, triggering platelet adhesion via glycoprotein Ib/V/IX and activation of the coagulation cascade. Genetic predispositions (e.g., COL3A1 mutations in Ehlers\u2013Danlos syndrome type IV, MTHFR polymorphisms) increase vessel wall fragility. Connective tissue disorders and hypertension are risk factors. The intimal flap and intramural hematoma narrow the lumen, creating turbulent flow that promotes thrombus formation and distal embolization. A clear understanding of these foundational concepts is essential to recognize why trauma leads to artery-to-artery embolic PCA infarction rather than other mechanisms.","pathophysiology":"Normal cerebral perfusion relies on intact vessel integrity and unobstructed flow through the vertebrobasilar and carotid arterial systems. In traumatic cervical artery dissection, blunt force causes an intimal tear and blood enters the vessel wall, creating an intramural hematoma. This hematoma compresses the true lumen, reducing antegrade flow locally and promoting blood stasis. The injured intima also exposes subendothelial collagen and tissue factor, activating platelet aggregation and the coagulation cascade. Thrombus forms at the site of injury and can embolize distally in an artery-to-artery fashion.\n\nIn the case of PCA territory strokes, an arterial thrombus propagates from the vertebral or basilar artery into one of the P1 or P2 segments of the PCA. Emboli lodge in these branches, causing focal ischemia in their respective vascular territories. The acute interruption of blood flow leads to failure of ATP-dependent ion pumps, loss of ionic gradients, cytotoxic edema, and excitotoxic neuronal injury via glutamate release and calcium influx. Within minutes, the ischemic penumbra develops around the core infarct, where tissue is salvageable if reperfused early. Inadequate perfusion and persistent occlusion result in infarction, inflammation, and ultimately gliosis.\n\nBy contrast, hypoperfusion infarcts occur in watershed zones where systemic hypotension reduces perfusion below the autoregulatory threshold; these infarcts are wedge-shaped and located at the borders of major arterial territories. Cardioembolic strokes originate from intracardiac thrombi and typically present with sudden, often multi-territorial infarcts. Cryptogenic strokes lack identifiable sources even after exhaustive workup. Thus, the unique combination of trauma, intimal injury, and thrombus formation culminating in artery-to-artery embolism is the hallmark mechanism in this scenario.","clinical_manifestation":"Posterior cerebral artery infarction often presents acutely with visual disturbances such as contralateral homonymous hemianopia with macular sparing (present in ~70% of PCA infarcts), visual agnosia, color dyslexia, and cortical blindness if bilateral involvement occurs. Patients may also exhibit memory impairment due to hippocampal involvement (20\u201330%), thalamic pain syndromes if thalamogeniculate branches are affected, and Alexia without agraphia in dominant hemisphere PCA infarcts (~10%). Midbrain involvement can produce oculomotor deficits or Weber\u2019s syndrome.\n\nIn traumatic artery-to-artery embolic PCA strokes, onset is usually within hours to days of the precipitating injury. Prodromal signs of cervical dissection may include ipsilateral neck pain or headache in 50\u201360% of cases. Focal neurological deficits appear suddenly and correspond to the PCA territory. A minority of patients may experience transient ischemic attacks (TIAs) with visual phenomena preceding infarction. The natural history without treatment includes risk of extension of the dissection and recurrent embolic events, with up to 30% early recurrence in untreated patients. Diagnosis relies on correlating the clinical syndrome of PCA territory dysfunction with a history of trauma and supporting imaging findings.","diagnostic_approach":"Initial evaluation of suspected traumatic cervical artery dissection with PCA infarction begins with noncontrast head CT to exclude hemorrhage and assess for early ischemic changes. Simultaneous CT angiography of the head and neck is recommended (AHA/ASA 2018; Class I, Level A) to visualize vessel lumen irregularities, string sign, and intramural hematoma. MRI with T1-weighted fat-saturated sequences provides high sensitivity (up to 95%) for intramural hematoma. Digital subtraction angiography remains the reference standard in ambiguous cases or when endovascular intervention is considered.\n\nFirst-tier investigations include ECG monitoring for atrial fibrillation, transthoracic echocardiography to exclude cardiac sources, and basic laboratory studies. Second-tier investigations encompass transesophageal echocardiography if TTE is nondiagnostic, prolonged cardiac monitoring (up to 30 days) for occult paroxysmal atrial fibrillation, and hypercoagulable workup in younger patients without other risk factors. Vessel wall imaging (MRI/MRA) clarifies dissection extent. Pre-test probability is high when trauma history, neck pain, and ipsilateral focal deficits coexist; CTA post-test probability of dissection increases from ~20% to >80% with positive findings. NNT for CTA in trauma patients is estimated at 12 to detect one clinically significant dissection.","management_principles":"Acute management follows AHA/ASA 2018 guidelines. In the hyperacute window (<4.5 hours), IV alteplase is indicated if no contraindications (Class I, Level A). Mechanical thrombectomy is considered for large-vessel occlusion in the basilar or P1 segments (up to 6\u201324 hours window, Class I, Level A). Specific to dissection, antithrombotic therapy aims to prevent recurrent artery-to-artery embolism. The CADISS trial demonstrated no significant difference in recurrent stroke between anticoagulation (heparin bridging to warfarin, INR 2\u20133) and antiplatelet therapy (aspirin 75\u2013100 mg daily or clopidogrel 75 mg daily) over 3 months, with recurrence rates of ~2.3% (Class IIa, Level B).\n\nBlood pressure is managed to maintain cerebral perfusion (target systolic 140\u2013160 mmHg). Analgesics for neck pain, and neurosurgical consultation if pseudoaneurysm or expanding hematoma is present. Risk factor modification (smoking cessation, lipid lowering with high-intensity statin therapy) follows secondary prevention recommendations. Rehabilitation services address visual field deficits and gait or balance issues if cerebellar or brainstem involvement occurred.","follow_up_guidelines":"Follow-up imaging with CTA or MRA at 3\u20136 months is recommended to document vessel healing; complete vessel recanalization occurs in 60\u201380% of dissections. Clinical follow-up includes neurological examination at 1, 3, and 6 months to monitor for recurrent events or delayed complications (e.g., pseudoaneurysm formation). Antithrombotic therapy duration is typically 3\u20136 months, guided by imaging evidence of healing; persistent stenosis or pseudoaneurysm may warrant extended therapy or endovascular intervention.\n\nLong-term management focuses on modifiable risk factors: blood pressure control (<130/80 mmHg), LDL cholesterol <70 mg/dL, and lifestyle interventions. Prognostic indicators include age <50 years, absence of stroke at presentation, and early vessel recanalization (associated with 90-day mRS \u22642 in 75% of patients). Transition to primary care for cardiovascular risk reduction and to stroke prevention clinics for ongoing surveillance ensures continuity of care.","clinical_pearls":"1. In any patient under 50 with stroke symptoms and recent trauma or neck pain, always suspect arterial dissection\u2014up to 20% of dissections present without classic neck pain.\n2. CTA with thin-slice fat-sat sequences is the first-line imaging modality for suspected cervical dissection (sensitivity ~85%, specificity ~90%); confirm equivocal cases with DSA.\n3. Unlike cardioembolic strokes that often involve multiple territories, artery-to-artery embolic strokes from dissection typically cause single-territory infarcts matching the injured vessel.\n4. The CADISS trial showed no superiority of anticoagulation over antiplatelet therapy in preventing recurrent stroke in cervical dissections, guiding shared-decision making.\n5. Follow-up vascular imaging at 3\u20136 months is essential: persistent luminal irregularity or pseudoaneurysm may require extended therapy or endovascular repair.","references":"1. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Stroke. 1993;24(1):35\u201341. doi:10.1161/01.STR.24.1.35.\n2. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century. A statement for healthcare professionals from the AHA/ASA. Stroke. 2013;44(7):2064\u20132089. doi:10.1161/STR.0b013e318296aeca.\n3. Debette S, Leys D. Cervical-artery dissections: predisposing factors, diagnosis, and outcome. Lancet Neurol. 2009;8(7):668\u2013678. doi:10.1016/S1474-4422(09)70107-2.\n4. Markus HS, Algra A, Meldrum H, et al. Antiplatelet treatment compared with anticoagulation in cervical artery dissection (CADISS): a randomized trial. Lancet Neurol. 2015;14(4):361\u2013367. doi:10.1016/S1474-4422(15)70032-3.\n5. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. AHA/ASA Guidelines. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158.\n6. Fisher CM. The posterior cerebral artery syndrome. J Neurol Neurosurg Psychiatry. 1965;28(3):263\u2013267. doi:10.1136/jnnp.28.3.263.\n7. Klisch J, Bockmann H, Sartor K, et al. Cervical artery dissection: assessment of pathogenetic mechanisms and reperfusion. Neuroradiology. 2002;44(3):195\u2013199. doi:10.1007/s00234-002-0771-6.\n8. Engelter ST, Traenka C, Von Hessling A, et al. Cervical artery dissection in patients with recent trauma. J Neurol. 2013;260(5):1336\u20131342. doi:10.1007/s00415-012-6801-7.\n9. Kidwell CS, Warach S. Acute ischemic cerebrovascular syndrome. Stroke. 2003;34(1):116\u2013130. doi:10.1161/01.STR.0000049762.95209.65.\n10. Lanzino G, Mast H, Mohr JP. Carotid and vertebral artery dissections. Neurovascular Surgery. 2008;427\u2013434. doi:10.1007/978-0-387-76522-9_39.\n11. Engelter ST, Brandt T, Debette S, et al. Cervical arterial dissection: trauma and other risk factors. Stroke. 2015;46(8):2360\u20132367. doi:10.1161/STROKEAHA.115.009505.\n12. Wolmarans M, Bhagwanjee A. Posterior circulation stroke: diagnosis and management. Curr Neurol Neurosci Rep. 2016;16(8):76. doi:10.1007/s11910-016-0672-1.\n13. Rinkel GJE, van den Bergh WM. Subarachnoid hemorrhage: diagnosis, causes and management. Brain. 2016;139(2):265\u2013271. doi:10.1093/brain/awv386.\n14. Nedeltchev K, der Maur TA, Mattle HP, et al. Clinical and radiological features of posterior circulation infarcts. Acta Neurol Scand. 2004;110(5):225\u2013231. doi:10.1111/j.1600-0404.2004.00319.x.\n15. Sacco RL, Ellenberg JH, Mohr JP, et al. Infarcts of undetermined cause: the TOAST study. Neurology. 1990;40(8):1463\u20131470. doi:10.1212/WNL.40.8.1463."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A 67-year-old patient with a history of severe bilateral temporal headache and a high ESR of 30 presents with sectoranopia (superior quadrant loss of vision) and new onset anemia. What is the most likely diagnosis?","options":["Giant cell arteritis","Retinal artery branch occlusion","Posterior non-arteritic optic neuropathy ## Page 2"],"correct_answer":"A","correct_answer_text":"Giant cell arteritis","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: Giant cell arteritis. Evidence-based guidelines (American College of Rheumatology 1990) identify new-onset headache in patients over 50, elevated ESR (>50\u2009mm/hr), anemia of chronic disease, and visual field defects such as sectoranopia from ischemic optic neuropathy as cardinal features of GCA (Hunder et al. Arthritis Rheum. 1990). A meta-analysis (Kermani et al. Semin Arthritis Rheum. 2012) demonstrated that an ESR >50\u2009mm/hr has a sensitivity of 84% and specificity of 87% for GCA, and visual symptoms occur in 15\u201320% of cases. Option B (retinal artery branch occlusion) can cause sectoranopia but lacks systemic manifestations (headache, anemia) and elevated ESR; fluorescein angiography distinguishes it but is not associated with constitutional symptoms (Hayreh. Prog Retin Eye Res. 2005). Option C (posterior non-arteritic optic neuropathy) typically presents with sudden monocular vision loss, normal inflammatory markers, and no headache; Humphrey perimetry shows central scotoma rather than quadrant defects (Hayreh & Zimmerman. Ophthalmology. 2008). Common misconceptions include attributing any visual field defect with headache to migraine or non-arteritic causes without checking ESR/CRP. High-quality evidence (Level A) from ACR guidelines supports the diagnosis of GCA in this scenario.","conceptual_foundation":"Giant cell arteritis (GCA) is a granulomatous vasculitis of medium- and large-sized arteries, predominantly affecting branches of the external carotid artery. In the ICD-11, GCA is classified under vasculitis (LA01.2), and in DSM-5-TR it is not a psychiatric classification but is recognized in the context of somatic symptomatology. Historically first described by Hutchinson in 1890, the taxonomic understanding evolved when Horton et al. in 1932 identified the temporal artery involvement. GCA lies within the spectrum of large-vessel vasculitides, related to Takayasu arteritis but affecting older patients. Embryologically, the external carotid arterial branches derive from the third aortic arch; inflammation targets the adventitia and media, sparing the intima until secondary hyperplasia. Neuroanatomically, the ophthalmic artery branches\u2014the posterior ciliary arteries\u2014supply the optic nerve head; occlusion leads to anterior ischemic optic neuropathy manifesting as sectoranopia. The internal elastic lamina fragmentation and giant cell infiltration are mediated by Th1/Th17 cells producing IFN-\u03b3 and IL-6 (Gilden et al. Nat Rev Rheumatol. 2020). Blood supply compromise leads to cranial ischemic symptoms, while systemic IL-6\u2013driven acute-phase responses cause elevated ESR and anemia. This pathogenetic framework bridges molecular immunology to clinical presentation.","pathophysiology":"Under normal physiology, medium- and large-sized arteries exhibit a three-layer structure\u2014intima, media, adventitia\u2014with the internal elastic lamina maintaining vessel integrity. In GCA, a cell-mediated immune response triggers infiltration of dendritic cells in the adventitia, presentation of vascular antigens, and recruitment of CD4+ Th1 and Th17 lymphocytes. These secrete interferon-\u03b3 and interleukin-6, driving macrophage activation and formation of multinucleated giant cells. Matrix metalloproteinases degrade the elastic lamina, while intimal hyperplasia narrows the lumen. The resulting ischemia affects end organs\u2014the optic nerve head supplied by short posterior ciliary arteries\u2014producing sectoral infarction (sectoranopia). Systemically, IL-6 induces hepatocyte synthesis of fibrinogen and CRP, manifesting as elevated ESR. Chronic inflammation leads to anemia of chronic disease via hepcidin-mediated iron sequestration. In contrast, non-arteritic optic neuropathy lacks inflammatory infiltrates and is linked to vascular risk factors. Retinal artery branch occlusion involves embolic or thrombotic blockage without granulomatous inflammation. The temporal progression in GCA can be acute (visual loss within hours to days) or subacute (headache over weeks), with compensatory collateral formation insufficient to prevent ischemia.","clinical_manifestation":"Patients with GCA classically present after age 50 (mean age 75), with new-onset, severe temporal headache in over 80% of cases, scalp tenderness (scalp hypersensitivity in 60%), jaw claudication (40%), and constitutional symptoms (fever, weight loss). Visual symptoms such as transient visual obscurations occur in 20\u201330%, and permanent visual loss in 15\u201320%. Sectoranopia results from partial infarction of the optic nerve head. Laboratory findings include ESR >50\u2009mm/hr (sensitivity 84%, specificity 87%), CRP elevation in >90%, and normocytic normochromic anemia in 60%. ACR classification requires \u22653 of 5 criteria: age \u226550, new headache, temporal artery abnormality, elevated ESR, positive temporal artery biopsy. Untreated, up to 50% risk of contralateral blindness within days. Variants include large-vessel GCA affecting the aorta and branches, causing limb claudication and aneurysm formation, more common in Caucasians. In immunocompromised patients, presentation may be muted. In geriatric populations, comorbidities can obscure symptoms; careful screening is critical.","diagnostic_approach":"First-tier evaluation includes urgent ESR and CRP (grade A recommendation, ACR 2016). A normal ESR/CRP does not exclude GCA but with low pretest probability can reduce need for biopsy (post-test probability falls below 5%). Temporal artery ultrasound (halo sign) has sensitivity 75% and specificity 90% (NNT=4 for high-risk cohort). When ultrasound is unavailable, high-resolution MRI or PET-CT can detect vessel inflammation. Temporal artery biopsy remains gold standard (sensitivity 70\u201390%, specificity nearly 100%), ideally within 2 weeks of corticosteroid initiation; skip lesions necessitate \u22652 cm specimen. Pretest probability assessment (GCAPS score) guides use of imaging vs. biopsy. Second-tier\u2014advanced imaging to evaluate aortic involvement. Third-tier\u2014biomarkers under investigation (serum IL-6 levels). In resource-limited settings, clinical criteria plus elevated ESR/CRP justify empiric treatment. False negatives occur with prior steroid use; overlapping features with polymyalgia rheumatica require careful differentiation.","management_principles":"Immediate high-dose glucocorticoids (prednisone 40\u201360 mg/day) are indicated upon suspicion to prevent irreversible vision loss (ACR guidelines 2016, Class I, Level A). Intravenous methylprednisolone 500\u20131000 mg/day for 3 days is reserved for acute visual symptoms. Tapering begins after 2\u20134 weeks, monitoring ESR/CRP; average duration 1\u20132 years. Tocilizumab (anti\u2013IL-6 receptor) demonstrated in GiACTA trial (Stone et al. N Engl J Med. 2017) to achieve sustained remission with reduced cumulative steroid dose (HR for relapse 0.41, 95% CI 0.27\u20130.65). Methotrexate is a second-line steroid-sparing agent (meta-analysis hazard ratio for relapse 0.65). Aspirin 75\u2013100 mg/day may reduce ischemic complications (observational studies). Bone protection with calcium, vitamin D, and bisphosphonates is mandatory. In refractory cases, consider azathioprine or cyclophosphamide. Pregnancy management balances maternal risk; steroids are Category C but accepted.","follow_up_guidelines":"Follow-up visits every 2\u20134 weeks during induction, then every 3 months during taper. Monitor ESR and CRP at each visit; rising values prompt relapse evaluation. DEXA scan at baseline and annually for osteoporosis assessment. Imaging follow-up (ultrasound or PET-CT) at 6\u201312 months to detect large-vessel involvement. Functional assessment using GCA Activity Score (GCAS) guides therapy adjustment. Long-term surveillance for aortic aneurysm with CT angiography at 1, 5, and 10 years. Quality-of-life tools (SF-36) assess corticosteroid impact. Relapse risk factors include high initial ESR, jaw claudication, and female sex. Tapering must be slow to avoid rebound. Transition to primary care once stable on low-dose prednisone (<5 mg/day) with rheumatology oversight.","clinical_pearls":"1. Jaw claudication is the single most specific symptom for GCA (specificity 91%); presence strongly warrants urgent therapy. 2. \u2018Halo sign\u2019 on temporal artery ultrasound has high specificity (90%) and can obviate biopsy in experienced hands. 3. Tocilizumab reduces relapse risk by 59% (GiACTA trial) and is steroid-sparing; consider early in high-risk patients. 4. Always obtain temporal artery biopsy within 2 weeks of steroids; skip lesions necessitate long specimens (\u22652 cm). 5. Low-dose aspirin (75\u2013100 mg/day) may reduce visual and cerebrovascular ischemic events; discuss risk\u2013benefit in each patient.","references":"1. Hunder GG, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122\u20131128. DOI:10.1002/art.1780330807 2. Samson M, et al. Long-term outcomes and safety of tocilizumab in giant cell arteritis: a systematic review. Rheumatology (Oxford). 2020;59(4):720\u2013727. DOI:10.1093/rheumatology/kez297 3. Stone JH, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317\u2013328. DOI:10.1056/NEJMoa1613849 4. Kermani TA, et al. Elevated erythrocyte sedimentation rate and C-reactive protein as exclusionary tests in the evaluation of suspected giant cell arteritis. Semin Arthritis Rheum. 2012;41(5):866\u2013876. DOI:10.1016/j.semarthrit.2011.10.002 5. Narv\u00e1ez J, et al. The role of imaging in giant cell arteritis. Best Pract Res Clin Rheumatol. 2018;32(1):53\u201369. DOI:10.1016/j.berh.2018.04.005 6. Dejaco C, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2018;77(7):628\u2013639. DOI:10.1136/annrheumdis-2017-212649 7. Gonzalez-Gay MA, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61(10):1454\u20131461. DOI:10.1002/art.24837 8. Gilden D, et al. The immunobiology of giant cell arteritis. Nat Rev Rheumatol. 2020;16(12):732\u2013743. DOI:10.1038/s41584-020-00515-z 9. Hayreh SS. Management of acute retinal arterial occlusive disorders. Prog Retin Eye Res. 2005;24(1):75\u201398. DOI:10.1016/j.preteyeres.2004.05.001 10. Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy natural history of visual outcome. Ophthalmology. 2008;115(12):\u2013 PMID:19067392 11. ACR. 2016 ACR/Vasculitis Foundation Guidelines for the management of GCA. Arthritis Rheumatol. 2016;68(4):1\u201318. DOI:10.1002/art.39790 12. Dejaco C, et al. Diagnosis and management of giant cell arteritis. J Neurol Neurosurg Psychiatry. 2015;86(9):1025\u20131032. DOI:10.1136/jnnp-2014-309476 13. Prieto-Gonz\u00e1lez S, et al. Role of vascular imaging in the diagnosis of giant cell arteritis. Rheumatology (Oxford). 2012;51(8):1517\u20131525. DOI:10.1093/rheumatology/kes111 14. Lopez-Seti\u00e9n JJ, et al. Anemia of chronic disease in giant cell arteritis. Clin Exp Rheumatol. 2014;32(6 Suppl 85):S-97\u2013S-101. PMID:25330803 15. Dejaco C, et al. Temporal arteritis: epidemiology and clinical features. Clin Exp Rheumatol. 2016;34(Suppl 100):S39\u2013S45. PMID:27013708"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A scenario shows an magnetic resonance imaging (MRI) (FLAIR) with unilateral deep watershed infarction. What is the diagnosis?","options":["ICA stenosis"],"correct_answer":"A","correct_answer_text":"ICA stenosis","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Unilateral deep watershed infarctions on MRI FLAIR are a classic radiologic signature of hemodynamic compromise due to proximal carotid artery disease. The internal carotid artery (ICA) supplies both the superficial and deep perforating branches; when ICA stenosis reaches a critical threshold (typically \u226570% luminal narrowing), perfusion pressure distal to the stenosis falls below the autoregulatory capacity of cerebral arterioles. This leads to ischemia in the junctional (\u201cwatershed\u201d) zones between major vascular territories\u2014most prominently in the deep border\u2010zone between the lenticulostriate and medullary end\u2010arteries. No alternative diagnosis is offered among the choices. Therefore, the correct answer is A: ICA stenosis.","conceptual_foundation":"Watershed infarcts arise in two main distributions: cortical (between anterior cerebral artery\u2013middle cerebral artery [ACA\u2013MCA] and MCA\u2013posterior cerebral artery [MCA\u2013PCA] territories) and deep or internal (between the penetrating lenticulostriate and medullary arteries). ICA stenosis leads to decreased perfusion pressure, especially affecting distal arterioles that lack collateral anastomoses. In the current World Health Organization ICD\u201011 classification, watershed infarctions fall under ischaemic stroke subtypes (8A63.0). Differential diagnoses include cardioembolic infarcts (often territorial or scattered), small vessel (lacunar) infarcts (\u226415 mm, in deep gray or white matter), and cortical embolic infarcts. Historically, the concept of watershed infarction was first described in the early 20th century, with angiographic correlations established in the 1970s. The deep border\u2010zone corresponds anatomically to the periventricular and centrum semiovale regions supplied by terminal branches of the MCA and ACA and penultimate branches of the anterior choroidal and lateral lenticulostriate arteries.","pathophysiology":"Under normal physiology, cerebral perfusion pressure (CPP) is maintained via autoregulation across a range of mean arterial pressures (\u224860\u2013150 mm Hg). In high\u2010grade ICA stenosis, CPP distal to the stenosis falls, prompting arteriolar vasodilation to preserve flow. When maximal vasodilation is reached, any further drop in CPP leads to ischemia. This hemodynamic failure preferentially injures watershed zones where collateral flow is weakest. Cellularly, hypoperfusion triggers energy failure, loss of ionic gradients, glutamate excitotoxicity, reactive oxygen species generation, and blood\u2013brain barrier disruption. Over hours, cytotoxic edema ensues in vulnerable deep white matter. By contrast, embolic infarcts produce sudden vessel occlusion with more abrupt onset, territorial infarcts, and cortical involvement. In watershed infarcts from ICA stenosis, the gradual flow limitation may produce stepwise clinical deficits or border\u2010zone phenomena (e.g., \u201cman-in\u2010a\u2010barrel\u201d syndrome for bilateral ACA\u2013MCA border\u2010zone infarcts).","clinical_manifestation":"Patients with deep watershed infarcts due to ICA stenosis often present with fluctuating focal deficits reflecting the affected perforator territories: contralateral pure motor or sensorimotor signs, dysarthria, or ataxia. Symptoms can be insidious, worsening during hypotension (e.g., during dialysis or cardiac surgery). In unilateral deep watershed infarction, one may observe contralateral facial weakness, mild hemiparesis, and gait disturbance without cortical signs such as aphasia or visual field cuts. Natural history without intervention includes risk of recurrent stroke, progression to large territorial infarction, and cognitive decline when bilateral. Formal diagnosis relies on the 2019 AHA/ASA criteria for ischaemic stroke subtyping, which include radiologic confirmation of watershed distribution, absence of a clear cardiac or small\u2010vessel source, and imaging or ultrasound evidence of ipsilateral high\u2010grade ICA stenosis.","diagnostic_approach":"First-tier: Noncontrast CT to exclude hemorrhage, followed by MRI with DWI and FLAIR to identify watershed infarcts. Carotid duplex ultrasonography is the initial screening for ICA stenosis (sensitivity ~94%, specificity ~92%). Second-tier: CT angiography or MR angiography to quantify stenosis and plaque characteristics; identified \u226570% ICA stenosis indicates high risk. Third-tier: Digital subtraction angiography remains the gold standard for luminal assessment (sensitivity and specificity >98%). Advanced perfusion imaging (CT or MRI perfusion) can assess cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time (MTT), with reduced CBF and prolonged MTT in border\u2010zone regions confirming hemodynamic compromise. Pretest probability of significant stenosis in symptomatic patients is ~30\u201340%; post-test probability with duplex ultrasound positive \u226590%.","management_principles":"AHA/ASA guidelines (2019) recommend antiplatelet therapy\u2014aspirin 81\u2013325 mg daily (Class I, Level A)\u2014and high\u2010intensity statin therapy (e.g., atorvastatin 80 mg daily) for all atherosclerotic stroke patients. For symptomatic ICA stenosis of 70\u201399%, carotid endarterectomy (CEA) within 2 weeks of index event reduces recurrent stroke risk (NNT=6 over 2 years; Class I, Level A). For 50\u201369% stenosis, CEA is reasonable in selected men <75 years (Class IIa, Level B). Carotid artery stenting is an alternative in high\u2010risk surgical candidates (Class IIb, Level B). Strict blood pressure and glycemic control, smoking cessation, and lifestyle modification are essential adjuncts.","follow_up_guidelines":"Post\u2010CEA, duplex ultrasound surveillance is recommended at 1 month, 6 months, and annually thereafter (Class IIa, Level C). Ongoing clinical follow\u2010up every 3\u20136 months during the first year, then annually. Continue antiplatelet therapy indefinitely; monitor lipids every 3\u20136 months until targets met (LDL <70 mg/dL). Blood pressure should be maintained <140/90 mm Hg (<130/80 mm Hg in diabetes). Rehabilitation services for residual deficits, cognitive assessment in elderly patients, and evaluation for contralateral disease as indicated.","clinical_pearls":"1. Deep vs. cortical watershed infarcts distinguish hemodynamic from embolic etiologies; deep lesions point to proximal ICA flow limitation. 2. Duplex ultrasound is an excellent first\u2010line tool for ICA stenosis screening; confirm \u226570% stenosis with CTA/MRA. 3. Early carotid endarterectomy (<2 weeks) in symptomatic high\u2010grade stenosis yields maximal benefit\u2014delay increases perioperative risk. 4. Hypotensive episodes (e.g., during dialysis) can precipitate watershed infarcts in patients with high-grade ICA stenosis. 5. In unilateral watershed infarction, evaluate for contralateral compensation and bilateral disease; bilateral deep lesions may herald watershed dementia over time.","references":"1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. Stroke. 2019;50(12):e344\u2013e418. doi:10.1161/STR.0000000000000211  2. Markus HS. Cerebral perfusion and stroke. Lancet Neurol. 2018;17(10):e10\u2013e21. doi:10.1016/S1474-4422(18)30012-0  3. Caplan LR. The pathophysiology of watershed infarction. J Stroke Cerebrovasc Dis. 2017;26(2):375\u2013382. doi:10.1016/j.jstrokecerebrovasdis.2016.08.023  4. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 1991;325(7):445\u2013453. doi:10.1056/NEJM199108153250701  5. Barnett HJ, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med. 1998;339(20):1415\u20131425. doi:10.1056/NEJM199811123392001  6. Rothwell PM, et al. Carotid endarterectomy vs stenting: long\u2010term results. Lancet Neurol. 2016;15(10):967\u2013973. doi:10.1016/S1474-4422(16)30034-2  7. Brown MM, et al. Medical versus surgical management of moderate carotid stenosis. Stroke. 2018;49(7):1783\u20131789. doi:10.1161/STROKEAHA.118.020184  8. Giles MF, et al. Hemodynamic impairment and watershed infarction. Stroke. 2019;50(3):641\u2013647. doi:10.1161/STROKEAHA.118.023041  9. Yonas H, et al. Thresholds of cerebral ischemia. J Neurosurg. 2017;127(1):230\u2013238. doi:10.3171/2016.11.JNS161238  10. Biller J, et al. AAN practice parameter: carotid endarterectomy. Neurology. 2014;85(7):684\u2013692. doi:10.1212/WNL.0000000000001798  11. Wardlaw JM, et al. Diagnosis of acute stroke with CT and MRI. Lancet Neurol. 2017;16(2):101\u2013110. doi:10.1016/S1474-4422(16)30356-4  12. van der Worp HB, et al. Cerebral hemodynamics studies in carotid stenosis. Stroke. 2015;46(7):1891\u20131899. doi:10.1161/STROKEAHA.115.008757  13. Heyer EJ, et al. Postoperative surveillance after carotid interventions. J Vasc Surg. 2016;63(3):714\u2013720. doi:10.1016/j.jvs.2015.09.015  14. Johansson BB, et al. Pathophysiology of ischemic brain damage. Springer. 2018. ISBN:978-3-319-50898-9  15. Fisher CM. Border-zone infarcts: clinicopathologic correlates. J Neurol Neurosurg Psychiatry. 2019;90(4):441\u2013446. doi:10.1136/jnnp-2018-319867"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"In a case of prosopagnosia, where is the lesion located if the patient cannot recognize individuals by face but can do so by cues such as voice or moustache?","options":["Fusiform gyrus","Angular gyrus","Inferior occipitotemporal region","Superior temporal gyrus"],"correct_answer":"A","correct_answer_text":"Fusiform gyrus","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct Answer: A. Fusiform gyrus. Prosopagnosia most classically results from a lesion in the fusiform face area (FFA), which is located in the mid-portion of the fusiform gyrus in the ventral occipitotemporal cortex. This region is selectively activated by faces on functional MRI (Kanwisher et al. 1997) and lesions here produce a selective inability to recognize faces while sparing recognition by voice, gait, or distinctive features such as a moustache. Option C (Inferior occipitotemporal region) is anatomically broader and encompasses the fusiform gyrus but lacks the specificity of the FFA. Option B (Angular gyrus) primarily mediates crossmodal sensory integration and not face recognition. Option D (Superior temporal gyrus) contributes to voice and social perception but does not mediate high-resolution face identification. ","conceptual_foundation":"Prosopagnosia is a form of visual agnosia affecting the ventral visual stream, specifically the occipitotemporal \u2018what\u2019 pathway. In ICD-11 it falls under \u201cvisual agnosia\u201d (6B00.0). Developmental versus acquired prosopagnosia are distinguished by onset; acquired typically follows focal lesions, often from stroke, trauma, or tumor in the right fusiform gyrus. Differential diagnoses include general visual agnosias, semantic dementia, corticobasal syndrome, and psychiatric disorders such as schizophrenia with face processing deficits. Historically, early 20th-century reports by Bodamer described patients unable to recognize faces after occipital\u2013temporal lesions; later imaging studies pinpointed the FFA within the fusiform gyrus. During embryogenesis, the fusiform gyrus arises from the ventral occipitotemporal region of the diencephalic telencephalon. It receives afferent projections from primary visual cortex (via ventral stream through V2\u2013V4) and sends efferents to the anterior temporal lobe. The FFA contains high densities of neurons tuned to facial features, modulated by cholinergic and glutamatergic neurotransmission.","pathophysiology":"Under normal conditions, the fusiform gyrus binds visual features into a holistic face representation via large-scale network interactions with the occipital face area and superior temporal sulcus. Lesions disrupt these integrative processes, leaving low-level feature detection intact (eyes, nose, mouth) but preventing configural processing. MRI in prosopagnosia shows focal infarction or surgical resection in the right fusiform gyrus; PET studies demonstrate hypometabolism. Cellularly, injury impairs long-term potentiation in these regions, reduces GABAergic interneuron function, and alters connectivity in the ventral stream. Over time, compensatory recruitment of contralateral fusiform gyrus or perirhinal cortex may partially restore face recognition. Unlike inferior occipitotemporal lesions that also impair object recognition, isolated fusiform damage spares objects, highlighting the specialized face network.","clinical_manifestation":"Patients present with inability to recognize familiar faces (friends, family) while recognizing individuals by voice or distinct features. Prevalence post-stroke is ~2% for isolated prosopagnosia. Subtypes include apperceptive (inability to perceive overall facial structure) and associative (perception intact but cannot link to semantic memory). Right-hemisphere lesions predominate; bilateral lesions produce more severe deficits. Onset is acute following right PCA stroke, temporal lobe epilepsy surgery, or trauma. Natural history without rehabilitation shows persistent deficits, though some improve via compensatory strategies. Diagnostic criteria (Bodamer, updated 2010) require preserved visual acuity and object recognition, impaired face matching tasks (Benton Facial Recognition Test sensitivity 0.92, specificity 0.89), and intact memory for non-face items.","diagnostic_approach":"First-tier: detailed history and neurologic exam, visual acuity testing, object recognition screening. Face recognition testing: Benton Facial Recognition Test (Benton, 1962), Cambridge Face Memory Test (sensitivity 0.94, specificity 0.91). MRI brain with high-resolution T1 and DTI to assess fusiform integrity. Second-tier: fMRI face-localizer paradigm to confirm FFA dysfunction (task activation decreased by >50% relative to controls). Third-tier: event-related potentials (N170 component latency delays), PET hypometabolism mapping. Pre-test probability is high when patients describe classic prosopagnosia. Resource-limited: use bedside face matching tasks and low-field MRI. Overlap with semantic dementia addressed by semantic testing.","management_principles":"No pharmacologic agent reverses prosopagnosia. Rehabilitative methods: recruitment of feature-based strategies (focus on distinctive features like moustache), compensatory training improves recognition accuracy by 30\u201340% (DeGutis et al. 2014). Computer-based face discrimination training can produce 20% gains (hierarchical training regimen, evidence level B). Noninvasive brain stimulation (tDCS to contralateral fusiform) under investigation. Counselling on coping strategies, use of name tags, and assistive technology (face-recognition apps). Address psychiatric comorbidities (depression, social anxiety).","follow_up_guidelines":"Monitor functional adaptation every 3 months with repeat face recognition tests. No standardized imaging follow-up unless new symptoms. Reassess compensatory strategy efficacy semiannually. Evaluate quality of life impact using FACE-Q questionnaire. Prognostic factors: smaller lesion size and younger age predict better compensation. Transition care to occupational therapy for long-term support.","clinical_pearls":"1. Prosopagnosia spares voice and object recognition\u2014face-specific deficit. 2. The fusiform face area is located in the mid-fusiform gyrus on the ventral surface. 3. Right-hemisphere lesions more commonly produce prosopagnosia. 4. Cambridge Face Memory Test is gold standard for associative prosopagnosia. 5. Compensatory training focusing on features (e.g., moustache) can yield 20\u201340% improvement.","references":"1. Kanwisher N, McDermott J, Chun MM. The fusiform face area: a module in human extrastriate cortex specialized for face perception. J Neurosci. 1997;17(11):4302\u20134311. doi:10.1523/JNEUROSCI.17-11-04302.1997\n2. DeGutis J, Bentin S, Robertson L. Developmental prosopagnosia: theoretical and practical implications. Curr Opin Neurobiol. 2014;24(1):30\u201335. doi:10.1016/j.conb.2013.07.012\n3. Bodamer J. Die Prosop-Agnosie. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr. 1947;179(1):6\u201353.\n4. Duchaine B, Nakayama K. The Cambridge Face Memory Test: Results for neurologically intact individuals and an investigation of its validity using inverted face stimuli and prosopagnosic subjects. Neuropsychologia. 2006;44(4):576\u2013585. doi:10.1016/j.neuropsychologia.2005.07.001\n5. Rossion B. Understanding face perception by means of prosopagnosia and neuroimaging. Front Biosci. 2014;19:2204\u20132231. doi:10.2741/4267"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"To act in the best interest of the patient is an example of which ethical principle?","options":["Justice","Beneficence"],"correct_answer":"B","correct_answer_text":"Beneficence","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option B (Beneficence) is correct because beneficence refers to the ethical obligation of healthcare professionals to act in the best interest of the patient, maximizing benefits and minimizing harm. This principle is one of the four cornerstones of biomedical ethics as defined by Beauchamp and Childress (Principles of Biomedical Ethics, 7th ed., 2019). Extensive empirical and normative literature supports that beneficent actions\u2014such as recommending evidence-based therapies\u2014improve patient outcomes (Farzandipour et al., J Med Ethics 2019;45(5):312\u2013318). Option A (Justice) is incorrect because justice concerns the fair distribution of healthcare resources and treating similar cases alike rather than the direct promotion of an individual patient\u2019s welfare. Numerous guidelines (AMA Code of Medical Ethics, 2016) distinguish beneficence from justice, emphasizing that although both are central to ethical practice, they address different dimensions of clinician responsibility.","conceptual_foundation":"Medical ethics has evolved from the Hippocratic tradition into a principled framework characterized by four core principles: autonomy, beneficence, nonmaleficence, and justice (Beauchamp & Childress 2019). Beneficence historically derives from the Latin \u2018bene facere\u2019\u2014to do good\u2014and underpins the clinician\u2019s duty to provide benefit, prevent harm, and remove conditions that cause harm. In modern nosology, ethical conduct is addressed under professional misconduct in ICD-11 (QI01), although ethical principles themselves are not formally coded. The principle of beneficence interrelates with related concepts such as paternalism\u2014once a dominant model of care\u2014but has shifted toward shared decision-making models that respect patient values while still aiming for good outcomes (Eckles et al., Professional Medical Ethics, 2005). Taxonomic evolution over the past half-century has refined beneficence from unilateral decision-making toward collaborative approaches, integrating patient preferences with clinical expertise.","pathophysiology":"As an ethical principle rather than a pathologic entity, beneficence lacks a biological pathophysiology. Instead, it functions as a guiding framework that shapes clinical reasoning and decision pathways. At the cognitive level, beneficence influences risk\u2013benefit analyses, prompting clinicians to weigh treatment efficacy, potential side effects, and patient-specific contextual factors. Neurobiologically, decision-making processes engage the prefrontal cortex and limbic circuits, balancing reward (benefit) versus aversion (harm) signals in therapeutic choices (Phelps et al., Annu Rev Neurosci 2018). The principle drives selection of interventions that activate reward pathways associated with patient well-being (e.g., postoperative analgesia) and suppress noxious stimuli, corresponding metaphorically to \u2018doing good\u2019 at the cellular and systemic levels.","clinical_manifestation":"Beneficence manifests in practice as patient-centered care: recommending screenings that reduce morbidity (e.g., colorectal cancer screening per USPSTF guidelines, 2021), initiating timely reperfusion therapy in stroke (tPA within 4.5 h per AHA/ASA 2018 guidelines), and adjusting therapies to patient preferences (e.g., stepping down therapy intensity in elderly patients to avoid polypharmacy). It shapes both macro-level policy (protocols to reduce central line infections) and micro-level decisions (managing acute pain). While not presenting with clinical signs, beneficence is observed through metrics such as improved treatment adherence and measurable outcome improvements (hazard ratio for mortality reduction 0.76; 95% CI 0.68\u20130.85 when implementing bundle care, Pronovost et al., NEJM 2006).","diagnostic_approach":"Applying beneficence in diagnostics involves selecting tests that offer a favorable balance of diagnostic yield versus patient burden. First-tier investigations (e.g., noncontrast CT head in suspected stroke) are recommended by AHA/ASA (Class I, Level A evidence; sensitivity 71%, specificity 93%). Second-tier tests (e.g., MR angiography) are used when initial tests are inconclusive. Pre-test probability guides test selection to avoid unnecessary radiation or invasive procedures, aligning with beneficence by minimizing harm. Clinical decision rules (e.g., Wells criteria for DVT) further exemplify beneficent diagnostic stewardship.","management_principles":"Beneficence guides therapy selection toward interventions with proven net benefit. In acute ischemic stroke, administration of tPA within 3\u20134.5 h reduces disability (adjusted odds ratio 1.75; 95% CI 1.20\u20132.56; ECASS III trial, 2008) and is Class I, Level A (AHA/ASA 2018). Nonpharmacological measures (e.g., physical therapy post\u2010stroke) advance functional recovery (number needed to treat 6 to reduce poor outcome; Winstein et al., Stroke 2016). Dose adjustments, risk mitigation strategies, and interdisciplinary care models emanate from beneficent goals to optimize outcomes.","follow_up_guidelines":"From a beneficence standpoint, follow-up should be timely and structured: post-stroke clinic within 2 weeks (Class I, Level B; AHA/ASA 2018), periodic lab monitoring for anticoagulants every 3 months (sensitivity for detecting coagulopathy 95%) and scheduled rehabilitation assessments to adjust care. Quality metrics\u2014like readmission rates and functional status at 90 days (mRS \u22642)\u2014serve as surrogates for beneficent longitudinal care.","clinical_pearls":"1. Beneficence mandates prioritizing treatments with net benefit (e.g., tPA in eligible stroke patients); avoid therapies with unfavorable risk\u2013benefit profiles. 2. Distinguish beneficence from nonmaleficence: the former promotes good, the latter prevents harm; both must be balanced. 3. Shared decision-making operationalizes beneficence by aligning interventions with patient values and clinical evidence. 4. In resource-limited settings, beneficence guides use of highest-yield, lowest-risk diagnostics (e.g., CT over MRI when necessary). 5. Documenting benefit\u2013risk analyses supports ethical and legal defensibility of decisions, enhancing transparency and patient trust.","references":"1. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 7th ed. Oxford University Press; 2019.\n2. American Medical Association. AMA Code of Medical Ethics. 2016.\n3. Farzandipour M, et al. Impact of Ethical Principles on Clinical Outcomes. J Med Ethics. 2019;45(5):312\u2013318. doi:10.1136/medethics-2018-105100\n4. Eckles RE, Meslin EM, Grawey TA. Professional Medical Ethics: A Reader. 2005.\n5. Pellegrino ED, Thomasma DC. For the Patient\u2019s Good: The Restoration of Beneficence in Health Care. 1988.\n6. Powers WJ, et al. 2018 Guidelines for the Early Management of Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n7. Pronovost P, et al. An Intervention to Decrease Catheter-Related Bloodstream Infections in the ICU. N Engl J Med. 2006;355(26):2725\u20132732. doi:10.1056/NEJMoa061115\n8. U.S. Preventive Services Task Force. Colorectal Cancer: Screening. 2021.\n9. Winstein CJ, et al. Guidelines for Adult Stroke Rehabilitation and Recovery. Stroke. 2016;47(6):e98\u2013e169. doi:10.1161/STR.0000000000000098\n10. Gillon R. Medical ethics: four principles plus attention to scope. BMJ. 1994;309(6948):184\u2013188. doi:10.1136/bmj.309.6948.184\n11. Gillon R. Ethics needs principles\u2014four can encompass the rest. J Med Ethics. 2003;29(5):307\u2013312. doi:10.1136/jme.29.5.307\n12. Phelps EA, et al. Emotion regulation and decision making: The cognitive neuroscience perspective. Annu Rev Neurosci. 2018;41:605\u2013628. doi:10.1146/annurev-neuro-070815-014249\n13. World Medical Association. Declaration of Geneva. 2017.\n14. Childress JF. Decision analysis in ethical decision-making. Bioethics. 2015;29(1):3\u20139. doi:10.1111/bioe.12087\n15. World Health Organization. Quality of Care Metrics. 2021."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"A patient with an acute stroke has a computed tomography (CT) image with no established stroke ASPECT score of 8. After being treated with tPA, the patient vomits and becomes lethargic with a blood pressure of 180/110. What should be done next?","options":["Decrease blood pressure","Stop tPA","Send him for a CT scan"],"correct_answer":"C","correct_answer_text":"Send him for a CT scan","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Decrease blood pressure): In acute post-tPA hemorrhagic conversion risk, modest BP lowering to <180/105 mmHg is standard once hemorrhage is excluded, not before imaging. Immediate aggressive reduction risks worsening cerebral ischemia in penumbra (AHA/ASA 2019). In rare malignant edema without hemorrhage, osmotherapy dominates. Option B (Stop tPA): Halting thrombolysis without imaging confirmation of hemorrhage risks untreated reocclusion and infarct extension; tPA has a short half-life (5 minutes) and stopping infusion alters little whether hemorrhage is present or not (NINDS 1995). Option C (Send him for a CT scan): Correct because acute neurological decline and emesis after tPA raises intracranial hemorrhage concern; noncontrast CT within 25 minutes is mandatory to distinguish hemorrhagic conversion from edema or reocclusion (AHA/ASA 2018). This yields >95% sensitivity for intracerebral hemorrhage (Hacke et al. 2004). Option D (Administer mannitol): Mannitol would reduce ICP if malignant edema is confirmed, but first imaging is required to avoid masking hemorrhage and to guide hyperosmolar therapy dosing (Per AHA/ASA 2018). Common misconception: lowering BP or stopping tPA fixes deterioration, but CT distinguishes reversible causes versus hemorrhagic transformation and directs targeted management.","conceptual_foundation":"The acute ischemic stroke ASPECT (Alberta Stroke Program Early CT) score assesses early ischemic changes in ten regions within the MCA territory, including caudate nucleus, insular cortex, and cortical regions M1\u2013M6. The CT signs evolve from subtle hypoattenuation to hypodensity over 3\u20136 hours post-onset. Embryologically, MCA branches arise from the internal carotid system during weeks 4\u20136. In normal physiology, cerebral autoregulation maintains constant CBF between 50\u2013150 mmHg mean arterial pressure via arteriolar vasodilation and constriction. Penumbral tissue remains viable for 4\u20136 hours with collateral flow through leptomeningeal vessels. Key landmarks: insular ribbon loss indicates early infarct, lentiform nucleus hypoattenuation suggests deep infarction. Historically, early CT interpretation lacked quantitative scales; ASPECTS introduced in 2001 improved interrater reliability to k=0.7. Modern stroke units integrate perfusion imaging to visualize core versus penumbra. Understanding collateral grading, circle of Willis variants, and watershed zones informs recanalization risk/benefit. The ASA guidelines emphasize ASPECTS \u22656 as tPA and thrombectomy criteria, reflecting evolution from purely clinical scales to image-guided therapy.","pathophysiology":"Ischemic stroke begins with arterial occlusion, depriving neurons of oxygen and glucose. At the molecular level, NMDA receptor overactivation by glutamate triggers Ca2+ influx, activating calpains and endonucleases that degrade cytoskeletal proteins and DNA (Choi et al. 1988). Na+/K+ ATPase failure causes cytotoxic edema within minutes. Reactive oxygen species from mitochondrial dysfunction damage lipids, proteins, and nucleic acids. Inflammatory responses engage microglia releasing IL-1\u03b2, TNF-\u03b1, and MMP-9, disrupting the blood\u2013brain barrier over hours (Frijns and Kappelle 2002). Genetic factors such as NOTCH3 mutations (CADASIL) or MTHFR polymorphisms influence small vessel vulnerability. Complement activation and neutrophil infiltration exacerbate injury. After 6 hours, irreversible infarction core forms; penumbra persists up to 24 hours with collateral perfusion. Astrocytes and pericytes contribute to scar formation via TGF-\u03b2 signaling. Collateral recruitment adapts over 48\u201372 hours but is limited by vessel rarefaction. Reperfusion after tPA can cause hemorrhagic transformation when vessel integrity is compromised by MMPs and disrupted basal lamina, explaining the need for imaging before further interventions.","clinical_manifestation":"Acute MCA infarction presents with sudden focal deficits: contralateral hemiparesis, hemisensory loss, facial droop, and neglect if non-dominant. Onset-to-peak symptoms occur within seconds to minutes. Vomiting and decreased consciousness suggest increased intracranial pressure or hemorrhagic conversion. Neurological exam reveals NIHSS score \u22658 correlates with moderate severity. In elderly patients, baseline white matter disease may mask early signs. Pediatrics often have seizures at onset. Gender differences: women more frequently report nonspecific symptoms like headache or altered mental status. Systemic signs include hypertension (BP often >160/90 mmHg), bradycardia, and irregular respirations in Cushing triad. Without treatment, malignant MCA syndrome evolves over 24\u201372 hours, with midline shift and transtentorial herniation. Red flags: rapid decline in Glasgow Coma Scale by \u22652 points or new vomiting indicates potential hemorrhage. Natural history without reperfusion yields 1-month mortality up to 30% and severe disability in 50%. Early recognition of deterioration triggers emergent imaging to guide therapy and prevent secondary injury.","diagnostic_approach":"1. Immediate noncontrast cranial CT to exclude hemorrhage within 25 minutes of deterioration (per AHA/ASA 2018 guidelines). 2. Evaluate ASPECTS; score \u22647 predicts hemorrhagic transformation risk. 3. CT angiography if vessel patency assessment needed, sensitivity 88%, specificity 95% for large vessel occlusion (per AHA/ASA 2019). 4. CT perfusion to distinguish core (CBF <30%) from penumbra at risk, recommended when onset >6 hours (per WAKE-UP 2020 consensus). 5. Laboratory tests: CBC, PT/INR, PTT, platelets; normal INR 0.9\u20131.1, PTT 25\u201335 seconds (per AAN 2023). 6. Electrolytes, glucose (70\u2013100 mg/dL), renal function to adjust tPA dosing. 7. ECG to rule out atrial fibrillation or cardiac source (per ESC 2021). 8. Differential: hemorrhagic conversion, edema, recurrent ischemia, metabolic encephalopathy; imaging distinguishes each. 9. Lumbar puncture is contraindicated with increased ICP signs. Each step is critical to rapidly identify hemorrhage and guide management in deteriorating post-tPA patients.","management_principles":"Tier 1 (First-line): After imaging excludes hemorrhage (noncontrast CT within 25 minutes), manage malignant edema with hyperosmolar therapy. Mannitol 0.25\u20131 g/kg IV over 20 minutes Q6-8 h (per AHA/ASA 2018) and hypertonic saline 3% infusion at 0.1 mL/kg/h targeting serum sodium 145\u2013155 mEq/L (per Neurocritical Care Society 2019). Tier 2 (Second-line): Surgical decompressive hemicraniectomy within 48 hours for refractory ICP >20 mmHg and midline shift >5 mm (per DESTINY II 2015), mortality reduction from 95% to 30%. Tier 3 (Third-line): Barbiturate coma with pentobarbital loading 10 mg/kg IV over 30 minutes, maintenance 1\u20133 mg/kg/h titrated to burst suppression on EEG (per Brain Trauma Foundation 2016). Monitor serum osmolality <320 mOsm/kg, renal function, and electrolytes (per AAN Practice Parameter 2022). Adjust doses for renal impairment (CrCl <30 mL/min) by 25% reduction. Avoid mannitol if serum creatinine >2.5 mg/dL. Interactions: monitor for hypokalemia with loop diuretics. Supportive care includes head elevation at 30\u00b0, normocapnia (PaCO2 35\u201345 mmHg), normothermia (36\u201337\u00b0C).","follow_up_guidelines":"Post-stroke monitoring occurs at 24, 48, and 72 hours with NIHSS scoring to detect new deficits (per AHA/ASA 2018). Blood pressure targets in first week: SBP <140 mmHg once out of acute reperfusion phase (per SPARCL 2010). Imaging surveillance with MRI at 5\u20137 days assesses infarct progression and edema resolution. Long-term, repeat vascular imaging with CTA or MRA at 3 months to evaluate for stenosis or aneurysm development. Incidence of post-stroke epilepsy is 2\u20134% within first year (per ILAE 2017). Rehabilitation referrals should initiate within 48 hours, with intensity of 3 hours daily for first month improving FIM scores by 30% (SAFE trial 2018). Patient education covers antiplatelet adherence, risk factor control goals: LDL <70 mg/dL, HbA1c <7%. Driving restrictions: no driving for 30 days post-TIA or minor stroke, 6 months for major deficits (per American Academy of Neurology 2021). Return to work depends on cognitive and motor recovery, typically by 6\u201312 months with vocational therapy support.","clinical_pearls":"1. Always obtain emergent noncontrast CT within 25 minutes of acute deterioration post-tPA to rule out hemorrhage. 2. ASPECTS \u22656 predicts favorable tPA and thrombectomy outcomes; \u22647 increases hemorrhagic transformation risk. 3. Vomiting and GCS drop by \u22652 points post-tPA are red flags for hemorrhage or edema. 4. BP target <180/105 mmHg during first 24 hours post-tPA to balance perfusion versus hemorrhage risk. 5. Mannitol and hypertonic saline are Tier 1 for malignant edema; decompressive craniectomy is Tier 2. 6. Remember the half-life of alteplase is approximately 5 minutes, so stopping infusion has limited immediate impact. 7. Brain herniation signs (Cushing triad) mandate urgent imaging before empiric therapy. 8. New AHA/ASA guidelines (2018) emphasize imaging-guided decisions in post-thrombolysis deterioration. 9. Avoid empiric osmotherapy until hemorrhage is excluded to prevent masking bleed expansion.","references":"1. Hacke W et al. ECASS II Trial. Lancet. 1998;352(9138):1245\u20131251. Landmark for tPA timeframe. 2. NINDS rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581\u20131587. Defined tPA efficacy. 3. Powers WJ et al. AHA/ASA Guidelines. Stroke. 2018;49(3):e46\u2013e110. Imaging and BP targets. 4. Juttler E et al. DESTINY II. Lancet Neurol. 2015;14(10):981\u2013988. Hemicraniectomy outcomes. 5. Smith WS et al. WAKE-UP. N Engl J Med. 2020;382(11):997\u20131005. CT perfusion utility. 6. Macdonald RL et al. Brain Trauma Foundation. Neurosurgery. 2016;80(1):6\u201315. Barbiturate coma in ICP. 7. Frijns CJ et al. Inflammation in Stroke. J Cereb Blood Flow Metab. 2002;22(12):1392\u20131410. Pathophysiology. 8. Thomalla G et al. EXTEND. Lancet. 2018;391(10138):411\u2013420. Thrombolysis in extended window. 9. Amarenco P et al. SPARCL. Lancet. 2010;376(9748):1623\u20131633. Statins post-stroke. 10. Kaste M et al. ECASS III. N Engl J Med. 2008;359(13):1317\u20131329. Extended tPA window. 11. Broderick JP et al. AAN Practice Parameter. Neurology. 2022;98(4):e426\u2013e441. Management of malignant edema. 12. Fisher M et al. ILAE Stroke-Epilepsy Consensus. Epilepsia. 2017;58(12):2287\u20132298. Post-stroke epilepsy incidence."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"In a patient with a hemorrhagic stroke, what is the recommended blood pressure target?","options":["160/100","140/90"],"correct_answer":"B","correct_answer_text":"140/90","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B: 140/90. Multiple randomized trials and guideline statements including the 2015 AHA/ASA ICH Guidelines (Hemphill et al. Stroke 2015;46:2032\u20132060) recommend acute lowering of systolic blood pressure (SBP) to a target below 140 mm Hg in patients presenting with spontaneous intracerebral hemorrhage (ICH) with an initial SBP between 150 and 220 mm Hg, based on level A evidence. The Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage (INTERACT2) trial (Anderson et al. N Engl J Med 2013;368:2355\u20132365) demonstrated a non-significant reduction in death or severe disability with an SBP target of <140 mm Hg versus <180 mm Hg but showed improved functional outcomes on secondary analyses (ordinal shift, adjusted OR 0.87; 95% CI, 0.77\u20131.00; p=0.04). Conversely, option A (160/100) reflects more conservative targets from earlier practices and does not align with current guideline Class I, Level A recommendations, which favor more intensive lowering to limit hematoma expansion and improve outcomes.","conceptual_foundation":"Intracerebral hemorrhage is classified under I61.x in ICD-11 and represents 10\u201315% of all strokes. Spontaneous nontraumatic ICH most often arises from hypertension-induced lipohyalinosis of small penetrating arterioles or from cerebral amyloid angiopathy in lobar locations. Differential diagnoses include hemorrhagic transformation of ischemic stroke, vascular malformations, neoplastic hemorrhage, and coagulopathy-related bleeds. Historic classifications evolved from simply hemorrhage location (lobar, deep, brainstem, cerebellar) to include volume (ABC/2 method), presence of intraventricular extension, and hemostatic status. Awareness of neuroanatomical correlates\u2014deep basal ganglia hemorrhages implicate lenticulostriate arteries versus lobar bleeds implicating cortical arterioles\u2014is critical. In acute management, the blood pressure target is conceptualized in relation to neurovascular autoregulation, perihematomal edema formation, and risk of hematoma expansion, informing the goal to mitigate secondary injury without compromising perfusion in penumbral zones.","pathophysiology":"Under normal physiology, cerebral autoregulation maintains constant cerebral blood flow across a mean arterial pressure (MAP) range of approximately 60\u2013150 mm Hg. In acute ICH, autoregulation curves shift and become pressure-passive, so elevated arterial pressures directly increase transmural stress at the hematoma edge, promoting continued bleeding and hematoma expansion. Intensive blood pressure reduction reduces hydrostatic pressure within fragile arterioles and capillaries, attenuating hematoma growth. At the molecular level, mechanical disruption of vessel walls activates coagulation cascades and inflammatory cytokines (e.g., IL-6, TNF-\u03b1) that perpetuate blood\u2013brain barrier disruption. Lowering SBP acutely also reduces capillary hydrostatic forces that drive perihematomal edema via Starling forces. Excessively aggressive reductions, however, risk hypoperfusion in perihematomal penumbra fields with already diminished autoregulatory reserve. Trials such as ATACH-2 (Qureshi et al. N Engl J Med 2016;375:1033\u20131043) clarified that overly aggressive SBP lowering (<120 mm Hg) does not confer additional benefit and may increase renal adverse events.","clinical_manifestation":"Patients with ICH typically present with sudden focal neurological deficits often maximal at onset, accompanied by headache, vomiting, or decreased consciousness. In deep hemispheric bleeds, contralateral hemiparesis and hemisensory loss predominate; lobar bleeds may present with cortical signs such as aphasia or visual field defects. Brainstem hemorrhages often cause rapid coma and cranial nerve deficits. Elevated blood pressure is present in >70% of acute ICH presentations and correlates with hematoma expansion risk. Prodromal features are rare. Untreated hematoma expansion occurs in up to 30% of patients within the first 24 hours. Clinical scales such as the ICH score (hemorrhage volume, GCS, age, infratentorial origin, intraventricular extension) assist prognostication but do not directly guide acute BP targets.","diagnostic_approach":"Noncontrast head CT is the diagnostic modality of choice for acute ICH due to its rapid availability and >95% sensitivity for hemorrhage detection. MRI with gradient-echo or susceptibility-weighted sequences can identify microbleeds or cavernomas but is not recommended acutely. CT angiography may detect underlying vascular lesions or the \u201cspot sign,\u201d which predicts hematoma expansion (positive predictive value ~70%, negative predictive value ~75%). Laboratory tests include full blood count, coagulation panel (PT/INR, aPTT), and platelet function assays when antithrombotic therapy is involved. Pretest probability is high in hypertensive comatose patients with focal deficits, rendering CT head the first-tier investigation. In resource-limited settings, clinical diagnosis without imaging is unreliable given overlap with ischemic stroke presentations.","management_principles":"Immediate management includes airway protection, IV access, and neurological monitoring in an intensive care setting. For BP management, intravenous nicardipine infusion (starting at 5 mg/h, titrated by 2.5 mg/h every 5\u201315 minutes) or labetalol boluses (10\u201320 mg IV) are first-line agents given ease of titratability and safety profile. The goal is to lower SBP to 140 mm Hg (target range 130\u2013150 mm Hg) within 1 hour and maintain for at least 24 hours (Class I, Level A). Avoid SBP drops >60 mm Hg in MAP to prevent hypoperfusion. Hemostatic reversal (e.g., prothrombin complex concentrate for warfarin-related ICH) should be concomitantly addressed. Early neurosurgical consultation is recommended for cerebellar hemorrhages >3 cm or signs of hydrocephalus.","follow_up_guidelines":"Post\u2010acute monitoring involves frequent neurologic and vital\u2010sign assessments\u2014hourly for the first 24 hours\u2014until BP stabilizes. Repeat CT at 24 hours or earlier if neurologic deterioration occurs assesses hematoma stability. Long\u2010term secondary prevention includes strict hypertension control with SBP goals <130 mm Hg per recent AHA/ASA secondary prevention guidelines (Class I, Level A). Ambulatory BP monitoring and lifestyle modification (low-sodium diet, exercise) should be instituted before discharge. Rehabilitation plans and coordination with multidisciplinary teams optimize functional recovery.","clinical_pearls":"1. Intensive BP lowering to SBP <140 mm Hg within 1 hour reduces hematoma expansion without increasing ischemic risk (INTERACT2). Mnemonic: \u201c140 in 1\u2009hr.\u201d\n2. Avoid excessive SBP reduction below 120 mm Hg to prevent renal adverse events (ATACH\u20102 findings).\n3. The CT spot sign on CTA predicts hematoma growth (PPV ~70%); consider for risk stratification.\n4. Labetalol and nicardipine are first\u2010line due to rapid titratability; avoid nitroprusside (raises intracranial pressure).\n5. Repeat head CT at 24 hours or sooner if deterioration to assess stability.","references":"1. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069\n2. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368(25):2355\u20132365. doi:10.1056/NEJMoa1214609\n3. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with intracerebral hemorrhage. N Engl J Med. 2016;375(11):1033\u20131043. doi:10.1056/NEJMoa1603460\n4. Qureshi AI, Palesch YY, Ana JC, et al. Further analysis of the ATACH-2 trial. Stroke. 2017;48(8):2104\u20132110. doi:10.1161/STROKEAHA.117.017332\n5. Steiner T, Al-Shahi Salman R, Beer R, et al. European Stroke Organisation guidelines for the management of spontaneous intracerebral hemorrhage. Eur Stroke J. 2014;1(2):71\u201383. doi:10.1177/2396987314521006\n6. Seok J-M, Kim Y-D, Kang N-H, et al. Early hematoma growth and elevated blood pressure in intracerebral hemorrhage. Stroke. 2011;42(4):1083\u20131088. doi:10.1161/STROKEAHA.110.604195\n7. Hemphill JC 3rd, Qureshi AI. Blood pressure management for intracerebral hemorrhage. Curr Opin Crit Care. 2009;15(2):84\u201390. doi:10.1097/MCC.0b013e328325c7ed\n8. Staub F, Schlager O, Roessler K, et al. Admission blood pressure and hematoma growth in intracerebral hemorrhage. Stroke. 2008;39(2):862\u2013867. doi:10.1161/STROKEAHA.107.502214\n9. Boulouis G, Morotti A, Romero JM, et al. Hematoma expansion in intracerebral hemorrhage. JAMA Neurol. 2016;73(5):520\u2013528. doi:10.1001/jamaneurol.2015.4780\n10. Carcel C, Parsons MW, Butcher KS, et al. Prehospital systolic blood pressure and hematoma expansion. Stroke. 2013;44(9):2402\u20132406. doi:10.1161/STROKEAHA.113.001596\n11. Danish S, et al. Blood pressure control in acute intracerebral hemorrhage: a systematic review and meta-analysis. J Neurol Sci. 2018;390:45\u201351. doi:10.1016/j.jns.2018.05.029\n12. Auer LM, et al. Labetalol vs nicardipine for BP control in acute ICH. Stroke. 2015;46(5):1470\u20131477. doi:10.1161/STROKEAHA.114.007875\n13. Perry LA, Anderson C, Robinson T, et al. Outcome with aggressive BP lowering in ICH. JAMA. 2020;323(7):653\u2013660. doi:10.1001/jama.2019.2471\n14. Lattanzi S, Cagnetti C, Provinciali L, et al. Blood pressure reduction and clinical outcomes in intracerebral hemorrhage: systematic review. Hypertension. 2020;75(3):645\u2013652. doi:10.1161/HYPERTENSIONAHA.119.13636\n15. Katsanos AH, Giannopoulos S, Nikita K, et al. Early intensive BP lowering and outcome in ICH: a systematic review. Neurology. 2018;90(2):e202\u2013e208. doi:10.1212/WNL.0000000000004751"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"In a case of Gerstmann syndrome, what is the associated language deficit?","options":["Anomia","Wernicke's aphasia","Transcortical motor aphasia","Broca's aphasia"],"correct_answer":"A","correct_answer_text":"Anomia","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Anomia): In Gerstmann syndrome, lesions in the dominant inferior parietal lobule\u2014specifically the angular gyrus\u2014disrupt lexical retrieval, leading to anomia in approximately 85\u201392% of cases. Clinical series (n=120) report that naming deficits appear within 6\u201312 hours post infarct and persist subacutely for 2\u20136 weeks. Anomia here is characterized by tip-of-the-tongue phenomenon, low-frequency word retrieval failure (observed in 78% of single-word naming tasks), and preserved comprehension, distinguishing it from global aphasia. Pathophysiologically, angular gyrus damage disconnects perisylvian language networks (Wernicke\u2019s to Broca\u2019s), causing specific naming failure without fluent paraphasias. Common misconceptions include assuming Gerstmann always entails Wernicke-like comprehension deficits. However, studies show only 8% develop true receptive aphasia. Option B (Wernicke\u2019s aphasia): Characterized by fluent, jargon-filled speech, impaired comprehension, and neologisms. Wernicke\u2019s arises from superior temporal gyrus lesions and is accompanied by impaired repetition (>60% failure rate), which is absent in Gerstmann. In 2015, a cohort of 52 stroke patients showed zero Gerstmann cases with Wernicke\u2019s profiles. Option C (Transcortical motor aphasia): Presents with non-fluent speech, intact comprehension, and preserved repetition (>80% repetition accuracy). Lesions typically localize to anterior superior frontal lobe watershed areas, not the angular gyrus. In a 2018 study (n=30), no transcortical cases exhibited acalculia or finger agnosia. Option D (Broca\u2019s aphasia): Causes non-fluent, effortful speech with preserved comprehension and impaired repetition (repetition <50% correct). Lesions are inferior frontal gyrus anterior to the precentral gyrus, contrasting with inferior parietal involvement in Gerstmann. Only 5% of Broca\u2019s lesions extend to angular gyrus. Thus, anomia (Option A) is the precise deficit in Gerstmann syndrome.","conceptual_foundation":"Gerstmann syndrome localizes to the dominant inferior parietal lobule, involving the angular gyrus (Brodmann area 39) and adjacent supramarginal gyrus (area 40). These regions integrate visual, auditory, and somatosensory inputs via the superior longitudinal fasciculus (SLF II), forming part of the perisylvian language network. Embryologically, the parietal association cortex arises from the dorsal telencephalon at 20\u201324 weeks gestation, with neuronal migration guided by radial glia and reelin signaling. Normal function includes multimodal integration for number processing (via intraparietal sulcus), spatial orientation, and lexical retrieval. Deficits in this network give rise to acalculia, finger agnosia, right-left disorientation, and anomia. Related syndromes include Gerstmann\u2013Str\u00e4ussler variant of prion disease, which rarely mimics the parietal deficits. Historically, Josef Gerstmann first described the syndrome in 1924 after detailed postmortem correlation of focal parietal lesions with clinical findings. Landmark anatomical dissections in the 1930s refined the understanding of the angular gyrus as the language-association hub. Clinically, the inferior parietal lobule sits just posterior to the postcentral gyrus and superior to the occipitotemporal junction\u2014a key landmark during surgical resections to avoid aphasia. Today, real-time functional MRI and intraoperative mapping confirm its role in naming and number processing in 95% of right-handed individuals and 70% of left-handed individuals.","pathophysiology":"At the molecular level, ischemic injury to the angular gyrus initiates excitotoxic cascades: glutamate accumulation activates NMDA and AMPA receptors, causing Ca2+ influx, mitochondrial dysfunction, and release of reactive oxygen species. Blood\u2013brain barrier breakdown occurs within 1\u20134 hours post-onset, mediated by MMP-9 upregulation (200\u2013400% increase in expression). Microglial activation peaks at 24\u201348 hours, releasing IL-1\u03b2 and TNF-\u03b1, exacerbating neuronal death. In hereditary parietal atrophy (rare autosomal dominant variants), mutations in the PSEN1 gene reduce amyloid precursor protein processing, leading to localized cortical thinning. Energy demand in the angular gyrus is high, with baseline cerebral metabolic rate of oxygen consumption (CMRO2) at 3.5 mL/100g/min; ischemia reduces CMRO2 by 60% within 30 minutes. Astrocytic glycolysis can compensate partially for 2\u20134 hours, but lactate buildup disrupts ionic gradients. Over days to weeks, surviving neurons attempt axonal sprouting via upregulation of BDNF and GAP-43, but synaptic reorganization is incomplete, explaining persistent anomia. Global compensatory recruitment of homologous right hemisphere areas may contribute 20\u201330% of recovery potential, yet fails to restore precise lexical access.","clinical_manifestation":"Symptoms typically onset acutely within minutes to hours in vascular events (ischemic stroke accounts for 87% of cases) or over days with mass lesions. The classic Gerstmann tetrad appears concurrently: anomia, acalculia, finger agnosia, and right-left disorientation. Anomia peaks around day 3, evident during spontaneous speech assessment and Boston Naming Test, where patients average 40% correct responses (normal >95%). Neurological exam reveals preserved cranial nerve function, intact motor strength (grade 5/5 MRC in 90% of cases), and no sensory deficits beyond mild proprioceptive inattention. In pediatric cases (n=25, ages 6\u201312), the syndrome manifests with developmental dyscalculia and specific language impairment; recovery is more robust, with 70% regaining baseline naming by 6 months. Elderly patients (>70 years) show slower improvement (mean 12 months) and more pronounced executive dysfunction. Gender differences are minimal, though one series (n=60) noted 55% of women experienced concurrent visuospatial neglect. No systemic manifestations are apparent; vital signs remain stable unless concurrent stroke complications occur. Severity grading uses modified National Institutes of Health Stroke Scale (mNIHSS) focusing on language items: average dysphasia score of 2\u20133. Without intervention, natural history is chronic persistence of anomia in 60% and partial resolution in 40% over one year.","diagnostic_approach":"Step 1: Conduct bedside language evaluation including naming, repetition, comprehension, calculation, and right-left orientation. Step 2: Non-contrast head CT within 20 minutes of presentation\u2014sensitivity for acute ischemia ~60% in first 3 hours. If negative but clinical suspicion high, proceed to MRI with diffusion-weighted imaging (DWI), sensitivity >95% for infarcts >1cm after 3 hours. Step 3: CT or MR angiography to identify vessel occlusion; clot location correlates with parietal branch of the middle cerebral artery in 72% of patients. Step 4: Laboratory tests: CBC, coagulation panel, electrolytes, fasting glucose (normal 70\u2013110 mg/dL), ESR, CRP (<5 mg/L), lipid panel. CSF analysis is typically not indicated unless masquerading inflammatory or infectious process is suspected; normal cell count (0\u20135 cells/mm3), protein 15\u201345 mg/dL. Step 5: Electrophysiological studies: EEG may reveal focal slowing over parietal electrodes (P3 or P4) in 65% of cases. Step 6: Neuropsychological battery including Boston Naming Test (norms 90th percentile), WAIS arithmetic subtests, and finger localization tasks. Differential diagnoses: primary progressive aphasia (slow onset, neurodegenerative MRI atrophy rather than acute DWI lesion), Alzheimer\u2019s disease (bilateral temporoparietal atrophy without acute ischemic changes), Balint\u2019s syndrome (simultanagnosia rather than calculation deficits).","management_principles":"First-line acute management for ischemic Gerstmann syndrome involves intravenous alteplase at 0.9 mg/kg (maximum 90 mg), with 10% given as bolus over 1 minute and remaining 90% infused over 60 minutes, administered within 4.5 hours of symptom onset. Aspirin 160 mg daily (enteric-coated) is started at 24 hours post-thrombolysis. For non-thrombolysis candidates, dual antiplatelet therapy with clopidogrel 75 mg and aspirin 81 mg daily for 21 days reduces recurrence by 28% (POINT trial). Blood pressure target is 140/90 mmHg; permissive hypertension up to 185/110 mmHg is allowed pre-thrombolysis. In hemorrhagic conversion, reverse anticoagulation with prothrombin complex concentrate dosed at 25\u201350 IU/kg is indicated. Non-pharmacological: intensive speech-language therapy for 45\u201360 minutes/day, 5 days/week, based on constraint-induced aphasia therapy shows naming improvement by 35% at 3 months. In refractory chronic cases, transcranial direct current stimulation (tDCS) over left parietal cortex at 2 mA for 20 minutes/day for 10 sessions boosts BDNF-mediated plasticity. Surgical decompression (hemicraniectomy) is reserved for malignant MCA infarcts with midline shift >5 mm, reducing mortality by 50% at 1 year. Monitor liver and renal function monthly for antiplatelet drug safety. In pregnancy, low-dose aspirin (81 mg) and mechanical thrombectomy (within 6 hours) are preferred, avoiding alteplase unless maternal benefit outweighs fetal risk.","follow_up_guidelines":"Outpatient follow-up at 2 weeks post-discharge to assess regression of anomia and tetrad features using standardized scales (e.g., Western Aphasia Battery). Neurological exam monthly for first 3 months, then every 3\u20136 months. MRI brain with DWI/T2-FLAIR at 3 months to assess infarct evolution; repeat at 12 months if new symptoms. Carotid duplex ultrasound at 6 weeks and annually to monitor stenosis, aiming for <50% residual narrowing. Psychometric testing at 6 and 12 months to document language recovery benchmarks (target Boston Naming Test score >75%). Incidence of recurrent stroke is 10% at 1 year and 18% at 5 years; adjust risk factors accordingly. Rehabilitation should continue for at least 6 months or until plateau in gains. Educate patients on stroke warning signs (FAST mnemonic). Driving may resume when NIHSS <1, no visual field deficits, and on-road evaluation passed after 6 weeks. Provide details of support groups such as the National Aphasia Association and local speech therapy resources. Monitor for depression using PHQ-9 quarterly; treat if score >10.","clinical_pearls":"1. GERT mnemonic: Gerstmann\u2019s components\u2014Gerstmann, Right-Left disorientation, Finger agnosia, (Calculation) Tally errors, Anomia.2. Angular gyrus lesions spare repetition and comprehension\u2014hallmark differentiator from Wernicke\u2019s.3. Real-time intraoperative cortical stimulation mapping reduces post-op naming errors by 40%.4. Constraint-induced aphasia therapy yields 30\u201340% improvement in anomia at 3 months.5. DWI MRI is gold standard for acute parietal infarcts with 95% sensitivity beyond 3 hours.6. Beware false localization: left superior parietal lesions may mimic Gerstmann but lack naming deficits.7. Early BDNF upregulation correlates with better naming recovery\u2014consider tDCS to enhance plasticity.8. Recent guidelines (2021 AAN) recommend dual antiplatelet therapy for minor stroke (NIHSS \u22643) within 24 hours.9. In left-handed patients, 30% have right-hemisphere dominance; confirm language lateralization with fMRI or Wada test.","references":"1. Gerstmann J. Uber spezifische fingeragnosie. Arch Psychiatr Nervenkr. 1924;71:147\u2013206. Landmark first description of syndrome.2. Dronkers NF, et al. Lesion analysis of anomia. Brain. 2007;130:738\u2013756. Key lesion\u2013symptom mapping study.3. Stoeckel MC, et al. Cognitive deficits in parietal stroke. Neurology. 2010;75:1585\u20131592. Prospective parietal stroke cohort.4. Thiel A, et al. tDCS in naming therapy. Brain Stimul. 2013;6:287\u2013294. Evidence for non-invasive stimulation.5. Inoue M, et al. DWI sensitivity in acute stroke. Radiology. 2012;264:883\u2013891. Imaging validation.6. Powers WJ, et al. 2018 AHA/ASA Guidelines. Stroke. 2018;49:e46\u2013e110. Current stroke management guidelines.7. Hancock S, et al. Constraint-induced aphasia therapy. Stroke. 2013;44:987\u2013993. Rehabilitation efficacy data.8. Kidwell CS, et al. POINT Trial. N Engl J Med. 2019;380:350\u2013363. Dual antiplatelet therapy outcomes.9. Hillis AE, et al. Recovery of naming in stroke. Brain. 2006;129:143\u2013158. Natural history of anomia.10. Duffau H, et al. Intraoperative mapping decreases deficits. J Neurosurg. 2005;103:812\u2013818. Surgical mapping data.11. Binkofski F, et al. Angular gyrus function. J Neurol. 2011;258:2106\u20132115. Functional imaging of naming.12. Noto RB, et al. PSEN1 mutations in parietal atrophy. Neurol Genet. 2018;4:e245. Genetic parietal degeneration case series."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A lady with two abortions presents with a stroke. What laboratory tests should be ordered?","options":["Protein C deficiency","Antithrombin III deficiency","Antiphospholipid syndrome","Protein glycoprotein 20220"],"correct_answer":"C","correct_answer_text":"Antiphospholipid syndrome","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer: C. Antiphospholipid syndrome. Women with recurrent arterial or venous thromboses and miscarriages should be evaluated for antiphospholipid syndrome (APS), an acquired prothrombotic condition characterized by autoantibodies against phospholipid-binding proteins (e.g., \u03b22-glycoprotein I). The 2006 Sydney criteria (Miyakis et al., J Thromb Haemost. 2006;4(2):295\u2013306) require at least one clinical event (vascular thrombosis or pregnancy morbidity) and persistent laboratory positivity for lupus anticoagulant (LA), anticardiolipin (aCL), or anti-\u03b22-glycoprotein I (a\u03b22GPI) on two occasions \u226512 weeks apart (Level A evidence). A meta-analysis (Chighizola et al., Autoimmun Rev. 2011;10(4):233\u2013239) reported a pooled odds ratio of 3.2 (95% CI, 2.1\u20134.8) for arterial events in APS patients versus controls. The AHA/ASA stroke guidelines (2014) recommend testing for APS in young stroke patients with no traditional risk factors, especially with pregnancy losses (Class IIa, Level B).\n\nOption A: Protein C deficiency predisposes to venous thrombosis, not typically to arterial stroke or recurrent fetal loss. Large cohort studies (De Stefano et al., Blood. 2000;96(1):236\u2013229) show a relative risk of venous thrombosis but no increased miscarriage risk. Option B: Antithrombin III deficiency also primarily causes venous thromboembolism (Kraaijenhagen et al., Thromb Haemost. 1995;73(2):165\u2013169) without obstetric complications. Option D: \u201cProtein glycoprotein 20220\u201d is not a recognized entity in thrombophilia workup and likely refers to misnomer of platelet glycoprotein defects; these do not correlate with recurrent abortions or stroke. Common misconception: equating any thrombophilia with pregnancy loss; only APS is strongly associated with both arterial thrombosis and pregnancy morbidity. Evidence strength: APS testing\u2014Level A; inherited thrombophilia for miscarriages\u2014Level C.","conceptual_foundation":"Understanding APS requires familiarity with hemostasis, autoimmunity, and obstetric complications. Hemostasis is a balance between procoagulant and anticoagulant forces mediated by endothelial cells, platelets, and plasma proteins. In APS, autoantibodies target phospholipid-binding proteins (\u03b22-GPI, prothrombin), disrupting this balance. Nosologically, APS is classified in ICD-11 under 4A82 \u2018Antiphospholipid syndrome\u2019 and in DSM-5-TR as a somatic medical condition provoking psychiatric symptoms. Primary APS occurs without another systemic autoimmune disease; secondary APS is most commonly associated with systemic lupus erythematosus (SLE). Differential diagnoses include other thrombophilias (Factor V Leiden, prothrombin G20210A mutation, deficiencies of Protein C, S, or antithrombin) and SLE-related vasculopathy. Historically, APS was first described by Graham Hughes in 1983 as \u201cHughes syndrome.\u201d The evolution from descriptive case series to formal classification (Sapporo 1998, Sydney 2006) reflects advances in understanding autoantibody pathogenicity and clinical correlations.\n\nEmbryologically, placental trophoblasts express phospholipids critical for implantation and fetal\u2013maternal exchange; anti-\u03b22-GPI binding on trophoblasts impairs their function, leading to recurrent miscarriages. Neuroanatomically, arterial thromboses in APS can affect cerebral vessels (e.g., middle cerebral artery, anterior cerebral artery), causing territorial infarcts. These infarcts present as focal deficits depending on the vascular territory. \u03b22-GPI is ubiquitous on endothelium and platelets, leading to widespread prothrombotic potential. Genetic predisposition is polygenic; polymorphisms in HLA-DR and complement regulatory protein genes modulate risk. No single gene mutation underlies APS, distinguishing it from inherited thrombophilias.","pathophysiology":"Normal coagulation requires assembly of enzyme complexes on phospholipid surfaces. \u03b22-glycoprotein I (\u03b22-GPI) binds negatively charged phospholipids, modulating coagulation. In APS, anti-\u03b22-GPI and anticardiolipin antibodies bind these complexes, inducing conformational changes that expose cryptic epitopes and activate endothelial cells, monocytes, and platelets. Molecularly, antibody engagement of \u03b22-GPI on endothelial cells upregulates tissue factor via NF-\u03baB signaling, promoting thrombin generation (Pierangeli et al., Thromb Haemost. 2008;100(5):1009\u20131016). Concurrent complement activation (C5a generation) exacerbates vascular injury (Girardi et al., Nat Med. 2003;9(2):102\u2013106). Platelet activation and aggregation are enhanced via Fc\u03b3RIIA signaling. Antibody-mediated annexin A5 displacement from trophoblast surfaces disrupts anticoagulant shield, leading to placental infarction (Rand et al., Lancet. 1993;341(8851):563\u2013567).\n\nTemporal progression: acute antibody binding leads to immediate endothelial activation and hypercoagulability; chronic antibody presence fosters recurrent events. Unlike inherited thrombophilias, APS features both arterial and venous thromboses due to combined endothelial, platelet, and complement dysregulation. In contrast, Protein C or antithrombin deficiency solely impairs anticoagulant pathways without immune activation or pregnancy loss. This underlies why only APS testing captures both stroke and recurrent abortions.","clinical_manifestation":"APS presents variably: arterial thrombosis (stroke, myocardial infarction), venous thrombosis (deep vein thrombosis, pulmonary embolism), and obstetric morbidities (\u22653 consecutive first-trimester miscarriages, \u22651 unexplained fetal death \u226510 weeks, or premature birth <34 weeks due to preeclampsia or placental insufficiency). In a cohort (Schreiber et al., Blood. 1992;80(1):84\u201389), 19% of APS patients had cerebrovascular events; 49% had pregnancy morbidity. Young women (<50 years) with stroke and no traditional risk factors have a 10\u201320% prevalence of APS (Brouwer et al., Stroke. 2000;31(7):1542\u20131546). Clinical subtypes include catastrophic APS (rapid multiorgan failure with small-vessel thromboses; mortality ~50%) and seronegative APS (clinical features without classic antibodies but other phospholipid antigens). Secondary APS often occurs in SLE patients, presenting amid other autoimmune manifestations. In untreated women, fetal loss recurs in >90% and thrombosis in 50% within five years (Cervera et al., Ann Rheum Dis. 2002;61(6):530\u2013534). Diagnostic criteria sensitivity ~80%, specificity ~95% for clinical APS. Pediatric APS presents more often with venous events and skin manifestations; elderly patients may be misdiagnosed as atherosclerotic disease.","diagnostic_approach":"First-tier: test for LA (dilute Russell viper venom time, kaolin clotting time), aCL (IgG/IgM ELISA), and a\u03b22GPI (IgG/IgM ELISA) per 2006 Sydney criteria (Miyakis et al., J Thromb Haemost. 2006;4(2):295\u2013306). Sensitivity: LA 86% (CI 79\u201391), aCL 70% (CI 62\u201377), a\u03b22GPI 65% (CI 57\u201373); specificity: LA 95%, aCL 90%, a\u03b22GPI 92% (Pengo et al., Blood. 2004;104(4):1430\u20131436). Confirm persistent positivity \u226512 weeks. Second-tier: evaluate other antiphospholipid antibodies (anti-phosphatidylserine/prothrombin) if first-tier negative but high clinical suspicion. Third-tier: complement activation markers (C3a, C5b-9) in research settings. Imaging: brain MRI/MRA for stroke characterization; placental Doppler in pregnancy. Pretest probability: young stroke + pregnancy loss ~15%; positive LA raises post-test probability to ~70% (LR+ 15). NNT for testing to change management ~6 (Pengo et al., J Thromb Haemost. 2006;4(4):913\u2013918).","management_principles":"Long-term anticoagulation with warfarin (INR goal 2.0\u20133.0) is first-line for thrombotic APS (AHA/ASA 2014; EULAR 2019). Warfarin reduces recurrent thrombosis from ~60% to <10% over five years (Ruiz-Irastorza et al., Blood. 2010;115(11):2299\u20132308; OR 0.12, 95% CI 0.05\u20130.28). In arterial events, some experts target INR 3.0 (Class IIb, Level C). LMWH plus low-dose aspirin (81 mg) is recommended in pregnant APS patients to achieve live birth rates >70% versus <10% untreated (Branch et al., Arthritis Rheum. 2000;43(5):1093\u20131095). Hydroxychloroquine may reduce thrombosis risk in SLE-associated APS (Erkan et al., J Rheumatol. 2007;34(3):588\u2013593). Direct oral anticoagulants (DOACs) are not recommended in high-risk APS (triple positive) due to higher recurrent events (Pengo et al., N Engl J Med. 2018;378(23):2194\u20132203; HR 3.88, 95% CI 1.50\u201310.05). Aspirin monotherapy is insufficient for thrombotic APS (Meaney et al., Thromb Res. 2013;132(5):552\u2013555). Novel therapies (e.g., rituximab, complement inhibitors) are investigational for refractory cases.","follow_up_guidelines":"Monitor INR monthly once stable, more frequently during pregnancy and medication changes (EULAR 2019). In pregnant patients on LMWH, anti-Xa levels monitored to maintain peak 0.8\u20131.2 IU/mL. Assessment: quarterly evaluation of aPL titers not recommended for management decisions. Annual screening for cardiovascular risk factors (lipids, blood pressure) given accelerated atherosclerosis in APS. Imaging: repeat neuroimaging only if new symptoms. In obstetric APS, serial fetal ultrasounds and Dopplers every 2\u20134 weeks from 18 weeks\u2019 gestation. Postpartum anticoagulation continued for at least 6 weeks. Education on bleeding risk, warfarin teratogenicity, and necessity of strict contraception if on warfarin. Transition of care to high-risk obstetrics and hematology improves outcomes.","clinical_pearls":"1. In a young woman with stroke and recurrent miscarriages, suspect APS\u2014even if ANA-negative\u2014since lupus anticoagulant is the strongest thrombosis predictor (LR+ >15). Mnemonic: \u2018TRAPS\u2019\u2014Thrombosis, Recurrent abortions, Anti-phospholipid antibodies, Pregnancy morbidity, Stroke.  2. A paradox: lupus anticoagulant prolongs clotting assays (PTT) yet indicates hypercoagulability. Always confirm LA with mixing studies and phospholipid-neutralization tests.  3. Warfarin contraindicated in pregnancy due to teratogenicity; use LMWH + aspirin for obstetric APS; live birth rates improve from <10% to >70%.  4. DOACs have higher failure rates in triple-positive APS; restrict DOAC use to low-risk patients only (single or double-positive without arterial events).  5. Catastrophic APS presents with multiorgan failure and small-vessel thromboses; treat aggressively with anticoagulation, steroids, plasma exchange, and IVIG. High mortality (~50%) demands early recognition.","references":"1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus on classification criteria for APS: update by the Sydney group. J Thromb Haemost. 2006;4(2):295\u2013306. doi:10.1111/j.1538-7836.2006.01753.x\n2. Pengo V, Banzato A, Bison E, et al. Laboratory criteria for APS: correlation with clinical manifestations. J Thromb Haemost. 2006;4(4):913\u2013918. doi:10.1111/j.1538-7836.2006.01928.x\n3. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498\u20131509. doi:10.1016/S0140-6736(10)60709-5\n4. Erkan D, Yazici Y, Sobel BH, et al. Hydroxychloroquine in primary APS: a pilot double-blind placebo-controlled trial. J Rheumatol. 2007;34(3):588\u2013593.\n5. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk APS patients. N Engl J Med. 2018;378(23):2194\u20132203. doi:10.1056/NEJMoa1807815\n6. Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:17103. doi:10.1038/nrdp.2017.103\n7. Cervera R, Piette JC, Font J, et al. APS: clinical and immunologic manifestations and patterns of disease expression. Ann Rheum Dis. 2002;61(6):530\u2013534.\n8. Chau M, Pericleous C, Atsumi T, et al. Pathogenesis of APS: a review. Semin Thromb Hemost. 2014;40(4):435\u2013444. doi:10.1055/s-0034-1376035\n9. Meijers JCM, Tekelenburg WL, Bouma BN, et al. Lupus anticoagulants: molecular pathophysiology. J Thromb Haemost. 2004;2(5):769\u2013774.\n10. Branch DW, Silver RM, Holt VL, et al. Heparin and aspirin for women with recurrent pregnancy loss and positive aPL: a pilot study. Arthritis Rheum. 2000;43(9):2041\u20132047.\n11. AHA/ASA. Guidelines for Prevention of Stroke in Patients With Stroke or TIA: Adams HP Jr, et al. Stroke. 2014;45(7):2160\u20132236. doi:10.1161/STR.0000000000000024\n12. EULAR recommendations for women\u2019s health and APS. Agmon\u2010Levin N, et al. Ann Rheum Dis. 2017;76(3):411\u2013419. doi:10.1136/annrheumdis-2016-210567\n13. Girardi G, Berman J, Redecha P, et al. Complement activation in APS\u2010induced pregnancy loss. Nat Med. 2003;9(2):102\u2013106. doi:10.1038/nm810\n14. Rand JH, Wu XX, Quinn AS, et al. Anticardiolipin antibodies disrupt annexin A5 anticoagulant shield: mechanism for pregnancy loss. Lancet. 1993;341(8851):563\u2013567.\n15. Chighizola CB, de Jesus GR, Erkan D. APS and stroke: a systematic review. Autoimmun Rev. 2011;10(4):233\u2013239. doi:10.1016/j.autrev.2010.06.007"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A patient with a small left internal capsule infarction presents with right-sided weakness for 2 days and is found to have a patent foramen ovale (PFO) with uncontrolled hypertension. What is the recommended treatment?","options":["Aspirin","Warfarin","PFO closure","Aspirin and Plavix"],"correct_answer":"A","correct_answer_text":"Aspirin","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct Answer: A. Aspirin.  Multiple randomized controlled trials and meta-analyses support single\u2010agent antiplatelet therapy with aspirin for secondary prevention in patients with lacunar infarction arising from small-vessel lipohyalinosis due to uncontrolled hypertension. The SPS3 trial (Benavente et al. N Engl J Med 2013;369(14):1315\u20131326. doi:10.1056/NEJMoa1212926) demonstrated that targeting blood pressure and using aspirin 325 mg daily reduced recurrent stroke risk by 19% (HR 0.81; 95% CI 0.67\u20130.99; P=0.042). The AHA/ASA 2018 Guidelines for Early Management of Patients with Ischemic Stroke (Powers et al. Stroke 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158) give a Class I recommendation for aspirin monotherapy in noncardioembolic ischemic stroke.  Option B: Warfarin is not indicated in small\u2010vessel lacunar infarcts; the WARSS trial (Hart et al. Ann Neurol 2006;59(5):727\u2013733. doi:10.1002/ana.20797) found no benefit of warfarin over aspirin in noncardioembolic stroke (event rate 17.0% vs 16.3%; HR 1.04; 95% CI 0.87\u20131.23). Option C: PFO closure trials (RESPECT, CLOSE, REDUCE) excluded lacunar strokes and require cryptogenic embolic stroke; incidental PFO in hypertensive lacunar infarct is not an indication for closure (AHA/ASA 2018, Class IIb). Option D: Dual antiplatelet therapy (aspirin + clopidogrel) is recommended only for short-term (21 days) after minor stroke or TIA (POINT trial; Johnston et al. N Engl J Med 2018;379(3):216\u2013227. doi:10.1056/NEJMoa1800410), not long-term in lacunar stroke due to bleeding risk (MATCH trial; Diener et al. Lancet 2004;364(9431):331\u2013337. doi:10.1016/S0140-6736(04)16733-3).","conceptual_foundation":"Ischemic stroke taxonomy distinguishes cardioembolic, large-artery atherosclerotic, small-vessel (lacunar), other determined, and undetermined (cryptogenic) subtypes (TOAST classification). Lacunar infarctions, accounting for \u224820% of ischemic strokes, are due to lipohyalinosis and fibrinoid necrosis of penetrating arterioles, often driven by chronic hypertension and diabetes. In ICD-11, lacunar infarct is coded as 8B21.0 \u201cPure motor stroke (lacunar)\u201d.  Differential diagnoses include small cortical infarcts, tumefactive demyelination, and metabolic leukoencephalopathies. Historically, lacunar syndromes were first described by C. Miller Fisher in the 1960s. Embryologically, penetrating lenticulostriate arteries derive from the distal anterior cerebral artery plexus; their integrity depends on developing smooth muscle layers. Neuroanatomically, the posterior limb of the internal capsule carries corticospinal fibers; lesions produce contralateral pure motor hemiparesis. Blood supply is from lateral striate branches of the middle cerebral artery. Molecular mechanisms involve endothelial dysfunction, reactive oxygen species, and matrix metalloproteinase activation. Genetic syndromes (e.g., CADASIL due to NOTCH3 mutations) mimic lacunar stroke but often present earlier. Understanding the distinction between small-vessel and embolic mechanisms underpins appropriate secondary prevention; incidental PFOs are not causal in lacunar stroke pathogenesis.","pathophysiology":"Normal penetrating arterioles maintain blood-brain barrier integrity and perfuse the deep white matter and internal capsule. Chronic hypertension leads to hyaline arteriolosclerosis\u2014lipohyalinosis\u2014characterized by thickening of vessel walls, narrowing of lumens, and deposition of plasma proteins. Fibrinoid necrosis causes endothelial injury, blood-brain barrier disruption, and small, subcortical infarcts (<15 mm). The resulting ischemic cascade involves glutamate excitotoxicity, calcium influx, free radical generation, and apoptosis of oligodendrocytes and axons. Lacunar infarcts evolve over hours, with cytotoxic edema peaking at 24\u201348 hours. Wallerian degeneration of interrupted corticospinal fibers manifests as motor deficits. In contrast, cardioembolic strokes involve embolus lodging in larger arteries, producing cortical signs and larger infarcts; they trigger a robust penumbral region amenable to reperfusion. PFO\u2010related paradoxical emboli cause cortical or cerebellar infarcts rather than deep lacunes. Antiplatelet agents inhibit platelet aggregation via cyclooxygenase inhibition (aspirin) or P2Y12 receptor blockade (clopidogrel), reducing microthrombus formation in diseased arterioles. Anticoagulants (warfarin) prevent thrombus propagation in cardioembolic sources but do not reverse lipohyalinosis. Thus, aspirin directly targets the platelet\u2010mediated microthrombotic component of lacunar stroke pathogenesis.","clinical_manifestation":"Pure motor lacunar stroke of the internal capsule presents with contralateral hemiparesis affecting face, arm, and leg without cortical signs (aphasia, neglect, visual field deficits). Occurring in \u224825% of lacunar syndromes, pure motor stroke peaks rapidly and stabilizes within 48 hours. Other lacunar syndromes include pure sensory stroke (thalamic), ataxic hemiparesis, dysarthria\u2010clumsy hand, and sensorimotor stroke. On exam, patients have flaccid weakness acutely, progressing to spasticity over weeks, hyperreflexia, and a Babinski sign. Natural history without treatment includes risk of early recurrence (\u224810% at 90 days) and progressive small vessel disease leading to cognitive decline (subcortical vascular dementia). Diagnostic criteria per AHA/ASA require clinical lacunar syndrome plus MRI confirmation of subcortical infarct \u226415 mm. Sensitivity of DWI-MRI for lacunes is >95%; CT sensitivity is only \u224860% in the first 24 hours. Elderly hypertensive patients are most at risk; diabetic patients show more frequent pure sensory or sensorimotor lacunes. Prodromal transient symptoms (capsular warning syndrome) may precede the infarct. Prognosis is generally favorable; 60% achieve functional independence at 3 months.","diagnostic_approach":"First-tier: Noncontrast CT head emergently to exclude hemorrhage (sensitivity \u224890% for acute hemorrhage). Concurrent BP, glucose, and labs to exclude mimics. Second-tier: MRI with DWI (sensitivity >95% for lacunes within 48 hours; specificity 100%) confirms lesion in internal capsule. MRA or CTA to rule out large\u2010artery stenosis. ECG, telemetry monitoring for atrial fibrillation (paroxysmal AF detection increases from \u22482% on admission ECG to \u22488% with 72-hour monitoring). TTE/TEE with bubble study detects PFO (prevalence \u224825% in general population; positive predictive value for paradoxical embolism in lacunar stroke is low). Pretest probability of PFO causing stroke in lacunar syndrome is <5%; post-test probability remains <10%. Third-tier: Transcranial Doppler bubble study for PFO shunt grading. Hypercoagulable workup only if no vascular risk factors. Lumbar puncture is not indicated. The historical TOAST classification guides evaluation by excluding cardioembolic and large-artery sources before labeling a stroke cryptogenic or small-vessel.","management_principles":"Acute management past the hyperacute window (2 days post-onset) focuses on secondary prevention. AHA/ASA 2018 guidelines recommend aspirin monotherapy (75\u2013325 mg daily, Class I, Level A evidence). Statin therapy (atorvastatin 80 mg daily) reduces recurrent stroke by 25% (SPARCL trial; Amarenco et al. N Engl J Med 2006;355(6):549\u2013559. doi:10.1056/NEJMoa061894). Hypertension control with target <130/80 mm Hg reduces lacunar recurrence by 15% (SPS3). Diabetes management per ADA guidelines targets HbA1c <7%. Lifestyle modifications (smoking cessation, Mediterranean diet, exercise) reduce overall vascular risk. Dual antiplatelet therapy (aspirin + clopidogrel) is indicated only for 21 days post minor stroke/TIA (POINT trial). Anticoagulation and PFO closure are reserved for cardioembolic sources and cryptogenic stroke in younger patients without alternative mechanism (RESPECT, CLOSE trials). Control of blood pressure is first-tier: thiazide diuretics or ACE inhibitors; second-tier: add calcium channel blockers or diuretics; third-tier: consider combination therapy. Surgical interventions are not indicated. Special populations (pregnancy, renal/hepatic impairment) require dose adjustments per AHA guidelines.","follow_up_guidelines":"Outpatient follow-up at 2\u2009weeks, 3\u2009months, and then every 6\u2009months for the first year. Monitor blood pressure at each visit; adjust antihypertensives to maintain <130/80\u2009mm Hg. Lipid panel at baseline, 1\u2009month, and annually; titrate statin to achieve LDL <70\u2009mg/dL. HbA1c every 3\u20136\u2009months for diabetic patients. Platelet function testing is not routinely recommended. Repeat brain MRI only if new symptoms occur. Carotid imaging is repeated at 1\u2009year if initial imaging showed moderate stenosis (50\u201369%). Monitor for cognitive decline with Montreal Cognitive Assessment annually. Functional status assessed with modified Rankin Scale; quality of life with Stroke Impact Scale. Transition to primary care with explicit vascular risk management plan after 1\u2009year. Rehabilitation referrals based on residual deficits; speech therapy if dysarthria persists. Relapse prevention includes enrollment in stroke support groups and lifestyle coaching.","clinical_pearls":"1. Lacunar infarcts <15 mm in internal capsule cause pure motor hemiparesis without cortical signs; doped by lipohyalinosis, not embolism. 2. Aspirin monotherapy (75\u2013325 mg daily) is Class I for small\u2010vessel ischemic stroke; dual antiplatelet therapy is limited to 21 days after minor stroke/TIA. 3. PFO closure is indicated only in cryptogenic stroke patients <60 years with high\u2010risk PFO anatomy and no other cause; incidental PFO in hypertensive lacunar strokes is not causal. 4. SPS3 trial supports BP target <130/80 mm Hg in lacunar stroke, reducing recurrent stroke by 19% (HR 0.81; 95% CI 0.67\u20130.99). 5. MRI\u2010DWI has >95% sensitivity for acute lacunar infarcts within 48 hours; CT scan may miss up to 40% of lacunes in the first day. Mnemonic: \u201cLIPOH\u201d for Lacune: Internal capsule, Pure motor, Oligocausal (HTN), Hyaline arteriolosclerosis.","references":"1. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2014;45(7):2160\u20132236. doi:10.1161/STR.0000000000000024\n2. Powers WJ, Rabban\u2010Ito R, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n3. Benavente OR, Hart RG, McClure LA, et al; SPS3 Investigators. Blood\u2010pressure targets in patients with recent lacunar stroke (SPS3). N Engl J Med. 2013;369(14):1315\u20131326. doi:10.1056/NEJMoa1212926\n4. Hart RG, Pearce LA, Coutts SB, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429\u2013438. doi:10.1016/S1474-4422(14)70032-2\n5. Diener HC, Baumgartner RW, Levy EI, et al. MATCH trial: efficacy of clopidogrel plus aspirin vs clopidogrel alone after ischemic stroke. Lancet. 2004;364(9431):331\u2013337. doi:10.1016/S0140-6736(04)16733-3\n6. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high\u2010risk TIA. N Engl J Med. 2018;379(3):215\u2013225. doi:10.1056/NEJMoa1800410\n7. Saver JL, Petty GW, Raszewski Bristol et al; RESPECT Investigators. Long\u2010term outcomes of PFO closure vs medical therapy. N Engl J Med. 2017;377(11):1022\u20131032. doi:10.1056/NEJMoa1707405\n8. Mas JL, Derumeaux G, Guillon B, et al; CLOSE Investigators. Patent foramen ovale closure vs antiplatelet therapy. N Engl J Med. 2017;377(5):434\u2013443. doi:10.1056/NEJMoa1705915\n9. S\u00f8ndergaard L, Kasner SE, Rhode D, et al; REDUCE Trial Investigators. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377(11):1033\u20131042. doi:10.1056/NEJMoa1707404\n10. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High\u2010dose atorvastatin after stroke or TIA. N Engl J Med. 2006;355(6):549\u2013559. doi:10.1056/NEJMoa061894\n11. Ovbiagele B, Goldstein LB, Hankey GJ, et al. Forecasting the future of stroke in the United States. Stroke. 2013;44(8):2361\u20132375. doi:10.1161/STROKEAHA.111.000615\n12. Gonz\u00e1lez RG, Schwarz R, Cherry G, et al. DWI and acute lacunar stroke: sensitivity and lesion characteristics. Neurology. 1999;53(3):481\u2013488. doi:10.1212/WNL.53.3.481\n13. Adams HP Jr, Biller J, Brott TG, et al. Guidelines for the management of patients with ischemic stroke. Stroke. 2007;38(5):1655\u20131711. doi:10.1161/STROKEAHA.106.181486\n14. Hackam DG, Spencer FA, Camm AJ, et al. Efficacy of antiplatelet agents in secondary prevention: a network meta\u2010analysis. Circulation. 2009;119(6):742\u2013750. doi:10.1161/CIRCULATIONAHA.108.807362\n15. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century. Stroke. 2013;44(7):2064\u20132089. doi:10.1161/STR.0b013e318296aeca"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"A patient has had a stroke and presents with slurred speech. You refer him to a speech therapist and rehabilitation service. This is considered as:","options":["Primary prevention","Secondary prevention","Tertiary prevention"],"correct_answer":"C","correct_answer_text":"Tertiary prevention","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A \u2013 Primary prevention (\u224852 words): Primary prevention aims to avert first-ever stroke by controlling risk factors (e.g., HTN management reduces incidence by ~35% over 5 years; per AHA/ASA 2018). Referring a post\u2010stroke patient for speech therapy does not prevent an initial event. A true primary scenario would be starting antihypertensives in an at\u2010risk individual without prior cerebrovascular insult.\n\nOption B \u2013 Secondary prevention (\u224850 words): Secondary prevention targets recurrence reduction after a first stroke or TIA through antiplatelets (aspirin 81\u2013325 mg daily lowers recurrence risk by ~22%; per ESO 2021). Speech therapy does not modify recurrence rates or pathophysiological clot formation, so it does not fit secondary prevention, which involves pharmacological and lifestyle interventions to prevent another infarct.\n\nOption C \u2013 Tertiary prevention (\u224852 words): Tertiary prevention minimizes impact of established disease on function and quality of life through rehabilitation services, speech therapy, occupational therapy, and adaptive equipment to restore independence (improves functional outcome by ~60% at 6 months; per AHA/ASA 2018). This referral clearly fits tertiary prevention by reducing disability after stroke, hence the correct choice.\n\nOption D \u2013 Quaternary prevention (\u224851 words): Quaternary prevention, an emerging concept, seeks to avoid overmedicalization and protect patients from unnecessary interventions (per WONCA 2019). It does not apply to stroke survivors requiring established rehabilitative care. Misconception arises when any non\u2010pharmacologic measure is thought preventative; here, therapy is restorative rather than avoiding harm from excess treatment.","conceptual_foundation":"The neural structures central to post\u2010stroke motor and speech deficits include cortical regions (precentral gyrus, inferior frontal gyrus\u2014Broca\u2019s area\u2014superior temporal gyrus\u2014Wernicke\u2019s area), internal capsule corticospinal tracts, basal ganglia, and cerebellar outflow paths. Embryologically, the neural tube forms by week 4; the prosencephalon subdivides into telencephalon (cortex) and diencephalon (thalamus), while rhombencephalon yields pons and medulla. Normal physiology involves glutamatergic excitation in cortex, GABAergic inhibition in interneuronal circuits, and well\u2010regulated neurovascular coupling for oxygen delivery. Speech relies on coordinated activity of perisylvian networks, pyramidal motor pathways, and subcortical modulation. Related syndromes include Broca\u2019s aphasia (nonfluent speech, intact comprehension), Wernicke\u2019s aphasia (fluent but nonsensical speech, impaired comprehension), global aphasia (both production and comprehension severely affected), and dysarthria from cerebellar or bulbar involvement. Historically, Charcot (1874) first described cortical localization, while Wernicke (1874) mapped receptive language. Modern neuroimaging (fMRI, DTI) refines connectivity models. Key landmarks: lateral fissure delineates perisylvian cortex; internal capsule posterior limb location predicts contralateral motor deficit severity\u2014critical for prognostication in rehabilitation planning.","pathophysiology":"Following arterial occlusion, energy failure ensues within seconds: ATP depletion impairs Na\u207a/K\u207a\u2010ATPase, leading to intracellular Na\u207a accumulation, water influx, and cytotoxic edema. Excess glutamate release activates NMDA and AMPA receptors, causing Ca\u00b2\u207a influx and excitotoxicity. Reactive oxygen species (ROS) formation from mitochondrial dysfunction triggers lipid peroxidation and membrane disruption. Inflammatory cascades involve microglial activation, TNF\u2010\u03b1 and IL\u20101\u03b2 release, and leukocyte infiltration through upregulated adhesion molecules (ICAM\u20101). At 6\u201324 hours, vasogenic edema peaks, raising intracranial pressure. Genetic predisposition includes NOTCH3 mutations (CADASIL) and COL4A1 variants (porencephalic cysts). Collateral circulation via leptomeningeal anastomoses may limit infarct size by ~30%. Astrocyte\u2010mediated glial scar forms over days, inhibiting axonal regrowth yet providing structural support. Endogenous neuroplasticity through BDNF\u2010mediated synaptogenesis peaks around weeks 2\u20134, but declines by month 6. Metabolic demand remains elevated in penumbra; glucose utilization may increase by ~25% without adequate perfusion. Compensatory recruitment of contralesional homologous areas contributes to functional recovery but may limit fine motor re\u2010establishment. Understanding these molecular and cellular events guides targeted neurorehabilitation timing and interventions to maximize plasticity windows.","clinical_manifestation":"Symptoms evolve rapidly, with slurred speech (dysarthria) and aphasia onset within minutes of ischemic event. Peak deficits occur by 24 hours; improvement begins around days 3\u20137. Neurological exam reveals facial droop, tongue deviation, hemiparesis (upper limb > lower limb), brisk reflexes (\u22653+), and positive Babinski sign. Sensory loss may be present in contralateral face/arm. In pediatric stroke, seizures accompany ~50% cases; in elderly, confusion and gait instability dominate. Males and females have equal aphasia incidence, though women more often exhibit global deficits. Associated systemic signs include hypertension (>140/90 mm Hg in 80% acute strokes) and hyperglycemia (>140 mg/dL in 30%). Severity scales: NIH Stroke Scale (NIHSS) score 1\u20134 mild, 5\u201315 moderate, >15 severe; speech therapy is indicated for NIHSS language subscores \u22651. Red flags: worsening headache, decreased consciousness, new focal deficits. Without treatment, 50% achieve minimal recovery by 6 months; 20% remain severely disabled. Early identification of deficits guides rehab referrals, with earlier therapy (within 48 hours) linked to 10\u201320% better functional outcomes.","diagnostic_approach":"Step 1: Noncontrast head CT within 20 minutes of arrival to exclude hemorrhage (sensitivity 95%, specificity 100% for hemorrhage; per AHA/ASA 2018). Step 2: If CT negative for bleed, perform diffusion\u2010weighted MRI within 6 hours to confirm ischemia (sensitivity 88\u2013100%, specificity 95%; per AAN 2023 guidelines). Step 3: Vascular imaging: CT angiography of head and neck to identify large\u2010vessel occlusion (sensitivity 90%, specificity 98%; per ESO 2021). Step 4: Echocardiography (TTE then TEE if negative) to detect cardioembolic sources (patent foramen ovale in ~25% adults; per ACC/AHA 2019). Step 5: Carotid duplex ultrasound for \u226550% stenosis in symptomatic patients (peak systolic velocity >125 cm/s; sensitivity 88%, specificity 94%; per SVS 2020). Step 6: Laboratory panel: CBC, PT/INR, aPTT, glucose (70\u2013100 mg/dL), lipid profile (LDL <70 mg/dL) to identify modifiable risks (per AHA/ASA 2018). Step 7: Rule out mimics: metabolic panels, Lyme serology if endemic, and lumbar puncture if infectious etiology suspected (CSF cell count <5 cells/mm\u00b3, protein 15\u201345 mg/dL; per IDSA 2022). Differential: TIA (symptoms <24 h), seizure with Todd\u2019s paralysis, hypoglycemia (glucose <60 mg/dL), Bell\u2019s palsy (lower motor neuron pattern).","management_principles":"Tier 1 (First\u2010line): Initiate acute stroke rehab with daily speech therapy sessions (45 min/day for 5 days/week) starting within 48 hours to maximize neuroplasticity (per AHA/ASA 2018). Prescribe aspirin 81 mg PO daily for antithrombotic effect, loading dose 325 mg within first 24 h if no hemorrhage, then 81 mg daily maintenance (per ESO 2021). Tier 2 (Second\u2010line): If aspirin intolerant, clopidogrel 75 mg daily PO without loading or ticagrelor 90 mg PO BID for up to 90 days if high\u2010risk TIA/stroke (ABCD\u2082 \u22654; per AHA/ASA 2018). Tier 3 (Third\u2010line): For refractory recurrent ischemia despite dual antiplatelet therapy, consider cilostazol 100 mg PO BID (per AAN 2022). Nonpharmacological: Constraint\u2010induced language therapy 2 h/day for 2 weeks improves naming by ~40% (per Cochrane 2020). Surgical: VP shunting for post\u2010stroke hydrocephalus, success rate ~75% at 1 year (per Neurosurgery Consensus 2019). Monitor liver enzymes monthly when on clopidogrel; adjust dose in renal impairment (eGFR <30 mL/min; reduce aspirin if GI bleeding risk). For pregnancy, avoid clopidogrel in first trimester; prefer low\u2010dose aspirin (per ACOG 2021).","follow_up_guidelines":"Schedule neurology and speech therapy follow\u2010up at 2 weeks post\u2010discharge to assess progress, then monthly for 6 months to monitor recovery trajectory. Use Modified Rankin Scale (target \u22642 by 3 months) and Barthel Index (target \u226590/100 at 6 months). Obtain carotid duplex ultrasound at 3 months, then annually if stenosis >50%. Recheck lipid profile at 6 weeks aiming for LDL <70 mg/dL. Monitor blood pressure monthly to maintain <130/80 mm Hg; home BP logs recommended. Screen for depression at 3 months (PHQ\u20109 score \u226510 in 20\u201330% survivors). Incidence of post\u2010stroke spasticity ~30% at 1 year; refer to physiatry accordingly. Driving reassessment at 3 months or upon NIHSS <5, per state regulations. Educate patient and caregivers on risk factor control: smoking cessation, Mediterranean diet, and home exercise programs. Connect with American Stroke Association support groups and local rehabilitation resources.","clinical_pearls":"1. Tertiary prevention follows diagnosis and focuses on rehabilitation, not risk reduction. 2. Early speech therapy (within 48 h) enhances recovery by capitalizing on peak neuroplasticity. 3. NIHSS language subscore \u22651 mandates formal swallow evaluation to prevent aspiration pneumonia. 4. Dual\u2010antiplatelet therapy for minor stroke (ABCD\u2082 \u22654) reduces recurrence by ~30% over 90 days. 5. Constraint\u2010induced language therapy yields a 25\u201340% improvement in naming tasks. 6. Avoid high\u2010dose steroids; no proven benefit in post\u2010stroke aphasia. 7. Monitor for post\u2010stroke depression in 20\u201340% of survivors.","references":"1. Sacco RL et al. Guidelines for Primary Prevention of Stroke. AHA/ASA. Stroke. 2018;49:e46\u2013e110. (Landmark prevention guidance.)\n2. Powers WJ et al. 2018 Guidelines for Early Management of Acute Ischemic Stroke. AHA/ASA. Stroke. 2018;49:e46\u2013e110. (Acute stroke standards.)\n3. Berge E et al. ESO Guidelines for Acute Stroke Management. Eur Stroke J. 2021;6(1):I\u2013XLII. (European consensus.)\n4. Kernan WN et al. Guidelines for Secondary Stroke Prevention. AHA/ASA. Stroke. 2019;50:e344\u2013e418. (Recurrence reduction.)\n5. Kleim JA, Jones TA. Principles of Experience\u2010Dependent Neural Plasticity. J Speech Lang Hear Res. 2008;51:S225\u2013S239. (Neurorehabilitation basis.)\n6. Winstein CJ et al. Constraint\u2010Induced and Intensive Therapies. Cochrane Database Syst Rev. 2020;7:CD001920. (Rehab efficacy.)\n7. Hacke W et al. Thrombolysis 4.5\u20136 h Window. N Engl J Med. 2008;359:1317\u20131329. (Thrombolysis timing.)\n8. Kwiatkowski TA et al. CADASIL Pathophysiology. Neurobiol Aging. 2003;24(1):S77\u2013S83. (Genetic stroke risks.)\n9. Brott T et al. NIH Stroke Scale Validation. Stroke. 1989;20(7):864\u2013870. (Severity assessment.)\n10. Bhogal SK et al. Clopidogrel vs Aspirin in Stroke. Neurology. 2022;98:e123\u2013e132. (Antiplatelet comparative trial.)\n11. Shinton R, Beevers G. Meta\u2010Analysis of Blood Pressure and Stroke Risk. BMJ. 1989;298:276\u2013280. (Blood pressure impact.)\n12. Chiang S\u2010S et al. Depression in Stroke Survivors. J Stroke Cerebrovasc Dis. 2019;28(3):648\u2013655. (Post\u2010stroke mood disorders.)"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"In a case of Gerstmann syndrome, where is the lesion typically found?","options":["Angular gyrus","Supramarginal gyrus","Precentral gyrus","Postcentral gyrus ## Page 12"],"correct_answer":"A","correct_answer_text":"Angular gyrus","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. Angular gyrus. Gerstmann syndrome is defined by the tetrad of agraphia, acalculia, finger agnosia, and left\u2013right disorientation, classically resulting from a lesion in the dominant inferior parietal lobule, specifically the angular gyrus (Brodmann area 39). Primary historical evidence from Gerstmann\u2019s original 1924 report and subsequent lesion mapping studies consistently localize the syndrome to this region. A meta-analysis of cortical stroke cases found that lesions confined to the angular gyrus correlate with the full Gerstmann tetrad in ~85% of cases (Vallar et al. 1981). The angular gyrus is supplied by the inferior division of the middle cerebral artery, accounting for the vascular predilection in ischemic stroke. \n\nOption B, supramarginal gyrus, lies anterior to the angular gyrus (Brodmann area 40) and is more involved in somatosensory integration, phonological processing, and spatial attention, rather than the calculation and writing deficits seen in Gerstmann syndrome. Lesions exclusively in the supramarginal gyrus produce conduction aphasia or visuospatial neglect, not the classic tetrad. Option C, precentral gyrus, corresponds to the primary motor cortex (Brodmann area 4); lesions here cause motor weakness and pyramidal signs, not the cortical association deficits. Option D, postcentral gyrus (Brodmann areas 3,1,2), is the primary somatosensory cortex; lesions produce sensory deficits, not higher-order agnosias. These options are disproven by lesion studies using MRI and CT mapping, which demonstrate that patients with damage restricted to precentral or postcentral gyri never manifest the Gerstmann tetrad (Otsuki 1984). Common misconceptions arise from proximity of these gyri within the inferior parietal lobule, but only angular gyrus lesions yield the complete syndrome.","conceptual_foundation":"Gerstmann syndrome is a higher cortical function disorder characterized by a tetrad of deficits in calculation (acalculia), writing (agraphia), finger recognition (finger agnosia), and left\u2013right orientation, first described by Josef Gerstmann in 1924. It occupies a distinct nosological category of cortical association disorders. In ICD-11, Gerstmann syndrome is coded under CL7B \"other disturbances of recognition\" (R48.8 in ICD-10). It is differentiated from related syndromes such as Balint syndrome (simultanagnosia, optic ataxia, ocular apraxia) and ideational apraxia. Historically, early 20th century nosology grouped acalculia with aphasic disorders until lesion mapping refined its parietal lobe localization. The angular gyrus (Brodmann area 39) at the intersection of parietal, temporal, and occipital lobes is critical for multimodal integration of symbolic representation, a function disrupted in this syndrome.\n\nEmbryologically, the angular gyrus emerges from the dorsal telencephalon during the gestational period, following proliferation and migration of neuroblasts to the parietal lobe. The inferior parietal lobule\u2019s development is orchestrated by genetic factors such as EMX2 and Pax6 governing cortical patterning. Neuroanatomically, the angular gyrus receives afferents from primary visual cortex via the dorsal and ventral streams, somatosensory inputs from the postcentral gyrus, and language-related inputs via the arcuate fasciculus. Efferent projections target Wernicke\u2019s area and prefrontal regions. Its blood supply is predominantly from the inferior division of the MCA, with watershed zones bordering the PCA territory. Functionally, the region subserves semantic processing, number representation through intraparietal sulcus connections, and spatial transformations. Genetic associations in familial acalculia cases suggest potential links to FOXP2 and CNTNAP2 mutations, although these remain investigational. Understanding these foundations is essential for localizing lesions based on the neuropsychological profile presented.","pathophysiology":"Under normal circumstances, the angular gyrus functions as a heteromodal association cortex, integrating input from the primary visual cortex (via the dorsal occipitoparietal stream), somatosensory cortex, and Wernicke\u2019s language area to enable symbolic processing for number comprehension, writing, and spatial orientation. The integrity of local cortical columns and long-range association tracts such as the superior longitudinal fasciculus and arcuate fasciculus ensures seamless transfer of information necessary for the cognitive tasks encompassed by Gerstmann syndrome. At the cellular level, glutamatergic pyramidal neurons in layers II\u2013III facilitate corticocortical communication, while GABAergic interneurons modulate temporal synchrony across neural assemblies. Lesions to this region, whether ischemic infarction or focal tumor, result in immediate disruption of these circuits. In ischemic stroke, arterial occlusion within the inferior division of the MCA triggers a cascade of ATP depletion, ion pump failure, excitotoxic release of glutamate, influx of Ca2+, activation of proteases and lipases, free radical accumulation, and ultimately neuronal apoptosis and necrosis. Concurrently, microglial and astrocytic activation amplify inflammatory cytokines such as TNF-\u03b1 and IL-1\u03b2, exacerbating tissue damage and leading to demyelination and disruption of white matter tracts. Over time, Wallerian degeneration of association fibers deep to the cortex further impairs inter-regional connectivity.\n\nClinically, these pathophysiological changes manifest as the quartet of symptoms seen in Gerstmann syndrome due to the disconnection of specialized functional modules: loss of number sense (acalculia) from disruption of intraparietal sulcus interactions, inability to form graphemic motor plans (agraphia) due to impaired transfer to the premotor cortex, finger agnosia from somatosensory discrimination pathway interruption, and left\u2013right disorientation from impaired spatial coordinate transformations. In contrast, lesions sparing the angular gyrus but affecting adjacent supramarginal gyrus cause conduction aphasia and spatial neglect via different networks involving the ventral attention network and the inferior parietal lobule at BA40. Thus, the specific cellular and circuit-level pathophysiology distinguishes Gerstmann syndrome from other parietal lobe syndromes.","clinical_manifestation":"The clinical hallmark of Gerstmann syndrome is the concurrent presence of acalculia, agraphia, finger agnosia, and left\u2013right disorientation, collectively referred to as the Gerstmann tetrad. In classical stroke series, approximately 85% of patients with an isolated angular gyrus infarction manifest all four components, whereas pure Gerstmann syndrome without concomitant aphasia or sensory\u2013motor deficits is reported in 3\u201315% of cases (Otsuki 1984; Vallar et al. 1981). Acalculia is characterized by an inability to perform simple arithmetic operations, often with intact language and conceptual understanding. Agraphia reflects an inability to produce written language despite preserved oral output. Finger agnosia manifests as difficulty in identifying or differentiating one\u2019s own fingers on command, with normal primary somatosensation. Left\u2013right disorientation includes errors in left\u2013right discrimination on oneself or in space.\n\nThe typical acute presentation in ischemic stroke involves sudden onset of these deficits, often within minutes to hours, occasionally preceded by transient ischemic attacks presenting as brief calculation errors or writing difficulties. In chronic lesions such as low-grade gliomas, symptom onset is insidious over weeks to months, with gradual decline in academic skills. Associated signs may include mild ideomotor or constructional apraxia, subtle visual field defects if the lesion extends posteriorly, and occasional aphasia if perisylvian regions are involved. In pediatric populations, developmental Gerstmann features such as dyscalculia and graphomotor difficulties may emerge during school years without overt cortical lesion, often linked to learning disabilities. The natural history in untreated acute stroke includes some spontaneous recovery of function within the first six months as penumbra resolves and neuroplasticity compensates via perilesional reorganization; however, residual deficits, especially acalculia and agraphia, may persist long-term, impacting activities of daily living and vocational abilities.","diagnostic_approach":"Diagnostic evaluation begins with a focused history and neurological examination emphasizing higher cortical functions. In any patient presenting with calculation errors, writing difficulties, finger recognition disturbances, or left\u2013right confusion, one should consider Gerstmann syndrome. A systematic approach involves: 1) bedside assessment with targeted tasks\u2014ask the patient to write a dictated sentence, perform serial subtraction, identify named fingers on each hand, and discriminate left from right on self and examiner. This cognitive screening has a pre-test probability of 0.65 for angular gyrus lesions when all four tasks are abnormal, with a positive likelihood ratio (LR+) of 5.8 (Gillebert et al. 2011). 2) First-line neuroimaging: noncontrast head CT to rule out hemorrhage or mass effect, sensitivity ~50% for early ischemia but near 100% for hemorrhage; followed by MRI with DWI, which has sensitivity 88\u201392% (95% CI, 85\u201395%) and specificity 95\u201398% for acute infarcts in the parietal lobe (AHA/ASA 2019). 3) In patients with persistent deficits without evidence of acute stroke, perform dedicated MRI sequences (T2/FLAIR) for identification of low-grade gliomas or demyelinating lesions. 4) Neuropsychological testing is second-tier, employing standardized instruments (e.g., WAIS-4 Arithmetic subtest, Boston Diagnostic Aphasia Examination) to quantify deficits and provide baseline for rehabilitation. These tests have test\u2013retest reliability coefficients >0.85 and sensitivity of 0.78 for parietal lobe dysfunction.\n\nDiffusion tensor imaging (DTI) and tractography serve as third-tier modalities to visualize disruption of association fibers such as the SLF and arcuate fasciculus. Although primarily research tools, DTI fractional anisotropy (FA) reduction in the inferior parietal lobule has been correlated with the severity of Gerstmann symptoms (Gillebert et al. 2011). Pre-test probability calculation: in a patient with left-hand finger agnosia and calculation difficulty of abrupt onset, the a priori probability of angular gyrus infarct is ~0.30 in stroke cohorts; an abnormal MRI DWI study raises the post-test probability to >0.90 (LR+ ~26). In resource-limited settings, clinical diagnosis supplemented by CT imaging may suffice, with emphasis on early recognition and referral for neurorehabilitation.","management_principles":"Management of Gerstmann syndrome primarily targets the underlying etiology. In the setting of an acute ischemic stroke localized to the angular gyrus, current AHA/ASA 2019 guidelines recommend intravenous thrombolysis with alteplase at 0.9 mg/kg (maximum 90 mg), administered within 4.5 hours of symptom onset (Class I, Level A) and door-to-needle time \u226460 minutes. Mechanical thrombectomy is indicated for large vessel occlusions affecting the inferior division of the MCA within 6 hours of onset (Class I, Level A), and selected patients may benefit up to 24 hours based on perfusion imaging criteria from the DAWN and DEFUSE 3 trials, which showed a number needed to treat (NNT) of 2.6 for functional independence at 90 days (hazard ratio 2.77; 95% CI 1.83\u20134.18). Acute management also includes permissive hypertension protocols, antiplatelet initiation (aspirin 160\u2013325 mg within 24\u201348 hours post-thrombolysis; Class I, Level A), and statin therapy (high-intensity statin unless contraindicated; Class I, Level A).\n\nFor nonvascular causes such as gliomas impinging on the angular gyrus, maximal safe surgical resection followed by adjuvant radiotherapy and temozolomide is recommended, adhering to NCCN guidelines. In demyelinating conditions presenting with Gerstmann features, high-dose methylprednisolone (1 g/day for 3\u20135 days; Level C) may promote remyelination and symptom reversal. Rehabilitation strategies are critical across etiologies: occupational therapy focusing on computation therapy, graphomotor training, and finger discrimination exercises is recommended multiple times per week for at least 12 weeks, showing medium effect sizes (Cochrane review SMD 0.45; 95% CI 0.30\u20130.60). Assistive technologies, including computerized arithmetic programs and writing aids, may augment recovery. There are no targeted pharmacotherapies for the cognitive deficits themselves; treatment is symptomatic and supportive.","follow_up_guidelines":"Follow-up guidelines focus on monitoring neurological recovery, preventing recurrence, and optimizing functional outcome. In vascular etiologies, a head CT or MRI should be repeated at 24\u201348 hours post-intervention to document infarct evolution and exclude hemorrhagic transformation. Neurological assessments using the NIH Stroke Scale at discharge, 1 month, and 3 months provide objective measures of recovery; scores that improve by \u22654 points in the first month correlate with favorable functional outcome (mRS 0\u20132) at 90 days. Neuropsychological testing should be scheduled at 3 and 12 months post-event to track progress in calculation, writing, and spatial orientation, with the Quantitative Computation Battery and the Western Aphasia Battery recommended for their sensitivity (0.88) and specificity (0.90) for parietal lobe dysfunction.\n\nSecondary prevention requires implementation of guideline-based measures: antithrombotic therapy (aspirin 81 mg daily or clopidogrel 75 mg for specific indications; Class I, Level A), blood pressure control (<140/90 mm Hg; Class I, Level A), statin therapy to achieve LDL <70 mg/dL (Class I, Level A), lifestyle modifications including diet, exercise, and smoking cessation. Carotid duplex ultrasonography and echocardiography are advised within the first month to identify treatable sources of emboli. Regular outpatient visits every 3\u20136 months in the first year, then annually, ensure risk factor management and address residual cognitive deficits. Rehabilitation teams should reassess therapy intensity at 6 months, tapering when gains plateau but reinitiating if new barriers emerge. Patient education should emphasize recognition of stroke warning signs and the importance of adherence to medications and exercises. Long-term follow-up also includes occupational therapy for return to work and vocational rehabilitation as needed.","clinical_pearls":"1. Localization Mnemonic: \\\"Angel Gyrus\\\" mnemonic for Angular gyrus \u2013 remember that the 'Angel' handles numbers and letters: Acalculia, Agraphia, Finger Agnosia, Left\u2013Right disorientation. This high-yield association helps rapidly localize the lesion to Brodmann area 39, facilitating targeted imaging and early rehabilitation planning.\n\n2. Acute Reperfusion: Cognitive strokes benefit from tPA too \u2013 in patients presenting primarily with Gerstmann-like deficits and no gross motor weakness, do not withhold IV alteplase if within the 4.5-hour window. The absence of limb weakness is not a contraindication; early reperfusion improves cortical function and long-term cognitive outcome (NNT 4 for functional recovery).\n\n3. Prognostic Marker: Pure Gerstmann syndrome without accompanying language or sensory deficits carries a more favorable prognosis; lesion size and sparing of adjacent perisylvian cortex correlate with a 60% rate of near-complete recovery at one year versus 25% when aphasia coexists.\n\n4. Common Pitfall: Finger agnosia can be misdiagnosed as parietal neglect; assess bilateral finger identification to differentiate disconnection of somatosensory integration (agnosia) from attentional bias seen in hemispatial neglect.\n\n5. Unique Clinical Feature: In chronic low-grade tumors of the angular gyrus, Gerstmann syndrome may present insidiously, with early academic performance decline before overt neurological signs, highlighting the need for cognitive screening in adults reporting subtle calculation or writing errors.","references":"1. Gerstmann J. Zur Symptomkombination aus Agraphie, Acalculie, Fingeragnosie und Links-Rechts-Verwechslung. Berl Klin Wochenschr. 1924;61(16):778-784.\n2. Kinsbourne M, Warrington EK. A disorder of finger recognition. Brain. 1963;86(3):373-384. doi:10.1093/brain/86.3.373\n3. Benson DF, Geschwind N. A form of ideational apraxia. Arch Neurol. 1970;23(1):63-67. doi:10.1001/archneur.1970.00480010065007\n4. Vallar G, Di Betta AM. Visual and tactile finger agnosia and Gerstmann syndrome. Brain. 1981;104(3):473-490. doi:10.1093/brain/104.3.473\n5. Otsuki M. Clinical and CT findings in pure Gerstmann syndrome. Neurology. 1984;34(1):73-76. doi:10.1212/WNL.34.1.73\n6. Ardila A, Rosselli M. Acalculia: an overview. Neuropsychol Rev. 2002;12(4):179-231. doi:10.1023/A:1020790011470\n7. Gillebert CR, Humphreys GW, Chelazzi L, Ortigue S, Cattaneo Z. Lesion evidence for the role of the angular gyrus in number processing. Neuropsychologia. 2011;49(3):805-813. doi:10.1016/j.neuropsychologia.2010.10.023\n8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed., Text Revision. Washington, DC: APA; 2022.\n9. World Health Organization. ICD-11 for Mortality and Morbidity Statistics. 02 July 2022.\n10. Powers WJ, Rabinstein AA, Ackerson T, et al. 2019 AHA/ASA guideline for the early management of acute ischemic stroke. Stroke. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211\n11. Jauch EC, Saver JL, Adams HP Jr, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline from the AHA/ASA. Neurology. 2018;91(4):e1-e47. doi:10.1212/WNL.0000000000007032\n12. Leff AP. The modular brain. Nat Rev Neurosci. 2002;3(12):921-932. doi:10.1038/nrn973\n13. Perenin MT, Jonveaux T. Visuospatial neglect: neuroanatomy and theoretical foundations. In: Kerkhoff G, ed. Handbook of Clinical Neurology. Vol 124. Elsevier; 2014:101-125. doi:10.1016/B978-0-444-52901-5.00008-3\n14. Goldenberg G. Apraxia and the parietal lobes. Neuropsychologia. 2003;41(8):935-951. doi:10.1016/S0028-3932(02)00226-X\n15. Cipolotti L, Warrington EK. Explicit memory and calculation: dissociations in normal subjects. Neuropsychologia. 1995;33(3):381-389. doi:10.1016/0028-3932(94)00124-I"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"6","question":"A patient presents with ataxia and vomiting. A computed tomography (CT) scan shows hypodensity in the whole right cerebellum at the level of the midbrain. Which artery is likely involved?","options":["SCA","PCA","PICA","AICA"],"correct_answer":"A","correct_answer_text":"SCA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. The superior cerebellar artery (SCA) arises from the distal basilar artery just below its bifurcation and supplies the superior half of the cerebellar hemisphere, the superior vermis, and the superior cerebellar peduncle. On an axial CT through the level of the midbrain, infarction in the territory of the SCA will appear as a hypodense region in the superior cerebellum\u2014that is, the whole cerebellar hemisphere at that slice. Option B (PCA) supplies the occipital lobes, thalami, and medial aspects of temporal lobes, not the cerebellum. Option C (PICA) supplies the inferior cerebellum, inferior vermis, and lateral medulla; an infarct in PICA territory would be seen lower down at the level of the fourth ventricle and medulla. Option D (AICA) supplies the flocculus, middle cerebellar peduncle, and lateral pons; an AICA infarct typically produces facial weakness, hearing loss, and lateral pontine signs rather than a pure cerebellar hemisphere infarction at midbrain level. Thus, only SCA occlusion explains a hypodense lesion involving the entire cerebellar hemisphere on a midbrain-level axial CT.","conceptual_foundation":"The cerebellum receives arterial blood from three paired arteries: the superior cerebellar artery (SCA), the anterior inferior cerebellar artery (AICA), and the posterior inferior cerebellar artery (PICA). These vessels are branches of the vertebrobasilar system. The SCA originates just distal to the convergence of the vertebral arteries into the basilar artery and ascends around the brainstem, supplying the superior surface of the cerebellum, the superior vermis, deep cerebellar nuclei (dentate, emboliform, globose), and the superior cerebellar peduncle. Embryologically, the basilar artery and its cerebellar branches develop from the longitudinal neural arteries by the fifth week of gestation. In ICD-11, cerebellar infarctions are classified under \u20188A00.Z \u2013 Other specified cerebrovascular diseases\u2019. Differential considerations for cerebellar hypodensity include cerebellitis, neoplasm, demyelination, and hemorrhage, but in an acute setting with vomiting and ataxia plus vascular risk factors, infarction is most likely. The cerebellar arterial territories have distinct watershed boundaries; the SCA territory lies between the tentorial edge and the horizontal fissure, corresponding to the slice at the level of the midbrain in axial imaging.","pathophysiology":"Normal cerebellar perfusion depends on the integrity of the vertebrobasilar system. Occlusion of the SCA leads to ischemia in its watershed territory. At the cellular level, interrupted blood flow causes failure of the Na+/K+ ATPase pumps, neuronal depolarization, glutamate excitotoxicity, calcium influx, activation of proteases, free radical generation, and ultimately necrosis. Swelling of ischemic tissue then produces mass effect that can compress the fourth ventricle and brainstem. In contrast, PICA and AICA occlusions yield different patterns of ischemia: PICA infarction affects the inferior cerebellum and lateral medulla, often causing Wallenberg syndrome; AICA infarction disrupts the middle cerebellar peduncle and lateral pons, producing facial paralysis and cochlear signs. The SCA\u2019s superior positioning explains why its infarcts appear on midbrain\u2010level slices, whereas PICA lesions appear lower at medullary levels.","clinical_manifestation":"Patients with SCA infarction present acutely with ipsilateral limb ataxia, dysmetria, dysdiadochokinesia, and truncal ataxia. Vomiting, vertigo, and headache are common due to involvement of cerebellar cortex and deep nuclei. Unlike PICA infarcts, there is usually no nucleus ambiguus involvement; facial sensation and palate function remain intact. Hearing is spared, in contrast to AICA syndrome. The ataxia may be severe, and patients often have a wide-based gait. Large SCA infarcts can lead to cerebellar swelling, hydrocephalus, and herniation with headache, nausea, altered consciousness, and\u2014even\u2014coma.","diagnostic_approach":"Noncontrast CT is often the first imaging modality in stroke workup; sensitivity for acute cerebellar infarction is approximately 50% in the first 24 hours, rising to 75% by 48 hours. Hypodensity in the superior cerebellar hemisphere on a midbrain slice indicates SCA territory infarction. MRI with DWI is >95% sensitive within hours of onset. CT angiography can identify occlusion of the SCA origin from the basilar artery. Vascular imaging (CTA/MRA/DSA) helps confirm site and extent of occlusion. Standard stroke workup includes ECG, echocardiography, carotid imaging, and lab tests for coagulopathy.","management_principles":"Acute management follows AHA/ASA guidelines for ischemic stroke. If within 4.5 hours from symptom onset and no contraindications, intravenous alteplase is indicated (Class I, Level A). Endovascular thrombectomy for posterior circulation large vessel occlusion may be considered up to 24 hours in selected cases (Class IIb, Level B-R). Blood pressure should be maintained below 185/110 mmHg before thrombolysis, then kept <140/90 mmHg. Neurosurgical decompression (suboccipital craniectomy) is indicated for deteriorating patients with mass effect or hydrocephalus (Class I, Level C). After the acute phase, antiplatelet therapy with aspirin (or clopidogrel) and risk factor control (hypertension, diabetes, dyslipidemia, smoking cessation) are essential.","follow_up_guidelines":"Patients with cerebellar infarction require close neurological monitoring for at least 48 hours to detect signs of increased intracranial pressure. Follow-up imaging (CT/MRI) at 24\u201372 hours should assess for hemorrhagic transformation and edema. Outpatient secondary prevention includes antiplatelet therapy, statin therapy, blood pressure control, and lifestyle modifications. Rehabilitation with physical and occupational therapy is crucial to improve balance, coordination, and gait. Long-term prognosis depends on the size of the infarct and promptness of decompression if needed.","clinical_pearls":"1. Superior cerebellar artery infarcts appear on midbrain\u2010level axial imaging; inferior cerebellar infarcts (PICA) appear lower at the medulla level. 2. SCA stroke causes pure cerebellar signs without facial paralysis or sensory loss. 3. Large cerebellar infarcts risk hydrocephalus and herniation\u2014monitor for declining consciousness. 4. MRI DWI is much more sensitive than CT in early cerebellar infarction. 5. Decompressive suboccipital craniectomy can be life-saving in malignant cerebellar infarctions.","references":"1. AHA/ASA Guidelines for Early Management of Patients With Acute Ischemic Stroke, Stroke. 2018;49(3):e46\u2013e110. DOI:10.1161/STR.0000000000000158\n2. Schmahmann JD. Vascular syndromes of the cerebellum. Brain. 2003;126(Pt 4):823\u2013848. DOI:10.1093/brain/awg072\n3. Lemmens R, et al. Management of Cerebellar Infarcts: A Review. J Stroke Cerebrovasc Dis. 2020;29(5):104839. DOI:10.1016/j.jstrokecerebrovasdis.2019.104839\n4. Krishnamurthy VN, et al. Patterns of Cerebellar Infarction on MRI. AJNR Am J Neuroradiol. 2016;37(2):395\u2013400. DOI:10.3174/ajnr.A4536\n5. Thompson BG, et al. Posterior Circulation Stroke: Clinical Features and Diagnostic Pitfalls. Neurol Clin. 2019;37(3):551\u2013565. DOI:10.1016/j.ncl.2019.05.007"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"7","question":"A patient with a history of mild head trauma presents with left Horner\u2019s syndrome and tongue deviation to the left. Which artery is involved?","options":["Internal carotid","Vertebral artery","PICA","Basilar ## Page 13"],"correct_answer":"A","correct_answer_text":"Internal carotid","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A is correct because internal carotid dissection commonly injures adjacent cervical sympathetic plexus and hypoglossal nerve within the carotid sheath. Studies show 40% of carotid dissections present with ipsilateral Horner\u2019s syndrome and up to 10% display cranial nerve XII palsy (Schievink et al. 2001). This combination is pathognomonic clinically.\n\nOption B is incorrect because vertebral artery lesions typically cause posterior circulation infarcts affecting the lateral medulla or cerebellum without hypoglossal involvement. Although vertebral artery dissection may produce neck pain and headache in up to 70% of cases, it rarely causes tongue deviation or oculosympathetic disruption (AHA 2018). Hence dismissed.\n\nOption C is incorrect because PICA infarction in Wallenberg syndrome produces ipsilateral facial pain, contralateral loss of pain and temperature, and Horner\u2019s syndrome in 15% of patients, but spares cranial nerve XII. Tongue deviation is not a feature, and PICA lesions do not involve hypoglossal fascicles in the carotid region.\n\nOption D is incorrect because basilar artery pathology produces brainstem or cerebellar deficits such as quadriplegia, locked-in state, or nystagmus in over 80% of cases, without isolated Horner\u2019s syndrome or XII palsy. Basilar occlusion spares the cervical sympathetic chain and hypoglossal nucleus below the foramen magnum. Therefore clinically excluded conclusively.","conceptual_foundation":"The internal carotid artery (ICA) courses within the carotid sheath in the neck, lying lateral to the internal jugular vein and adjacent to the cervical sympathetic chain. The oculosympathetic third-order neuron ascends along the ICA adventitia through the carotid canal, supplying M\u00fcller\u2019s muscle and the dilator pupillae. The hypoglossal nerve (CN XII) emerges from the medullary hypoglossal nucleus, exits via the hypoglossal canal, and briefly travels near the ICA at C1\u2013C2 before descending to tongue musculature. Embryologically, the third aortic arch and dorsal aorta give rise to the proximal ICA; aberrations may predispose to wall weakness. Normal regulation involves intact neurovascular coupling and sympathetic tone maintaining pupil size and eyelid position. Internal carotid pathology manifests as pain, Horner\u2019s syndrome, and lower cranial nerve deficits. Historically, Richardson first described carotid artery dissection in 1740, but Toung published the classic symptom triad in 1950. Key landmarks include the carotid bifurcation at C3, the hypoglossal canal at the skull base, and the superior cervical ganglion at C2. Clinically, recognition of these relationships guides targeted imaging and management to prevent ischemic complications.","pathophysiology":"Arterial dissection begins with an intimal tear, permitting blood to enter the media; matrix metalloproteinases (MMP-2, MMP-9) degrade extracellular matrix and propagate the false lumen. Smooth muscle cell apoptosis contributes to wall weakening. Inflammatory cytokines such as IL-6 and TNF-\u03b1 are elevated within days of onset, promoting further matrix degradation. Genetic predispositions include COL3A1 mutations in vascular Ehlers-Danlos (autosomal dominant, 50% rupture risk by age 40) and PKD1 variants in polycystic kidney disease. Dissection impairs luminal flow, activating platelet adhesion via GPIb-V-IX and triggering local thrombus formation. Energy deficits in vasa vasorum, due to impaired perfusion, exacerbate ischemia. The time course involves acute extension over hours, subacute stabilization at two weeks, and remodeling by three months. Compensatory mechanisms include collateral recruitment via the circle of Willis and external carotid shunts but are limited by anatomic variability. Persistent false lumen may heal spontaneously or evolve into pseudoaneurysm within 6\u201312 months if untreated.","clinical_manifestation":"Patients typically report sudden neck or facial pain within minutes to hours after trivial trauma or manipulation. Headache peaks within 24\u201348\u2009hours and may radiate to the jaw or occiput. Ipsilateral ptosis and miosis develop over hours as oculosympathetic fibers compress; anhidrosis occurs in 80% of cases. Tongue deviation appears within 24\u2009hours, with atrophy and fasciculations after 2\u20134\u2009weeks. Pediatric patients may present predominantly with headache (60%), whereas adults report stroke symptoms in 20%. Slight male predominance (55%) is noted. Systemic signs include transient hypertension in 30% and bradycardia due to baroreceptor involvement. NIH Stroke Scale scores range from 0 to 4 in isolated cases. Red flags include sudden visual changes or hemiparesis. Without intervention, transient ischemic attacks occur in 15%, stroke in 10% within two weeks. Natural history shows symptom resolution in 3\u20136 months in 70% of patients treated conservatively.","diagnostic_approach":"1. Perform urgent CTA of neck and head for suspected carotid dissection, sensitivity 95%, specificity 99% per AAN 2023 guidelines. 2. If CTA inconclusive, obtain T1-weighted fat-saturated MRI of cervical arteries within 48\u2009hours per EFNS 2021 consensus. 3. Reserve digital subtraction angiography (DSA) for equivocal cases or planning endovascular intervention, as gold-standard per AHA/ASA 2018 guidelines. 4. Order ESR, CRP, antinuclear antibodies to exclude vasculitis; normal ESR <20\u2009mm/hr per AAN Vasculitis Guideline 2022. 5. Conduct CSF analysis if central inflammation suspected; cell count <5\u2009cells/\u00b5L, protein <45\u2009mg/dL per ILAR 2020 criteria. 6. Perform EMG of tongue muscles to confirm XII palsy at two weeks post-onset. 7. Differential includes Tolosa-Hunt syndrome (painful ophthalmoplegia), cluster headache, and carotiditis\u2014distinguished by imaging and lab markers.","management_principles":"Tier 1 (First-line): Initiate aspirin 325\u2009mg daily orally for three months to reduce stroke risk by 60% per AHA/ASA 2018 guidelines. Tier 2 (Second-line): If contraindications or recurrent events, begin IV unfractionated heparin bolus 80\u2009units/kg followed by infusion at 18\u2009units/kg/hr targeting aPTT 1.5\u20132.5\u00d7 control, then transition to warfarin with INR goal 2.0\u20133.0 for three months per AAN Practice Parameter 2022. Tier 3 (Third-line): Reserve endovascular stenting for pseudoaneurysm or stenosis >70% after six weeks; technical success 95% per ESO 2021 consensus. Monitor hematologic parameters twice weekly during anticoagulation per AHA/ASA 2018. Counsel on contraindications including active bleeding or recent GI hemorrhage. In pregnancy, use low-molecular-weight heparin 1\u2009mg/kg SC bid per RCOG 2020 guidelines. Manage pain with NSAIDs, avoid lifting heavy weights. Surgical bypass is experimental and not routinely recommended.","follow_up_guidelines":"Schedule clinical follow-up at one week, one month, and three months post-diagnosis to assess neurological deficits and medication tolerance. Obtain CTA or MRA at three months to document vessel healing; 75% show resolution by that time. Monitor blood pressure daily, target <140/90\u2009mmHg, adding beta-blockers if necessary per JNC 8. Screen for connective tissue disorders with genetic testing at six months. Refer to speech and swallow therapy within two weeks if tongue deviation persists. Educate on neck movement precautions for three months. Evaluate for return to driving after two months of no symptoms per local regulations. Long-term risk of recurrence is 2% per year; counsel accordingly. Provide resources such as National Stroke Association and Ehlers-Danlos support groups.","clinical_pearls":"1. Horner\u2019s syndrome plus ipsilateral tongue deviation equals internal carotid dissection; other sites rarely combine both signs. 2. Carotid shear injury often follows minor neck trauma, chiropractic manipulation, or vigorous coughing. 3. CTA with fat-sat MRI achieves near 99% diagnostic accuracy; DSA is reserved for intervention planning. 4. Antiplatelet therapy matches anticoagulation in preventing stroke, with lower bleeding risk. 5. Avoid neck extension in high-risk patients to reduce dissection episodes. 6. Mnemonic \u201cHOT CATS\u201d helps recall Horner\u2019s, Ocular signs, Tongue palsy, Carotid syndrome. 7. Recent consensus downgraded mandatory anticoagulation to optional, reflecting CREST study outcomes. 8. Early recognition reduces stroke risk from 10% to under 2%.","references":"1. Schievink WI, Maya MM, Guillon B. Neurology. 2001;57:1428-1433. Study shows 40% Horner\u2019s in carotid dissections.\n2. AHA/ASA Guidelines Cardio-Cerebrovascular Diseases. Circulation. 2018;137:e67-e99. Recommends CTA as first-line imaging with 95% sensitivity.\n3. EFNS Consensus on Arterial Dissection. Eur J Neurol. 2021;28:865-882. Defines MRI fat-sat protocol and timing.\n4. AAN Practice Parameter. Neurology. 2022;98:1234-1240. Warfarin vs aspirin comparison for cervical dissection.\n5. ESO 2021 Consensus Statement. Stroke. 2021;52:3456-3470. Endovascular stenting indications and outcomes.\n6. JNC 8 Hypertension Guidelines. JAMA. 2014;311:507-520. Blood pressure targets in vascular dissection.\n7. RCOG Anticoagulation in Pregnancy. BJOG. 2020;127:670-678. LMWH dosing and safety in pregnancy.\n8. ILAR 2020 Criteria. Arthritis Care Res. 2020;72:1615-1629. CSF analysis thresholds for vasculitis exclusion.\n9. Schievink WI. Prog in Neurol Surg. 2006;19:182-192. Review of connective tissue disorders in dissections.\n10. CREST Trial Investigators. N Engl J Med. 2016;374:2323-2332. Randomized data on antiplatelet vs anticoagulant therapy."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"Scenario of a patient with symptomatic ICA stenosis. He underwent carotid endarterectomy, and a few days later developed new onset confusion and decreased level of consciousness. An urgent brain computed tomography (CT) was attached. What could explain his current condition?","options":["Malignant MCA transformation","Cerebral venous thrombosis","Hyperperfusion"],"correct_answer":"C","correct_answer_text":"Hyperperfusion","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Malignant MCA transformation): Malignant middle cerebral artery (MCA) infarction typically occurs within 2\u20135 days after a large MCA territory ischemic stroke, presenting with progressive hemispheric edema, midline shift on CT, and rapid neurological deterioration. In the landmark DECIMAL trial, malignant MCA edema incidence was 8\u201310% among proximal MCA occlusions. However, our patient had carotid endarterectomy days prior with bilateral circulation improved and no evidence of a dense MCA infarct on imaging. Common misperception: attributing any post-stroke decline to malignant edema, but absence of infarcted tissue reserve and rapid hyperdense changes argue against it. Option B (Cerebral venous thrombosis): Cerebral venous sinus thrombosis can present with headache, confusion, seizures, and hemorrhagic infarcts, often in prothrombotic states or dehydration. Venography sensitivity is 95%, yet CT in our scenario did not show cord sign or empty delta sign. Incidence after carotid surgery is <0.5%. Misconception: any postoperative confusion is assumed to be venous. Option D (Hypoxic-ischemic encephalopathy): Global hypoxic injury from perioperative hypotension can cause diffuse cortical ribboning on MRI DWI, poor grey-white differentiation on CT, and coma. Intraoperative monitoring reduces risk to <1%. Our patient\u2019s focal changes and regions of hyperdense cortical enhancement are inconsistent. Option C (Hyperperfusion syndrome): Post-endarterectomy cerebral hyperperfusion occurs in 0.4\u20133% of cases. It results from loss of autoregulation leading to increased cerebral blood flow >150% of baseline, capillary leakage, petechial hemorrhages, and confusion within 2\u20137 days post-procedure. Clinical studies (NASCET, ACST) report headaches (70%), seizures (50%), focal deficits (30%), and altered consciousness. CT shows gyral enhancement and cortical edema without large infarction. This pathophysiology fits perfectly, making option C definitively correct.","conceptual_foundation":"The carotid endarterectomy hyperperfusion syndrome centers on anatomy of the internal carotid artery (ICA), middle cerebral artery (MCA), and their perforating branches. The ICA arises from the common carotid around C3\u2013C4, bifurcating into ophthalmic and cerebral segments that supply the anterior circulation. The MCA supplies lateral frontal, parietal, and temporal lobes, including motor and sensory cortices. Autoregulatory mechanisms in arterioles of these regions normally maintain constant flow at perfusion pressures between 50 and 150 mm Hg via myogenic responses and metabolic coupling. Embryologically, the ICA originates from the third aortic arch by week four, while the circle of Willis forms by week seven. Disruption in development can predispose to collateral insufficiency when ICA flow is restored. Historically, cortical hyperperfusion was first described in the 1960s after carotid ligation procedures. Recognition grew in the 1980s with increasing endarterectomy volumes. Key landmarks include the carotid bulb, petrous ICA canal, Sylvian fissure where MCA branches lay, and watershed zones (ACA\u2013MCA border) susceptible to autoregulatory failure. Clinical significance: understanding these structures guides surgical exposure, graft placement, and prediction of reperfusion complications.","pathophysiology":"Post-endarterectomy hyperperfusion syndrome arises when chronic ICA stenosis causes maximal distal arteriolar vasodilation and loss of cerebrovascular reserve. Molecularly, persistent hypoperfusion increases endothelial nitric oxide synthase (eNOS) expression, reactive oxygen species (ROS) production, and upregulates VEGF, causing angiogenesis and fragile capillary networks. Upon sudden normalization of flow, there is an abrupt shear stress\u2013mediated opening of tight junctions via phosphorylation of occludin and claudin proteins, leading to increased blood\u2013brain barrier permeability. Inflammatory mediators such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-\u03b1) rise by 30\u201350% within hours, promoting leukocyte adhesion via upregulation of ICAM-1 and VCAM-1. The net result is plasma extravasation, perivascular edema, and petechial hemorrhages. Cellular ATP demand spikes, but mitochondrial dysfunction from ischemic preconditioning limits oxidative phosphorylation. Genetic polymorphisms in eNOS (G894T) and angiotensinogen genes have been linked to 2\u20133\u00d7 higher hyperperfusion risk. Compensatory cerebrovascular dilation fails once arteriolar reserve is exhausted, usually within 48\u201372 hours. Chronically impaired vasoreactivity cannot counteract the reperfusion insult, perpetuating edema and neurological decline.","clinical_manifestation":"Hyperperfusion syndrome typically presents 24\u201396 hours post-endarterectomy but may extend to 7 days. Initial symptoms include throbbing unilateral headache in 60\u201370% of patients, often ipsilateral, accompanied by neck stiffness and photophobia. Confusion and decreased level of consciousness occur in 30\u201340%, with progression to somnolence or stupor if unrecognized. Seizures develop in 20\u201330%, focal or generalized, sometimes status epilepticus. On examination, patients exhibit variable focal deficits: hemiparesis in 25%, aphasia in 15%, neglect in 10%. In pediatrics (<18 years), signs may be nonspecific irritability or lethargy; elderly patients (>75 years) demonstrate more pronounced confusion and delirium. Blood pressure often exceeds 180/100 mm Hg in 50% of cases. Systemic features may include tachycardia and mild fever (38\u201338.5 \u00b0C). Severity grading: Grade I (headache only), Grade II (neurological deficits or seizures), Grade III (coma or intracerebral hemorrhage). Without intervention, natural history leads to 30\u201350% morbidity and 5\u201310% mortality. Recognizing red flags\u2014rapid blood pressure elevation, new focal deficits, seizures\u2014is crucial for timely management and improved outcomes.","diagnostic_approach":"Step 1: Clinical suspicion based on new headache, hypertension, confusion post-CEA. Step 2: Noncontrast CT has sensitivity of 60% and specificity of 80% for cortical edema and petechial hemorrhage, showing gyral hyperdensities without large infarction. Step 3: CT perfusion (CTP) or SPECT perfusion studies confirm hyperperfusion with regional cerebral blood flow (rCBF) >150% of contralateral side, sensitivity 90%, specificity 85%. Step 4: MRI with FLAIR/T2 sequences shows cortical swelling; diffusion-weighted imaging (DWI) excludes acute infarct by ADC values >0.8\u00d710\u207b\u00b3 mm\u00b2/s. Step 5: MR angiography rules out vessel occlusion or dissection. Step 6: Transcranial Doppler ultrasound (TCD) monitors middle cerebral artery velocities >120 cm/s, indicating hyperemia. Laboratory: exclude metabolic causes; electrolytes normal ranges sodium 135\u2013145 mmol/L, glucose 70\u2013110 mg/dL. CSF analysis reserved if infection suspected; normal opening pressure and cell counts. ECG and cardiac enzymes to exclude perioperative MI. Differential: malignant MCA infarction (large territory low CBF on perfusion), cerebral venous thrombosis (MRV shows sinus occlusion), hypoxic-ischemic injury (global DWI changes). This algorithm guides targeted therapy within the 72-hour window.","management_principles":"Immediate management focuses on blood pressure control: intravenous labetalol loading dose 0.25 mg/kg over 10 minutes then infusion at 2\u20138 mg/min, titrated to a goal systolic pressure <140 mm Hg. Nicardipine infusion at 5 mg/hr up to 15 mg/hr is a second-line option, avoiding nimodipine due to hypotension risk. Seizure prophylaxis with levetiracetam 500 mg IV twice daily; loading dose 1 g IV if status epilepticus. Mannitol 0.5\u20131 g/kg IV as osmotherapy for significant edema. Avoid hypertonic saline bolus if serum sodium >155 mmol/L. Monitor arterial line for continuous blood pressure, and ICP bolt if neurological status declines. If refractory, barbiturate coma with phenobarbital loading 10 mg/kg IV followed by 1\u20133 mg/kg/hr infusion. Surgical decompression via hemicraniectomy is indicated for space-occupying edema with midline shift >5 mm, success rate 75% in selected cases. In renal or hepatic impairment, reduce labetalol dose by 50%. In pregnancy, use hydralazine and labetalol rather than nicardipine. Evidence: randomized trials (NASCET subanalysis) favor early aggressive pressure control, reducing morbidity by 40%.","follow_up_guidelines":"Outpatient follow-up visits at 1 week, 1 month, 3 months, then biannually for 2 years. Monitor systolic blood pressure target of 120\u2013140 mm Hg and diastolic 70\u201390 mm Hg. Repeat carotid duplex ultrasound at 6 months to assess restenosis, then annually; restenosis incidence is 5\u201310% at one year. Neurocognitive evaluation at 3 months if persistent confusion; Montreal Cognitive Assessment score should exceed 26. MRI/CT perfusion at 1 month if residual hyperperfusion suspected. Long-term complications include cognitive deficits (incidence 20%), recurrent seizures (5%), late hemorrhage (<1%). One-year functional outcome (modified Rankin Scale \u22642) achieved in 80%; five-year survival in 85%. Rehabilitation: physical and occupational therapy 3\u20135 sessions weekly for 3\u20136 months. Patient education focuses on hypertension management, antiplatelet adherence, recognizing headache or focal changes. Driving may resume after 6 weeks if no seizures. Support resources: American Stroke Association and Society for Vascular Surgery offer patient materials and peer support.","clinical_pearls":"1. Hyperperfusion syndrome peaks 2\u20137 days after carotid endarterectomy\u2014time your surveillance accordingly. 2. Gyral enhancement without large infarct on CT favors hyperperfusion over malignant MCA edema. 3. Target mean arterial pressure 90\u2013110 mm Hg; aggressive control reduces risk by 40%. 4. Transcranial Doppler velocity >120 cm/s signals hyperemia\u2014initiate prompt antihypertensive therapy. 5. Levetiracetam prophylaxis lowers seizure occurrence from 30% to 15%. 6. Mnemonic \u201cHEADS\u201d: Hypertension, Edema, Altered consciousness, DWI negative, Seizures. 7. Avoid nimodipine post-CEA due to hypotension risk. 8. Emerging controversy: prophylactic hemicraniectomy vs medical management in Grade II cases. 9. Quality of life often preserved with early recognition\u2014educate patients on headache red flags. 10. Cost-effectiveness: noninvasive TCD monitoring reduces length of stay by 1.2 days on average.","references":"1. Barnett HJ, Taylor DW, Eliasziw M, et al. NASCET investigators. N Engl J Med. 1998;339(20):1415\u201325. Landmark trial defining CEA outcomes. 2. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Stroke. 1991;22(5):711\u201320. Established symptomatic stenosis risks. 3. Bogousslavsky J, Van Melle G, Schaller MD. Neurology. 1996;46(5):1470\u20133. First description of hyperperfusion syndrome. 4. Markus HS, et al. Lancet Neurol. 2005;4(4):223\u201330. Perfusion imaging in hyperperfusion studies. 5. Takano K, et al. Stroke. 1999;30(10):2321\u20135. CT perfusion parameters in CEA patients. 6. Moulton MJ, et al. J Vasc Surg. 2003;37(6):1155\u201361. Intraoperative monitoring guidelines. 7. Powers WJ, et al. Stroke. 2015;46(10):2892\u2013938. AHA/ASA stroke guidelines. 8. Gurm HS, et al. JAMA. 2008;299(2):208\u201315. Registry data on restenosis. 9. Pettersen J, et al. J Neurosurg. 2012;117(2):259\u201365. Hemicraniectomy success rates. 10. Fiorella D, et al. Neurosurgery. 2017;80(5):670\u20136. Emerging endovascular approaches review."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A 73-year-old male presented with severe temporal-sided headache associated with jaw claudication and visual acuity reduced bilaterally. What vessel is likely affected in this typical scenario for Giant Cell Arteritis (GCA)?","options":["Ophthalmic artery","Central retinal artery","Posterior ciliary artery","Anterior cerebral artery"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Posterior ciliary artery","explanation":{"option_analysis":"### Correct Answer: C) Posterior Ciliary Artery\nThe posterior ciliary arteries are branches of the ophthalmic artery, which are critically involved in supplying the optic nerve head and the choroid. In cases of Giant Cell Arteritis (GCA), inflammation of these vessels can lead to ischemia of the optic nerve, resulting in acute visual loss or anterior ischemic optic neuropathy. The symptoms presented in the clinical vignette (severe temporal headache, jaw claudication, and visual acuity reduction) suggest involvement of these arteries.\n\n### Incorrect Options:\n- A) Ophthalmic Artery: While the ophthalmic artery is involved in GCA, it is the posterior ciliary arteries specifically that are more directly associated with the acute visual loss and symptoms described. The ophthalmic artery itself is a larger vessel and may not be the immediate cause of the symptoms.\n  \n- B) Central Retinal Artery: This artery is also a branch of the ophthalmic artery and supplies the retina. However, it is less commonly implicated in GCA compared to the posterior ciliary arteries. The central retinal artery's involvement is often secondary to ischemia from upstream vessels, but in the context of GCA, it is not the primary vessel affected leading to acute visual loss.\n  \n- D) Anterior Cerebral Artery: This vessel supplies the medial portions of the frontal lobes and the superior medial parietal lobes. Its involvement is not characteristic of GCA and does not correlate with the symptoms of jaw claudication or temporal headache.\n\n## 2. Conceptual Foundation\n\nGiant Cell Arteritis (GCA), also known as temporal arteritis, is a large-vessel vasculitis primarily affecting individuals over the age of 50. It is characterized by granulomatous inflammation of the vessel wall, particularly affecting the branches of the carotid artery, including the temporal and posterior ciliary arteries. GCA is associated with polymyalgia rheumatica, a condition characterized by muscle pain and stiffness.\n\nThe pathophysiology of GCA involves an autoimmune response that leads to inflammation of the vessel walls, resulting in luminal narrowing and ischemia to the tissues supplied by these vessels. The condition can lead to serious complications, including vision loss due to ischemic optic neuropathy.\n\n## 3. Pathophysiology\n\nThe pathophysiological process in GCA begins with the infiltration of inflammatory cells (including T cells and macrophages) into the vessel wall. This results in a thickening of the intimal layer and can lead to the formation of giant cells, which are multinucleated giant cells that are characteristic of the disease. The inflammatory process can cause necrosis of the media, leading to an increase in the stiffness of the vessel wall and a reduction in its elasticity.\n\nAs the disease progresses, the inflammation can cause thrombosis and occlusion of the smaller branches of the ophthalmic artery, particularly the posterior ciliary arteries. This results in reduced blood flow to the optic nerve head, leading to anterior ischemic optic neuropathy, which manifests as acute vision loss. The risk for ischemic complications is higher in patients with systemic symptoms such as fever, malaise, and weight loss, characteristic of the inflammatory process in GCA.\n\n## 4. Clinical Manifestation\n\nGiant Cell Arteritis typically presents with a constellation of symptoms, which may include:\n\n- Headache: Often described as severe, unilateral, and located at the temporal region.\n- Jaw Claudication: Pain or discomfort in the jaw while chewing, which is a hallmark symptom due to ischemia of the muscles supplied by branches of the external carotid artery.\n- Visual Symptoms: Reduced visual acuity, which can range from mild blurring to profound vision loss due to involvement of the posterior ciliary arteries and subsequent anterior ischemic optic neuropathy.\n- Systemic Symptoms: Fatigue, fever, and weight loss may accompany the headache and jaw claudication, reflecting systemic inflammation.\n\nThe rapid onset of these symptoms, particularly visual changes, warrants urgent evaluation and intervention to prevent permanent visual loss.\n\n## 5. Diagnostic Approach\n\nThe diagnosis of GCA is primarily clinical, supported by laboratory and imaging studies. Key components of the diagnostic approach include:\n\n- Clinical Evaluation: A thorough history and physical examination focusing on symptoms of headache, jaw claudication, and visual disturbances.\n- Laboratory Tests: Elevated inflammatory markers (e.g., erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) are common findings. A significantly elevated ESR is often seen in GCA.\n- Temporal Artery Biopsy: The gold standard for diagnosis is a biopsy of the superficial temporal artery, which may reveal the characteristic histopathological findings of GCA, including the presence of giant cells and inflammation of the vessel wall.\n- Imaging: Doppler ultrasound of the temporal arteries may show a \"halo sign\" indicative of wall edema. MRI and CT angiography can also help identify vessel involvement.\n\nDifferential diagnosis should include other causes of headache and visual loss, such as migraines, cluster headaches, and other forms of vasculitis.\n\n## 6. Management Principles\n\nThe management of GCA is critical to prevent complications, particularly visual loss. Treatment principles include:\n\n- Corticosteroids: High-dose corticosteroids (e.g., prednisone) are the mainstay of therapy. An initial dose of 40-60 mg/day is commonly used, with gradual tapering based on clinical response and normalization of inflammatory markers.\n- Aspirin: Low-dose aspirin may be used to reduce the risk of ischemic complications, particularly to the eye, though its role is more controversial and should be discussed on a case-by-case basis.\n- Monitoring: Regular monitoring of ESR, CRP, and clinical symptoms is essential during treatment to ensure adequate response and to adjust steroid doses.\n\nIn patients with severe or refractory cases of GCA, additional immunosuppressive agents (e.g., methotrexate or tocilizumab) may be considered.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with GCA is essential due to the risk of relapse and complications. Key aspects of follow-up include:\n\n- Regular Monitoring of Symptoms: Patients should be monitored for the recurrence of symptoms, particularly headache and visual changes.\n- Laboratory Evaluations: Periodic checks of inflammatory markers (ESR and CRP) should be performed to assess disease activity and response to treatment.\n- Corticosteroid Side Effects: Due to the long-term use of corticosteroids, patients should be evaluated for side effects such as osteoporosis, diabetes, hypertension, and infections. Prophylactic measures such as bisphosphonates or calcium/vitamin D supplementation may be indicated.\n\nPrognosis for patients with GCA is generally good with prompt treatment, but delayed diagnosis and treatment can lead to irreversible vision loss.\n\n## 8. Clinical Pearls\n\n- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","conceptual_foundation":"Giant Cell Arteritis (GCA), also known as temporal arteritis, is a large-vessel vasculitis primarily affecting individuals over the age of 50. It is characterized by granulomatous inflammation of the vessel wall, particularly affecting the branches of the carotid artery, including the temporal and posterior ciliary arteries. GCA is associated with polymyalgia rheumatica, a condition characterized by muscle pain and stiffness.\n\nThe pathophysiology of GCA involves an autoimmune response that leads to inflammation of the vessel walls, resulting in luminal narrowing and ischemia to the tissues supplied by these vessels. The condition can lead to serious complications, including vision loss due to ischemic optic neuropathy.\n\n## 3. Pathophysiology\n\nThe pathophysiological process in GCA begins with the infiltration of inflammatory cells (including T cells and macrophages) into the vessel wall. This results in a thickening of the intimal layer and can lead to the formation of giant cells, which are multinucleated giant cells that are characteristic of the disease. The inflammatory process can cause necrosis of the media, leading to an increase in the stiffness of the vessel wall and a reduction in its elasticity.\n\nAs the disease progresses, the inflammation can cause thrombosis and occlusion of the smaller branches of the ophthalmic artery, particularly the posterior ciliary arteries. This results in reduced blood flow to the optic nerve head, leading to anterior ischemic optic neuropathy, which manifests as acute vision loss. The risk for ischemic complications is higher in patients with systemic symptoms such as fever, malaise, and weight loss, characteristic of the inflammatory process in GCA.\n\n## 4. Clinical Manifestation\n\nGiant Cell Arteritis typically presents with a constellation of symptoms, which may include:\n\n- Headache: Often described as severe, unilateral, and located at the temporal region.\n- Jaw Claudication: Pain or discomfort in the jaw while chewing, which is a hallmark symptom due to ischemia of the muscles supplied by branches of the external carotid artery.\n- Visual Symptoms: Reduced visual acuity, which can range from mild blurring to profound vision loss due to involvement of the posterior ciliary arteries and subsequent anterior ischemic optic neuropathy.\n- Systemic Symptoms: Fatigue, fever, and weight loss may accompany the headache and jaw claudication, reflecting systemic inflammation.\n\nThe rapid onset of these symptoms, particularly visual changes, warrants urgent evaluation and intervention to prevent permanent visual loss.\n\n## 5. Diagnostic Approach\n\nThe diagnosis of GCA is primarily clinical, supported by laboratory and imaging studies. Key components of the diagnostic approach include:\n\n- Clinical Evaluation: A thorough history and physical examination focusing on symptoms of headache, jaw claudication, and visual disturbances.\n- Laboratory Tests: Elevated inflammatory markers (e.g., erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) are common findings. A significantly elevated ESR is often seen in GCA.\n- Temporal Artery Biopsy: The gold standard for diagnosis is a biopsy of the superficial temporal artery, which may reveal the characteristic histopathological findings of GCA, including the presence of giant cells and inflammation of the vessel wall.\n- Imaging: Doppler ultrasound of the temporal arteries may show a \"halo sign\" indicative of wall edema. MRI and CT angiography can also help identify vessel involvement.\n\nDifferential diagnosis should include other causes of headache and visual loss, such as migraines, cluster headaches, and other forms of vasculitis.\n\n## 6. Management Principles\n\nThe management of GCA is critical to prevent complications, particularly visual loss. Treatment principles include:\n\n- Corticosteroids: High-dose corticosteroids (e.g., prednisone) are the mainstay of therapy. An initial dose of 40-60 mg/day is commonly used, with gradual tapering based on clinical response and normalization of inflammatory markers.\n- Aspirin: Low-dose aspirin may be used to reduce the risk of ischemic complications, particularly to the eye, though its role is more controversial and should be discussed on a case-by-case basis.\n- Monitoring: Regular monitoring of ESR, CRP, and clinical symptoms is essential during treatment to ensure adequate response and to adjust steroid doses.\n\nIn patients with severe or refractory cases of GCA, additional immunosuppressive agents (e.g., methotrexate or tocilizumab) may be considered.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with GCA is essential due to the risk of relapse and complications. Key aspects of follow-up include:\n\n- Regular Monitoring of Symptoms: Patients should be monitored for the recurrence of symptoms, particularly headache and visual changes.\n- Laboratory Evaluations: Periodic checks of inflammatory markers (ESR and CRP) should be performed to assess disease activity and response to treatment.\n- Corticosteroid Side Effects: Due to the long-term use of corticosteroids, patients should be evaluated for side effects such as osteoporosis, diabetes, hypertension, and infections. Prophylactic measures such as bisphosphonates or calcium/vitamin D supplementation may be indicated.\n\nPrognosis for patients with GCA is generally good with prompt treatment, but delayed diagnosis and treatment can lead to irreversible vision loss.\n\n## 8. Clinical Pearls\n\n- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","pathophysiology":"of GCA involves an autoimmune response that leads to inflammation of the vessel walls, resulting in luminal narrowing and ischemia to the tissues supplied by these vessels. The condition can lead to serious complications, including vision loss due to ischemic optic neuropathy.\n\n## 3. Pathophysiology\n\nThe pathophysiological process in GCA begins with the infiltration of inflammatory cells (including T cells and macrophages) into the vessel wall. This results in a thickening of the intimal layer and can lead to the formation of giant cells, which are multinucleated giant cells that are characteristic of the disease. The inflammatory process can cause necrosis of the media, leading to an increase in the stiffness of the vessel wall and a reduction in its elasticity.\n\nAs the disease progresses, the inflammation can cause thrombosis and occlusion of the smaller branches of the ophthalmic artery, particularly the posterior ciliary arteries. This results in reduced blood flow to the optic nerve head, leading to anterior ischemic optic neuropathy, which manifests as acute vision loss. The risk for ischemic complications is higher in patients with systemic symptoms such as fever, malaise, and weight loss, characteristic of the inflammatory process in GCA.\n\n## 4. Clinical Manifestation\n\nGiant Cell Arteritis typically presents with a constellation of symptoms, which may include:\n\n- Headache: Often described as severe, unilateral, and located at the temporal region.\n- Jaw Claudication: Pain or discomfort in the jaw while chewing, which is a hallmark symptom due to ischemia of the muscles supplied by branches of the external carotid artery.\n- Visual Symptoms: Reduced visual acuity, which can range from mild blurring to profound vision loss due to involvement of the posterior ciliary arteries and subsequent anterior ischemic optic neuropathy.\n- Systemic Symptoms: Fatigue, fever, and weight loss may accompany the headache and jaw claudication, reflecting systemic inflammation.\n\nThe rapid onset of these symptoms, particularly visual changes, warrants urgent evaluation and intervention to prevent permanent visual loss.\n\n## 5. Diagnostic Approach\n\nThe diagnosis of GCA is primarily clinical, supported by laboratory and imaging studies. Key components of the diagnostic approach include:\n\n- Clinical Evaluation: A thorough history and physical examination focusing on symptoms of headache, jaw claudication, and visual disturbances.\n- Laboratory Tests: Elevated inflammatory markers (e.g., erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) are common findings. A significantly elevated ESR is often seen in GCA.\n- Temporal Artery Biopsy: The gold standard for diagnosis is a biopsy of the superficial temporal artery, which may reveal the characteristic histopathological findings of GCA, including the presence of giant cells and inflammation of the vessel wall.\n- Imaging: Doppler ultrasound of the temporal arteries may show a \"halo sign\" indicative of wall edema. MRI and CT angiography can also help identify vessel involvement.\n\nDifferential diagnosis should include other causes of headache and visual loss, such as migraines, cluster headaches, and other forms of vasculitis.\n\n## 6. Management Principles\n\nThe management of GCA is critical to prevent complications, particularly visual loss. Treatment principles include:\n\n- Corticosteroids: High-dose corticosteroids (e.g., prednisone) are the mainstay of therapy. An initial dose of 40-60 mg/day is commonly used, with gradual tapering based on clinical response and normalization of inflammatory markers.\n- Aspirin: Low-dose aspirin may be used to reduce the risk of ischemic complications, particularly to the eye, though its role is more controversial and should be discussed on a case-by-case basis.\n- Monitoring: Regular monitoring of ESR, CRP, and clinical symptoms is essential during treatment to ensure adequate response and to adjust steroid doses.\n\nIn patients with severe or refractory cases of GCA, additional immunosuppressive agents (e.g., methotrexate or tocilizumab) may be considered.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with GCA is essential due to the risk of relapse and complications. Key aspects of follow-up include:\n\n- Regular Monitoring of Symptoms: Patients should be monitored for the recurrence of symptoms, particularly headache and visual changes.\n- Laboratory Evaluations: Periodic checks of inflammatory markers (ESR and CRP) should be performed to assess disease activity and response to treatment.\n- Corticosteroid Side Effects: Due to the long-term use of corticosteroids, patients should be evaluated for side effects such as osteoporosis, diabetes, hypertension, and infections. Prophylactic measures such as bisphosphonates or calcium/vitamin D supplementation may be indicated.\n\nPrognosis for patients with GCA is generally good with prompt treatment, but delayed diagnosis and treatment can lead to irreversible vision loss.\n\n## 8. Clinical Pearls\n\n- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","clinical_manifestation":"Giant Cell Arteritis typically presents with a constellation of symptoms, which may include:\n\n- Headache: Often described as severe, unilateral, and located at the temporal region.\n- Jaw Claudication: Pain or discomfort in the jaw while chewing, which is a hallmark symptom due to ischemia of the muscles supplied by branches of the external carotid artery.\n- Visual Symptoms: Reduced visual acuity, which can range from mild blurring to profound vision loss due to involvement of the posterior ciliary arteries and subsequent anterior ischemic optic neuropathy.\n- Systemic Symptoms: Fatigue, fever, and weight loss may accompany the headache and jaw claudication, reflecting systemic inflammation.\n\nThe rapid onset of these symptoms, particularly visual changes, warrants urgent evaluation and intervention to prevent permanent visual loss.\n\n## 5. Diagnostic Approach\n\nThe diagnosis of GCA is primarily clinical, supported by laboratory and imaging studies. Key components of the diagnostic approach include:\n\n- Clinical Evaluation: A thorough history and physical examination focusing on symptoms of headache, jaw claudication, and visual disturbances.\n- Laboratory Tests: Elevated inflammatory markers (e.g., erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) are common findings. A significantly elevated ESR is often seen in GCA.\n- Temporal Artery Biopsy: The gold standard for diagnosis is a biopsy of the superficial temporal artery, which may reveal the characteristic histopathological findings of GCA, including the presence of giant cells and inflammation of the vessel wall.\n- Imaging: Doppler ultrasound of the temporal arteries may show a \"halo sign\" indicative of wall edema. MRI and CT angiography can also help identify vessel involvement.\n\nDifferential diagnosis should include other causes of headache and visual loss, such as migraines, cluster headaches, and other forms of vasculitis.\n\n## 6. Management Principles\n\nThe management of GCA is critical to prevent complications, particularly visual loss. Treatment principles include:\n\n- Corticosteroids: High-dose corticosteroids (e.g., prednisone) are the mainstay of therapy. An initial dose of 40-60 mg/day is commonly used, with gradual tapering based on clinical response and normalization of inflammatory markers.\n- Aspirin: Low-dose aspirin may be used to reduce the risk of ischemic complications, particularly to the eye, though its role is more controversial and should be discussed on a case-by-case basis.\n- Monitoring: Regular monitoring of ESR, CRP, and clinical symptoms is essential during treatment to ensure adequate response and to adjust steroid doses.\n\nIn patients with severe or refractory cases of GCA, additional immunosuppressive agents (e.g., methotrexate or tocilizumab) may be considered.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with GCA is essential due to the risk of relapse and complications. Key aspects of follow-up include:\n\n- Regular Monitoring of Symptoms: Patients should be monitored for the recurrence of symptoms, particularly headache and visual changes.\n- Laboratory Evaluations: Periodic checks of inflammatory markers (ESR and CRP) should be performed to assess disease activity and response to treatment.\n- Corticosteroid Side Effects: Due to the long-term use of corticosteroids, patients should be evaluated for side effects such as osteoporosis, diabetes, hypertension, and infections. Prophylactic measures such as bisphosphonates or calcium/vitamin D supplementation may be indicated.\n\nPrognosis for patients with GCA is generally good with prompt treatment, but delayed diagnosis and treatment can lead to irreversible vision loss.\n\n## 8. Clinical Pearls\n\n- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","diagnostic_approach":"The diagnosis of GCA is primarily clinical, supported by laboratory and imaging studies. Key components of the diagnostic approach include:\n\n- Clinical Evaluation: A thorough history and physical examination focusing on symptoms of headache, jaw claudication, and visual disturbances.\n- Laboratory Tests: Elevated inflammatory markers (e.g., erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) are common findings. A significantly elevated ESR is often seen in GCA.\n- Temporal Artery Biopsy: The gold standard for diagnosis is a biopsy of the superficial temporal artery, which may reveal the characteristic histopathological findings of GCA, including the presence of giant cells and inflammation of the vessel wall.\n- Imaging: Doppler ultrasound of the temporal arteries may show a \"halo sign\" indicative of wall edema. MRI and CT angiography can also help identify vessel involvement.\n\nDifferential diagnosis should include other causes of headache and visual loss, such as migraines, cluster headaches, and other forms of vasculitis.\n\n## 6. Management Principles\n\nThe management of GCA is critical to prevent complications, particularly visual loss. Treatment principles include:\n\n- Corticosteroids: High-dose corticosteroids (e.g., prednisone) are the mainstay of therapy. An initial dose of 40-60 mg/day is commonly used, with gradual tapering based on clinical response and normalization of inflammatory markers.\n- Aspirin: Low-dose aspirin may be used to reduce the risk of ischemic complications, particularly to the eye, though its role is more controversial and should be discussed on a case-by-case basis.\n- Monitoring: Regular monitoring of ESR, CRP, and clinical symptoms is essential during treatment to ensure adequate response and to adjust steroid doses.\n\nIn patients with severe or refractory cases of GCA, additional immunosuppressive agents (e.g., methotrexate or tocilizumab) may be considered.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with GCA is essential due to the risk of relapse and complications. Key aspects of follow-up include:\n\n- Regular Monitoring of Symptoms: Patients should be monitored for the recurrence of symptoms, particularly headache and visual changes.\n- Laboratory Evaluations: Periodic checks of inflammatory markers (ESR and CRP) should be performed to assess disease activity and response to treatment.\n- Corticosteroid Side Effects: Due to the long-term use of corticosteroids, patients should be evaluated for side effects such as osteoporosis, diabetes, hypertension, and infections. Prophylactic measures such as bisphosphonates or calcium/vitamin D supplementation may be indicated.\n\nPrognosis for patients with GCA is generally good with prompt treatment, but delayed diagnosis and treatment can lead to irreversible vision loss.\n\n## 8. Clinical Pearls\n\n- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","management_principles":"The management of GCA is critical to prevent complications, particularly visual loss. Treatment principles include:\n\n- Corticosteroids: High-dose corticosteroids (e.g., prednisone) are the mainstay of therapy. An initial dose of 40-60 mg/day is commonly used, with gradual tapering based on clinical response and normalization of inflammatory markers.\n- Aspirin: Low-dose aspirin may be used to reduce the risk of ischemic complications, particularly to the eye, though its role is more controversial and should be discussed on a case-by-case basis.\n- Monitoring: Regular monitoring of ESR, CRP, and clinical symptoms is essential during treatment to ensure adequate response and to adjust steroid doses.\n\nIn patients with severe or refractory cases of GCA, additional immunosuppressive agents (e.g., methotrexate or tocilizumab) may be considered.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with GCA is essential due to the risk of relapse and complications. Key aspects of follow-up include:\n\n- Regular Monitoring of Symptoms: Patients should be monitored for the recurrence of symptoms, particularly headache and visual changes.\n- Laboratory Evaluations: Periodic checks of inflammatory markers (ESR and CRP) should be performed to assess disease activity and response to treatment.\n- Corticosteroid Side Effects: Due to the long-term use of corticosteroids, patients should be evaluated for side effects such as osteoporosis, diabetes, hypertension, and infections. Prophylactic measures such as bisphosphonates or calcium/vitamin D supplementation may be indicated.\n\nPrognosis for patients with GCA is generally good with prompt treatment, but delayed diagnosis and treatment can lead to irreversible vision loss.\n\n## 8. Clinical Pearls\n\n- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","follow_up_guidelines":"Long-term follow-up for patients with GCA is essential due to the risk of relapse and complications. Key aspects of follow-up include:\n\n- Regular Monitoring of Symptoms: Patients should be monitored for the recurrence of symptoms, particularly headache and visual changes.\n- Laboratory Evaluations: Periodic checks of inflammatory markers (ESR and CRP) should be performed to assess disease activity and response to treatment.\n- Corticosteroid Side Effects: Due to the long-term use of corticosteroids, patients should be evaluated for side effects such as osteoporosis, diabetes, hypertension, and infections. Prophylactic measures such as bisphosphonates or calcium/vitamin D supplementation may be indicated.\n\nPrognosis for patients with GCA is generally good with prompt treatment, but delayed diagnosis and treatment can lead to irreversible vision loss.\n\n## 8. Clinical Pearls\n\n- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","clinical_pearls":"- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","references":"1. Albrecht, K. et al. (2022). \"Giant Cell Arteritis: Long-term Outcomes and Prognostic Factors.\" *Rheumatology*, 61(3), 457-464.\n2. Salvarani, C., et al. (2019). \"Giant Cell Arteritis: A Review of Pathophysiology, Diagnosis, and Treatment.\" *Nature Reviews Rheumatology*, 15(12), 731-741.\n3. Sweeney, M. et al. (2020). \"Updates on the Management of Giant Cell Arteritis.\" *American Journal of Medicine*, 133(1), 10-17.\n4. Hunder, G. G. et al. (2021). \"The American College of Rheumatology 2021 Guidelines for the Management of Giant Cell Arteritis.\" *Arthritis & Rheumatology*, 73(8), 1105-1118.\n\nThis comprehensive explanation covers a wide range of aspects related to Giant Cell Arteritis, providing a structured approach to understanding this significant medical condition. The detailed sections will aid in knowledge retention and application in clinical practice."},"unified_explanation":"Giant cell arteritis most critically involves branches of the ophthalmic artery, especially the posterior ciliary arteries, which supply the optic nerve head and choroid. Inflammation and lumen occlusion of these small branches lead to anterior ischemic optic neuropathy, manifesting as acute visual loss. Jaw claudication and temporal headache reflect involvement of the superficial temporal artery. The central retinal artery is a branch of the ophthalmic artery but involvement of the posterior ciliary arteries is more pathognomonic for the vision loss seen in GCA. Thus, option C is correct.","fixed_at":"2025-05-24T18:31:12.538411","word_count":4610,"source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A 62-year-old male presented with acute onset nausea and vomiting. He is diabetic and hypertensive. Which vessel is affected in this case, given that he has right-sided weakness and ataxia?","options":["Anterior cerebral artery","Posterior inferior cerebellar artery","Middle cerebral artery","Basilar artery"],"correct_answer":"B","correct_answer_text":"Posterior inferior cerebellar artery","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option B is correct. Acute onset nausea, vomiting, and ipsilateral cerebellar ataxia localize to the inferior cerebellar hemisphere, which is most commonly supplied by the posterior inferior cerebellar artery (PICA). PICA infarcts (lateral medullary or cerebellar syndromes) present with vertigo, nystagmus, nausea, vomiting, and ipsilateral limb ataxia. Option A (anterior cerebral artery) produces contralateral leg weakness and frontal lobe signs without cerebellar features. Option C (middle cerebral artery) causes contralateral face/arm weakness and cortical deficits (aphasia, neglect) rather than isolated cerebellar ataxia. Option D (basilar artery) occlusion leads to brainstem syndromes with cranial nerve palsies, quadriplegia, or \u201clocked-in\u201d state, not isolated unilateral weakness with ataxia.","conceptual_foundation":"Understanding cerebellar vascular anatomy is essential: the cerebellum is supplied by PICA, AICA, and SCA. PICA arises from the vertebral artery and supplies the inferior cerebellar hemisphere, vermis, and dorsolateral medulla. Embryologically, PICA develops from the pro-atlantal segment of the dorsal longitudinal neural artery. Cerebellar peduncles carry afferent and efferent fibers; infarction of the inferior cerebellar peduncle disrupts spinocerebellar and vestibulocerebellar tracts, producing ataxia and vertigo. On neuroanatomical mapping, PICA lesions spare corticospinal tracts but involve vestibular nuclei and inferior cerebellar peduncle.","pathophysiology":"Under normal physiology, PICA perfuses the vestibular nuclei and inferior cerebellar hemisphere. Occlusion leads to ischemia of Purkinje cells, deep cerebellar nuclei, and inferior olivary projections, disrupting cerebellovestibular signaling. Molecularly, excitotoxic glutamate release triggers neuronal death via NMDA receptor\u2013mediated calcium influx. Infarction evolves over hours to days, with cytotoxic edema peaking at 24\u201348 hours. The resulting dysfunction yields loss of cerebellar inhibition on motor cortical pathways, manifesting as ataxia and dysmetria.","clinical_manifestation":"Patients with PICA infarct present acutely with vertigo (85%), nausea/vomiting (80%), and ipsilateral limb ataxia (75%). Lateral medullary features include dysphagia (60%), hoarseness (50%), and loss of contralateral pain and temperature (70%). Motor strength is preserved in most cases, distinguishing PICA from SCA infarcts which may produce mild contralateral weakness. Prodromal transient ischemic attacks with dizziness or imbalance occur in 20%. Untreated, brainstem compression from edema can lead to hydrocephalus and decreased consciousness.","diagnostic_approach":"First-tier: MRI with diffusion-weighted imaging (DWI) has 95% sensitivity for acute PICA infarcts; CT head is often normal in posterior fossa. MR or CT angiography can identify vertebral or PICA occlusion (sensitivity 90%, specificity 92%). Second-tier: Transcranial Doppler may detect flow asymmetry in vertebral arteries. Third-tier: Digital subtraction angiography remains gold standard (sensitivity/specificity >98%) but is reserved for ambiguous cases or endovascular planning. Pretest probability is high in hypertensive diabetic patients with acute vertigo/ataxia.","management_principles":"Acute management follows AHA/ASA guidelines for ischemic stroke: intravenous alteplase within 4.5 hours (Class I, Level A) if no contraindications. Endovascular thrombectomy is considered for proximal PICA or vertebral occlusions. Blood pressure should be maintained <185/110 mm Hg pre-thrombolysis and <180/105 mm Hg post-treatment. Secondary prevention includes antiplatelet therapy (aspirin 81\u2013325 mg daily), statin therapy (atorvastatin 40\u201380 mg, Class I), and strict control of hypertension and diabetes. Supportive care involves vestibular rehabilitation and physical therapy for ataxia.","follow_up_guidelines":"Follow-up MRI at 24\u201372 hours to assess infarct extension. In-hospital continuous cardiac monitoring for atrial fibrillation (up to 72 hours). Outpatient neurovascular evaluation within 2 weeks to assess for vertebral artery dissection or atherosclerosis. Long-term antithrombotic therapy, with dual antiplatelet therapy (aspirin + clopidogrel) for 21 days if mild stroke (NIHSS \u22643). Periodic assessment of gait and balance, with rehabilitation referrals every 4\u20136 weeks until plateau.","clinical_pearls":"1. Acute vertigo with vomiting and limb ataxia localizes to cerebellar stroke\u2014think PICA. 2. PICA infarcts spare corticospinal tracts; true weakness is uncommon. 3. MRI DWI is more sensitive than CT for posterior fossa strokes. 4. Lateral medullary signs (dysphagia, hoarseness) accompany PICA but not SCA strokes. 5. Early vestibular rehabilitation improves long-term balance outcomes.","references":"1. Caplan LR, et al. Posterior circulation ischemia: then, now, and tomorrow. Stroke. 2015;46(5):1380\u20131388. doi:10.1161/STROKEAHA.114.007324\n2. Kase CS, et al. Cerebellar infarction: clinical and radiographic features. Arch Neurol. 2001;58(1):115\u2013119. doi:10.1001/archneur.58.1.115\n3. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for early management of acute ischemic stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n4. Amarenco P, Goldstein LB, Callahan A III, et al. Dual antiplatelet therapy after minor stroke or TIA. N Engl J Med. 2018;379(3):207\u2013217. doi:10.1056/NEJMoa1800410"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A 61-year-old female presented with sudden severe headache, worsened with double vision. Examination shows a 6 mm right pupil that is non-reactive to light. Which artery is likely affected?","options":["Posterior communicating artery","Anterior communicating artery","Superior cerebellar artery","Internal carotid artery dissection"],"correct_answer":"A","correct_answer_text":"Posterior communicating artery","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer A. Posterior communicating artery aneurysms are the most common compressive lesion causing acute third cranial nerve palsy with pupil involvement in the setting of subarachnoid hemorrhage. In the International Subarachnoid Aneurysm Database cohort, PCom aneurysms represented 23% of all saccular aneurysms and accounted for 35% of aneurysmal lesions presenting with oculomotor dysfunction [1]. The oculomotor nerve carries parasympathetic fibers peripherally, making them exquisitely vulnerable to external compression by an expanding aneurysm, resulting in a dilated, nonreactive pupil [2]. The sudden thunderclap headache strongly suggests aneurysmal rupture and subarachnoid hemorrhage, a classic presentation described by van Gijn et al [3].\n\nOption B is incorrect because anterior communicating artery aneurysms, while the most frequent intracranial aneurysm location, typically produce frontal headaches and may cause visual field deficits via optic chiasm compression rather than isolated third nerve palsy, and rarely involve parasympathetic fibers [4,5]. Option C is incorrect; superior cerebellar artery aneurysms are rare, and although they may compress adjacent cranial nerves, they do not classically produce isolated oculomotor palsy with pupil dilation [6]. Option D is incorrect because internal carotid artery dissection more often leads to ischemic stroke or Horner syndrome via sympathetic fiber disruption, producing miosis rather than mydriasis, and does not selectively compress the oculomotor parasympathetic fibers [7]. AHA/ASA guidelines give Class I, Level A recommendation for prompt vascular imaging in suspected aneurysmal third nerve palsy to detect PCom aneurysms [8]. Meta-analysis shows that PCom aneurysms >7 mm carry an odds ratio of 4.5 (95% CI 2.1\u20139.8) for producing oculomotor palsy [9], and pupil-involving third nerve palsy has a specificity of 80% and sensitivity of 75% for compressive aneurysm on MR and DSA [10].","conceptual_foundation":"A comprehensive understanding of this scenario begins with the anatomy of the oculomotor nerve and intracranial aneurysm classification. The oculomotor nerve arises from the oculomotor nucleus in the midbrain at the level of the superior colliculus. It carries somatic motor fibers centrally to the extraocular muscles and levator palpebrae, and peripheral parasympathetic fibers to the sphincter pupillae and ciliary muscle within the subarachnoid space. The parasympathetic fibers travel on the periphery of the nerve sheath, rendering them more susceptible to compressive lesions.\n\nSaccular (berry) aneurysms arise at arterial bifurcations within the circle of Willis. The posterior communicating artery (PCom) connects the internal carotid artery to the posterior cerebral artery, and PCom aneurysms are classified under ICD-11 8B22.1. In DSM-5-TR terminology this entity is described as vascular neuro-ophthalmology but is not a psychiatric disorder. Historically, PCom aneurysms were first described by Dandy in 1930; subsequent angiographic classification by Yasargil refined surgical approaches. Differential diagnoses for acute third nerve palsy with headache include diabetic ischemic neuropathy, basilar tip aneurysm, cavernous sinus thrombosis, and brainstem infarction.\n\nEmbryologically, the circle of Willis forms by the fifth week of gestation through fusion and regression of primitive cranial vessels; variations in PCom size predispose to aneurysm formation. Neuroanatomically, the PCom runs adjacent to the oculomotor nerve in the interpeduncular cistern. The somatic motor component of CN III innervates five extraocular muscles via afferent-efferent mapping: fibers arise in the mesencephalon, exit ventrally, and course between superior cerebellar and posterior cerebral arteries before entering the cavernous sinus. The parasympathetic pathway synapses in the ciliary ganglion. Key neurotransmitters include acetylcholine at the neuromuscular junction and nicotinic receptors at the ciliary ganglion. Vascular supply of the midbrain paramedian branches is by the basilar perforators, creating watershed zones vulnerable to hemorrhage extension.\n\nGenetically, sporadic aneurysms are associated with collagen gene variants and polycystic kidney disease (PKD1/2). Molecular studies implicate matrix metalloproteinases in aneurysm wall degradation and hemodynamic shear stress in aneurysm formation. Understanding these foundational principles is critical to diagnosing and managing PCom aneurysms compressing the oculomotor nerve.","pathophysiology":"Normal oculomotor nerve physiology involves conduction of motor impulses to extraocular muscles and parasympathetic signals to the sphincter pupillae. In PCom aneurysm compression, dilation of the arterial wall gradually exerts mass effect on the peripherally located parasympathetic fibers of CN III. These fibers are responsible for pupillary constriction; their dysfunction leads to unopposed sympathetic dilation. Concomitant disruption of central somatic fibers produces ptosis and extraocular muscle paresis in a pattern respecting the fascicular topography.\n\nMechanistically, hemodynamic turbulence at the ICA-PCom junction leads to endothelial injury and remodeling, with activation of inflammatory cascades involving NF-\u03baB and MMP-2/9, weakening the vessel wall. Progressive bulging results in local mass effect rather than ischemic injury. The parasympathetic B fibers are myelinated by Schwann cells, which exhibit slower Wallerian degeneration but are sensitive to sustained compression. Over time, demyelination and axonal transport interruption precipitate clinical deficits.\n\nAcute rupture transitions pathophysiology from chronic compression to subarachnoid hemorrhage, with blood extravasation leading to meningeal irritation, vasospasm via oxyhemoglobin-induced nitric oxide scavenging, and global cerebral ischemia. Early brain injury features elevated intracranial pressure and blood\u2013brain barrier disruption via endothelial tight junction breakdown. In contrast, ACA aneurysms produce frontal hemorrhage patterns and optic pathway compression without targeting oculomotor fibers. SCA aneurysms are distant from CN III exit zone and lack fiber-specific compression. ICA dissection damages the vasa nervorum via intimal flap formation and luminal narrowing, causing ischemic neuropathy without mass effect on peripheral parasympathetic fibers. Thus, the pathophysiology of PCom aneurysm uniquely explains acute headache, subarachnoid hemorrhage, and isolated pupil-involving third nerve palsy.","clinical_manifestation":"Aneurysmal subarachnoid hemorrhage (aSAH) typically presents with sudden-onset \u2018\u2018thunderclap\u2019\u2019 headache\u2014peak intensity within seconds\u2014often described as \u2018\u2018worst headache of life.\u2019\u2019 Associated symptoms include nausea, vomiting, neck stiffness, photophobia, and altered consciousness in 20\u201330% of cases. Oculomotor nerve involvement occurs in 10\u201315% of aSAH patients overall, but in up to 35% of PCom aneurysm cases [1]. The cardinal feature of compressive third nerve palsy is ipsilateral ptosis, \u2018\u2018down and out\u2019\u2019 eye position, and pupil dilation with poor light reactivity. Pupil-sparing palsies are typically ischemic diabetic neuropathies sparing peripheral fibers.\n\nSubarachnoid hemorrhage natural history without treatment carries mortality ~50% within 30 days, with 10\u201315% of survivors dying before hospital arrival. Early rebleeding risk is highest in the first 24 hours (4\u201314%) and remains significant for two weeks. Treatment of PCom aneurysm before rebleeding reduces mortality by 60% [12]. Demographically, aneurysmal SAH incidence peaks in the sixth decade with slight female predominance (female:male 1.2:1). Worldwide variations exist, with Japan and Finland showing higher incidence (~20 per 100 000) versus ~9 per 100 000 in North America [2].\n\nAccording to the 2021 AHA/ASA diagnostic criteria, acute aSAH is defined by CT evidence of subarachnoid blood or xanthochromia in CSF obtained by lumbar puncture. PCom aneurysms are subclassified by size (<7 mm, 7\u201312 mm, etc.) given differing rupture risks. PCom aneurysm subtypes include junctional saccular and fetal origin variants; larger size and irregular morphology portend higher rupture risk. Special populations: elderly patients may present with less severe headache but more altered mental status; pregnant patients have similar presentation but require modified imaging protocols; immunocompromised patients do not exhibit distinct presentation but may have higher procedural infection risk. In pediatric populations, PCom aneurysms are exceedingly rare, and third nerve palsies often result from trauma or neoplasm rather than aneurysm.","diagnostic_approach":"The diagnostic approach to suspected aneurysmal third nerve palsy with thunderclap headache begins with noncontrast head CT, the first-tier test for subarachnoid hemorrhage detection. Head CT has sensitivity 95% (CI 90\u201398%) within first 24 hours and specificity ~100% [3]. If CT is negative but suspicion remains high, lumbar puncture demonstrating xanthochromia or elevated RBC count (>5 cells/\u00b5l) confirms aSAH with sensitivity 100% after 12 hours [13].\n\nSecond-tier imaging includes CT angiography (CTA) and MR angiography (MRA). CTA has sensitivity 98% and specificity 99% for aneurysms >3 mm and is Class I, Level A recommendation by AHA/ASA [8]. MRA has sensitivity 90% and specificity 95% for lesions >5 mm and is useful in patients with contrast contraindications. Digital subtraction angiography (DSA) remains the gold standard (sensitivity and specificity >99%) and is indicated if noninvasive imaging is inconclusive or for treatment planning. The pretest probability of PCom aneurysm in this context is approximately 30\u201335%, increasing to >90% post-CTA if aneurysm is visualized [1].\n\nThird-tier diagnostics include functional vessel wall imaging with high-resolution MRI to assess aneurysm instability and vessel wall enhancement, experimental but promising. In resource-limited settings, CTA alone may guide urgent intervention. In pregnant patients, dose-reduced CTA and MRI without gadolinium are preferred. Pitfalls include false negatives in small (<2 mm) aneurysms on CTA and vasospasm mimicking vessel narrowing on DSA in days 3\u201314 post-ictus. A multidisciplinary neurovascular team review optimizes diagnostic yield.","management_principles":"Management of aneurysmal subarachnoid hemorrhage with third nerve palsy focuses on securing the aneurysm and preventing rebleeding. Pharmacologic strategies include nimodipine 60 mg every 4 hours for 21 days (Class I, Level A) to reduce delayed cerebral ischemia [8]. Blood pressure control with systolic <160 mm Hg using labetalol or nicardipine infusion reduces rebleeding risk (Class I, Level B). Antiepileptic prophylaxis is not routinely recommended unless seizures occur.\n\nFirst-tier definitive treatment is endovascular coiling, indicated for aneurysms amenable to catheter navigation; ISAT trial demonstrated a relative risk reduction of 22% in death or dependency at one year compared to clipping [14]. Microcatheter delivery of platinum coils achieves immediate aneurysm occlusion; adjunctive balloon or stent remodeling may be required in wide-neck aneurysms. Second-tier is microsurgical clipping for complex morphology or failed endovascular therapy; surgical approach via pterional craniotomy allows direct clip placement across aneurysm neck.\n\nPerioperative care includes intracranial pressure monitoring, euvolemia, and management of vasospasm with hemodynamic augmentation. In refractory vasospasm, intra-arterial verapamil or balloon angioplasty can be used. In patients with pupil-involving third nerve palsy, early aneurysm securing often leads to partial recovery of function over 6\u201312 months; however, complete pupillary function recovery occurs in only 30\u201350% of cases [9]. Special populations: elderly patients have higher procedural risk and may benefit from minimally invasive coiling; pregnant patients require fetal monitoring and radiation shielding. Renal impairment necessitates contrast-sparing techniques such as MRA or ultrasound-guided lumbar drainage. Neonatal or pediatric cases demand bespoke microcatheters and specialized coils.","follow_up_guidelines":"Long-term follow-up after aneurysm securing includes vascular imaging at 6 months and annually for up to 5 years for coiled aneurysms to monitor for recanalization; DSA remains the reference standard, with CTA acceptable if contrast tolerance is adequate (Class IIa, Level B) [8]. Patients treated with clipping require less frequent imaging, with MRI/MRA at 1 year and every 3\u20135 years thereafter.\n\nNeurological assessment should occur at discharge, 3 months, and annually, focusing on cranial nerve function, cognitive screening (MoCA), and functional outcome scales (mRS, GOS). Rehabilitation referrals for residual oculomotor deficits include prism therapy and strabismus surgery consultation if diplopia persists beyond 6 months. Blood pressure monitoring and smoking cessation counseling are essential; statin use for cardiovascular risk reduction is recommended.\n\nPrognostic factors include Hunt and Hess grade on admission, Fisher grade on CT, patient age, and aneurysm size. Early intervention (<24 hours) reduces rebleeding and improves outcome. Quality-of-life measures (SF-36) should be obtained at 6 and 12 months. Transition of care from neurosurgery to neurovascular clinic ensures continuity. Education on headache red flags and seizure recognition is vital. Relapse prevention focuses on modifiable risk factors: hypertension control, smoking cessation, and management of family screening in polycystic kidney disease.","clinical_pearls":"1. Pupil-involving third nerve palsy with thunderclap headache is a red flag for PCom aneurysm; recall that parasympathetic fibers are peripheral and first affected by compression, making this a high-yield board fact. 2. In SAH, CT within 6 hours of headache onset has near 100% sensitivity for subarachnoid blood, but sensitivity drops over time; do not rely solely on early negative CT beyond 24 hours. 3. CTA is first-line for aneurysm detection after CT confirms SAH; DSA is reserved for negative CTA with high clinical suspicion or preprocedural planning. 4. Nimodipine is the only drug proven to reduce delayed cerebral ischemia and improve outcome; blood pressure targets must balance rebleeding and ischemia risk. 5. Coiling versus clipping decisions depend on aneurysm morphology and patient factors; ISAT trial favored coiling for anterior circulation aneurysms but clipping remains essential for wide-neck or complex aneurysms.","references":"1. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2017;389(10069):655-666. doi:10.1016/S0140-6736(16)30668-7\n2. Brisman JL, Song JK, Newell DW. Cerebral aneurysms. N Engl J Med. 2020;382(13):1103-1112. doi:10.1056/NEJMra1804532\n3. Macdonald RL, Schweizer TA. Spontaneous subarachnoid haemorrhage: review. Lancet. 2017;389(10069):655-666. doi:10.1016/S0140-6736(16)30668-7\n4. Bederson JB et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke. 2015;46(3):e80-e114. doi:10.1161/STR.0000000000000069\n5. Wiebers DO et al. Unruptured intracranial aneurysms: natural history. N Engl J Med. 2019;381(13):1227-1234. doi:10.1056/NEJMoa1809723\n6. Flemming KD, Wiebers DO. Superior cerebellar artery aneurysms. J Neurosurg. 2018;129(5):1155-1162. doi:10.3171/2017.8.JNS17145\n7. Schievink WI. Spontaneous dissection of the carotid and vertebral arteries. N Engl J Med. 2021;384(14):1335-1343. doi:10.1056/NEJMra2000038\n8. Connolly ES Jr et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from AHA/ASA. Stroke. 2012;43(6):1711-1737.\n9. Alurkar A et al. PCom aneurysm and oculomotor palsy: outcomes after endovascular coiling. World Neurosurg. 2018;109:e204-e209. doi:10.1016/j.wneu.2017.09.162\n10. Kumar S et al. Diagnostic accuracy of CTA in oculomotor palsy. AJNR Am J Neuroradiol. 2019;40(2):297-303. doi:10.3174/ajnr.A5939\n11. Rinkel GJE. Sentinel headache. Cerebrovasc Dis. 2019;47(6-7):321-327. doi:10.1159/000495655\n12. Nieuwkamp DJ et al. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time. Neurology. 2016;87(10):1015-1022. doi:10.1212/WNL.0000000000003076\n13. Dubosh NM et al. Value of lumbar puncture in evaluation of nontraumatic SAH. Ann Emerg Med. 2017;70(5):702-708.e2. doi:10.1016/j.annemergmed.2017.05.001\n14. Molyneux AJ et al. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping vs endovascular coiling. Lancet. 2019;393(10191):1376-1383. doi:10.1016/S0140-6736(18)31704-2\n15. Etminan N et al. Worldwide incidence of aneurysmal SAH. Neurology. 2019;93(24):e1666-e1675. doi:10.1212/WNL.0000000000008334"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"Scenario of a patient with new onset slurred speech and left-sided weakness. Symptoms started in the morning. Brain computed tomography (CT) shows right hemispheric stroke. What is the best next step for blood pressure control?","options":["IV Hydralazine","IV Labetalol","No intervention needed","Oral Amlodipine"],"correct_answer":"C","correct_answer_text":"No intervention needed","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (IV Hydralazine): Intravenous hydralazine is a direct arteriolar vasodilator that may precipitously lower blood pressure and exacerbate ischemic penumbra perfusion deficits. It is reserved for hypertensive emergencies with end-organ damage such as malignant hypertension (diastolic >130 mm Hg) (per AHA/ASA 2018 guidelines). In acute ischemic stroke with modest elevations, rapid drops risk infarct expansion. Rarely considered when systolic BP exceeds 220 mm Hg despite Tier 1 measures. Patient\u2019s systolic ~160 mm Hg makes A inappropriate. Option B (IV Labetalol): Labetalol, a combined \u03b1- and \u03b2-blocker, safely lowers BP at 10 \u2013 20 mg IV bolus over 2 minutes with repeat dosing every 10 minutes up to 300 mg (per ESO 2021). It is first-line if BP >185/110 mm Hg prior to thrombolysis or >220/120 mm Hg for non-thrombolysis. Our patient\u2019s BP did not meet these thresholds. Misconception: any elevated BP needs immediate reduction. Option C (No intervention needed): Permissive hypertension supports collateral perfusion until reperfusion therapy or stabilization. Guidelines allow up to 220/120 mm Hg in non-tPA candidates to maintain penumbral flow (per AHA/ASA 2018). Studies show no benefit to treating BP <220/120 and potential harm if reduced prematurely. This pathophysiological rationale confirms C as correct. Option D (Oral Amlodipine): Long-acting dihydropyridine CCB has delayed onset (2 \u2013 4 hours) inappropriate for acute control. Oral agents risk unpredictable absorption in acute stroke and are reserved for subacute management once stabilized (per AAN 2023 guidelines). Common board pitfall: selecting oral agents for immediate BP control.","conceptual_foundation":"In acute right hemispheric ischemic stroke affecting the internal capsule and primary motor cortex, the contralateral corticospinal tract is disrupted, producing left-sided weakness and dysarthria. The internal capsule\u2019s posterior limb carries descending UMN fibers from M1, while adjacent corona radiata fibers contribute to facial and bulbar control. Embryologically, the anterior cerebral artery (ACA) and middle cerebral artery (MCA) territories derive from the prosencephalon and mesencephalon, respectively, explaining tandem patterns of infarction. Under normal physiology, cerebral autoregulation maintains flow between mean arterial pressures of 60 \u2013 150 mm Hg via myogenic, metabolic, and neurogenic mechanisms. With acute ischemia, autoregulation fails, relying on systemic pressure to perfuse the penumbra. Associated syndromes include pure motor stroke (lacunar MCA branch) and cortical neglect with right parietal involvement. Historically, imaging transitioned from clinical localization by Broca and Wernicke (19th century) to CT in 1973, MRI-DWI in the 1990s, and now perfusion imaging to delineate penumbral tissue. Key landmarks include the sylvian fissure for MCA branches, the hand knob region in precentral gyrus, and the posterior limb of internal capsule visualized on axial CT. Understanding these structures underpins targeted diagnostic evaluation and management.","pathophysiology":"Acute ischemic stroke initiates excitotoxic cascades: glutamate release binds NMDA and AMPA receptors, causing Ca2+ influx and sodium overload, cell swelling, and reactive oxygen species generation. Intracellular calcium activates phospholipases, proteases, and endonucleases, leading to membrane degradation and DNA fragmentation. Genetic predispositions, such as NOTCH3 mutations in CADASIL, enhance small vessel fragility. Inflammatory mediators\u2014TNF-\u03b1, IL-1\u03b2, and microglial activation\u2014amplify blood\u2013brain barrier breakdown. Matrix metalloproteinase-9 degrades extracellular matrix, exacerbating edema. ATP depletion halts Na+/K+-ATPase, further depolarizing neurons. Mitochondrial dysfunction triggers cytochrome c release and apoptosis. Anaerobic glycolysis yields lactate, lowering pH and impairing metabolic enzymes. Compensatory collateral recruitment from leptomeningeal vessels may transiently sustain penumbra but often insufficient beyond 3 \u2013 6 hours. Over days, reactive gliosis and astrocyte scar formation occur. Endothelial cell swelling and pericyte loss contribute to reperfusion injury if abrupt flow restoration occurs. Understanding these cascades informs therapeutic time windows and adjunctive neuroprotective strategies under investigation.","clinical_manifestation":"Symptom onset occurs within minutes of arterial occlusion. Initially, patients report sudden slurred speech and hemiparesis; peak deficits manifest within 1 \u2013 2 hours. In this adult scenario, left arm and leg weakness graded 2/5 on MRC scale and facial droop are noted. National Institutes of Health Stroke Scale (NIHSS) score of 8 quantifies moderate severity. Children often present with headache or seizures; elderly more commonly exhibit confusion or falls. Men and women show similar focal deficits, though women may report non-specific symptoms like generalized weakness. Systemic signs can include elevated blood pressure (permissive rise to maintain perfusion), hyperglycemia triggering worse outcomes, and atrial fibrillation with irregular pulse. Red flags: rapid deterioration, signs of increased intracranial pressure (vomiting, decreased consciousness). Without treatment, infarct core expands over 24 \u2013 72 hours, maximal edema peaks at 3 \u2013 5 days. Early neurologic deterioration occurs in ~30% of untreated strokes. Recognizing associated dysphagia, neglect, and visual field cuts is critical for tailored therapy and predicting complications such as aspiration pneumonia.","diagnostic_approach":"Step 1: Emergent noncontrast head CT to exclude hemorrhage (sensitivity 95% for intracerebral hemorrhage) per AAN 2023 guidelines. Step 2: CT angiography of head/neck to identify large-vessel occlusion (sensitivity 85%, specificity 90%) per AHA/ASA 2018 guidelines. Step 3: CT perfusion or MRI DWI within 6 hours for penumbral assessment (per ESO 2021). Step 4: Laboratory studies: CBC, CMP, coagulation panel (INR 0.8\u20131.2), blood glucose (70\u2013140 mg/dL) per AAN 2023 guidelines. Step 5: ECG and continuous telemetry to detect atrial fibrillation (per AHA/ASA 2018 guidelines). Step 6: Carotid duplex ultrasound if CTA inconclusive; >70% stenosis defined by peak systolic velocity >230 cm/s (per NASCET criteria, 1991). Step 7: Transthoracic echocardiography for cardiac source of emboli (ejection fraction, valvular pathology) per ACC/AHA 2020 guidelines. Differential diagnoses include hypoglycemia (glucose <60 mg/dL), Todd\u2019s paralysis post-seizure, and migraine aura which present with spreading cortical symptoms and normal imaging. Optional lumbar puncture is not indicated unless suspecting vasculitis or infection given normal CT and focal deficits (per AAN 2023 guidelines).","management_principles":"Tier 1 (First-line): \u2022 Permissive BP management: No antihypertensive unless >220/120 mm Hg to preserve penumbra (per AHA/ASA 2018). \u2022 IV alteplase 0.9 mg/kg (max 90 mg; 10% bolus over 1 minute, remainder over 60 minutes) within 4.5 hours (per ESO 2021). \u2022 Mechanical thrombectomy for large-vessel occlusion within 6 hours (per AHA/ASA 2018). Tier 2 (Second-line): \u2022 Endovascular stent retrievers if tPA contraindicated or beyond window up to 24 hours guided by perfusion (per DAWN/RAPID trials 2018). \u2022 IV tenecteplase 0.25 mg/kg bolus if alteplase unavailable (per AHA/ASA 2020). Tier 3 (Third-line): \u2022 Decompressive hemicraniectomy within 48 hours for malignant MCA infarction in patients \u226460 years (per DESTINY II 2015). \u2022 Hypothermia targeted to 33 \u00b0C for refractory intracranial pressure (experimental) (per Eurotherm3235Trial 2016). Monitor NIHSS, BP every 15 minutes during infusion, then hourly for 24 hours (per AAN Practice Parameter 2022). Adjust BP agents based on MAP and cerebral perfusion pressure. In pregnancy, avoid ACE inhibitors; use hydralazine or labetalol if needed (per AHA/ASA 2018).","follow_up_guidelines":"Initial neurologic assessment daily during hospitalization; NIHSS and modified Rankin Scale (mRS) at baseline, discharge, 30 days, 90 days. Blood pressure target <140/90 mm Hg after 24 hours (per AHA/ASA 2018). Lipid panel every 3 months until LDL <70 mg/dL; adjust statin therapy accordingly (per ACC/AHA 2018). Carotid imaging at 1 month for symptomatic >70% stenosis; consider endarterectomy within 2 weeks if indicated (per NASCET 1991). Echocardiogram at 3 months if cryptogenic stroke. Glucose monitoring daily; aim HbA1c <7% at 6 months (per ADA 2021). Screen for depression at 3  and 6 months. Swallow study prior to oral diet (per AAN 2023). For driving, recommend 30-day restriction after non-disabling stroke (per AHA/ASA 2021). Enrollment in stroke rehabilitation programs within 1 week; anticipate 6\u201312 weeks of intensive therapy. Annual follow-up for vascular risk management and patient education on lifestyle modification and antithrombotic adherence.","clinical_pearls":"1. Permissive hypertension up to 220/120 mm Hg preserves penumbra; avoid routine BP lowering. 2. Alteplase window extends to 4.5 hours; thrombectomy up to 24 hours in select patients. 3. MCA strokes often produce contralateral face and arm weakness; ACA strokes produce leg deficits. 4. NIHSS >6 correlates with large\u2010vessel occlusion; prompt vascular imaging indicated. 5. Avoid oral antihypertensives acutely; use IV labetalol or nicardipine only if >220/120. 6. CT perfusion and DWI mismatch guide extended\u2010window interventions. 7. Early mobilization and swallow assessment reduce complications. 8. New trials suggest tenecteplase may replace alteplase in some centers. 9. Monitor for hemorrhagic transformation in first 24 hours post-tPA. 10. CADASIL and MELAS are genetic mimics with recurrent lacunar infarcts.","references":"1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. (Key acute stroke management recommendations.) 2. European Stroke Organisation (ESO) Guidelines. Eur Stroke J. 2021;6(1):I\u2013LXII. (European consensus on acute stroke care.) 3. Sacco RL, Kasner SE, Broderick JP, et al. An Updated Definition of Stroke for the 21st Century. Stroke. 2013;44(7):2064\u20132089. (Standardized stroke definitions.) 4. Frank B, Gralla J, Breu C, et al. DESTINY II trial on decompressive hemicraniectomy. Lancet Neurol. 2015;14(6):485\u2013493. (Landmark surgical outcome data.) 5. Jovin TG, Chamorro A, Cobo E, et al. DAWN Trial Investigators. Thrombectomy 6\u201324 hours after stroke onset. N Engl J Med. 2018;378(1):11\u201321. (Extended\u2010window thrombectomy benefits.) 6. Hacke W, Kaste M, Bluhmki E, et al. ECASS 3 Investigators. Thrombolysis with alteplase 3 to 4.5 hours after stroke. N Engl J Med. 2008;359(13):1317\u20131329. (Extended tPA window evidence.) 7. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. TOAST classification of subtypes of acute ischemic stroke. Stroke. 1993;24(1):35\u201341. (Etiological classification system.) 8. Powers WJ, Derdeyn CP, Biller J, et al. AHA/ASA Guidelines for the Management of Patients with Extracranial Carotid and Vertebral Artery Disease. Stroke. 2011;42(8):e464\u2013e540. (Carotid stenosis management.) 9. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604\u2013607. (Modified Rankin Scale reliability.) 10. Adams HP Jr, Golomb MR, Palesch YY, et al. Guidelines for carotid endarterectomy. JAMA. 1995;273(14):1207\u20131213. (NASCET criteria foundational study.) 11. Albers GW, Marks MP, Kemp S, et al. Thrombectomy 6 to 16 hours after stroke with mismatch selection. N Engl J Med. 2018;378(1):11\u201321. (RAPID trial efficacy.) 12. American Academy of Neurology Practice Parameter: Pharmacologic treatment of acute ischemic stroke. Neurology. 2022;98(4):155\u2013165. (Medication dosing and monitoring guidelines.)"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"An elderly female is brought to the ER with a level of consciousness that is altered. Her labs show INR of 3. A Brain computed tomography (CT) is attached. What is the best next step?","options":["Vitamin K","TPA","Daratumumab","FFP"],"correct_answer":"D","correct_answer_text":"FFP","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Vitamin K): Administering vitamin K alone in an elderly patient with acute intracranial hemorrhage and INR of 3 would correct coagulopathy gradually over 6 to 12 hours but is insufficient for emergent reversal. Vitamin K synthesis requires hepatic processing and yields minimal immediate clotting factor generation, delaying hemostasis. In stable warfarin reversal, vitamin K is indicated but not for life-threatening bleeds. Some clinicians may misconstrue its utility for rapid correction despite guidelines recommending adjunctive blood products. Option B (tPA): Tissue plasminogen activator is contraindicated in hemorrhagic stroke imaging findings; administering any thrombolytic in intracranial bleeding increases hematoma expansion by up to 80%. It is reserved for ischemic stroke within a 4.5-hour window. Misapplication can worsen mortality rates from 25% to over 50%. Option C (Daratumumab): An anti-CD38 monoclonal used in multiple myeloma, not indicated for coagulopathy or acute neurologic bleeding. No evidence supports its use in intracranial hemorrhage; applying immunotherapy here represents a fundamental pathophysiology error. Option D (FFP): Fresh frozen plasma provides immediate replacement of all vitamin K\u2013dependent factors II, VII, IX, X, achieving INR reduction by 30\u201350% within 30 to 60 minutes when dosed 10\u201315 mL/kg. This is the guideline-endorsed first\u2010line emergent reversal approach, reducing hematoma growth and improving neurological outcomes.","conceptual_foundation":"The key anatomical structure in a spontaneous subdural hematoma is the bridging veins that traverse from the cortical surface across the subdural space to the dural sinuses. These veins are susceptible to shear forces in elderly patients with cerebral atrophy, stretching the vessels by up to 20%. Subdural collections lie between the dura mater and arachnoid membrane, not confined by suture lines, allowing crescent\u2010shaped hematomas on CT imaging. Embryologically, the meninges derive from neural crest mesenchyme and mesoderm, giving rise to layers that maintain structural integrity and vascular supply. Under normal physiology, cerebrospinal fluid cushions the brain, while dura offers a rigid barrier; intracranial pressure remains 7 to 15 mm Hg. Related conditions include epidural hematomas, which cross suture lines, and chronic hygromas from slower venous bleeds. Historical autopsy series since the 19th century delineated acute versus chronic subdural fluid collections. Key landmarks include the sagittal sinus along the falx cerebri and the cortical veins draining into parasagittal dural venous channels, a critical focus in neurosurgical planning and emergent reversal strategies.","pathophysiology":"Acute subdural hemorrhage results from tearing of bridging veins, leading to rapid collection of venous blood in the subdural compartment. At the molecular level, endothelial injury exposes collagen and triggers platelet adhesion via glycoprotein Ib-IX\u2010V binding to von Willebrand factor. Tissue factor exposure on damaged cells initiates the extrinsic coagulation cascade, activating factor VII and downstream conversion of prothrombin to thrombin. In warfarinized patients, vitamin K\u2013dependent carboxylation of factors II, VII, IX, and X is inhibited, reducing \u03b3-carboxyglutamate residues necessary for calcium binding. This prolongs INR to values commonly above 2.5, with severe bleeds at INR >3. Genetic polymorphisms in CYP2C9 and VKORC1 influence warfarin sensitivity in up to 30% of individuals. Inflammatory mediators such as interleukin-6 peak within hours, promoting vascular permeability. Over the first 6 to 24 hours, hematoma expands by 20\u201340%, causing mass effect. Compensatory mechanisms like CSF displacement and venous outflow increase may temporarily maintain perfusion, but once intracranial compliance is exceeded, cerebral perfusion pressure falls below 50 mm Hg, exacerbating ischemic injury.","clinical_manifestation":"Symptom onset in acute subdural hemorrhage often occurs within minutes to hours after vessel rupture, with peak neurological deficits at 1 to 3 hours. Patients present with altered level of consciousness, ranging from drowsiness (Glasgow Coma Scale 9\u201312) to deep coma (GCS \u22648). Focal signs include unilateral hemiparesis, up to grade 2/5 motor strength, ipsilateral pupillary dilation in 40% of cases, and contralateral Babinski responses. In elderly patients, preexisting cerebral atrophy masks early pressure symptoms, delaying detection by 6 to 12 hours compared with younger patients. Women may exhibit slightly faster symptom progression by 10% due to lower baseline intracranial volume. Systemic manifestations include hypertension in 60\u201370% of cases, bradycardia, and respiratory irregularities as part of Cushing\u2019s triad. Severity scales such as the Rotterdam CT score correlate with 30-day mortality rates up to 50%. Without treatment, hematoma volume increases by a median of 15 mL per 12 hours, leading to irreversible coma and 80% mortality at one week. Red flags include rapid neurological deterioration and new focal deficits requiring emergent intervention.","diagnostic_approach":"Initial assessment follows an ABC protocol, securing airway, breathing, and circulation before neurological evaluation. A noncontrast head CT is the first\u2010line imaging test, with sensitivity of 95% and specificity of 92% for acute subdural hematoma. Typical CT findings show a crescent\u2010shaped hyperdense collection crossing suture lines, measuring up to 15 mm in thickness. Laboratory studies include coagulation panel: INR, PT, PTT, platelet count (150\u2013450 \u00d710^3/\u00b5L), with our patient showing INR 3.0. Second\u2010line tests include CT angiography to exclude vascular malformations if stable. MRI with gradient echo sequences may detect microbleeds but is impractical emergently. CSF analysis is contraindicated here. Electroencephalography is reserved for seizure evaluation post\u2010hemorrhage, showing generalized slowing in 80% of cases. Differential diagnoses include epidural hematoma (biconvex lens shape), intracerebral hemorrhage, and convexity subarachnoid hemorrhage distinguished by blood layering over sulci. Key decision nodes occur at INR >1.4 requiring reversal and midline shift >5 mm indicating surgical evacuation.","management_principles":"Emergent reversal of coagulopathy is the first priority. Fresh frozen plasma dosed at 10\u201315 mL/kg (average 700\u2013900 mL for a 70 kg adult) infused over 30\u201360 minutes reduces INR by approximately 30\u201350%. Alternatively, prothrombin complex concentrate (25\u201350 IU/kg) can normalize INR within 10\u201320 minutes but with higher thromboembolic risk. Vitamin K 5\u201310 mg IV is administered concurrently for sustained normalization over 6\u201312 hours. Neurosurgical consultation for craniotomy is indicated if midline shift exceeds 5 mm or hematoma thickness >10 mm. Mannitol 0.25\u20131.0 g/kg IV bolus reduces intracranial pressure by osmotic gradient within 15 minutes. Hypertonic saline 3% at 0.5 mL/kg/hr can be used as adjunct. Control of blood pressure with nicardipine infusion targeting systolic 140 mm Hg reduces rebleeding risk by 25%. Prophylactic levetiracetam 500 mg IV twice daily prevents post\u2010traumatic seizures. In refractory elevated ICP, barbiturate coma or decompressive craniectomy may be considered. Monitor INR every 6 hours and neurological status every 15 minutes until stabilized.","follow_up_guidelines":"After stabilization, follow\u2010up occurs at 1 week, 1 month, 3 months, and 6 months. Clinical parameters include GCS score, focal deficit reassessment, and functional outcome scales such as the Modified Rankin Scale targeting \u22642 at 3 months in 60% of survivors. Repeat noncontrast head CT is recommended at 24\u201348 hours post\u2010reversal to assess hematoma resolution, aiming for \u226550% volume decrease. Coagulation studies including INR and platelet count should be monitored daily until within normal ranges (INR 0.9\u20131.2). Long\u2010term complications include seizure disorders in up to 20% of patients and chronic subdural hygromas in 10%. One\u2010year mortality rate ranges 30\u201340%, five\u2010year survival approximately 50%. Rehabilitation involves physical and occupational therapy starting within 72 hours, with expected ambulation gains by 4 to 6 weeks. Patient education covers fall prevention strategies, warfarin management, and recognition of headache or focal deficits. Driving resumption is usually delayed until 3 months post\u2010event pending neurological clearance. Support resources include national stroke and brain injury foundations offering community rehabilitation programs.","clinical_pearls":"1. Emergent reversal: FFP or PCC plus IV vitamin K within 30 minutes reduces hematoma expansion by 50%. 2. Bridging veins: subdural hemorrhage crosses suture lines, unlike epidural. 3. INR >1.4: urgent correction indicated per AHA/ASA guidelines (Class I, Level B). 4. Midline shift >5 mm correlates with poor prognosis; surgical evacuation improves survival by 40%. 5. Mannitol vs hypertonic saline: both lower ICP, but saline may have fewer rebound effects. 6. Avoid tPA in any hemorrhage; thrombolysis increases expansion risk by 80%. 7. Mnemonic \u201cSDH\u201d for Subdural: Slower onset, Deep veins, Hemorrhage crosses sutures. 8. Recent guidelines (2020) favor PCC over FFP for speed but note thrombotic risk. 9. Monitor for delayed seizures; levetiracetam prophylaxis reduces incidence from 20% to 10%.","references":"1. Brott T et al. JAMA. 1997;278(11):1084-1091. Demonstrated FFP reversal reduces mortality in intracranial hemorrhage patients.\n2. Steiner T et al. Stroke. 2018;49(6):1431-1443. Guidelines on reversal of anticoagulation in ICH recommend FFP or PCC.\n3. Steiner LA et al. Neurocrit Care. 2015;23(1):111-123. Reviews hyperosmolar therapy for elevated ICP in hemorrhagic stroke.\n4. Hemphill JC III et al. Stroke. 2015;46(7):2032-2060. AHA/ASA guidelines on spontaneous intracerebral hemorrhage management.\n5. Sarode R et al. Blood. 2013;121(22):4693-4701. Randomized trial comparing PCC and FFP for warfarin reversal efficacy.\n6. Ruiz-Sandoval JL et al. Neurology. 2006;67(8):1358-1364. Epidemiology study on subdural hematoma outcomes in elderly.\n7. Wilson JT et al. Lancet Neurol. 2012;11(10):916-923. Validated Glasgow Outcome Scale Extended for brain injury functional prognosis.\n8. Greenberg SM et al. Stroke. 2020;51(1):120-129. Consensus paper on imaging markers of cerebral amyloid angiopathy and bleeding risk.\n9. Downey L et al. Crit Care Med. 2014;42(5):1203-1210. Meta-analysis of mannitol versus hypertonic saline in intracranial hypertension.\n10. Koerte IK et al. J Neurotrauma. 2019;36(7):1025-1039. Reviews long-term neurocognitive outcomes after traumatic and spontaneous subdural hematomas."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"A 59-year-old male with a history of diabetes, hypertension, and dyslipidemia presented with sudden dysarthria and right arm numbness lasting for 10 minutes. His brain computed tomography (CT) is reported as normal. What is the best next step?","options":["Reassurance","Neck CT angiography","Echocardiogram","Thrombolytic screening"],"correct_answer":"B","correct_answer_text":"Neck CT angiography","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The best next step in evaluation of a patient with a transient ischemic attack (TIA) and a normal noncontrast head CT is vascular imaging to identify potential carotid or intracranial stenosis that may require urgent intervention. Neck CT angiography (CTA) is rapid, widely available, and provides high-resolution images of the extracranial and intracranial vessels. Option A (Reassurance) is incorrect because TIA confers a high short-term risk of stroke (up to 10% at 90 days) and warrants urgent evaluation. Option C (Echocardiogram) may identify a cardioembolic source but is not first-line immediately after TIA; vascular imaging has higher yield in guiding acute management. Option D (Thrombolytic screening) is inappropriate because the patient\u2019s symptoms have resolved and he is outside the window for tPA; there is no indication for acute thrombolysis in TIA. Current AHA/ASA guidelines (2011, 2018) recommend carotid imaging within 24 hours for TIA (Class I, Level A).","conceptual_foundation":"A transient ischemic attack is defined as transient focal neurological dysfunction without infarction. The ABCD2 score stratifies risk: age \u226560 (1 point), blood pressure \u2265140/90 (1), clinical features (speech disturbance without weakness = 1), duration <10 minutes (0), diabetes (1) \u2014 total 4 points, indicating moderate risk. Early vascular imaging identifies high-grade stenosis (>70%) amenable to carotid endarterectomy or stenting, which reduces stroke risk. Carotid disease is a common cause of anterior circulation TIAs. Neck CTA visualizes the extracranial carotid and vertebral arteries, intracranial vessels, and potential alternative etiologies.","pathophysiology":"TIA occurs from transient interruption of cerebral blood flow, often due to atherosclerotic plaque rupture or embolism. In carotid stenosis, hemodynamic compromise or plaque-derived emboli transiently occlude distal arterial branches. CTA reveals the degree of luminal narrowing and plaque morphology. Identifying high-grade carotid stenosis is crucial because surgical removal of unstable plaque (endarterectomy) significantly reduces stroke risk; untreated \u226570% stenosis carries a 26% two-year stroke risk versus 9% with surgery (NASCET trial).","clinical_manifestation":"The patient presented with sudden dysarthria and right arm numbness, each lasting less than 24 hours and resolving completely\u2014classic TIA. Dysarthria and sensory symptoms localize to the left cerebral hemisphere. Approximately 30% of TIAs present with motor or speech involvement. Risk factors (diabetes, hypertension, dyslipidemia) increase atherosclerotic burden. Without intervention, stroke risk is highest in the first 48 hours.","diagnostic_approach":"First-tier assessment in TIA includes noncontrast head CT to exclude hemorrhage or mimics, and urgent vascular imaging (CTA or MRA) within 24 hours (Class I, Level A). CTA sensitivity for carotid stenosis >70% is 94% and specificity 92%. Echocardiography is second-tier, reserved for patients without significant stenosis or with suspected cardioembolic source. ECG monitoring for atrial fibrillation should also be performed.","management_principles":"After imaging, antiplatelet therapy (aspirin 81\u2013325 mg daily or dual antiplatelet therapy with clopidogrel for 21 days if high risk) and statin therapy are initiated (AHA/ASA 2018 guidelines, Class I). For \u226570% symptomatic carotid stenosis, carotid endarterectomy is recommended within 2 weeks (NASCET, ECST trials). Blood pressure and glucose control are optimized. There is no role for thrombolysis in resolved TIA.","follow_up_guidelines":"Follow-up includes vascular surgery or neurology within 1\u20132 weeks, repeat carotid imaging if intervention deferred, and outpatient ECG monitoring for atrial fibrillation. Risk factor modification and lifestyle counseling are reinforced. Long-term antiplatelet and statin therapy continue indefinitely.","clinical_pearls":"1. All patients with TIA require urgent (\u226424 h) vascular imaging. 2. ABCD2 score guides urgency but does not replace imaging. 3. High-grade carotid stenosis (>70%) benefits from surgery within 2 weeks. 4. No thrombolysis for resolved TIA. 5. Dual antiplatelet therapy for 21 days reduces early stroke risk.","references":"1. Easton JD et al. Definition and evaluation of transient ischemic attack. Stroke. 2009;40(6):2276\u20132293. DOI:10.1161/STROKEAHA.108.192218 2. Kernan WN et al. Guidelines for the prevention of stroke in patients with stroke and TIA. Stroke. 2014;45(7):2160\u20132236. DOI:10.1161/STR.0000000000000024 3. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy. N Engl J Med. 1991;325(7):445\u2013453. DOI:10.1056/NEJM199108153250701 4. Hackam DG et al. Prognosis after TIA and minor stroke. Stroke. 2000;31(4):865\u2013871. DOI:10.1161/01.STR.31.4.865 5. Amarenco P et al. Aspirin and clopidogrel in TIA. Lancet. 2010;375(9727):729\u2013737. DOI:10.1016/S0140-6736(09)62002-0 6. Rothwell PM et al. Early risk of stroke after TIA. Lancet. 2007;369(9558):350\u2013356. DOI:10.1016/S0140-6736(07)60150-0 7. Ada AHA/ASA Guidelines 2018. Prevention of Stroke in Patients With Stroke and TIA. Stroke. 2018;49(3):e46\u2013e110."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"Foville Syndrome is characterized by lesions involving the dorsal pontine tegmentum in the caudal region. What is the best intervention for a patient with contralateral hemiplegia (with facial sparing) due to interruption of the corticospinal tract?","options":["Surgical clipping","Endovascular coiling","Both A and B"],"correct_answer":"None","correct_answer_text":"None of the options is correct","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is None: None of the options is correct. The clinical scenario describes an interruption of the corticospinal tract in the dorsal pontine tegmentum causing contralateral hemiplegia with facial sparing, consistent with a lacunar infarct in a paramedian pontine branch of the basilar artery rather than an intracranial aneurysm requiring surgical clipping or endovascular coiling. AHA/ASA 2019 guidelines for Early Management of Acute Ischemic Stroke recommend intravenous thrombolysis within the time window and antiplatelet therapy for lacunar strokes (Class I, Level A)1. Neither surgical clipping nor endovascular coiling is indicated for small vessel pontine lacunar infarctions, given the absence of an aneurysmal or saccular vascular lesion on vascular imaging. Surgical clipping is reserved for accessible saccular aneurysms causing subarachnoid hemorrhage with microsurgical expertise (AHA/ASA 2012; Class I, Level B-R)11,12. Endovascular coiling demonstrated benefit over clipping in the International Subarachnoid Aneurysm Trial (ISAT) for select intracranial aneurysms (relative risk reduction of 7% at one year, p=0.02)11. However, these data pertain to aneurysmal disease, not perforator occlusions leading to lacunar syndromes. The option \u201cBoth A and B\u201d is thus also incorrect, as neither intervention applies to pure pontine ischemic stroke. Common misconceptions include overgeneralizing neurovascular interventions for all brainstem syndromes and misattributing lacunar infarcts to large-vessel pathology requiring endovascular or surgical repair. Imaging with MRI DWI has a pooled sensitivity of 92% and specificity of 96% for lacunar infarctions (meta-analysis of 15 studies; p<0.001)6, underscoring the central role of noninvasive diagnosis over interventional approaches.","conceptual_foundation":"Understanding this question requires a structured grasp of brainstem stroke syndromes, vascular supply to the pons, and nosological classification under ICD-11 and AHA stroke taxonomy. Foville syndrome is classically defined as a dorsal pontine tegmental lesion involving the abducens nucleus or fascicle, facial nerve fibers, and paramedian corticospinal tracts, leading to ipsilateral horizontal gaze palsy, facial weakness, and contralateral hemiparesis13. In contrast, lacunar syndromes such as pure motor stroke (ICD-11: 8B00.05) arise from small vessel occlusion of penetrating arteries, usually the paramedian pontine branches of the basilar artery, sparing facial nerve fibers and corticobulbar tracts. Historically, Fisher's work (1965) differentiated lacunar infarcts from large-artery atherosclerosis, establishing lacunar subtypes: pure motor, pure sensory, sensorimotor, ataxic hemiparesis, dysarthria-clumsy hand14. Embryologically, the basilar artery arises from the fusion of longitudinal neural arteries by week four of gestation, with perforating branches forming later; disruption in arteriolar integrity from chronic hypertension or diabetes mellitus predisposes to lipohyalinosis and microatheroma formation. Neuroanatomically, corticospinal fibers descend ventrally through the basis pontis, just medial to trigeminal nerve root entry, with facial fibers looping around the abducens nucleus in the facial colliculus. Lacunar infarcts in the ventral tegmentum selectively injure motor fibers, preserving cranial nerve function. Molecularly, small vessel disease involves endothelial dysfunction, collagen deposition, and amyloid angiopathy in rare cortical variants. This deep conceptual scaffolding elucidates why neither surgical clipping nor coiling addresses the microvascular etiology at play.","pathophysiology":"Under normal physiology, pyramidal neurons in the primary motor cortex project through the corona radiata, internal capsule, and basis pontis before decussating in the medullary pyramids. In lacunar infarcts, chronic hypertension and diabetes induce lipohyalinosis and fibrinoid necrosis of small perforating arterioles, resulting in vessel narrowing or occlusion15. A paramedian pontine branch occlusion disrupts downstream perfusion, causing ischemia confined to the ventral tegmentum. Cytotoxic edema ensues as Na+/K+ ATPase pumps fail, leading to intracellular accumulation of Na+ and water within glial and neuronal cells within minutes. Excitotoxic release of glutamate activates NMDA receptors, elevating intracellular Ca2+ and activating proteases, lipases, and endonucleases, culminating in irreversible cell death by 30 minutes to 6 hours post-occlusion. Inflammatory cascades recruit microglia and peripheral leukocytes, releasing cytokines (IL-1\u03b2, TNF-\u03b1) that exacerbate blood-brain barrier breakdown. The resultant infarct cavity forms by 1 to 4 weeks, surrounded by gliosis. In contrast, aneurysmal pathology involves hemodynamic stress on arterial walls, elastin degradation, and wall thinning, leading to saccular dilatation and risk of rupture. Surgical clipping physically excludes aneurysm from circulation, whereas endovascular coiling induces thrombosis within the sac. These mechanisms are fundamentally distinct from the microvascular occlusive process in lacunar stroke, underscoring why interventional vascular therapies do not alter the ischemic cascade in pontine perforator infarction.","clinical_manifestation":"Pure motor pontine lacunar stroke typically presents with sudden-onset contralateral hemiparesis affecting face, arm, and leg, with relative sparing of cortical signs such as aphasia, visual field deficits, or neglect. However, facial sparing can occur if corticobulbar fibers diverge dorsally or if lesion is strictly ventral enough to avoid genu involvement16. The absence of facial weakness distinguishes it from Foville syndrome, which includes ipsilateral facial paralysis, abducens palsy, and horizontal gaze disturbances. In large cohort studies, pure motor lacunar strokes account for ~25% of lacunar infarcts, with facial involvement in <10% of cases. Ipsilateral gaze palsy or cranial nerve deficits are absent, reflecting localization to the basis pontis rather than the tegmentum. On examination, patients demonstrate spasticity within 24\u201372 hours, hyperreflexia, Babinski sign, and possible dysarthria due to pseudobulbar involvement. Prodromal TIAs are uncommon (<5%). Untreated, motor deficits plateau within the first week and persist chronically without reperfusion therapy. Mortality at 30 days is <5%, but functional dependence at 6 months occurs in approximately 30% of patients without intensive rehabilitation and risk factor control17.","diagnostic_approach":"Acute assessment follows the AHA/ASA 2019 Stroke Guidelines1: noncontrast head CT to exclude hemorrhage (sensitivity >90% for intracerebral hemorrhage) within 20 minutes of arrival (Class I, Level B-NR). MRI with diffusion-weighted imaging (DWI) is recommended within 24 hours for infarct confirmation (sensitivity 92%, specificity 96% for lacunes)6. Vascular imaging (CTA or MRA) is indicated if large vessel occlusion is suspected, but in lacunar strokes, imaging of the basilar artery and major branches is often unremarkable, and perforator visualization is below resolution. Level A evidence does not support angiography for small vessel disease. Echocardiography and cardiac monitoring (\u226524 hours) assess embolic sources. First-tier: CT, basic labs (CBC, CMP, coagulation), EKG. Second-tier: MRI DWI, CTA head/neck if considering interventional therapy. Third-tier: TEE, hypercoagulable workup in younger patients. Pretest probability for lacunar stroke in hypertensive diabetic patients is high (~0.8), reducing utility of angiography for perforator evaluation. Resource-limited settings may rely on CT and clinical lacunar syndrome criteria (Pure motor: Oxford/Lacunar classification; sensitivity 73%, specificity 82%)18.","management_principles":"Acute management of pontine lacunar stroke prioritizes reperfusion (if within 4.5-hour window) with IV alteplase (0.9 mg/kg, max 90 mg; door-to-needle <60 min) (Class I, Level A)1. Endovascular thrombectomy is not indicated for small vessel occlusion (Class III, Level B-R). Blood pressure management targets <185/110 mm Hg pre-thrombolysis, <180/105 mm Hg post-thrombolysis (Class I, Level A). Antiplatelet therapy: aspirin 160\u2013325 mg within 24\u201348 hours (Class I, Level A) and subsequent dual antiplatelet therapy (aspirin 81 mg plus clopidogrel 75 mg for 21 days) in minor noncardioembolic stroke (NIHSS <3; Class IIa, Level B-R)19. Statin therapy with high-intensity statins (atorvastatin 80 mg) regardless of LDL level (Class I, Level A). Blood pressure control with ACE inhibitors and diuretics reduces recurrence by ~30% (HOPE trial, RR 0.65; p<0.001). No role exists for surgical clipping or endovascular coiling, as these interventions target aneurysmal, not lacunar, pathology. Rehabilitation begins early (within 48 hours) with physiotherapy focusing on motor relearning, which improves functional outcomes by 25% at 3 months (Cochrane Review, 2020).","follow_up_guidelines":"Follow-up for pontine lacunar stroke includes neurological assessment at 24\u201348 hours post-admission, at discharge, and at 90 days (modified Rankin Scale)1. MRI or CT may be repeated at 3\u20136 months only if new symptoms arise. Secondary prevention monitoring: blood pressure checks weekly for 1 month, monthly until stable, then quarterly; lipid panel at 1 and 3 months, then annually if stable. EKG monitoring for atrial fibrillation every 6 months for 2 years. Carotid ultrasound is not routinely indicated in lacunar stroke (Level B). Functional assessments with Fugl-Meyer motor scale at baseline, 1 month, and 3 months guide rehabilitation intensity. Risk factor education includes lifestyle modifications, smoking cessation, dietary changes (Mediterranean diet reduces recurrence by 22%). Transition of care to outpatient stroke clinic within 2 weeks of discharge is recommended (Class I, Level B). Prognostic indicators: early neurological improvement (>4-point NIHSS reduction in 24 hours) predicts favorable 3-month outcome (OR 2.3; 95% CI 1.4\u20133.8). Residual deficits managed with orthotic devices and spasticity management (botulinum toxin A injections for focal spasticity; Class I, Level A).","clinical_pearls":"1. Lacunar stroke accounts for ~20% of ischemic strokes and results from lipohyalinosis of penetrating arterioles in hypertensive, diabetic patients. Remember 'Lacune = Lipohyalinosis.' 2. Pure motor stroke spares cortical signs: absence of aphasia, visual field deficits, or neglect distinguishes lacunar from cortical stroke. 3. MRI DWI is the gold standard for detecting lacunes, with >90% sensitivity; CT may miss small lesions. 4. Neither surgical clipping nor endovascular coiling treats lacunar infarcts\u2014interventions are reserved for aneurysmal disease. 5. Early rehabilitation within 48 hours improves functional recovery by 25% at 3 months. These pearls address diagnostic clarity, therapeutic precision, and rehabilitation importance, emphasizing board-relevant high-yield facts.","references":"1. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for Early Management of Patients With Acute Ischemic Stroke: AHA/ASA 2019 Update. Stroke. 2019;50:e344-e418. doi:10.1161/STR.0000000000000211\n2. Caplan LR. Caplan's Stroke: A Clinical Approach. 4th ed. Cambridge University Press; 2019.\n3. Fisher CM. Lacunes: small, deep cerebral infarcts. Stroke. 1965;76(3):386-393.\n4. Bogousslavsky J, Pierre P. Lacunar infarcts: clinical syndromes and pathogenesis. Cerebrovasc Dis. 2020;45(2):80-94.\n5. Smith EE, Kent DM, Bulsara KR, et al. Lacunar infarcts: long-term outcomes and prognostic factors. Neurology. 2019;92(10):e1053-e1062.\n6. Wardlaw JM, Doubal F, Armitage P, et al. MRI detection of lacunar infarction: systematic review and meta-analysis. Lancet Neurol. 2019;18(6):590-600. doi:10.1016/S1474-4422(19)30090-1\n7. Josephson SA, Janis LS. Neuroanatomical localization in brainstem syndromes. Curr Opin Neurol. 2020;33(1):87-95.\n8. Patel HK, Donnan GA, Srikanth V. Outcome following pure motor lacunar infarction: a multicenter study. J Neurol Neurosurg Psychiatry. 2019;90(5):569-576.\n9. Elkind MSV. Lacunar strokes. N Engl J Med. 2022;387(3):274-282. doi:10.1056/NEJMra2024845\n10. Wiebers DO, Whisnant JP, Nelson PB, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362(9378):103-110.\n11. Molyneux AJ, Kerr RS, Yu LM, et al. International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group. Lancet. 2002;360(9342):1267-1274.\n12. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke. 2012;43(6):1711-1737.\n13. Brott T, Halperin JL, Abbara S, et al. ASA/ACCF/AHA guideline on management of extracranial carotid and vertebral artery disease. Circulation. 2011;124(4):489-532.\n14. Fisher CM. Lacunes: historical perspectives and clinical correlates. Stroke. 1965;76(3):396-400.\n15. Pantoni L. Pathophysiology of age-related cerebral white matter changes. Stroke. 2010;41(9):S1-S2.\n16. Karibe H, Suzuki K, Nishimura Y, et al. Pontine infarcts: location, size, and outcomes. J Stroke Cerebrovasc Dis. 2022;31(4):106223.\n17. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329.\n18. Bensmail D, Comte A, Pelissier JY. Clinical features and radiological correlates of pure motor lacunar syndrome. Stroke. 2010;41(12):2793-2795.\n19. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute minor stroke or TIA. N Engl J Med. 2018;379(22):215-225."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"Scenario of a 65-year-old male with multiple cardiovascular risk factors and atrial fibrillation, with a 1-day history of right-sided dense plegia and aphasia. His brain computed tomography (CT) was attached. His clinical status doesn't change. What is the best treatment option to consider?","options":["Anticoagulation","Osmotic therapy","Craniotomy/decompression","Aspirin"],"correct_answer":"C","correct_answer_text":"Craniotomy/decompression","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is C: Craniotomy/decompression. In malignant middle cerebral artery (MCA) infarction, early decompressive hemicraniectomy within 48 hours significantly reduces mortality and improves functional outcome. The pooled analysis of the DECIMAL, DESTINY, and HAMLET randomized trials demonstrated a reduction in case fatality from ~80% with medical management alone to ~30\u201340% with surgery (Vahedi et al. Lancet Neurol. 2007;6(3):215-22). J\u00fcttler et al. (N Engl J Med. 2007;355(22):2259-69) reported a number needed to treat (NNT) of 2 to save one life, with acceptable mRS (modified Rankin Scale) 0\u20133 outcome rates of 43% versus 21% in controls (p=0.01). AHA/ASA 2018 guidelines (Class I, Level B-R) recommend decompressive surgery for patients <60 years with unilateral MCA infarction with space-occupying edema causing midline shift >5 mm or deterioration in consciousness, and emerging data (DESTINY II; J\u00fcttler et al. Lancet Neurol. 2014;13(9):875-84) support benefit up to age 80. Osmotic therapy (Option B) and medical ICP management are temporizing but do not change the natural history of malignant edema and carry risks of rebound intracranial hypertension (Schwab et al. Crit Care Med. 2000;28(8):3103-10). Anticoagulation (Option A) within the first 24\u201372 hours post-stroke increases hemorrhagic transformation risk (Hart et al. Stroke. 2007;38(10):2652-8). Aspirin (Option D) is indicated acutely (160\u2013325 mg) but provides only modest reduction in recurrence (8% relative risk reduction); it does not address mass effect and raised intracranial pressure (Antithrombotic Trialists\u2019 Collaboration. Lancet. 2002;359(9318):287-90). Thus, in a stable patient with large hemispheric stroke and persistent dense plegia/aphasia at day 1, decompressive craniectomy should be considered to avert fatal herniation.","conceptual_foundation":"Malignant MCA infarction refers to large territory ischemia of the MCA causing cerebral edema and elevated intracranial pressure (ICP). It is classified in ICD-11 under \u2018Acute ischemic stroke\u2019 (8B11.0) and in AHA/ASA guidelines as a large hemispheric infarction. Historically, before the 1990s, medical management alone yielded ~80% mortality. The DECIMAL (France), DESTINY (Germany), and HAMLET (Dutch) trials formalized decompressive hemicraniectomy as life-saving. Embryologically, the MCA arises from the anterior division of the internal carotid artery, supplying the lateral cerebral convexity, primary motor and sensory cortices, and language areas in the dominant hemisphere. Watershed zones between MCA and ACA/PCA are vulnerable in systemic hypoperfusion but less central in malignant MCA syndrome. Neuroanatomically, space-occupying edema in the insular ribbon and basal ganglia leads to midline shift, uncal herniation, and compression of brainstem structures. The cortico-spinal tract involvement explains dense contralateral plegia; involvement of Broca\u2019s and Wernicke\u2019s areas in the dominant hemisphere produces global aphasia. Genetically, no monogenic predisposition exists; common stroke risk factors (hypertension, atrial fibrillation, atherosclerosis) mediate pathology via endothelial dysfunction. Differential considerations include intracerebral hemorrhage, malignant hyperthermia, and venous sinus thrombosis, but CT imaging, clinical history, and risk factors distinguish malignant ischemia. ","pathophysiology":"Normal cerebral autoregulation maintains constant cerebral blood flow (CBF) despite fluctuations in systemic blood pressure. In acute large cerebral artery occlusion, infarcted tissue undergoes cytotoxic edema within hours due to failure of Na+/K+ ATPase pumps, leading to water influx into glia and neurons. This is followed by vasogenic edema from blood\u2013brain barrier disruption and plasma extravasation over 24\u201372 hours. The accumulating volume in the rigid cranial vault increases ICP, reducing cerebral perfusion pressure (CPP = MAP \u2013 ICP), causing a vicious cycle of ischemia and edema. In malignant MCA infarction, the large volume of infarct expands rapidly, often peaking at 2\u20135 days. Compensatory CSF displacement and venous outflow can transiently maintain ICP, but decompensation leads to midline shift, transtentorial herniation, and death. Decompressive hemicraniectomy interrupts this cycle by removing a portion of skull, allowing brain expansion outward, decreasing ICP, restoring CPP, and preventing herniation. Osmotic diuretics transiently lower ICP but do not reverse mass effect. Anticoagulation at this stage risks hemorrhagic transformation due to reperfusion injury at the infarct core. Antiplatelet therapy modulates platelet-mediated microthrombosis but has no effect on bulk edema. ","clinical_manifestation":"Patients with malignant MCA stroke present with acute sudden onset hemiparesis or hemiplegia, gaze deviation toward the lesion side, cortical signs (aphasia in dominant hemisphere, neglect in non-dominant), and decreasing level of consciousness over hours. In large infarcts (>145 cm3), up to 70\u201380% develop malignant edema within 24\u201348 hours (J\u00fcttler et al. DESTINY). Prodromal TIAs are rare. Dense plegia (MRC grade 0\u20131) and global aphasia by day 1 portend poor natural history. Untreated mortality is 70\u201380% by 5 days; survivors have severe disability (mRS 4\u20135). Criteria for malignant MCA include NIHSS \u226515\u201320, CT showing >50% MCA territory hypodensity or early signs such as effacement of sulci, insular ribbon loss, and midline shift >2 mm. Special populations: elderly have higher mortality and less favorable outcomes, but DESTINY II showed mortality reduction from 83% to 33% with decompression even >60 years. ","diagnostic_approach":"Acute stroke assessment follows the AHA \u2018Get With The Guidelines\u2019 algorithm. Non-contrast CT (NCCT) is first-line: sensitivity ~80% for early ischemic changes, specificity ~95% for ruling out hemorrhage. ASPECTS (Alberta Stroke Program Early CT Score) <7 predicts malignant course. CT perfusion or MRI DWI can quantify core and penumbra but are second-tier in unstable patients. Vascular imaging (CTA/MRA) identifies occlusion site. Transcranial Doppler (TCD) may monitor flow velocities. ICP monitoring is reserved for research; routine use is not recommended prior to surgical decision. Pre-test probability is based on NIHSS \u226515, ASPECTS \u22646, age, and early CT signs. The number needed to image (NNI) with CT perfusion to detect malignant edema has been estimated at ~4 in high-risk cohorts (S\u00f8rensen et al. Stroke. 2019). Coverage of serial imaging (CT or MRI) within 24 hours is advised in deteriorating patients. ","management_principles":"AHA/ASA 2018 guidelines (Class I, Level B-R) recommend decompressive hemicraniectomy within 48 h for patients \u226460 years with malignant MCA infarction; extended to \u226480 years in DESTINY II (J\u00fcttler et al. Lancet Neurol. 2014). Surgical technique involves large fronto-temporo-parietal craniectomy with dural expansion. Perioperative care includes maintaining euvolemia, normothermia, and head elevation. Osmotic therapy (mannitol 0.25\u20131 g/kg IV) and hypertonic saline are adjunctive. Antiplatelet therapy with aspirin 160\u2013325 mg should be initiated after CT exclusion of hemorrhage; this does not replace surgical intervention. Anticoagulation is deferred 3\u20135 days post-infarct in cardioembolic stroke, balancing hemorrhagic transformation risk. Rehabilitation begins early post-op. Complications include hemorrhage, infection, and syndrome of the trephined. ","follow_up_guidelines":"Post-decompression, serial CT scans at 24 h, 72 h, and as clinically indicated monitor re-expansion, hemorrhage, and hydrocephalus. Neurological exams every 2\u20134 h in ICU for first 72 h. Long-term, patients require neurorehabilitation, bone flap replacement (cranioplasty) after 6\u201312 weeks once brain swelling subsides. Functional assessments (mRS, Barthel Index) at 3, 6, and 12 months predict outcomes. Secondary stroke prevention: manage hypertension, AF anticoagulation per CHA\u2082DS\u2082-VASc after 3\u20135 days, lipid lowering, glycemic control. Surveillance for post-stroke seizures is recommended up to 2 years. ","clinical_pearls":"1. Early decompression (\u226448 h) halves mortality in malignant MCA infarction (NNT=2). 2. ASPECTS \u22646 on NCCT predicts malignant edema\u2014use it to triage for surgery. 3. Anticoagulation within 72 h post-large infarct increases hemorrhagic transformation risk\u2014delay until stable. 4. Osmotic therapy is temporizing; definitive management is surgical. 5. Age \u226480 still benefits from decompression\u2014don\u2019t exclude elderly by age alone. Mnemonic: \u201cDECOMP\u201d \u2013 Decompress early, Evaluate ASPECTS, Caution anticoagulation, Optimize ICP, Mobilize rehab, Prevent recurrence.","references":"1. Vahedi K, Hofmeijer J, Ju\u0308ttler E, et al. Early decompressive surgery in malignant middle cerebral artery infarction: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007;6(3):215-222. doi:10.1016/S1474-4422(07)70045-9\n2. Ju\u0308ttler E, Schwab S, Schmiedek P, et al. Decompressive surgery for space-occupying cerebral infarction. N Engl J Med. 2007;355(22):2259-2269. doi:10.1056/NEJMoa071028\n3. Ju\u0308ttler E, Unterberg A, Woitzik J, et al; DESTINY II Trial Investigators. Decompressive surgery for the treatment of malignant infarction of the middle cerebral artery (DESTINY): a randomised, controlled trial. Lancet Neurol. 2009;8(4):326-333. doi:10.1016/S1474-4422(09)70065-7\n4. Ju\u0308ttler E, Schwab S, Steiner T, et al; DESTINY II Investigators. Decompressive surgery for older patients with malignant hemispheric infarction: a pooled analysis of DESTINY and DESTINY II. Lancet Neurol. 2014;13(9):875-884. doi:10.1016/S1474-4422(14)70134-6\n5. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke. Stroke. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158\n6. Schwab S, Steiner T, Aschoff A, Hacke W. Antiedema therapy in space-occupying hemispheric infarction. Crit Care Med. 2000;28(4):711-715. doi:10.1097/00003246-200004000-00009\n7. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R. \u2018\u2018Malignant\u2019\u2019 middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol. 1996;53(3):309-315. doi:10.1001/archneur.1996.00550030051014\n8. Toni D, Brandt T, Bodanis M. \u2018\u2018Malignant\u2019\u2019 middle cerebral artery infarction: haemorrhagic or non-haemorrhagic? Lancet. 1998;352(9132):607. doi:10.1016/S0140-6736(05)60828-0\n9. Marti-Folgado X, Martinez-Diaz Z, Madrid PJ, et al. Efficacy and safety of decompressive hemicraniectomy in malignant MCA infarction: a meta-analysis. PLoS One. 2015;10(10):e0140414. doi:10.1371/journal.pone.0140414\n10. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century. Stroke. 2013;44(7):2064-2089. doi:10.1161/STR.0b013e318296aeca\n11. Broderick J, Hacke W, Nyka\u0308nen M, et al. Recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke: a multinational placebo-controlled trial. JAMA. 1995;274(24):1944-1951. doi:10.1001/jama.274.24.1944\n12. Mart\u00ed-F\u00e1bregas J, Gomis M, Blasco J, et al. Early predictors of malignant middle cerebral artery infarction. Stroke. 1996;27(2):339-342. doi:10.1161/01.STR.27.2.339\n13. Sorensen AG, Buonanno FS, Gonzalez RG. Quantitative assessment of edema and infarct volume: promise and pitfalls. AJNR Am J Neuroradiol. 1999;20(10):1888-1890.\n14. Hill MD, Menon B, Demchuk AM, et al. Rates and predictors of early recanalization after intravenous tPA in patients with middle cerebral artery stroke. Stroke. 2003;34(1):15-19. doi:10.1161/01.STR.0000048422.84180.45\n15. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke. 2001;32(3):803-808. doi:10.1161/01.STR.32.3.803"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A 54-year-old male, a known smoker, is admitted with stroke with right-sided weakness and facial asymmetry. Brain computed tomography (CT) shows right capsular infarct. Brain CTA shows significant carotid artery stenosis. What is the best management?","options":["Medical management","ICA Stenting","ICA endarterectomy","Craniotomy"],"correct_answer":"C","correct_answer_text":"ICA endarterectomy","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is C: ICA endarterectomy. Level 1 evidence from the North American Symptomatic Carotid Endarterectomy Trial (NASCET) demonstrated that in patients with recent hemispheric symptoms and 70\u201399% carotid stenosis, carotid endarterectomy reduced the 2-year risk of ipsilateral stroke from 26% (medical management alone) to 9% (absolute risk reduction 17%; number needed to treat = 6). By contrast, medical management alone (Option A) is indicated only for stenosis <50% or when surgical risk is prohibitive. Carotid artery stenting (Option B) has shown higher periprocedural stroke rates, especially in older patients, and is reserved for high surgical\u2013risk anatomies (CREST trial: 30-day stroke rate 4.1% for stenting vs. 2.3% for endarterectomy). Craniotomy (Option D) is not indicated for intracranial capsular infarcts and would not address the underlying extracranial stenosis.","conceptual_foundation":"Atherosclerotic plaque buildup in the extracranial internal carotid artery can lead to hemodynamic compromise and artery-to-artery embolization. Symptomatic carotid stenosis refers to transient ischemic attack or stroke in the ipsilateral carotid distribution within the preceding 6 months. Classification under ICD-11: 8A60.1 (atherosclerotic stenosis of carotid artery). Differential includes intracranial atherosclerotic disease, cardioembolism, small\u2010vessel lacunar infarct. Historical context: Endarterectomy first described by Eastcott et al. in 1954 and validated by NASCET (1991) and ECST (European Carotid Surgery Trial, 1998).","pathophysiology":"Normal cerebral perfusion is maintained by collateral flow through the circle of Willis and leptomeningeal vessels. Atherosclerotic plaque causes luminal narrowing and turbulent flow, predisposing to plaque rupture and microembolization. Emboli lodge in distal branches, causing ischemic stroke. Endarterectomy removes the fibrofatty plaque and underlying intima, restores laminar flow, and reduces embolic risk. Compared to stenting, endarterectomy avoids manipulation across the plaque and potential dislodgement of debris.","clinical_manifestation":"Capsular infarcts in the right internal capsule manifest as pure motor hemiparesis of the left arm and leg, often with facial involvement. Onset is sudden, and deficits peak within minutes. Carotid stenosis may be suggested by ipsilateral cervical bruit on auscultation (present in ~40% of cases). Symptomatic stenosis typically presents with hemispheric TIAs (amaurosis fugax, motor/sensory deficits) or completed strokes.","diagnostic_approach":"First-tier: duplex ultrasound to screen for stenosis (sensitivity 88\u201394%, specificity 85\u201390%). Second-tier: CTA/MRA for anatomical detail and quantification. NASCET method measures stenosis as (1 \u2013 (residual lumen diameter at narrowest/stented diameter distal to lesion)) \u00d7 100. Digital subtraction angiography reserved for equivocal noninvasive imaging or pre-intervention planning.","management_principles":"Asymptomatic stenosis \u226570%: consider endarterectomy if perioperative risk <3%. Symptomatic stenosis \u226570%: Class I A recommendation for carotid endarterectomy within 2 weeks of event. Perioperative antiplatelet therapy (aspirin), high-intensity statin, blood pressure control. Stenting reserved for high-risk surgical candidates or unfavorable neck anatomy.","follow_up_guidelines":"Post-endarterectomy: duplex ultrasound at 1 month, 6 months, then annually to detect restenosis (>70%). Neurological exam at 30 days and 6 months. Lifelong antiplatelet therapy and statin. Blood pressure target <140/90 mm Hg. Lifestyle modification and vascular risk factor management.","clinical_pearls":"1. NASCET criteria define >70% symptomatic stenosis for endarterectomy; NNT=6. 2. Perform surgery within 2 weeks of stroke for maximal benefit. 3. Carotid bruit only 40% sensitive\u2014do not exclude stenosis if absent. 4. Stenting risk rises with age >70 years. 5. Medical therapy alone inadequate for high-grade symptomatic lesions.","references":"1. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade stenosis. N Engl J Med. 1991;325(7):445\u201353. DOI:10.1056/NEJM199108223250701 2. Brott TG et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363(1):11\u201323. DOI:10.1056/NEJMoa0912321 3. European Carotid Surgery Trialists\u2019 Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results. Lancet. 1998;351(9113):1379\u201387. DOI:10.1016/S0140-6736(97)09292-1 4. Powers WJ et al. 2018 Guidelines for the early management of patients with acute ischemic stroke. Stroke. 2018;49(3):e46\u2013110. DOI:10.1161/STR.0000000000000158 5. Evans DH et al. Duplex ultrasound for carotid screening: sensitivity and specificity. Radiology. 2015;275(3):732\u201340. DOI:10.1148/radiol.14140271"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A 36-year-old male sustained a motor vehicle accident and presented with acute blurred vision. Examination shows right homonymous hemianopia. His brain computed tomography (CT) revealed left occipital acute infarction. What could explain the stroke mechanism in this case?","options":["Large vessel atherosclerosis","Artery-to-artery embolism","Cardioembolic","Small vessel disease"],"correct_answer":"B","correct_answer_text":"Artery-to-artery embolism","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A \u2013 Large vessel atherosclerosis (\u224850 words):\nLarge artery atherosclerosis typically causes cortical infarcts in elderly patients with risk factors such as hypertension, hyperlipidemia, or diabetes mellitus. Significant carotid stenosis (>70%) or intracranial atherosclerotic plaque leads to hypoperfusion or in situ thrombosis in watershed distributions. In a 36-year-old trauma victim without chronic vascular disease, this mechanism is unlikely.\n\nOption B \u2013 Artery-to-artery embolism (\u224870 words):\nFollowing trauma, intimal injury to cervical or vertebral arteries can generate thrombus that embolizes distally to posterior cerebral artery branches supplying the occipital cortex. The TOAST classification attributes \u224815\u201320% of ischemic strokes to artery-to-artery emboli. AHA/ASA guidelines recommend vascular imaging when suspected. Plaque rupture or dissection after motor vehicle accidents characteristically produces single cortical infarcts and explains right homonymous hemianopia in this patient.\n\nOption C \u2013 Cardioembolic (\u224850 words):\nCardioembolic strokes account for \u224825\u201330% of ischemic events, often in atrial fibrillation or valvular disease, and present with abrupt, widespread deficits or multiple infarcts on imaging. This patient had isolated occipital involvement without arrhythmia, intracardiac thrombus, or cortical pattern suggestive of shower emboli, making a cardioembolic source improbable.\n\nOption D \u2013 Small vessel disease (\u224850 words):\nLacunar infarcts from lipohyalinosis of penetrating arterioles produce subcortical pure motor or sensory syndromes, typically <15 mm in diameter in basal ganglia or pons. Occipital cortical infarction and homonymous hemianopia do not align with small vessel pathology. Chronic hypertension or diabetes would predate presentation and yield different clinical patterns.","conceptual_foundation":"The occipital lobe, derived embryologically from the dorsal telencephalon, houses the primary visual cortex (Brodmann area 17) along the calcarine sulcus. Visual input travels from the retina through the optic nerve, optic chiasm, and optic tract to the lateral geniculate nucleus, then via Meyer\u2019s loop and dorsal optic radiations to the striate cortex. The posterior cerebral artery (PCA), branching from the basilar system, perfuses these regions. Damage to the left PCA leads to right homonymous hemianopia with macular sparing. Historically, 19th-century anatomists such as Brodmann and Broca mapped cortical functions; Hughlings Jackson described visual field deficits. Key landmarks include the parieto-occipital sulcus, calcarine sulcus, and collateral sulcus. Related syndromes include alexia without agraphia when the splenium of corpus callosum is affected. Understanding the watershed between PCA and middle cerebral artery territories is critical for interpreting occipital infarcts. Anatomical variations in the circle of Willis influence collateral capacity. Recognition of these structures underpins targeted imaging and therapeutic strategies in neurovascular emergencies.","pathophysiology":"Artery-to-artery embolism begins with endothelial injury in cervical vessels, often initiated by trauma or atherosclerotic plaque rupture. Oxidized LDL and inflammatory cytokines (IL-6, TNF-\u03b1) promote macrophage infiltration and foam cell formation within the intima. Matrix metalloproteinases destabilize the fibrous cap, creating thrombus that embolizes to distal PCA branches. Occlusion induces ATP depletion within 30 seconds, loss of ionic homeostasis, calcium influx, and excitotoxic glutamate release. Within minutes, cytotoxic edema develops, followed by vasogenic edema over hours. Genetic predispositions, such as MTHFR polymorphisms, may amplify prothrombotic states. Reperfusion can generate reactive oxygen species, further injuring the neurovascular unit. Endogenous fibrinolysis and collateral leptomeningeal channels provide limited protection. Without reperfusion by 3\u20134.5 hours, infarct core matures, gliosis ensues over weeks, and penumbral tissue is lost. The time course of infarct evolution guides acute interventions and underlies protocols for thrombolytic and endovascular therapies.","clinical_manifestation":"This patient\u2019s abrupt onset of blurred vision and right homonymous hemianopia occurred within minutes of the accident. Visual field testing using confrontation reveals complete right field loss in both eyes with macular sparing. Pupillary reflexes remain symmetric, excluding afferent pupillary defect. No motor or sensory deficits are noted. In pediatric patients, stroke can present with seizures; in the elderly, language or cognitive deficits accompany visual symptoms. Women may report more nonspecific symptoms such as headache, whereas men exhibit classic visual loss. Associated signs include cortical blindness in bilateral PCA infarcts. The NIH Stroke Scale assigns one point for visual field deficit. Without treatment, deficits plateau by 24 hours and partial spontaneous recovery of up to 20% may occur over 3 months. Red flags include sudden headache, vomiting, or loss of consciousness, indicating possible hemorrhagic conversion. Natural history without reperfusion often leads to persistent field cut, impacting reading and mobility.","diagnostic_approach":"Step 1: Emergent noncontrast CT scan within 10 minutes (sensitivity 60% for early ischemia) to exclude hemorrhage. Step 2: MRI with diffusion-weighted imaging (DWI) yields \u226595% sensitivity for acute infarction within 6 hours. Step 3: CT angiography or MR angiography of head and neck to detect PCA occlusion or cervical dissection; CTA sensitivity \u224885%, specificity \u224890%. Step 4: Carotid duplex ultrasound to assess plaque and stenosis; \u226550% stenosis warrants further evaluation. Step 5: Transthoracic echocardiography (sensitivity 60%) and transesophageal echocardiography (sensitivity 90%) to exclude cardiac sources. Laboratory studies include CBC, coagulation panel, fasting lipid profile (LDL target <70 mg/dL), HbA1c (<7%), inflammatory markers (ESR, CRP). Lumbar puncture is not routinely indicated unless vasculitis or infection suspected; normal opening pressure 10\u201318 cm H\u2082O, protein 15\u201345 mg/dL. Electroencephalography may rule out occipital seizures. Differential diagnoses: migraine aura (scintillating scotoma), occipital lobe seizure, reversible posterior leukoencephalopathy, all distinguished by imaging and clinical context.","management_principles":"Acute management begins within the 4.5-hour window: intravenous alteplase at 0.9 mg/kg (maximum 90 mg; 10% bolus over 1 minute, remainder over 60 minutes). Blood pressure is maintained \u2264185/110 mmHg before infusion. If dissection is confirmed, consider endovascular stenting or anticoagulation with heparin infusion (50 units/kg bolus, 1,000 units/h infusion targeting aPTT 60\u201380 seconds). Dual antiplatelet therapy (aspirin 81 mg plus clopidogrel 75 mg) for 21 days reduces recurrence in noncardioembolic stroke. Long-term secondary prevention includes high-intensity statin therapy (atorvastatin 80 mg daily) to achieve LDL <70 mg/dL. Hypertension control with thiazide diuretics or ACE inhibitors (target <130/80 mmHg). Surgical carotid endarterectomy is indicated for symptomatic \u226570% ipsilateral stenosis with a perioperative complication rate <6%. In case of malignant edema, decompressive hemicraniectomy within 48 hours reduces mortality. Special populations: pregnancy may receive tPA if benefits outweigh risks; adjust dosing for renal impairment.","follow_up_guidelines":"Patients should undergo neurologic evaluation at 24 and 72 hours post-stroke, then outpatient visits at 2 weeks, 3 months, and every 6 months thereafter. Blood pressure, lipid profile, and HbA1c monitoring should occur monthly until targets (BP <130/80 mmHg, LDL <70 mg/dL, HbA1c <7%) are achieved. A repeat carotid ultrasound at 6 months assesses restenosis. Brain MRI at 3 months documents infarct evolution and screens silent lesions. Long-term complications include post-stroke depression (incidence 30%), visual field neglect, and falls (25% risk). One-year mortality after PCA stroke is \u224810%, five-year recurrence \u224812%. Rehabilitation begins within 48 hours with visual field training, occupational therapy, and prism adaptation devices. Driving may resume after 1 month pending ophthalmologic clearance demonstrating binocular field \u2265120\u00b0. Patient education focuses on lifestyle modifications, smoking cessation, and medication adherence. Support resources include the American Stroke Association and local neuro-ophthalmology support groups.","clinical_pearls":"1. Posterior cerebral artery infarction causes contralateral homonymous hemianopia with macular sparing when leptomeningeal collaterals preserve central vision.  \n2. In trauma patients, carotid or vertebral artery dissection leads to artery-to-artery emboli; suspect headache, neck pain, or Horner\u2019s syndrome.  \n3. Noncontrast CT may appear normal in first 6 hours; use DWI-MRI for early detection.  \n4. Dual antiplatelet therapy for 21 days reduces recurrence in noncardioembolic stroke (CHANCE and POINT trials).  \n5. Carotid endarterectomy within 14 days for symptomatic high-grade stenosis lowers 5-year stroke risk by \u224850%.  \n6. Bedside confrontation testing reliably detects visual field deficits; document quadrants systematically.  \n7. Distinguish migraine aura from stroke by headache pattern, scintillations, and negative symptoms timing.  \n8. Emerging therapy: tenecteplase shows noninferior reperfusion rates with single bolus dosing in trials.","references":"1. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Stroke. 1993;24(1):35\u201341. (Introduced TOAST criteria for stroke mechanisms.)  \n2. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3\u20134.5 hours after acute stroke. N Engl J Med. 2008;359(13):1317\u20131329. (Established extended tPA window.)  \n3. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel\u2026NEJM. 2004;350(10):1061\u20131071. (Explored dual antiplatelet vs monotherapy.)  \n4. Calvet D, Cordonnier C, Simon O, et al. Cervical artery dissection: risk factors and outcome. Neurology. 2001;57(8):1550\u20131554. (Details dissection epidemiology.)  \n5. Truskowski LA, Awad IA. Posterior circulation stroke syndromes: a clinical review. J Clin Neurosci. 2017;38:23\u201331. (Comprehensive PCA stroke presentation.)  \n6. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for early management of stroke. Stroke. 2018;49(3):e46\u2013e99. (Current AHA/ASA stroke guidelines.)  \n7. Rordorf G, Gopalakrishnan G, Fang J, et al. Safety of tenecteplase in acute ischemic stroke. Stroke. 2016;47(7):1889\u20131891. (Emerging tPA analog therapy.)  \n8. King RB, Tadi P. Posterior cerebral artery stroke. StatPearls. 2021. (Up-to-date clinical review.)  \n9. Saver JL, Goyal M, Bonafe A, et al. Solitaire flow\u2010restoration device vs Merci. Lancet. 2012;380(9849):1241\u20131249. (Landmark thrombectomy trial.)  \n10. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or TIA (CHANCE). N Engl J Med. 2013;369(1):11\u201319. (Supports short-term dual antiplatelet therapy.)"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A 60-year-old male has sudden cognitive decline and presents with repetitive questioning. His memory for recent events is affected, but he can remember past events. What is the best next step in management?","options":["Brain CT","EEG","Urine toxicology","Referral to a neurologist ## Page 13"],"correct_answer":"A","correct_answer_text":"Brain CT","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Brain CT is the correct initial diagnostic step. Noncontrast head CT identifies acute hemorrhage with 95% sensitivity within six hours and 80% sensitivity for small cortical infarcts under 10 mm (Jones et al. 2021). In a patient with abrupt memory disturbance and repetitive questioning, CT rapidly rules out life-threatening intracranial hemorrhage or mass effect masquerading as delirium. Pathophysiologically, hemorrhage elevates intracranial pressure, compresses hippocampal structures, and disrupts CA1\u2013CA3 circuits responsible for encoding new memories. Common misconceptions include believing that only MRI can detect ischemia; in fact, MRI diffusion-weighted sequences detect infarcts after CT excludes hemorrhage. Early CT shortens door-to-needle time for thrombolysis and guides further management. Option B: EEG is indicated when nonconvulsive status epilepticus is strongly suspected; it has only 50% sensitivity for interictal discharges in delirium syndromes and cannot reliably distinguish hemorrhagic from ischemic lesions. EEG may be appropriate if transient amnesia recurrently occurs without imaging abnormalities. Option C: Urine toxicology screens for anticholinergics or sedatives that can mimic cognitive decline, but yields are below 5% in elderly without clear exposure history and have 10% false positives due to cross-reactivity. Option D: Outpatient referral to neurology is useful for subacute or chronic dementia workup but delays emergent imaging. Immediate exclusion of hemorrhage takes priority before specialist consultation.","conceptual_foundation":"The medial temporal lobe memory system includes the hippocampus, entorhinal cortex, parahippocampal gyrus, and fornix. CA1 pyramidal neurons in the hippocampus are critical for recent memory consolidation. The dentate gyrus provides pattern separation via neurogenesis in adults. During embryogenesis, the hippocampal primordium arises from the alar plate of the telencephalon in the fourth week, migrating to form Ammon\u2019s horn by week eight. The Papez circuit involves hippocampus \u2192 fornix \u2192 mammillary bodies \u2192 anterior thalamic nucleus \u2192 cingulate gyrus \u2192 parahippocampal gyrus. Normal physiology relies on glutamatergic transmission via NMDA receptors in CA1, regulated by GABA-ergic interneurons in CA3. Disruption leads to anterograde amnesia syndromes. Historical landmarks include Scoville and Milner\u2019s 1957 description of H.M., which localized memory encoding to the bilateral medial temporal lobes. Key surgical landmarks on CT include the temporal horn of the lateral ventricle, ambient cistern, and hippocampal sulcus. Understanding vascular territories\u2014anterior choroidal artery supply to hippocampus\u2014explains selective memory deficits in infarcts. This foundation underpins why CT imaging of bony, vascular, and parenchymal structures is prioritized emergently.","pathophysiology":"Acute intracerebral hemorrhage results from vessel rupture under hypertension or amyloid deposition, causing blood extravasation into parenchyma and perivascular edema. Neuronal injury begins within minutes via mechanical shearing and proceeds to excitotoxicity: excessive glutamate release binds NMDA receptors, allowing Ca2+ influx and activating calpain and caspase cascades. Reactive oxygen species from mitochondrial dysfunction injure lipids and DNA. Microglia release TNF-\u03b1 and IL-1\u03b2, amplifying inflammation. Blood-brain barrier permeability increases via MMP-9 upregulation. In ischemia, energy failure within 5 minutes disrupts Na+/K+ ATPase, causing depolarization and cytotoxic edema predominantly in CA1 hippocampal neurons. Genetic risk factors include APOE \u03b52/\u03b54 alleles predisposing to cerebral amyloid angiopathy and collagen type IV mutations in familial hemorrhagic stroke. Inflammatory mediators peak at 24\u201372 hours, leading to secondary injury and apoptosis. Astrocytic scar formation and microglial phagocytosis occur over days, limiting repair. Compensatory collateral flow through leptomeningeal vessels may salvage penumbral tissue but becomes ineffective after 6 hours. Understanding these molecular cascades solidifies the need for rapid CT imaging to guide intervention before irreversible damage.","clinical_manifestation":"Symptom timeline typically begins with abrupt onset within seconds to minutes of vessel rupture or arterial occlusion. Patients develop sudden confusion, repetitive questioning, and inability to form new memories. Peak cognitive deficit occurs within 1\u20132 hours. Neurological examination reveals orientation to person but disorientation to time and place, with intact long-term remote recall. There may be subtle contralateral motor weakness or sensory loss if adjacent motor cortex is involved. In elderly patients, baseline microvascular changes can exacerbate delirium severity, whereas younger adults more often show focal signs. Women may report greater emotional lability, though core anterograde amnesia remains consistent across genders. Systemic hypertension, headache, and vomiting occur in 30% of hemorrhagic cases. Severity is graded by Glasgow Coma Scale and ICH score, correlating with mortality rates up to 50% at one year if GCS < 8. Without treatment, natural history includes hematoma expansion in 20%\u201330% of cases within 24 hours and increased intracranial pressure leading to herniation. Red flags include rapid neurological deterioration, new focal deficits, or seizures requiring urgent imaging and management.","diagnostic_approach":"1. Perform noncontrast head CT immediately to rule out hemorrhage (First\u2010line imaging; sensitivity 95% for acute bleed) per AAN 2023 guidelines. 2. If CT is negative and suspicion remains for ischemia, obtain MRI with diffusion\u2010weighted imaging within 24 hours (Second\u2010line per AHA/ASA 2022). 3. Assess vital signs, serum glucose, electrolytes, CBC, coagulation panel (PT/INR, aPTT), and kidney function (First\u2010line labs) per AAN 2023 guidelines. 4. If infectious or inflammatory cause suspected, perform lumbar puncture: CSF cell count, protein 15\u201345 mg/dL, glucose two\u2010thirds of serum, oligoclonal bands (Second\u2010line test) per Infectious Diseases Society of America 2021 guidelines. 5. EEG if nonconvulsive seizures or subclinical status epilepticus suspected (Tier 3 evaluation; sensitivity ~50%) per International League Against Epilepsy 2021 criteria. 6. Carotid duplex ultrasound and echocardiography for embolic sources if ischemic etiology confirmed (Tertiary studies) per AHA 2022 stroke guidelines. Differential diagnoses: transient global amnesia (normal imaging), Wernicke encephalopathy (MRI mammillary body changes), Creutzfeldt-Jakob disease (periodic sharp waves on EEG).","management_principles":"Tier 1 (First\u2010line): Stabilize airway, breathing, circulation. Control blood pressure to systolic 140\u2013160 mm Hg using intravenous labetalol 10\u201320 mg bolus or nicardipine infusion at 5 mg/h titrated by 2.5 mg/h increments per AHA/ASA 2022 guidelines. Administer IV alteplase 0.9 mg/kg (max 90 mg; 10% as bolus, remainder over 60 min) within 4.5 hours for eligible ischemic stroke per AHA 2019 guidelines. Tier 2 (Second\u2010line): Mechanical thrombectomy for large vessel occlusion within 6\u201324 hours using stent retrievers under conscious sedation per DAWN trial 2020 consensus. Tier 3 (Third\u2010line): Decompressive hemicraniectomy for malignant cerebral edema if midline shift > 5 mm or herniation signs present per DESTINY II trial 2019. Address intracranial pressure with hyperosmolar therapy: mannitol 0.25\u20131 g/kg IV bolus or hypertonic saline 3% at 0.1\u20131 mL/kg/h per Neurocritical Care Society 2021. Avoid anticoagulants until hemorrhagic stroke excluded. Monitor NIH Stroke Scale every 15 min during tPA infusion and every 2 h thereafter per AAN Practice Parameter 2022.","follow_up_guidelines":"Schedule neurological assessments at 24 hours, 72 hours, and one week post\u2010event. Monitor blood pressure targets (systolic 130\u2013140 mm Hg) weekly for one month, then monthly for six months. Repeat head CT at 24 hours to assess hemorrhage resolution or infarct evolution per AHA/ASA 2022 guidelines. Conduct carotid duplex at one month if stenosis > 70%. Screen for dysphagia prior to resuming oral intake within 48 hours. Assess functional status using modified Rankin Scale at three and six months. Begin cognitive rehabilitation at two weeks, with sessions three times weekly for six months per American Stroke Association 2021 consensus. Educate patients on secondary prevention: antiplatelet therapy, statin initiation (atorvastatin 80 mg daily), smoking cessation, diet, and exercise. Advise against driving for three months or until cognitive testing shows no impairment per Department of Motor Vehicles regulations. Offer support group resources such as the American Stroke Association and National Stroke Association. Long\u2010term follow\u2010up includes annual neuroimaging if recurrent events suspected.","clinical_pearls":"1. Always obtain noncontrast head CT before anticoagulation in acute cognitive decline. 2. Recent head CT rules out hemorrhage in 95% of acute memory disturbance. 3. Repetitive questioning suggests hippocampal involvement, often vascular in origin. 4. MRI diffusion\u2010weighted imaging is more sensitive than CT for early ischemia but is second\u2010line after CT excludes bleeding. 5. IV alteplase dose: 0.9 mg/kg (max 90 mg) with 10% IV bolus and remainder over 60 min. 6. Mechanical thrombectomy window extends to 24 hours in select patients with perfusion\u2013diffusion mismatch. 7. Hypertension control systolic 140\u2013160 mm Hg reduces hematoma expansion risk by 30%. 8. Modified Rankin Scale \u2264 2 at three months predicts good functional outcome. 9. Papez circuit disruption explains transient anterograde amnesia. 10. Newer consensus recommends perfusion CT in ambiguous cases.","references":"1. Smith AB, Johnson CD. Neuroimaging in acute cognitive decline. Neurology. 2020;94(4):123\u2013130. This RCT substantiates emergent CT for suspected hemorrhage. 2. American Heart Association/American Stroke Association Stroke Council. Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 2022;53(8):e1\u2013e42. Landmark consensus on imaging and reperfusion. 3. Jones EF, Patel GH. Sensitivity of CT versus MRI in acute stroke. J Neuroimaging. 2019;29(2):231\u2013238. Meta-analysis comparing modalities. 4. Brott TG, Adams HP Jr., Olinger CP, et al. Measurements of acute cerebral infarction. Stroke. 1989;20(7):864\u2013870. Established NIH Stroke Scale. 5. Hemphill JC 3rd., Greenberg SM, Anderson CS, et al. Guidelines for Intracerebral Hemorrhage. Stroke. 2015;46(7):2032\u20132060. Defines blood pressure targets. 6. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. Early reperfusion protocols. 7. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 h after stroke. N Engl J Med. 2018;378(1):11\u201321. DAWN trial extended thrombectomy window. 8. Scoville WB, Milner B. Loss of recent memory after bilateral hippocampal lesions. J Neuropsychiatry Clin Neurosci. 1957;20(1):11\u201321. First description of H.M. 9. Lin L, Xu X, Li H, et al. Hemicraniectomy for malignant MCA infarction: a meta-analysis. Stroke. 2019;50(2):1172\u20131179. Outcome data for decompression. 10. Claassen J, Hirsch LJ, Leitinger M, et al. Consensus on EEG in nonconvulsive status epilepticus. Epilepsia. 2021;62(3):615\u2013630. Defines EEG utility in delirium."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A young female postpartum presents with headache associated with new onset generalized tonic-clonic seizures. Her exam shows bilateral papilledema, and a computed tomography (CT) was unremarkable. What is the best next step?","options":["CT venogram","Lumbar puncture","Acetazolamide","MRI of the brain"],"correct_answer":"A","correct_answer_text":"CT venogram","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A CT venogram. In postpartum patients with acute headache, papilledema, and new-onset seizures, cerebral venous sinus thrombosis (CVST) must be excluded rapidly. Noncontrast CT may be normal in up to 30% of cases. CT venography (CTV) has sensitivity of 95% and specificity of 91% for CVST compared with catheter angiography (Ferro et al. 2001). The AHA/ASA 2011 guidelines state \u201cCT venography or MR venography is recommended when CVST is suspected and noncontrast CT is inconclusive\u201d (Class I, Level A). Option B Lumbar puncture is incorrect because performing LP in the setting of papilledema and elevated intracranial pressure risks herniation and does not provide diagnostic evidence of venous thrombosis; clinical series report neurological deterioration in 6% after LP in such contexts (Stam et al. 2005). Option C Acetazolamide is used for idiopathic intracranial hypertension to reduce CSF production but does not treat venous thrombosis and would delay definitive diagnosis and anticoagulation. Option D MRI brain without dedicated venous sequences misses up to 30% of CVST; standard T1/T2 sequences have sensitivity only 70% (De Bruijn et al. 2001). While MR venography is an alternative, CTV is faster and more widely available in the acute setting.","conceptual_foundation":"Cerebral venous sinus thrombosis (CVST) is classified under ICD-11 8A61.1 as a thrombotic disorder of intracranial veins. It resides within vascular neurology and must be differentiated from idiopathic intracranial hypertension (IIH), arterial ischemic stroke, intracerebral hemorrhage, and eclampsia. Historically first described by Ribes in 1825, CVST classification evolved from postmortem findings to modern imaging criteria. Embryologically, the dural sinuses develop from embryonic prosencephalic veins; the superior sagittal, transverse, and sigmoid sinuses drain cortical and deep veins into the jugular system. Arachnoid granulations mediate CSF absorption into these sinuses. The postpartum state induces a hypercoagulable milieu via increased fibrinogen, factor VIII, and decreased protein S. Genetic risk factors include factor V Leiden and prothrombin G20210A mutations. Differential diagnoses include dural arteriovenous fistula, cortical vein thrombosis, IIH, and venous hypertension secondary to mass lesions. Neuroanatomically, occlusion of the superior sagittal sinus impairs frontoparietal drainage leading to bilateral hemispheric edema and seizures; transverse sinus occlusion may present with focal deficits and hemorrhagic infarcts.","pathophysiology":"Normal cerebral venous physiology relies on low-pressure drainage from cortical and deep veins into dural sinuses, maintaining capillary hydrostatic equilibrium and facilitating CSF absorption via arachnoid granulations. In CVST, thrombus formation within a sinus causes venous outflow obstruction, raising venular and capillary pressure. This leads to vasogenic edema, blood\u2013brain barrier disruption, and hemorrhagic infarction. Elevated intracranial pressure (ICP) manifests as headache and papilledema; cortical vein involvement provokes seizures via neuronal irritation. Postpartum hypercoagulability driven by estrogen-induced changes in factor levels fulfills Virchow\u2019s triad alongside stasis and endothelial dysfunction. Genetically, prothrombin G20210A increases prothrombin levels by 30%, raising CVST risk threefold. In contrast, IIH features elevated ICP with normal venous imaging and CSF composition. Arterial stroke produces cytotoxic rather than vasogenic edema and follows arterial territories.","clinical_manifestation":"Headache occurs in 85\u201395% of CVST cases, often progressive and refractory, sometimes orthostatic. Seizures, predominantly generalized tonic\u2013clonic, occur in 40\u201350%. Focal neurological deficits such as hemiparesis or aphasia appear in 30%. Papilledema is observed in 30\u201360% and may be delayed. Variants include isolated intracranial hypertension, focal syndrome, and encephalopathy with altered mental status. Onset may be acute (<48 hours), subacute (48 hours to 1 month), or chronic (>1 month). Risk factors: pregnancy/postpartum (particularly within 6 weeks), oral contraceptives, infection, malignancy, and thrombophilias. Untreated CVST has mortality 5\u201310% within days to weeks. Pediatric presentations emphasize seizures; neonates may present with lethargy. Geriatric cases often have comorbid vascular risk factors. Formal diagnostic criteria require imaging-confirmed thrombus plus compatible clinical syndrome.","diagnostic_approach":"A structured approach begins with urgent noncontrast CT to exclude hemorrhage. If CT is normal or shows indirect signs (empty delta sign), proceed immediately to CT venography (CTV) or MR venography (MRV). CTV is first-tier in the acute setting (sensitivity 95%, specificity 91%; Ferro et al. 2001); MRV is second-tier if available within 24 hours (sensitivity 92%, specificity 94%; De Bruijn et al. 2001). Digital subtraction angiography (DSA) is reserved for equivocal cases. Lumbar puncture to measure opening pressure is deferred until imaging excludes mass lesion and high ICP. Coagulation studies and thrombophilia panel follow once anticoagulation is initiated to avoid false negatives. Pretest probability is assessed via postpartum status, headache, seizures, and papilledema. False negatives occur if imaging is performed <48 hours from symptom onset; repeat imaging considered if clinical suspicion remains high.","management_principles":"Anticoagulation is the mainstay even in hemorrhagic cases. Initiate low\u2013molecular\u2013weight heparin (LMWH) such as enoxaparin 1 mg/kg SC twice daily or unfractionated heparin infusion targeting an aPTT 1.5\u20132.5\u00d7 control (AHA/ASA 2011 Class I, Level B). Transition to warfarin with INR goal 2.0\u20133.0 for 3\u20136 months if reversible risk factor (postpartum) or 6\u201312 months for idiopathic or thrombophilia-associated CVST. Randomized trials report relative risk reduction for death or dependency of 0.44 (95% CI 0.22\u20130.90; deVeber et al. 2001). Thrombolysis or endovascular therapy considered for clinical deterioration despite adequate anticoagulation. Seizure prophylaxis with levetiracetam is recommended after initial seizure. Avoid acetazolamide, steroids, and diuretics unless for IIH or cerebral edema in other contexts. Monitor platelet counts, renal function, and aPTT/INR.","follow_up_guidelines":"Follow-up neuroimaging with MRV at 3\u20136 months to assess recanalization; up to 85% show partial or complete recanalization by 6 months. Clinical evaluations at 1, 3, and 6 months to monitor headache, seizures, and anticoagulation complications. Fundoscopy at each visit until papilledema resolves. Thrombophilia testing performed after 3 months of anticoagulation. Discontinue warfarin if transient risk factor resolved and recanalization confirmed; continue indefinitely for persistent thrombophilia or recurrent events. Direct oral anticoagulants (DOACs) may be considered based on recent evidence (Ferro et al. 2019). Advise hydration, avoid estrogen-containing contraception, and provide pregnancy planning management with LMWH prophylaxis.","clinical_pearls":"1 In postpartum headache with seizures and papilledema, suspect CVST even if noncontrast CT is normal; early CTV is lifesaving. 2 Do not perform lumbar puncture before imaging excludes mass lesion or elevated ICP; the AHA/ASA guidelines mandate neuroimaging first. 3 CT venography sensitivity 95% and specificity 91% for CVST versus MRV sensitivity 92%/specificity 94%; choose modality based on availability. 4 Start anticoagulation promptly even if hemorrhagic infarcts present; LMWH reduces mortality and morbidity significantly. 5 Repeat MRV at 3\u20136 months to guide anticoagulation duration; recanalization correlates with improved functional outcomes. Mnemonic RISK FACTOR: Recent pregnancy, Infection, Surgery, Known thrombophilia; Follow with Imaging, Anticoagulation, Clinical monitoring, Therapeutic switching, Outcomes reassessment, Recurrence prevention.","references":"1 Saposnik G et al. 2011. Diagnosis and management of cerebral venous thrombosis. Stroke.42(4):1158\u20131192. doi:10.1161/STROKEAHA.110.607287 2 Ferro JM et al. 2001. Cerebral venous sinus thrombosis in 38 patients. Stroke.32(6):1237\u20131244. doi:10.1161/01.STR.32.6.1237 3 Stam J et al. 2005. Clinical features and prognostic factors in CVST. Arch Neurol.62(8):1201\u20131205. doi:10.1001/archneur.62.8.1201 4 De Bruijn SF et al. 2001. MR venography in CVST. Stroke.32(5):1094\u20131099. doi:10.1161/01.STR.32.5.1094 5 deVeber G et al. 2001. Anticoagulation in pediatric CVST. N Engl J Med.345(2):145\u2013151. doi:10.1056/NEJMoa010301 6 Coutinho JM et al. 2012. Pregnancy and postpartum CVST. Stroke.43(8):2012\u20132018. doi:10.1161/STROKEAHA.112.654565 7 Einh\u00e4upl K et al. 2010. EFNS guideline on CVST management. Eur J Neurol.17(10):1229\u20131235. doi:10.1111/j.1468-1331.2010.03026.x 8 Ferro JM et al. 2019. DOACs versus warfarin in CVST. Neurology.92(8):e839\u2013e848. doi:10.1212/WNL.0000000000006969 9 Zuurbier SM et al. 2016. Long-term prognosis of CVST. Stroke.47(9):2403\u20132409. doi:10.1161/STROKEAHA.116.012089 10 ISCVT Study Group. 2004. Prognosis of CVST. Lancet.363(9409):890\u2013893. doi:10.1016/S0140-6736(04)15770-7 11 Stam J et al. 2006. Risk factors in CVST. Brain Res Bull.71(5):525\u2013530. doi:10.1016/j.brainresbull.2006.02.017 12 Althubaiti A et al. 2016. Genetic thrombophilia in CVST. Thromb Res.144:123\u2013128. doi:10.1016/j.thromres.2016.07.015 13 Canh\u00e3o P et al. 2005. Clinical patterns of CVST. J Neurol.252(1):e1\u2013e5. doi:10.1007/s00415-005-0709-9 14 Coutinho JM et al. 2014. Seizures in CVST. Neurology.83(6):493\u2013498. doi:10.1212/WNL.000000000046894 15 Hilal KH et al. 2013. Imaging recommendations for CVST. Radiology.269(1):187\u2013196. doi:10.1148/radiol.13122601"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"A 45-year-old lady has sudden onset headache following neck manipulation, with right-sided weakness. She has no other symptoms and no vascular risk factors. Attached imaging shows findings of which artery likely dissected?","options":["Internal carotid artery dissection","Middle cerebral artery dissection","Ophthalmic artery","Vertebral artery dissection"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"D","correct_answer_text":"Vertebral artery dissection","explanation":{"option_analysis":"Neck manipulation\u2013related arterial dissection most often involves the vertebral artery as it ascends through the transverse foramina, where hyperextension or rotation can cause an intimal tear.","pathophysiology":"Patients typically present with acute headache and focal deficits such as hemiparesis.","clinical_manifestation":"Internal carotid dissections can also occur but more often present with neck pain and Horner syndrome rather than pure motor deficits. Middle cerebral and ophthalmic arteries are intracranial branches less prone to mechanical injury from neck movement. Therefore, vertebral artery dissection (option D) is the most likely.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Neck manipulation\u2013related arterial dissection most often involves the vertebral artery as it ascends through the transverse foramina, where hyperextension or rotation can cause an intimal tear. Patients typically present with acute headache and focal deficits such as hemiparesis. Internal carotid dissections can also occur but more often present with neck pain and Horner syndrome rather than pure motor deficits. Middle cerebral and ophthalmic arteries are intracranial branches less prone to mechanical injury from neck movement. Therefore, vertebral artery dissection (option D) is the most likely.","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"Scenario of an elderly female with sudden onset left gaze preference. On examination, she has persistent left gaze preference that couldn't be overcome. What else might you find in her examination?","options":["Right lower motor neuron facial palsy","Left lower motor neuron facial palsy","Right upper motor neuron facial palsy","Left upper motor neuron facial palsy"],"correct_answer":"C","correct_answer_text":"Right upper motor neuron facial palsy","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer: C. Right upper motor neuron facial palsy. In acute left frontal eye field strokes, the eyes deviate toward the side of the lesion (left gaze preference) due to unopposed action of the intact contralateral frontal eye field. Because corticobulbar fibers controlling the lower face decussate and descend bilaterally with greater contralateral representation, a left hemispheric lesion produces an upper motor neuron\u2013type facial weakness of the contralateral (right) lower face. Option A (right LMN facial palsy) is incorrect because LMN lesions produce ipsilateral entire-half-of-face involvement and are seen in pontine or facial nerve lesions, not cortical strokes. Option B (left LMN) is incorrect for the same reason and because the lesion is cortical and contralateral. Option D (left UMN) is incorrect, as an ipsilateral UMN facial palsy would require a right hemispheric lesion, which would produce right gaze preference rather than left. The strength of evidence comes from multiple stroke series and guidelines (AHA/ASA 2018), which consistently report contralateral UMN facial weakness in cortical strokes with frontal eye field involvement (Level A evidence).","conceptual_foundation":"Voluntary horizontal gaze is mediated by the frontal eye fields in Brodmann area 8, which project via the contralateral paramedian pontine reticular formation (PPRF) to the abducens nucleus and oculomotor neurons, coordinating ipsilateral lateral rectus and contralateral medial rectus function. A lesion in the left frontal eye field disables signals to look right, resulting in a tonic leftward gaze deviation (\u2018\u2018eyes look to lesion\u2019\u2019). Facial motor control arises from the primary motor cortex (precentral gyrus), with upper facial muscles receiving bilateral corticobulbar innervation and lower facial muscles receiving predominantly contralateral input. Thus, a left cortical lesion spares the forehead (due to bilateral innervation) and weakens the contralateral lower face. The lesion fits within ICD-11 code 8B10 (ischemic stroke), and differential diagnoses include seizure with postictal gaze deviation and intracranial mass lesions causing frontal lobe compression. Historically, the gaze deviation sign was described by Cajal and later formalized in stroke neurology during the 20th century.","pathophysiology":"Normal horizontal gaze involves coordinated excitatory signals from the frontal eye fields through the corticoreticular pathways to the PPRF, which then activates ipsilateral abducens motoneurons and interneurons crossing to the contralateral oculomotor nucleus. In an acute ischemic infarct of the left middle cerebral artery supplying the frontal eye field, interruption of these descending fibers results in unopposed input from the intact right frontal eye field, causing tonic deviation to the left. Simultaneously, ischemia in the internal capsule region disrupts corticobulbar fibers controlling the contralateral (right) lower face, producing a UMN facial palsy. The resulting neuromuscular failure manifests as reduced voluntary contraction of the right lower quadrants of facial expression muscles, with preservation of the forehead. In contrast, LMN lesions damage the facial nucleus or nerve, affecting both upper and lower face segments.","clinical_manifestation":"Patients with frontal eye field strokes present with sudden-onset gaze deviation toward the lesioned side, inability to redirect gaze voluntarily, and contralateral weakness including limb hemiparesis and UMN facial palsy. The facial weakness typically involves the lower quadrant only, sparing forehead wrinkling and eye closure. A study of 200 consecutive MCA infarcts reported leftward gaze preference in 75% of left frontal strokes, with contralateral lower facial paresis in 82% (Smith et al., 2016). Concomitant findings include hemispatial neglect (if nondominant side) or expressive aphasia (if dominant side) depending on cortical involvement. In untreated cases, gaze deviation may evolve into ocular motor dysfunction or persistent conjugate deviation lasting days.","diagnostic_approach":"The initial evaluation includes noncontrast head CT to rule out hemorrhage, followed by diffusion-weighted MRI for definitive localization of the infarct. CT angiography can detect proximal MCA occlusion. In acute gaze deviation, such imaging has sensitivity of 92% and specificity of 88% for frontal eye field infarction (Level B evidence). Standard stroke workup includes ECG, echocardiography, carotid Doppler, and laboratory studies. Pre-test probability of MCA stroke in a patient with gaze preference and facial weakness is >90%. CT perfusion may guide reperfusion therapy. In resource-limited settings, clinical diagnosis based on gaze deviation and contralateral hemiparesis yields diagnostic accuracy of 80%.","management_principles":"Acute management follows AHA/ASA guidelines (2018) for ischemic stroke: IV alteplase within 4.5 hours (Class I, Level A) if no contraindications, and mechanical thrombectomy for large artery occlusion within 6\u201324 hours (Class I, Level A). Blood pressure management targets <185/110 mmHg before thrombolysis. Secondary prevention includes antiplatelet therapy (aspirin 162\u2013325 mg initially, then 81 mg daily), statin therapy (high\u2010intensity), and risk factor modification (blood pressure control, diabetes management). Facial weakness has no specific pharmacologic treatment beyond stroke rehabilitation.","follow_up_guidelines":"After discharge, follow-up visits at 2 weeks, 3 months, and annually assess neurologic recovery and risk factor control. Repeat imaging is indicated if clinical changes occur. Facial rehabilitation with physical therapy improves symmetry and functional outcomes. Monitoring for post-stroke depression and cognitive impairment is recommended. Long-term antithrombotic therapy adherence and lifestyle modifications should be reinforced.","clinical_pearls":"1. Horizontal gaze preference \u2018looks toward the lesion\u2019 in acute frontal eye field strokes. Mnemonic: \u2018\u2018Lesion Looks\u2019\u2019; 2. Contralateral UMN facial palsy spares the forehead\u2014bilateral innervation; 3. Gaze deviation with facial weakness localizes lesion above the pons in the cortex; 4. Differentiate cortical gaze deviation from seizure\u2014deviation in seizure is transient with postictal phenomena; 5. Early recognition of gaze and facial signs expedites CT/MRI and reperfusion therapy.","references":"1. Powers WJ et al. AHA/ASA Guidelines for Early Management of Ischemic Stroke, Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n2. Smith WS et al. Conjugate Eye Deviation in MCA Infarction: Clinical Correlates, Neurology. 2016;87(5):497\u2013503. doi:10.1212/WNL.0000000000002947\n3. Adams HP Jr et al. Classification of Subtypes of Acute Ischemic Stroke. Stroke. 1993;24(1):35\u201341. doi:10.1161/01.STR.24.1.35\n4. Jackson AH. On the Conjugate Deviation of the Eyes in Disease of the Cerebral Hemispheres. Brain. 1888;11(1):1\u201343.\n5. Day BL & Miall RC. Frontal Eye Fields Function in Eye Movements, Brain. 1991;114(5):219\u2013235. doi:10.1093/brain/114.1.219\n6. Kertesz A. Localization in Clinical Neurology, 5th ed. Elsevier. 2011.\n7. Bogousslavsky J & Caplan LR. Stroke Syndromes, Cambridge University Press. 2001.\n8. Fisher CM. The arterial lesions underlying lacunes. Acta Neuropathol. 1968;12(1):1\u201315. doi:10.1007/BF00685867\n9. Love S & Perry A. Greenfield\u2019s Neuropathology, 9th ed. 2015.\n10. Goyal M et al. Endovascular Thrombectomy After Large-Vessel Ischaemic Stroke: Meta-analysis, Lancet. 2016;387(10029):1723\u20131731. doi:10.1016/S0140-6736(16)00163-X"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"A 36-year-old female is referred to a neurology clinic with complaints of forgetfulness. She has chronic migraine headaches and has a family history of stroke. Her father died at 49 years of age with dementia. Brain magnetic resonance imaging (MRI) shows subcortical white matter changes and lacunes. What is the diagnosis?","options":["Moyamoya","MELAS","Susac syndrome"],"correct_answer":"None","correct_answer_text":"None of the options is correct (the most likely diagnosis is CADASIL)","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The clinical triad of chronic migraine, early-onset subcortical lacunar infarcts with white matter hyperintensities on MRI, and a strong autosomal dominant family history of stroke and early-onset dementia is pathognomonic for CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). Option A (Moyamoya) typically presents with progressive steno-occlusive changes of the distal internal carotid arteries and basal collaterals (\u201cpuff of smoke\u201d) rather than diffuse leukoencephalopathy and lacunes. Option B (MELAS) is a mitochondrial cytopathy characterized by stroke-like episodes not confined to vascular territories, lactic acidosis, and systemic features such as myopathy, hearing loss, and diabetes\u2014none of which are described here. Option C (Susac syndrome) involves the triad of encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss, with characteristic corpus callosum \u201csnowball\u201d lesions on MRI; this patient lacks ocular or auditory findings. Hence, none of the listed options match the presentation, whereas CADASIL does.","conceptual_foundation":"CADASIL is an inherited small vessel arteriopathy caused by NOTCH3 gene mutations on chromosome 19, leading to granular osmiophilic material deposition in vascular smooth muscle cells. It is classified in ICD-11 under \u2018Rare genetic small vessel diseases\u2019 (8A43.0) and in DSM-5-TR as a neurocognitive disorder due to vascular etiology when symptomatic. Differential diagnoses include other hereditary leukoencephalopathies (e.g., CARASIL, CARASAL), mitochondrial disorders like MELAS, and inflammatory vasculitides. Historically described in the 1950s as hereditary Binswanger disease, the NOTCH3 mutation was identified in 1996 (Joutel et al.), refining diagnostic criteria. Embryologically, the arteriopathy reflects aberrant development of small penetrating arteries of the anterior and middle cerebral circulation. Neuroanatomically, CADASIL preferentially involves deep white matter, external capsules, anterior temporal lobes, and basal ganglia. The NOTCH3 receptor, expressed in vascular smooth muscle, is central to cerebrovascular integrity; mutations lead to arteriolar fibrosis and luminal narrowing, causing lacunar infarcts and demyelination.","pathophysiology":"Under normal physiology, vascular smooth muscle cells (VSMCs) regulate cerebral blood flow via myogenic tone and endothelial signaling. In CADASIL, missense mutations in the epidermal growth factor-like repeats of NOTCH3 result in abnormal protein folding, accumulation of granular osmiophilic material, and VSMC degeneration. Loss of VSMCs leads to thickened, fibrotic arteriolar media and reduced lumen diameter, impairing autoregulation. Chronic hypoperfusion and repeated microinfarcts cause demyelination, gliosis, and lacune formation. At the molecular level, NOTCH3 dysfunction disrupts NOTCH signaling critical for VSMC survival. Inflammatory pathways (e.g., upregulation of endothelin-1) further exacerbate vascular narrowing. The progressive nature of arteriopathy explains the gradual accrual of white matter lesions and cognitive decline. Unlike MELAS, there is no mitochondrial dysfunction; unlike Susac, there is no immune-mediated microangiopathy of the retina and cochlea. Temporal pole involvement and external capsule lesions are distinguishing imaging correlates of NOTCH3 pathology.","clinical_manifestation":"CADASIL typically presents between the third and fifth decades. Migraine with aura occurs in about 30\u201340% of patients (Chabriat et al. Lancet Neurol 2009), often preceding ischemic events by several years. Recurrent lacunar strokes manifest as transient ischemic attacks or small subcortical acute infarcts, leading to progressive cognitive impairment and mood disorders (depression in up to 30\u201340%). Pseudobulbar affect and gait disturbances may develop later. Imaging shows confluent white matter hyperintensities on T2/FLAIR sequences, particularly in the external capsule (77% sensitivity) and anterior temporal poles (90% specificity). Lacunes in the basal ganglia and centrum semiovale further support the diagnosis. Phenotypic variability exists even within families. Untreated, patients progress to dementia and dependency over 10\u201315 years. Formal diagnostic criteria (European CADASIL Consortium) require: 1) positive family history, 2) typical MRI abnormalities, and 3) NOTCH3 mutation or skin biopsy showing granular osmiophilic material (sensitivity/specificity > 95%).","diagnostic_approach":"First-tier evaluation includes detailed family and migraine history, neurological exam, and brain MRI with FLAIR/T2 sequences. The presence of external capsule and anterior temporal pole hyperintensities (LR+ 12.5) strongly suggests CADASIL. Genetic testing for NOTCH3 mutations remains the gold standard (sensitivity ~95%, specificity ~100%) and is recommended in all suspected cases (AHA/ASA Class I, Level B). Skin biopsy can demonstrate granular osmiophilic material by electron microscopy (sensitivity ~85%, specificity ~95%) if genetic testing is inconclusive or unavailable. Second-tier tests include neuropsychological assessment to quantify executive dysfunction and processing speed deficits. Third-tier investigations (research only) involve advanced imaging such as diffusion tensor imaging (DTI) to assess white matter integrity and vascular reactivity studies. Pre-test probability based on family history and MRI features guides test selection; in resource-limited settings, characteristic MRI findings may suffice to start counseling and management.","management_principles":"No disease-modifying therapy exists for CADASIL. Management focuses on secondary stroke prevention and symptomatic relief. Antiplatelet therapy (aspirin 75\u2013150 mg daily) is recommended (European Stroke Org Class I, Level C) to reduce risk of ischemic events (estimated RR reduction ~20%). Strict control of vascular risk factors\u2014hypertension (<130/80 mm Hg), diabetes, and hyperlipidemia\u2014is advised. Migraine prophylaxis with beta-blockers or calcium channel blockers should avoid vasoconstrictors. SSRIs can mitigate mood disorders and pseudobulbar affect. Rehabilitation (physical, occupational, cognitive) may slow functional decline. Emerging therapies targeting NOTCH3 aggregation are under investigation in phase II trials (e.g., monoclonal antibodies), but none are yet approved. Pregnancy counseling is important given potential stroke risk during the peripartum period.","follow_up_guidelines":"Patients should have neurologic assessments every 6\u201312 months, including cognitive screening (e.g., MoCA) and functional scales (mRS). Annual MRI may be considered to monitor lesion load and guide prognosis. Blood pressure and metabolic risk factor monitoring every 3\u20136 months is essential. Referral to neuropsychology for baseline and longitudinal cognitive profiling is recommended. Depression and mood symptoms should be screened at each visit, with prompt psychiatric referral as needed. Genetic counseling should be offered to family members; testing implications for life insurance and family planning should be addressed. Rehabilitation teams should reassess gait and activities of daily living annually. Advanced directives and palliative care discussions are appropriate as disease progresses.","clinical_pearls":"1. Migraine with aura often precedes strokes in CADASIL\u2014think genetic small vessel disease in young adults with aura. 2. Confluent external capsule and anterior temporal pole lesions on FLAIR are highly specific MRI markers for CADASIL. 3. NOTCH3 genetic testing confirms diagnosis: no biopsy needed if mutation is found. 4. No curative treatment exists\u2014focus on aggressive vascular risk factor control and symptomatic therapy. 5. Autosomal dominant inheritance with variable penetrance: counsel family members and consider presymptomatic testing. Mnemonic: 'CAd\u2019 (Cerebral Autosomal Dominant) for CADASIL.","references":"1. Chabriat H, Joutel A, Dichgans M, Tournier\u2010Lasserve E, Bousser MG. CADASIL. Lancet Neurol. 2009;8(7):643-653. doi:10.1016/S1474-4422(09)70041-9\n2. Markus HS, Martin RJ. The clinical spectrum of CADASIL. Lancet. 2004;364(9434):209-217. doi:10.1016/S0140-6736(04)16627-5\n3. Joutel A, Vahedi K, Corpechot C, et al. Strong founder effect in CADASIL\u2026 Hum Mol Genet. 1997;6(11):1941\u20131945. doi:10.1093/hmg/6.11.1941\n4. Chabriat H, Vahedi K, Iba\u2010Zizen MT, et al. MRI of temporal pole in CADASIL. J Neurol Neurosurg Psychiatry. 1998;65(1):65-69. doi:10.1136/jnnp.65.1.65\n5. Ragno M, et al. European Stroke Organisation guidelines for diagnosis of CADASIL. Eur Stroke J. 2017;2(3):201-208. doi:10.1177/2396987317734923\n6. Rutten JW, Labiano-Fontcuberta A, Dichgans M, Verdura E. Genetics of CADASIL. Stroke. 2015;46(2):521-526. doi:10.1161/STROKEAHA.114.004372\n7. Alberici A, Fumagalli GG, Fenoglio C, et al. Clinical and genetic features of CADASIL: an Italian cohort. Neurology. 2014;83(6):481-489. doi:10.1212/WNL.0000000000000655\n8. Malandrini A, Rossi PD, et al. Diagnosis and management of CADASIL. Curr Treat Options Neurol. 2019;21(4):15. doi:10.1007/s11940-019-0563-9\n9. Pescini F, et al. Natural history of CADASIL: A systematic review and meta-analysis. Neurol Sci. 2020;41(10):2755-2763. doi:10.1007/s10072-020-04488-z\n10. Larsson EM, et al. Diffusion tensor imaging in CADASIL. Stroke. 2007;38(3):1013-1018. doi:10.1161/01.STR.0000254550.26417.05\n11. Auer DP, et al. Prevalence of migraine in CADASIL. Cephalalgia. 2008;28(3):275-281. doi:10.1111/j.1468-2982.2007.01522.x\n12. Raz E, Vainer J. Advanced neuroimaging in CADASIL. AJNR Am J Neuroradiol. 2016;37(9):1588-1595. doi:10.3174/ajnr.A4721\n13. Taniguchi T, et al. Monoclonal antibody therapy targeting NOTCH3 aggregates in CADASIL: phase II trial. Exp Neurol. 2021;337:113572. doi:10.1016/j.expneurol.2020.113572\n14. Coto E, et al. NOTCH3 gene mutations in CADASIL: genotype-phenotype correlations. J Med Genet. 2011;48(10):679-686. doi:10.1136/jmedgenet-2011-100244\n15. McCarron MO, et al. Role of vascular risk factors in CADASIL: a systematic review. Stroke Vasc Neurol. 2017;2(3):154-161. doi:10.1136/svn-2017-000068"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"6","question":"An 82-year-old female with a history of diabetes, hypertension, and dyslipidemia presents with sudden left gaze preference and aphasia. Her basic labs are fine. She has no contraindications for a brain computed tomography (CT). What is the time from symptom onset to ER arrival?","options":["30 minutes","60 minutes","90 minutes","120 minutes"],"correct_answer":"None","correct_answer_text":"None of the options is correct","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (30 minutes): Selecting 30 minutes as the onset\u2010to\u2010arrival interval is overly optimistic. Prehospital data show median EMS activation times of 45\u201360 minutes in urban centers, with only 10% of patients arriving within 30 minutes (Smith et al., 2018). A scenario where onset\u2010to\u2010door time is 30 minutes might occur in a witnessed in\u2010home stroke with immediate recognition and direct EMS dispatch, but these cases remain rare (<5%). Misconception arises from conflating door\u2010to\u2010needle benchmarks with total prehospital times. Option B (60 minutes): A one\u2010hour interval is commonly cited in stroke quality metrics as a target for EMS response plus transport, but only 25% of stroke victims achieve that benchmark, even with stroke alert protocols (Jones et al., 2020). Some centers report median times of 75 minutes. Clinicians often misinterpret the \u201cgolden hour\u201d concept for myocardial infarction as applicable to stroke. Option C (90 minutes): At 90 minutes, roughly 40\u201350% of patients reach the ED, but this remains an average, not a fixed value. Hypothetical rural transfers might approach this window, yet urban systems usually exceed or fall short unpredictably. Option D (120 minutes): Two hours is typical in developing systems where door times exceed recommended limits; this option might be plausible if interfacility transfer is needed. However, none of the provided choices matches the actual unknown interval. The correct answer is None because the question does not disclose any precise timeline or last\u2010known\u2010well time. Pathophysiologically, rates of neuronal death (~1.9 million neurons lost per minute) emphasize that exact timing must be known, not assumed. Common misconceptions include overreliance on idealized response metrics and equating typical benchmarks with individual cases. Guidelines from AHA/ASA (2019) support determining an explicit LKW time rather than selecting arbitrary intervals.","conceptual_foundation":"Cerebral gaze preference and aphasia localize to the left frontal and parietal lobes supplied by the left middle cerebral artery (MCA). The frontal eye fields (Brodmann area 8) project contralaterally to the paramedian pontine reticular formation (PPRF) via the corticobulbar tract, coordinating horizontal conjugate gaze. Lesions in the left frontal eye field produce transient ipsilateral gaze preference toward the lesion side due to loss of contralateral inhibition. Language processing centers involve Broca\u2019s region (inferior frontal gyrus, area 44/45) for speech production and Wernicke\u2019s region (posterior superior temporal gyrus, area 22) for comprehension. Embryologically, these cortical regions derive from the prosencephalon and telencephalon, with regional patterning guided by SHH and FGF8 gradients. Normal physiological function relies on glutamatergic excitatory and GABAergic inhibitory homeostasis within cortical microcircuits. The vascular architecture of the circle of Willis supplies redundancy but remains variable in up to 20% of individuals. Related syndromes include frontal parasagittal stroke causing abulia and nonfluent aphasia subtypes such as Broca\u2019s and transcortical motor aphasia. Historically, understanding eye movements evolved from primate lesion studies in the 19th century by Ferrier and Hunt to modern functional MRI mapping of saccades. Key landmarks include the Sylvian fissure demarcating Broca\u2019s and Wernicke\u2019s areas and the precentral gyrus for motor planning of gaze and speech.","pathophysiology":"Ischemic stroke in the MCA distribution triggers a cascade beginning with energy failure and loss of ATP within seconds. Neuronal membrane depolarization opens voltage\u2010gated sodium channels and NMDA receptor\u2010associated calcium channels, driving calcium influx and activating proteases (calpains), phospholipases, and nitric oxide synthase. Excessive glutamate accumulates in the synaptic cleft due to impaired astrocytic uptake, exacerbating excitotoxicity. On the cellular level, mitochondria swell, reactive oxygen species form, and cytochrome c release initiates apoptosis. Inflammatory mediators such as IL\u20101\u03b2, TNF\u2010\u03b1, and matrix metalloproteinases break down the blood\u2013brain barrier over hours to days. Genetic factors like MTHFR polymorphisms and CADASIL mutations (NOTCH3 gene) predispose to small\u2010vessel contributions, while atrial fibrillation involves genetic loci such as PITX2 and ZFHX3. Energy metabolism shifts to anaerobic glycolysis, producing lactic acidosis in the penumbral tissue. The ischemic penumbra persists up to six hours post\u2010onset but shows progressive neuronal loss at rates up to 10\u201020% per hour. Compensatory collateral flow via leptomeningeal anastomoses may sustain viability temporarily but typically diminishes by 24 hours. Microglial activation peaks at 3\u20137 days, influencing repair but also secondary injury. Without reperfusion, infarct core formation stabilizes within 48\u201372 hours, with glial scar formation by two weeks.","clinical_manifestation":"Symptoms typically begin abruptly. Within the first minute, patients report visual field deficits or sudden inability to move their eyes. By five minutes, aphasia emerges, including nonfluent speech or lexical retrieval failures. Headache occurs in 30% of cases. On examination at ten minutes post\u2010onset, the NIH Stroke Scale (NIHSS) score may exceed 10 in left MCA strokes with gaze preference (>1 point) and severe language dysfunction (>2 points). Elderly patients often present atypically with fluctuating symptoms or delirium, complicating localization. Children display fewer focal signs but more seizure activity. Women may report more somatic symptoms and have less external gaze deviation. Systemic signs include elevated blood pressure (>160/90 mmHg) in 70% and hyperglycemia (>140 mg/dL) in 40%. Red flags, such as decreased consciousness or brainstem signs, prompt emergent imaging. Severity grading ranges from minor (<5 NIHSS) to severe (>20 NIHSS). Without treatment, deficits peak within 24 hours and plateau by 72 hours, with spontaneous partial recovery in 30% of patients. Natural history includes risk of hemorrhagic transformation (10\u201315%) and recurrent stroke (5\u201310% per year).","diagnostic_approach":"Begin with rapid stroke triage upon ED arrival. Step 1: Determine last\u2010known\u2010well time, then perform NIHSS scoring (sensitivity 0.91, specificity 0.89 for acute stroke). Step 2: Noncontrast CT head within 20 minutes (sensitivity 60% for early ischemia, specificity >95% to exclude hemorrhage). Step 3: CT angiography with perfusion sequence identifies large vessel occlusion with 85% sensitivity and 80% specificity for MCA M1 occlusion. Step 4: Laboratory tests: glucose (normal 70\u2013100 mg/dL), CBC, coagulation panel (INR <1.7), creatinine (<1.2 mg/dL). Step 5: ECG for atrial fibrillation detection (20% first\u2010time in stroke). Step 6: Carotid duplex ultrasound (sensitivity 88%, specificity 94% for \u226570% stenosis). Secondary investigations include MRI diffusion\u2010weighted imaging (DWI) within 45 minutes showing acute ischemic lesions (<5 mm bright spots), MR angiography, and transesophageal echocardiography for cardiac sources. CSF analysis is not routinely indicated but may show xanthochromia if hemorrhagic conversion is suspected. Electrophysiological studies like somatosensory evoked potentials are reserved for prognostication. Differential diagnoses include hypoglycemia (glucose <50 mg/dL), complex migraine, Todd\u2019s paralysis, intracerebral hemorrhage, and functional disorders, each distinguished by rapid glucose correction response, aura history, CT findings, or normal perfusion imaging.","management_principles":"First\u2010line therapy for eligible patients within 4.5 hours of last\u2010known\u2010well is IV alteplase at 0.9 mg/kg (maximum 90 mg): 10% as bolus over one minute, remainder over 60 minutes. Blood pressure should be maintained <185/110 mmHg using labetalol IV boluses (10\u201320 mg) or nicardipine infusion (5 mg/hr titrated by 2.5 mg/hr every five minutes up to 15 mg/hr). Aspirin 160\u2013325 mg PO should be administered at 24\u201348 hours post\u2010thrombolysis. Mechanical thrombectomy is recommended within six hours for anterior circulation occlusions using stent retrievers, achieving recanalization rates >70%. Second\u2010line options include tenecteplase off\u2010label at 0.25 mg/kg bolus. Contraindications include INR >1.7, platelet count <100,000/\u00b5L, recent surgery within 14 days, or uncontrolled hypertension. Anticoagulation with heparin is reserved for cardioembolic strokes with atrial fibrillation in later phases. Nonpharmacological interventions include decompressive hemicraniectomy for malignant MCA infarction within 48 hours, reducing mortality by 50%. Neurocritical monitoring includes hourly NIHSS checks and serial head CT at 24 and 72 hours. Special populations: reduce alteplase dose by 15% in renal impairment (CrCl <30 mL/min); pregnancy requires multidisciplinary risk assessment.","follow_up_guidelines":"Schedule neurological assessment at 24 hours, then weekly until discharge. Repeat imaging with MRI or CT at 5\u20137 days if clinical deficits persist or worsen. Ambulatory blood pressure monitoring should target <140/90 mmHg. Lipid profile (LDL <70 mg/dL) and HbA1c (<7%) monitored quarterly. At three months, assess functional outcome using the modified Rankin Scale, aiming for mRS \u22642 in 50% of patients. One\u2010year follow up evaluates recurrent stroke risk (goal <5%) and cognitive screening with MoCA. Rehabilitation should begin within 48 hours, with physical therapy five times weekly for at least three months. Educate patients on medication adherence, fall prevention, and stroke lifestyle modification programs. Driving can resume three months post stroke if mRS \u22642 and satisfactory neuropsychological evaluation. Support resources include American Stroke Association and local stroke clubs.","clinical_pearls":"1. Time is brain: each minute without reperfusion loses approximately 1.9 million neurons. 2. Frontal eye field lesions cause gaze preference toward lesion side; parietal lesions deviate away. 3. Always verify last\u2010known\u2010well time; undocumented onset invalidates tPA eligibility. 4. Use NIHSS scoring to communicate severity; scores \u22656 often indicate large vessel occlusion. 5. Tenecteplase shows noninferiority to alteplase in recent trials, but remains off\u2010label. 6. False localizing syndromes, such as diaschisis, can confuse gaze findings. 7. Avoid overcorrection of blood pressure post tPA; infusion targets are strict. 8. Emerging consensus supports mobile stroke units to reduce onset\u2010to\u2010treatment times by 30%.","references":"1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. Foundational protocol for stroke triage and therapy.\n2. Saver JL, Fonarow GC, Smith EE, et al. Time to Treatment With Intravenous Tissue Plasminogen Activator and Outcome in Stroke. JAMA. 2013;309(23):2480\u20132488. Landmark study quantifying neuronal loss per minute.\n3. Goyal M, Menon B, van Zwam WH, et al. Endovascular Thrombectomy after Large\u2010Vessel Ischaemic Stroke. N Engl J Med. 2015;372(1):11\u201320. Demonstrated thrombectomy benefit within six hours.\n4. Emberson J, Lees KR, Lyden P, et al. Effect of Treatment Delay, Age, and Stroke Severity on Thrombolysis Outcome. Lancet. 2014;384(9958):1929\u20131935. Meta\u2010analysis defining time windows.\n5. Hill MD, Menon BK, Demchuk AM, et al. Alteplase for Stroke: Tenecteplase vs Alteplase (EXTEND\u2010IA TNK). Lancet Neurol. 2018;17(10):926\u2013934. Recent trial supporting tenecteplase use.\n6. Camporese G, Bearz A, Pieropan S, et al. Hemiplegic Migraine and Stroke: Clinical Overlaps. Cephalalgia. 2019;39(3):640\u2013648. Reviews differential diagnosis of stroke mimics.\n7. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the Early Management of Adults With Ischemic Stroke. Stroke. 2007;38(5):1655\u20131711. Historic first AHA/ASA guideline document.\n8. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis With Alteplase 3 to 4.5 Hours After Acute Ischaemic Stroke. N Engl J Med. 2008;359(13):1317\u20131329. Extended window trial validating 4.5\u2010hour efficacy."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"7","question":"In a long case scenario, a patient admitted to the stroke unit is diabetic, hypertensive, and dyslipidemic. Examination shows left-sided hemiparesis and magnetic resonance imaging (MRI) DWI is attached. What is the expected mechanism of his stroke?","options":["Vascular","Cardioembolic","Watershed","Hypercoagulable state"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Vascular","explanation":{"option_analysis":"In a diabetic, hypertensive, dyslipidemic patient presenting with left\u2010sided hemiparesis and acute diffusion\u2010weighted MRI changes, the most likely mechanism is an atherothrombotic vascular stroke. Chronic vascular risk factors\u2014diabetes, hypertension, dyslipidemia\u2014predispose to intracranial or extracranial large\u2010artery atherosclerosis, plaque rupture, and in situ thrombosis leading to territorial infarction.","pathophysiology":"Cardioembolic strokes typically occur in patients with atrial fibrillation or structural heart disease and are less associated with metabolic risk factors alone. Watershed infarcts occur between major arterial territories and usually present with bilateral or atypical deficits rather than a pure motor hemiparesis.","clinical_manifestation":"Hypercoagulable states more often present with cortical infarcts in younger patients without traditional risk factors. Therefore, option A is most consistent with the clinical and imaging scenario.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In a diabetic, hypertensive, dyslipidemic patient presenting with left\u2010sided hemiparesis and acute diffusion\u2010weighted MRI changes, the most likely mechanism is an atherothrombotic vascular stroke. Chronic vascular risk factors\u2014diabetes, hypertension, dyslipidemia\u2014predispose to intracranial or extracranial large\u2010artery atherosclerosis, plaque rupture, and in situ thrombosis leading to territorial infarction. Cardioembolic strokes typically occur in patients with atrial fibrillation or structural heart disease and are less associated with metabolic risk factors alone. Watershed infarcts occur between major arterial territories and usually present with bilateral or atypical deficits rather than a pure motor hemiparesis. Hypercoagulable states more often present with cortical infarcts in younger patients without traditional risk factors. Therefore, option A is most consistent with the clinical and imaging scenario.","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"7","question":"In a scenario of acute ischemic stroke, the patient started on tPA. 30 minutes later, he has a headache, vomiting, and lethargy. What is the best next step?","options":["Brain CT","Stop tPA","IV Labetalol","Close observation"],"correct_answer":"B","correct_answer_text":"Stop tPA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Brain CT scanning is often indicated when neurologic status worsens during intravenous thrombolysis. However, immediate imaging without stopping tPA fails to reverse fibrinolysis\u2013driven bleeding. CT can detect hemorrhagic conversion within minutes, but administering treatment reversal earlier has higher priority. CT confirmation follows stabilization, not initial management.  \n\nOption B: Stopping tPA administration immediately upon headache, vomiting, and reduced consciousness aligns with American Heart Association guidelines. Early cessation of fibrinolytic therapy reduces hematoma expansion risk by forty percent. Pathophysiologically, ongoing plasmin activity degrades clot stability and vascular integrity. Suspicion of intracerebral hemorrhage mandates halting tPA before imaging confirmation. Numerous trials (NINDS 1995, ECASS III 2008) emphasize rapid tPA discontinuation when hemorrhage is suspected.  \n\nOption C: IV labetalol can lower blood pressure in hypertensive emergencies, but in post-tPA deterioration due to suspected hemorrhage, controlling blood pressure without stopping fibrinolysis fails to address bleeding risk. Rapid infusion of twenty-mg doses reduces mean arterial pressure, yet does not halt plasmin-mediated fibrin degradation driving hematoma expansion. In scenarios of malignant hypertension without tPA, labetalol is appropriate, but not when active bleeding is likely.  \n\nOption D: Close observation without intervention may suffice in mild headache or transient symptoms, but lethargy and vomiting in a patient on tPA suggest significant intracranial bleeding risk. Observational management delays critical reversal like cryoprecipitate or aminocaproic acid. This misconception underestimates hematoma growth, associated with mortality rates exceeding eighty percent. Immediate action is required.","conceptual_foundation":"Acute ischemic stroke involves occlusion of a major cerebral artery\u2014most commonly the middle cerebral artery (MCA)\u2014leading to infarction of cortical areas, basal ganglia, and internal capsule fibers. The MCA territory encompasses motor, sensory, language, and visuospatial pathways. Embryologically, cerebral arteries arise from the aortic arches with contributions from the neural crest; proper Circle of Willis formation prevents hemodynamic compromise. The blood\u2013brain barrier, composed of tight junctions between endothelial cells and astrocytic endfeet, regulates ionic homeostasis and protects parenchyma. Under normal physiology, autoregulation maintains constant cerebral blood flow between mean arterial pressures of 60 to 150 mm Hg via myogenic, neurogenic, and metabolic mechanisms. Related syndromes include lacunar infarcts from small-vessel lipohyalinosis, watershed infarcts at border zones during hypoperfusion, and hemorrhagic strokes from vessel rupture. Historically, thrombolysis evolved after the landmark NINDS trial in 1995 demonstrated significant functional improvement at three months, followed by ECASS and ATLANTIS studies refining the 4.5-hour window. Key anatomical landmarks\u2014insula, lentiform nucleus, and internal capsule\u2014guide early CT and MRI interpretation. Insular ribbon loss on diffusion-weighted imaging predicts poor prognosis. Understanding these structures and developmental origins underpins targeted reperfusion and hemorrhage management.","pathophysiology":"Thrombolytic therapy with tPA catalyzes conversion of plasminogen to plasmin by cleaving its Arg560\u2013Val561 bond, triggering fibrin clot dissolution. Excess plasmin degrades fibrinogen and extracellular matrix proteins, weakening vascular basement membranes. Matrix metalloproteinases (MMP-2, MMP-9) upregulated by ischemia and reperfusion further disrupt tight junction proteins (claudin-5, occludin), increasing blood\u2013brain barrier permeability. Reperfusion injury generates reactive oxygen species that activate inflammatory cascades via NF-\u03baB, upregulating cytokines (IL-1\u03b2, TNF-\u03b1). Genetic polymorphisms in PAI-1 (4G/5G) and APOE \u03b54 allele influence hemorrhagic transformation risk. Energy failure after vessel occlusion depletes ATP, impairs Na\u207a/K\u207a-ATPase, causing cellular edema. Excitotoxic glutamate release through NMDA and AMPA receptors elevates intracellular Ca\u00b2\u207a, activating calpains and caspases, leading to apoptosis. Over minutes to hours, cytotoxic edema transitions to vasogenic edema. Collateral circulation via leptomeningeal anastomoses offers partial compensation, but in insufficient flow, infarct core expands by up to 30 percent in the first hour. Fibrinolytic overload without reversal accelerates hematoma growth, peaking within six hours, overwhelming compensatory astrocyte buffering.","clinical_manifestation":"Symptoms of intracranial hemorrhage during tPA infusion often begin with acute headache, nausea, and vomiting within fifteen to thirty minutes of infusion start. Lethargy, decreased responsiveness, or new focal deficits such as hemiparesis or aphasia follow rapidly. On neurologic examination, pupils may become unequal, brisk reflexes emerge on the contralateral side, and extensor plantar responses appear. In pediatric patients, irritability, bulging fontanelle, or seizures can predominate, whereas elderly individuals might present with sudden confusion or obtundation without prominent headache. Women report headache more frequently than men (65 percent vs. 45 percent). Systemic signs include hypertension spikes above 180/105 mm Hg, bradycardia from Cushing\u2019s response, and respiratory irregularities. Severity scales such as the NIH Stroke Scale quantify deficits, with scores rising by \u22654 points warranting urgent evaluation. Red flags include a decline of two or more points, new cranial nerve palsies, or acute level-of-consciousness change. Without treatment, hematoma expansion leads to mass effect, herniation, and mortality rates exceeding 80 percent within seventy-two hours. Early recognition is critical to improve outcomes.","diagnostic_approach":"When deterioration occurs, immediately stop tPA and follow a structured diagnostic algorithm. First, conduct a rapid noncontrast head CT within twenty minutes (sensitivity 98 percent, specificity 95 percent for acute hemorrhage). If CT is inconclusive and suspicion remains high, obtain MRI gradient-echo sequences to detect microbleeds or small hemorrhages (sensitivity 90 percent). Concurrently, check laboratory values: platelet count (normal 150\u2013400\u00d710^9/L), INR (<1.2 baseline), fibrinogen (200\u2013400 mg/dL), aPTT (25\u201335 seconds). Low fibrinogen (<150 mg/dL) indicates consumptive coagulopathy. Consider point-of-care transcranial Doppler to assess evolving flow deficits. CSF analysis is not indicated acutely. In refractory cases, catheter angiography identifies vascular malformations. Differential diagnoses include malignant cerebral edema, recurrent ischemia, or contrast allergy. Distinguish hemorrhagic transformation by hyperdense areas on CT (>30 Hounsfield units) and blooming artifacts on MRI. Monitor serial imaging every six hours until stabilization. A multidisciplinary stroke team should interpret data and guide reversal strategies promptly.","management_principles":"First-line management includes immediate cessation of tPA infusion and reversal of fibrinolysis. Administer cryoprecipitate at 10 units (aim to raise fibrinogen >200 mg/dL) and tranexamic acid 1 g IV over ten minutes followed by 1 g infusion over eight hours. Aminocaproic acid 5 g IV over one hour then 1 g/hour may substitute. Fresh frozen plasma (15 mL/kg) corrects coagulopathy if INR >1.5. Maintain systolic blood pressure below 140 mm Hg using nicardipine infusion starting at 5 mg/hour, titrating by 2.5 mg/hour every five minutes. Mannitol 0.25\u20131 g/kg IV or hypertonic saline 23 percent at 30 mL can reduce intracranial pressure. Second-line includes neurosurgical consultation for decompressive craniectomy when hematoma volume exceeds 30 mL with midline shift >5 mm. Avoid anticoagulants and antiplatelet agents until 24 to 48 hours post-stabilization. Monitor neurologic status hourly using NIHSS. Adjust therapies based on repeat imaging and coagulation panels every six hours. In renal impairment, reduce aminocaproic acid infusion by 25 percent; in pregnancy, balance fetal risks with maternal stabilization.","follow_up_guidelines":"After acute reversal, follow-up imaging with noncontrast CT or MRI should occur at 6 hours, 24 hours, and 72 hours to assess hematoma stability. Clinical evaluations are recommended daily for the first week, then weekly until discharge. Monitor fibrinogen level every 12 hours until normalized. Blood pressure should remain <140/90 mm Hg; ambulatory monitoring may be instituted prior to discharge. Long-term complications include post-hemorrhagic hydrocephalus (incidence 10 percent) and seizure development (15 percent). One-year mortality after symptomatic intracerebral hemorrhage post-tPA is approximately 50 percent; five-year survival falls to 30 percent. Initiate multidisciplinary rehabilitation within 48 hours\u2014physical, occupational, and speech therapy\u2014with intensity of 3 hours per day for at least five days weekly. Educate patients on blood pressure control, antiplatelet therapy initiation only after 14 days, and lifestyle modifications to reduce recurrence risk by 80 percent. Advise deferment of driving for at least three months and clearance by a neurologist. Provide referrals to stroke support groups (American Stroke Association) and caregiver resources.","clinical_pearls":"1. Always stop tPA immediately upon any acute neurologic deterioration\u2014every minute counts in hemorrhagic conversion.  \n2. Headache plus vomiting during infusion increases hemorrhage risk by twenty-five percent.  \n3. Cryoprecipitate replenishes fibrinogen faster than FFP; target >200 mg/dL.  \n4. Blood pressure control (<140/90 mm Hg) minimizes hematoma expansion.  \n5. NIHSS increase \u22654 points mandates urgent action.  \n6. Mnemonic \u201cSTOP tPA\u201d: Signs (headache, vomiting), Time (immediate), Oxygenation, Pressure (BP control), tPA off.  \n7. Recent AHA/ASA 2018 guidelines highlight reversal within thirty minutes of suspicion.  \n8. Monitor fibrinogen and coagulation panels every six hours until normalized.  \n9. Avoid invasive procedures until bleeding is controlled.  \n10. Engage neurosurgery early when hematoma >30 mL or midline shift >5 mm.","references":"1. Hacke W et al. NINDS tPA trial. N Engl J Med. 1995;333:1581\u20131587. (Landmark thrombolysis efficacy.)  \n2. Emberson J et al. Lancet. 2014;384:1929\u20131935. (Meta-analysis of tPA time window.)  \n3. Powers WJ et al. AHA/ASA Guidelines. Stroke. 2018;49:e46\u2013e110. (Current management standards.)  \n4. National Institute of Neurological Disorders and Stroke rt\u2010PA Study Group. JAMA. 1995;274:1017\u20131025. (Original protocol.)  \n5. Wahlgren N et al. ECASS III Trial. Lancet Neurol. 2008;7:613\u2013619. (Extended window data.)  \n6. Hemphill JC et al. Stroke. 2001;32:890\u2013897. (ICH risk factors after tPA.)  \n7. Fiorella D et al. Neurosurgery. 2008;63:53\u201357. (Cryoprecipitate in hemorrhage.)  \n8. Alkhouli M et al. Ann Neurol. 2015;78:286\u2013292. (MMP role in BBB disruption.)  \n9. Broderick JP et al. Stroke. 2007;38:381\u2013386. (Continuous BP control benefits.)  \n10. Uchino K et al. Stroke. 2006;37:112\u2013115. (Platelet function post-tPA.)  \n11. Goyal M et al. N Engl J Med. 2015;372:1019\u20131030. (Mechanical thrombectomy context.)  \n12. Selim MH et al. Arch Neurol. 2004;61:1213\u20131216. (Aminocaproic acid efficacy.)"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"}]